PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10901303-1 2000 I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 110-124 10764626-1 2000 The P-glycoprotein (P-gp)-negative epidermoid pharyngeal carcinoma cells KB-3-1 were grown in 0.25 mM benzo[a]pyrene (BaP) for 3 months and increased resistance to doxorubicin, but not to vinblastine, colchicine, or cisplatin, was found. Doxorubicin 164-175 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 10737719-2 2000 In adriamycin-resistant human chronic myelogenous leukemia K562 cells (K562/ADM), which overexpress mdr1 mRNA, the accumulation of VP-16 was only about 10% that in wild-type K562 cells. Doxorubicin 3-13 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 10639187-6 2000 The effect on P-glycoprotein expression was reflected in the induction of resistance against adriamycin cytotoxicity. Doxorubicin 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 10872505-1 2000 The MDR1 multidrug resistance gene encodes a high molecular weight membrane-spanning cell surface protein, P-glycoprotein, that confers multidrug resistance by pumping various cytotoxic drugs, including vinblastine, doxorubicin or paclitaxel, out of cells. Doxorubicin 216-227 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 10872505-1 2000 The MDR1 multidrug resistance gene encodes a high molecular weight membrane-spanning cell surface protein, P-glycoprotein, that confers multidrug resistance by pumping various cytotoxic drugs, including vinblastine, doxorubicin or paclitaxel, out of cells. Doxorubicin 216-227 ATP binding cassette subfamily B member 1 Homo sapiens 107-121 10663638-0 2000 Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates. Doxorubicin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 10745175-4 2000 Unlike in previous reports the mdr1 promoter was no more active in two cancer cell lines with mutations in the p53 gene than in two other lines with wild-type p53, and its expression level could not be increased by either doxorubicin or taxol. Doxorubicin 222-233 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 10663638-2 2000 We studied the effects of the Pgp inhibitor, cyclosporin A (CsA), on the cerebrospinal fluid (CSF) penetration of the Pgp substrate, doxorubicin, in non-human primates. Doxorubicin 133-144 ATP binding cassette subfamily B member 1 Homo sapiens 118-121 10585596-2 2000 We have now investigated the behavior of different liposomal DOX formulations in MDA435LCC6/MDR-1 human breast cancer solid tumor xenograft models to identify liposome characteristics associated with enhanced therapeutic activity and the mechanism whereby increased chemosensitization is achieved. Doxorubicin 61-64 ATP binding cassette subfamily B member 1 Homo sapiens 92-97 10655559-2 2000 METHODS: The resistance phenotype of doxorubicin-selected MCF-7(DXR) human breast adenocarcinoma cell line was characterized by cellular and nuclear daunorubicin efflux, P-gp and MRP expression and apoptosis induction. Doxorubicin 37-48 ATP binding cassette subfamily B member 1 Homo sapiens 170-174 11417747-7 2000 In contrast, each compound, at doses as low as 0.25 microM, sensitized NCI/ADR cells to vinblastine, actinomycin D, Taxol, and doxorubicin, indicating that they effectively reverse Pgp-mediated multidrug resistance (MDR). Doxorubicin 127-138 ATP binding cassette subfamily B member 1 Homo sapiens 181-184 11144235-0 2000 The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance. Doxorubicin 69-80 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Doxorubicin 218-229 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Doxorubicin 218-229 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Doxorubicin 4-15 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 10600530-3 1999 In the case of hexanoylglucosylceramide, inhibition of Pgp activity by was reflected by a regained doxorubicin sensitivity of cells, which were grown in medium supplemented with the lipid. Doxorubicin 99-110 ATP binding cassette subfamily B member 1 Homo sapiens 55-58 10600530-4 1999 Our results lead to the conclusion that a direct transmodulation of Pgp activity by glycolipids occurs, depending on lipid headgroup structure, which can result in reduced resistance to the chemotherapeutic agent doxorubicin. Doxorubicin 213-224 ATP binding cassette subfamily B member 1 Homo sapiens 68-71 10635304-0 1999 [Merocyanine 540-mediated photodynamic therapy inhibits P-glycoprotein (P-gp) activity in adriamycin-resistant K562 cells]. Doxorubicin 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 10635304-0 1999 [Merocyanine 540-mediated photodynamic therapy inhibits P-glycoprotein (P-gp) activity in adriamycin-resistant K562 cells]. Doxorubicin 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 10571255-0 1999 Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Doxorubicin 12-23 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 10571255-5 1999 Verapamil (10 micromol/L), and even more markedly, carvedilol (10 micromol/L) increased cellular uptake of P-gp-transported calcein of a P-gp-expressing breast cancer cell line (Hs578T-Dox). Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 10576649-7 1999 Binding of [3H]-vinblastine to P-gp in MES-Dx5 membranes was inhibited by GF120918 (K = 5+/-1 nM), verapamil (Ki = 660+/-350 nM) and doxorubicin (Ki = 6940+/-2100 nM). Doxorubicin 133-144 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Doxorubicin 4-15 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Doxorubicin 4-15 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Doxorubicin 249-260 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 10576649-1 1999 The doxorubicin-selected, P-glycoprotein (P-gp)-expressing human sarcoma cell line MES-Dx5 showed the following levels of resistance relative to the non-P-gp-expressing parental MES-SA cells in a 72 h exposure to cytotoxic drugs: etoposide twofold, doxorubicin ninefold, vinblastine tenfold, taxotere 19-fold and taxol 94-fold. Doxorubicin 249-260 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 10632461-0 1999 Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. Doxorubicin 129-140 ATP binding cassette subfamily B member 1 Homo sapiens 0-22 10589744-0 1999 Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 20-24 10589744-6 1999 In four of five patients, a 3-15-fold (median, 6.8) increase in MDR1 RNA levels was detected in tumors at 50 min after administration of doxorubicin. Doxorubicin 137-148 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 10632461-0 1999 Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance. Doxorubicin 129-140 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 10632461-9 1999 Our results show that multidrug resistance-1 expression in a human chondrosarcoma cell line results in resistance to doxorubicin in vitro. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 22-44 10569469-2 1999 The current thinking is that, of the several agents used for the treatment of osteosarcoma, only doxorubicin is involved in drug resistance mediated by P-glycoprotein. Doxorubicin 97-108 ATP binding cassette subfamily B member 1 Homo sapiens 152-166 10573204-0 1999 Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Doxorubicin 29-40 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 10569469-4 1999 The expression of P-glycoprotein in tumor specimens was assessed by immunohistochemistry in 37 nonmetastatic, operable osteosarcomas treated at a single institution with doxorubicin as a single adjuvant drug. Doxorubicin 170-181 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 10411657-1 1999 Selection of human cells for resistance to vincristine or doxorubicin often induces overexpression of the multidrug resistance 1 gene (MDR1), which encodes the cell surface P-glycoprotein, as a result of gene amplification or transcriptional activation. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 106-128 10652569-16 1999 In conjunction with these toxicity buffering effects, the effect of PGP blockade on the cellular uptake of DOX in the tumor may be able to be selectively increased using liposomal carriers. Doxorubicin 107-110 ATP binding cassette subfamily B member 1 Homo sapiens 68-71 10652569-18 1999 By studying the toxicity and efficacy properties of liposome encapsulated DOX in combination with the MDR modulator PSC 833 we have been able to demonstrate that two factors play a major role in determining the effectiveness of chemosensitization approaches to overcome MDR; 1) optimizing selective localization of anticancer drug localization in tumor tissue and 2) effective blockade of PGP in tumor cells under conditions that do not compromise anticancer drug accumulation into the tumor. Doxorubicin 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 270-276 10652569-18 1999 By studying the toxicity and efficacy properties of liposome encapsulated DOX in combination with the MDR modulator PSC 833 we have been able to demonstrate that two factors play a major role in determining the effectiveness of chemosensitization approaches to overcome MDR; 1) optimizing selective localization of anticancer drug localization in tumor tissue and 2) effective blockade of PGP in tumor cells under conditions that do not compromise anticancer drug accumulation into the tumor. Doxorubicin 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 389-392 10420992-0 1999 Drug concentration-dependent expression of multidrug resistance-associated protein and P-glycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines. Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 10420992-4 1999 MRP was at first expressed at low concentrations of less than 5 x IC50 (100 ng/ml) of doxorubicin followed by the overexpression of Pgp with concentrations of more than 12.5 x IC50 (250 ng/ml) of doxorubicin. Doxorubicin 196-207 ATP binding cassette subfamily B member 1 Homo sapiens 132-135 10473106-8 1999 A relationship between mdr1 mRNA expression and response to doxorubicin was demonstrated in >90% of our tumor lines. Doxorubicin 60-71 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 10467374-3 1999 Furthermore, the resistance to doxorubicin was abolished by preincubation with the MDR1 inhibitor verapamil while resistance to MNU was ablated by the specific ATase inactivator, O6-benzylguanine (O6-beG) confirming that resistance to doxorubicin and MNU was conferred by MDR1 and ATase, respectively. Doxorubicin 31-42 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 10399954-6 1999 Resistance to a P-gp-associated drug, doxorubicin, could be reversed with P-gp circumventing agents such as cyclosporin A and verapamil, but these substances had no effect on resistance to 5-fluorouracil. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 10399954-6 1999 Resistance to a P-gp-associated drug, doxorubicin, could be reversed with P-gp circumventing agents such as cyclosporin A and verapamil, but these substances had no effect on resistance to 5-fluorouracil. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 10411657-1 1999 Selection of human cells for resistance to vincristine or doxorubicin often induces overexpression of the multidrug resistance 1 gene (MDR1), which encodes the cell surface P-glycoprotein, as a result of gene amplification or transcriptional activation. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 10378794-2 1999 In this study, we undertook to clarify the relationship between P-glycoprotein positivity (%PPG) and doxorubicin binding ability (%DB) in human osteosarcomas in order to determine which is a more sensitive index of histologic response to chemotherapy. Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 64-78 10340550-6 1999 The iMDR1-sRz- and 196MDR1-sRz-transduced Daudi/MDR20 cells completely restored chemosensitivity to VCR and doxorubicin, and were accompanied by blocked expression of MDR1 mRNA and P-glycoprotein as well as overexpression of anti-MDR1 Rz. Doxorubicin 108-119 ATP binding cassette subfamily B member 1 Homo sapiens 5-9 10340550-6 1999 The iMDR1-sRz- and 196MDR1-sRz-transduced Daudi/MDR20 cells completely restored chemosensitivity to VCR and doxorubicin, and were accompanied by blocked expression of MDR1 mRNA and P-glycoprotein as well as overexpression of anti-MDR1 Rz. Doxorubicin 108-119 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 10340550-6 1999 The iMDR1-sRz- and 196MDR1-sRz-transduced Daudi/MDR20 cells completely restored chemosensitivity to VCR and doxorubicin, and were accompanied by blocked expression of MDR1 mRNA and P-glycoprotein as well as overexpression of anti-MDR1 Rz. Doxorubicin 108-119 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 9888978-10 1999 The developed method has been applied extensively to a clinical study to examine the pharmacokinetics and metabolism of doxorubicin in patients cotreated with a potent inhibitor of MDR1 P-glycoprotein activity, GF120918. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 181-185 10368637-4 1999 The multidrug resistance gene 1 (mdr-1) encoded P-glycoprotein (P-gp) was weakly expressed in these cells upon exposure to Doxorubicin, and exerted no influence on the extent of cellular drug efflux. Doxorubicin 123-134 ATP binding cassette subfamily B member 1 Homo sapiens 4-38 10368637-4 1999 The multidrug resistance gene 1 (mdr-1) encoded P-glycoprotein (P-gp) was weakly expressed in these cells upon exposure to Doxorubicin, and exerted no influence on the extent of cellular drug efflux. Doxorubicin 123-134 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 10368637-4 1999 The multidrug resistance gene 1 (mdr-1) encoded P-glycoprotein (P-gp) was weakly expressed in these cells upon exposure to Doxorubicin, and exerted no influence on the extent of cellular drug efflux. Doxorubicin 123-134 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 10368668-2 1999 We used colon carcinoma SW620 cells and their doxorubicin resistant SW620 Ad300 derived cells, the latter express p-glycoprotein and have multidrug resistance phenotype. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 10226171-3 1999 However, the amount of P-glycoprotein present was used to predict the capacity of these cells to extrude rhodamine-123 (R-123) and their resistance to adriamycin, a cytotoxic drug. Doxorubicin 151-161 ATP binding cassette subfamily B member 1 Homo sapiens 23-37 9888978-10 1999 The developed method has been applied extensively to a clinical study to examine the pharmacokinetics and metabolism of doxorubicin in patients cotreated with a potent inhibitor of MDR1 P-glycoprotein activity, GF120918. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 186-200 10412950-7 1999 P-glycoprotein function was determined by intracellular doxorubicin accumulation and/or cytotoxicity assays before and after CaN and FKBP12 were independently inhibited by pharmacological antagonists. Doxorubicin 56-67 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 10321019-3 1999 We have recently found that P-glycoprotein is expressed also in the nucleus of MDR cell lines selected in doxorubicin (DXR), suggesting the possible involvement of this protein in the direct extrusion of the drug from the nucleus of resistant cells. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 9914470-4 1999 A similar twofold acceleration of doxorubicin flip-flop rate across membranes was observed with neutral mild detergents, including Tween 20, Nonidet P-40 and Triton X-100, and certain Pgp modulators, such as verapamil and progesterone. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 184-187 10367753-9 1999 Doxorubicin-resistant cells, demonstrated to overexpress the MDR1 multi-drug-resistance protein were equally as sensitive to flavopiridol as the parental cells. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 10228815-2 1999 One of the major problems associated with cancer chemotherapy is drug-resistance of tumor cells, and resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 9923448-1 1999 A subclone HL60/DOX was selected from a human leukemic HL60 cell line for resistance to doxorubicin (DOX) by exposure to stepwise increasing concentrations of the drug and coexposure to a potential P-glycoprotein (P-gp) inhibitor, cepharanthine (a biscoclaurine alkaloid). Doxorubicin 16-19 ATP binding cassette subfamily B member 1 Homo sapiens 198-212 9923448-1 1999 A subclone HL60/DOX was selected from a human leukemic HL60 cell line for resistance to doxorubicin (DOX) by exposure to stepwise increasing concentrations of the drug and coexposure to a potential P-glycoprotein (P-gp) inhibitor, cepharanthine (a biscoclaurine alkaloid). Doxorubicin 16-19 ATP binding cassette subfamily B member 1 Homo sapiens 214-218 9923448-4 1999 The P-gp expression was not detectable by the monoclonal antibody, C219, in the HL60/DOX cells, and that was consistent with extremely low levels of mdr1 mRNA expression determined by CRT-PCR in this clone. Doxorubicin 85-88 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 10228815-2 1999 One of the major problems associated with cancer chemotherapy is drug-resistance of tumor cells, and resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein. Doxorubicin 128-131 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 10228815-3 1999 We have tried to prove the correlation between P-glycoprotein expression and DOX-sensitivity in highly purified fresh human colorectal cancer and, moreover, to prove the differentiation of P-glycoprotein expression between the different kinds of cancers, including gastric cancer. Doxorubicin 77-80 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 10228815-5 1999 RESULTS: DOX-sensitivity decreased in proportion to P-glycoprotein expression in colorectal cancer. Doxorubicin 9-12 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 10228815-7 1999 Particularly, P-glycoprotein expression in colorectal cancer in the DOX low-sensitivity group was higher than in the DOX high-sensitivity group. Doxorubicin 68-71 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 10228815-7 1999 Particularly, P-glycoprotein expression in colorectal cancer in the DOX low-sensitivity group was higher than in the DOX high-sensitivity group. Doxorubicin 117-120 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 10757444-3 1999 Pretreatment with MMC led to a 5- to 10-fold decrease in the ED50 for cell killing by a subsequent agent such as the Pgp substrate, doxorubicin, but did not affect killing by the non-Pgp substrate, cisplatin. Doxorubicin 132-143 ATP binding cassette subfamily B member 1 Homo sapiens 117-120 10638482-11 1999 CONCLUSIONS: We conclude that: 1) Doxorubicin microcapsules retain activity in vitro and appear to overcome p-glycoprotein mediated Dox resistance. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 10638482-11 1999 CONCLUSIONS: We conclude that: 1) Doxorubicin microcapsules retain activity in vitro and appear to overcome p-glycoprotein mediated Dox resistance. Doxorubicin 34-37 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 9823967-0 1998 Inhibition of protein kinase C-alpha isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure. Doxorubicin 145-156 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 9834236-1 1998 Selection of human cells for resistance to vincristine or doxorubicin often induces overexpression of the multidrug resistance 1 gene (MDR1), which encodes the cell surface P-glycoprotein, as a result of gene amplification or transcriptional activation. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 106-128 9834236-1 1998 Selection of human cells for resistance to vincristine or doxorubicin often induces overexpression of the multidrug resistance 1 gene (MDR1), which encodes the cell surface P-glycoprotein, as a result of gene amplification or transcriptional activation. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 9834236-1 1998 Selection of human cells for resistance to vincristine or doxorubicin often induces overexpression of the multidrug resistance 1 gene (MDR1), which encodes the cell surface P-glycoprotein, as a result of gene amplification or transcriptional activation. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 173-187 10452234-1 1999 The resistance to doxorubicin (DOX) by some tumor cells is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 10452234-1 1999 The resistance to doxorubicin (DOX) by some tumor cells is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 117-139 10452234-1 1999 The resistance to doxorubicin (DOX) by some tumor cells is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 10452234-1 1999 The resistance to doxorubicin (DOX) by some tumor cells is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 10452234-1 1999 The resistance to doxorubicin (DOX) by some tumor cells is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 117-139 10452234-1 1999 The resistance to doxorubicin (DOX) by some tumor cells is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 10452234-2 1999 We tried to prove the correlations between P-glycoprotein expression and the sensitivity for anticancer drugs including DOX and other cytotoxic drugs that are currently used for gastrointestinal cancer patients. Doxorubicin 120-123 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 10452234-6 1999 A significant correlation was also seen between the inhibition rates for DOX and P-glycoprotein expression, whereas only a slight correlation between the sensitivity for MMC and P-glycoprotein expression was observed. Doxorubicin 73-76 ATP binding cassette subfamily B member 1 Homo sapiens 81-95 10452234-7 1999 We should therefore pay close attention to the effect of P-glycoprotein when treating cancer patients, especially if both the inhibition rates of DOX and MMC are low based on the findings of an MTT assay. Doxorubicin 146-149 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 9835508-3 1998 HIV PIs also enhanced the cytotoxic activity of doxorubicin, a known substrate for MDR1 and MRP1, in both VBL100 and VM-1-5 CEM lines. Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 9914792-0 1998 Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 9846505-1 1998 BACKGROUND AND OBJECTIVES: Although the mechanism of P-glycoprotein (Pgp)-related resistance of doxorubicin is known, it has not been clarified for other anthracycline derivatives. Doxorubicin 96-107 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 9914792-1 1998 The inhibitory effects of SDZ PSC 833 (PSC833), a non-immunosuppressive cyclosporin derivative, on the P-glycoprotein (P-gp)-mediated transport of doxorubicin and vinblastine were compared with those of cyclosporin A (Cs-A). Doxorubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 9846505-1 1998 BACKGROUND AND OBJECTIVES: Although the mechanism of P-glycoprotein (Pgp)-related resistance of doxorubicin is known, it has not been clarified for other anthracycline derivatives. Doxorubicin 96-107 ATP binding cassette subfamily B member 1 Homo sapiens 69-72 9914792-1 1998 The inhibitory effects of SDZ PSC 833 (PSC833), a non-immunosuppressive cyclosporin derivative, on the P-glycoprotein (P-gp)-mediated transport of doxorubicin and vinblastine were compared with those of cyclosporin A (Cs-A). Doxorubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 9914792-3 1998 Both PSC833 and Cs-A inhibited P-gp-mediated transport of doxorubicin and vinblastine in a concentration-dependent manner and increased the intracellular accumulation of doxorubicin and vinblastine in LLC-GA5-COL150 cells. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 9780138-6 1998 P-glycoprotein effluxes a variety of anticancer drugs, such as doxorubicin, vinca alkaloids, etoposide and taxol, and thereby allows cancer cells to show resistance to these drugs. Doxorubicin 63-74 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 9799532-1 1998 Doxorubicin, a drug largely used in chemotherapy, is transported by P-glycoprotein, a protein involved in the multidrug-resistance phenotype. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 68-82 9799532-9 1998 Since this cation is essential for P-glycoprotein activity, it can be concluded that in these conditions the accurate evaluation of P-glycoprotein-catalyzed doxorubicin transport will be obtained from the Mg2+-sensitive transport into DNA-loaded proteoliposomes. Doxorubicin 157-168 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 9799532-9 1998 Since this cation is essential for P-glycoprotein activity, it can be concluded that in these conditions the accurate evaluation of P-glycoprotein-catalyzed doxorubicin transport will be obtained from the Mg2+-sensitive transport into DNA-loaded proteoliposomes. Doxorubicin 157-168 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 9806185-6 1998 In contrast, gp-170 expression increased and then was suppressed in acquired MDR sublines of RCC8701 cultured in increasing concentrations of adriamycin. Doxorubicin 142-152 ATP binding cassette subfamily B member 1 Homo sapiens 13-19 9806185-8 1998 The resistant cell line cultured long-term in 800 ng/mL adriamycin, RCC8701/ADR800, was 122 times more resistant to adriamycin and 238 times more resistant to epirubicin than the parent cell line: the pattern differed from that in native RCC cell lines and was unrelated to the expression of gp-170. Doxorubicin 56-66 ATP binding cassette subfamily B member 1 Homo sapiens 292-298 9713996-8 1998 In an adriamycin-selected resistant colon cancer line (S48-3s/Adr), WCP4/WCP7 revealed t(4;7)(q31;q21) and BAC-derived probes demonstrated that the breakpoint lay between MDR1 and sequences 500-1000 KB telomeric to it. Doxorubicin 6-16 ATP binding cassette subfamily B member 1 Homo sapiens 171-175 9685354-3 1998 Expression of MRP1 alone confers resistance to several drugs representing the multidrug resistance phenotype, drugs including doxorubicin, vincristine, etoposide, and mitoxantrone. Doxorubicin 126-137 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 9763226-0 1998 S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 20-34 9705821-0 1998 Cellular resistance to adriamycin conferred by enhanced Rb expression is associated with increased MDR1 expression. Doxorubicin 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 9713512-5 1998 Using a retrovirus, we introduced the antisense RNAs of MDR1 and MRP genes into doxorubicin-selected, multidrug-resistant GAOK cells, a cell which overexpresses both MDR1 and MRP genes. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 9724909-0 1998 HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. Doxorubicin 21-31 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 9713512-5 1998 Using a retrovirus, we introduced the antisense RNAs of MDR1 and MRP genes into doxorubicin-selected, multidrug-resistant GAOK cells, a cell which overexpresses both MDR1 and MRP genes. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 166-170 9649010-10 1998 Among the 30 patients who had received doxorubicin- or etoposide-containing combination chemotherapy, 3 (10%; 95% confidence interval, 3%-27%) were designated positive for MDR-1 expression. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 172-177 9558371-1 1998 To overcome the problem of multidrug resistance, we investigated the effectiveness of phosphrothioate antisense oligonucleotides (MDR1-AS) in suppressing multidrug resistance gene (mdr1) expression in drug-resistant acute myelogenous leukemia (AML) blast cells and the K562 adriamycin-resistant cell line K562/ADM. Doxorubicin 274-284 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 9485370-2 1998 Although MRP has been identified as an organic anion transporter and Pgp as a transporter of certain positively charged compounds, there is considerable overlap in resistance spectrum, suggesting that both proteins transport important anticancer agents such as doxorubicin, etoposide, and vincristine. Doxorubicin 261-272 ATP binding cassette subfamily B member 1 Homo sapiens 69-72 9585065-0 1998 Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 9585065-4 1998 Exposure of canine osteosarcoma cells to doxorubicin resulted in overexpression of MDR1 mRNA and P-glycoprotein. Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 97-111 9506534-9 1998 P-gp function modulators (verapamil and cyclosporin A) were able to modify DOX intracytoplasmic distribution and to increase drug intracellular concentration and cytotoxic effect in melanoma cells. Doxorubicin 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 9504636-3 1998 Drug resistance towards Dau, Dox and Etop was correlated to the MDR1 expression of the AML cells (P<0.05) with high MDR1 expression being associated with high drug resistance towards these drugs. Doxorubicin 29-32 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 9504636-3 1998 Drug resistance towards Dau, Dox and Etop was correlated to the MDR1 expression of the AML cells (P<0.05) with high MDR1 expression being associated with high drug resistance towards these drugs. Doxorubicin 29-32 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 9506530-0 1998 Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Doxorubicin 52-63 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 9506530-6 1998 The P-glycoprotein-mediated multidrug resistance (MDR)-reversing agents verapamil, cyclosporin A, quinidine, sodium orthovanadate and tamoxifen significantly increased dox fluorescence at this depth, whereas genistein, indomethacin, probenecid and brefeldin A, which reverse multidrug-resistance-associated protein (MRP) function, exerted no effect. Doxorubicin 168-171 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 11717919-5 1998 The result of Northern blot assay showed that the expressed ribozyme could decrease the level of mdr1 mRNA expression by 83.5%; and the expressed ribozyme could inhibit the formation of P-glycoprotein detected by immuno-cytochemistry assay and could reduce the cell"s resistance to adriamycin; this means that the resistant cells were 1,000-fold more resistant than the parental cell line (MCF-7), whereas those cell clones that showed ribozyme expression were only 6-fold more resistant than the parental cell line. Doxorubicin 282-292 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 11717919-5 1998 The result of Northern blot assay showed that the expressed ribozyme could decrease the level of mdr1 mRNA expression by 83.5%; and the expressed ribozyme could inhibit the formation of P-glycoprotein detected by immuno-cytochemistry assay and could reduce the cell"s resistance to adriamycin; this means that the resistant cells were 1,000-fold more resistant than the parental cell line (MCF-7), whereas those cell clones that showed ribozyme expression were only 6-fold more resistant than the parental cell line. Doxorubicin 282-292 ATP binding cassette subfamily B member 1 Homo sapiens 186-200 9514088-3 1998 In a search for a possible mechanism, we found that tamoxifen at a clinically achievable concentration (2.5 microM) significantly enhanced doxorubicin-induced cytotoxicity and apoptosis of Hep-3B cells, a multidrug resistance (MDR)-1 expressing HCC cell line. Doxorubicin 139-150 ATP binding cassette subfamily B member 1 Homo sapiens 205-233 9700723-2 1998 All three N276 compounds almost completely reversed the acquired resistance to vincristine (VCR), vinblastine (VBL), and doxorubicin (DXR) in MDR1-overexpressing human cancer cell lines (KB/VJ300 and T24/VCR). Doxorubicin 121-132 ATP binding cassette subfamily B member 1 Homo sapiens 142-146 9516927-0 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Doxorubicin 135-146 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 9516927-0 1998 Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Doxorubicin 135-146 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 9516927-1 1998 To determine whether multidrug resistance (MDR1) P-glycoprotein (Pgp) expression correlated with clinical MDR1-related drug resistance, we established a protocol for quantitative measurement of Pgp expression and in vitro drug resistance in doxorubicin resistant MCF7 breast cancer cell lines and 359 freshly resected specimens of breast carcinoma. Doxorubicin 241-252 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 9516927-1 1998 To determine whether multidrug resistance (MDR1) P-glycoprotein (Pgp) expression correlated with clinical MDR1-related drug resistance, we established a protocol for quantitative measurement of Pgp expression and in vitro drug resistance in doxorubicin resistant MCF7 breast cancer cell lines and 359 freshly resected specimens of breast carcinoma. Doxorubicin 241-252 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 9516927-1 1998 To determine whether multidrug resistance (MDR1) P-glycoprotein (Pgp) expression correlated with clinical MDR1-related drug resistance, we established a protocol for quantitative measurement of Pgp expression and in vitro drug resistance in doxorubicin resistant MCF7 breast cancer cell lines and 359 freshly resected specimens of breast carcinoma. Doxorubicin 241-252 ATP binding cassette subfamily B member 1 Homo sapiens 65-68 9516927-7 1998 Compared with Pgp-negative tumors, a significant increase in doxorubicin and Taxol resistance was seen for breast cancers that expressed Pgp, regardless of prior treatment. Doxorubicin 61-72 ATP binding cassette subfamily B member 1 Homo sapiens 137-140 9516927-8 1998 A strong correlation between the degree of Pgp expression and in vitro resistance to Taxol and doxorubicin (but not to 5-fluorouracil) was found when either IHC scores or image analysis-based methods were used to quantify Pgp expression (n = 185, P < 0.0001). Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 43-46 9516927-8 1998 A strong correlation between the degree of Pgp expression and in vitro resistance to Taxol and doxorubicin (but not to 5-fluorouracil) was found when either IHC scores or image analysis-based methods were used to quantify Pgp expression (n = 185, P < 0.0001). Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 222-225 9619752-5 1998 The complex was used to treat two P-glycoprotein-producing MDR cell lines: MCF-7/R human breast cancer cells resistant to doxorubicin and MOLT-3/TMQ800 human ALL cells resistant to trimetrexate (TMQ). Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 9482283-9 1998 When MCS were incubated with verapamil, cyclosporin A, orthovanadate, and quinidine, which are known to reverse P-glycoprotein (Pgp)-mediated multidrug resistance (MDR), Dox accumulated also in deeper cell layers. Doxorubicin 170-173 ATP binding cassette subfamily B member 1 Homo sapiens 128-131 9443942-8 1998 Two anthracyclines, the doxorubicin derivative pirarubicin and 2"-bromo-4"-epi-DNR seemed to have a slightly higher Ka value for Pgp than for MRP. Doxorubicin 24-35 ATP binding cassette subfamily B member 1 Homo sapiens 129-132 9815817-6 1997 Mitomycin C pretreatment also significantly increased the sensitivity of cancer cells to subsequent killing by the P-glycoprotein substrate doxorubicin, decreasing the ED50 by 5- to 10-fold. Doxorubicin 140-151 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 9477189-10 1997 CONCLUSION: Reduced drug accumulation in doxorubicin-resistant cells was mediated by MRP instead of PgP indicating that MRP-mediated drug efflux functions in a limited manner for drug resistance. Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 100-103 9345322-2 1997 We have attempted to reverse the multidrug resistance (MDR) phenotype by treating vincristine (VCR) and adriamycin (ADM) resistant KBV200 cells with MDR1 antisense RNA. Doxorubicin 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 9345322-2 1997 We have attempted to reverse the multidrug resistance (MDR) phenotype by treating vincristine (VCR) and adriamycin (ADM) resistant KBV200 cells with MDR1 antisense RNA. Doxorubicin 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 9793179-0 1998 Resistance to adriamycin in human chronic promyeloleukemia line K562 correlates with directed genome destabilization--amplification of MDR1 gene and nonrandom changes in karyotype structure. Doxorubicin 14-24 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 9464458-1 1997 Doxorubicin, an anticancer drug, is extruded from multidrug resistant (MDR) cells and from the brain by P-glycoprotein located in the plasma membrane and the blood-brain barrier, respectively. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 9494563-4 1997 C6,5 x 10(-7) Dox cells expressed high levels of P-glycoprotein (Pgp), known to function as an energy-dependent efflux pump for lipophilic drugs causing the multidrug resistance phenotype. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 9494563-4 1997 C6,5 x 10(-7) Dox cells expressed high levels of P-glycoprotein (Pgp), known to function as an energy-dependent efflux pump for lipophilic drugs causing the multidrug resistance phenotype. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 65-68 9494563-5 1997 Pgp, which normally has a molecular weight of 170 to 180 kd, appears in C6,5 x 10(-7) Dox cells as two bands with a molecular weight of 140 and 120 kd in western blots. Doxorubicin 86-89 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 28481204-3 1997 The unique functional features of this transporter include its ability to mediate ATP-dependent transmembrane movement of organic anions such as glutathione conjugates, as well as weakly cationic amphiphilic compounds such as doxorubicin and other substrates of P-glycoprotein. Doxorubicin 226-237 ATP binding cassette subfamily B member 1 Homo sapiens 262-276 9220975-5 1997 The drug-resistance profile of cells stably expressing each mutated P-glycoprotein was investigated by comparing their relative resistance to vinblastine, colchicine, VP16, and adriamycin. Doxorubicin 177-187 ATP binding cassette subfamily B member 1 Homo sapiens 68-82 9639738-5 1997 RESULT: Ovarian carcinoma cells with positive MDR1 gene expression showed cross drug-resistance to ADM, daunorubicin (DNR), vincristine (VCR) and etoposide (VP-16), the value of inhibiting concentration (IC50) is 4.1-15.5 times of that of the cells with negative MDR1 gene expression. Doxorubicin 99-102 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 9177449-0 1997 Enhancement of mdr1 gene expression by transforming growth factor-beta1 in the new adriamycin-resistant human leukemia cell line ME-F2/ADM. Doxorubicin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 9205007-7 1997 Human myeloma cell lines, 8226/Dox, that are resistant to natural product agents and overexpress MDR1/Pgp are important for standardizing results and offer a means of comparing inter- and intra-patient results. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 9205007-7 1997 Human myeloma cell lines, 8226/Dox, that are resistant to natural product agents and overexpress MDR1/Pgp are important for standardizing results and offer a means of comparing inter- and intra-patient results. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 102-105 9227790-1 1997 We have established an Adriamycin (ADM)-resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM 100, which shows multifactorial mechanisms of resistance to ADM, such as over-expression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II activity. Doxorubicin 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 193-207 9227790-1 1997 We have established an Adriamycin (ADM)-resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM 100, which shows multifactorial mechanisms of resistance to ADM, such as over-expression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II activity. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 193-207 9155147-4 1997 We recently found that amino acid substitutions in the first predicted transmembrane domain of P-glycoprotein increase the ability to confer resistance to important anti-cancer drugs adriamycin and VP-16. Doxorubicin 183-193 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 9109439-2 1997 Deletion of the first 68 residues of MDR-1 in an adriamycin-selected cell line after a 4;7 translocation, t(4q;7q), resulted in a hybrid mRNA containing sequences from both MDR-1 and a novel chromosome 4 gene. Doxorubicin 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 37-42 9109439-2 1997 Deletion of the first 68 residues of MDR-1 in an adriamycin-selected cell line after a 4;7 translocation, t(4q;7q), resulted in a hybrid mRNA containing sequences from both MDR-1 and a novel chromosome 4 gene. Doxorubicin 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 173-178 9136943-0 1997 Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. Doxorubicin 25-36 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 9086008-0 1997 Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. Doxorubicin 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 9275020-5 1997 In contrast, all three intracerebrally transplanted human glioma xenografts (icX) were resistant to P-gp-mediated drugs VCR and DOX, but were sensitive to the non-P-gp-mediated drug ACNU. Doxorubicin 128-131 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 9038218-8 1997 Transfection of the mutant mdr1 gene into drug-sensitive MES-SA sarcoma cells confers resistance to both doxorubicin and PSC 833. Doxorubicin 105-116 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 9038218-9 1997 Our study demonstrates that survival of cells exposed to doxorubicin and PSC 833 in a multistep selection occurred as a result of a P-glycoprotein mutation in transmembrane region 6. Doxorubicin 57-68 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 9073309-3 1997 Uptake experiments showed that VX-710 at 0.5-2.5 microM fully restored intracellular accumulation of [14C]doxorubicin in multidrug resistant cells, suggesting that VX-710 inhibits the drug efflux activity of P-glycoprotein. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 208-222 10453556-0 1997 [Fully length MDR1 cDNA transfer conferring resistance to adriamycine on sensitive cells GLC]. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 8968098-6 1996 The cytoplasmic location of P-glycoprotein in the MDR10V cells is associated with a redistribution of doxorubicin. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 9155054-5 1997 P-gp levels measured by Western blot mirrored the change in doxorubicin sensitivity. Doxorubicin 60-71 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 9272134-11 1997 Our previous study indicated that expression of P-glycoprotein in ATL cells might be involved in resistance to chemotherapeutic agents, particularly doxorubicin, vincristine, and etoposide. Doxorubicin 149-160 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 9116319-2 1997 The de novo p-gp expression rate was 26% and increased up to 58% (p = 0.03) with the FAC (5-fluorouracil, adriamycin, cyclophosphamide) regimen. Doxorubicin 106-116 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 9443650-0 1997 Correlation of expression levels of P-glycoprotein with resistance to adriamycin in a renal adenocarcinoma cell line. Doxorubicin 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 9048492-1 1996 The expression of p-glycoprotein (p-gp) was evaluated in pre- and post-chemotherapy states after the administration of adriamycin-based chemotherapy in 24 gastric cancer patients. Doxorubicin 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 8940082-9 1996 Under conditions optimal for JNK activation, Adriamycin, vinblastine, and VP-16 all induced MDR1 mRNA expression in KB-3 cells. Doxorubicin 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 9042212-0 1996 Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Doxorubicin 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 29-32 8912533-4 1996 P-glycoprotein function was examined after accumulation of the fluorescent drug, doxorubicin, by flow cytometry. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8892677-18 1996 In addition, it is an effective inhibitor of P-gp mediated efflux of doxorubicin in myeloma tumor cells in vitro. Doxorubicin 69-80 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 9020922-0 1996 Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Doxorubicin 127-138 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 9020922-5 1996 However, when considering separately each group of drugs, it appeared that the most potent drug in inhibiting azidopine labelling of P-glycoprotein (P-gp) was also the most potent in restoring doxorubicin accumulation. Doxorubicin 193-204 ATP binding cassette subfamily B member 1 Homo sapiens 133-147 9020922-5 1996 However, when considering separately each group of drugs, it appeared that the most potent drug in inhibiting azidopine labelling of P-glycoprotein (P-gp) was also the most potent in restoring doxorubicin accumulation. Doxorubicin 193-204 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 8954828-1 1996 The resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 97-119 8954828-1 1996 The resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 8954828-1 1996 The resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 97-119 8954828-1 1996 The resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance-1 (mdr1) gene. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 8917702-3 1996 Thirty-eight pesticides representing several classes of compounds were evaluated for their potential to bind to P-gp, as measured by the inhibition of efflux of the P-gp substrate doxorubicin. Doxorubicin 180-191 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 8917702-3 1996 Thirty-eight pesticides representing several classes of compounds were evaluated for their potential to bind to P-gp, as measured by the inhibition of efflux of the P-gp substrate doxorubicin. Doxorubicin 180-191 ATP binding cassette subfamily B member 1 Homo sapiens 165-169 9048492-1 1996 The expression of p-glycoprotein (p-gp) was evaluated in pre- and post-chemotherapy states after the administration of adriamycin-based chemotherapy in 24 gastric cancer patients. Doxorubicin 119-129 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 9048492-8 1996 These data suggest that p-gp can be induced by an adriamycin-based chemotherapy in gastric cancer. Doxorubicin 50-60 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 9048492-9 1996 Thus, we suggest that the prognosis of gastric cancer may be poor if a multidrug resistance (MDR)-related regimen is used in the presence of p-gp after neoadjuvant chemotherapy with an adriamycin-based regimen, even if the initial response is good. Doxorubicin 185-195 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 8855972-6 1996 Thus, many osteosarcomas exhibited intrinsic expression of MDR1 mRNA before multidrug regimens which invariably included doxorubicin and, in most cases, MDR1 expression was not induced following chemotherapeutic treatment. Doxorubicin 121-132 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 8900436-4 1996 In the present study we show that these compounds are also able to inhibit up-regulation of MDR1 gene expression caused by cytarabine (ARA-C) and doxorubicin in human tumor cell lines H9 and KB 3-1, which express minimal levels of MDR1 mRNA. Doxorubicin 146-157 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 8827016-9 1996 The function of Pgp was analyzed by measuring accumulation of the fluorescent drug doxorubicin by flow cytometry. Doxorubicin 83-94 ATP binding cassette subfamily B member 1 Homo sapiens 16-19 8827016-16 1996 The cytokine-mediated effects on mdr1 expression resulted in increased chemosensitivity of the transduced cells to doxorubicin and vincristine (P < .0460). Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 8891227-3 1996 A comparative study between radioactively labeled PCR (32P-PCR) and QPCR was performed to analyze the MDR1 gene expression in the drug-resistant (Doxorubicin) cell lines Dox40, Dox6, the parental cell line 8226/S, CEM Dox1 and three acute myeloid leukemia (AML) patient samples. Doxorubicin 146-157 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 8831775-3 1996 The fact that active compounds increase adriamycin accumulation in the resistant KB-A1 cells, and not in the sensitive KB-3-1 cells, suggests they act predominantly by inhibiting the P-glycoprotein-catalyzed efflux of cytotoxic agents. Doxorubicin 40-50 ATP binding cassette subfamily B member 1 Homo sapiens 183-197 8913275-2 1996 The augmentation of DOX sensitivity by TAM and CEP was significantly correlated with the P-glycoprotein expression. Doxorubicin 20-23 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 8913275-3 1996 The cytotoxic effect of DOX with TAM and CEP was significantly higher than that of DOX alone, or DOX with TAM, and this synergistic effect was dominant in cell lines with high expression of P-glycoprotein. Doxorubicin 24-27 ATP binding cassette subfamily B member 1 Homo sapiens 190-204 8913275-3 1996 The cytotoxic effect of DOX with TAM and CEP was significantly higher than that of DOX alone, or DOX with TAM, and this synergistic effect was dominant in cell lines with high expression of P-glycoprotein. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 190-204 8913275-3 1996 The cytotoxic effect of DOX with TAM and CEP was significantly higher than that of DOX alone, or DOX with TAM, and this synergistic effect was dominant in cell lines with high expression of P-glycoprotein. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 190-204 8875050-5 1996 Overexpression of Pgp correlated inversely with retention of Dox, Rh-123, and DiOC2(3); however, under identical experimental conditions (1 h reincubation in drug-free medium), no retention difference of the three agents was detected between parental and MRP-expressing resistant cells. Doxorubicin 61-64 ATP binding cassette subfamily B member 1 Homo sapiens 18-21 8782646-9 1996 Moreover, treatments of MCF-7/Adr cells with P-glycoprotein (P-gp) modulators, cyclosporin A and verapamil increased doxorubicin and vincristine-induced DNA fragmentation about 1.4- and 2.5-fold, indicating that P-gp is involved in the development of resistance to chemotherapy-induced apoptosis in this cell line. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 45-59 8782646-9 1996 Moreover, treatments of MCF-7/Adr cells with P-glycoprotein (P-gp) modulators, cyclosporin A and verapamil increased doxorubicin and vincristine-induced DNA fragmentation about 1.4- and 2.5-fold, indicating that P-gp is involved in the development of resistance to chemotherapy-induced apoptosis in this cell line. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 8782646-9 1996 Moreover, treatments of MCF-7/Adr cells with P-glycoprotein (P-gp) modulators, cyclosporin A and verapamil increased doxorubicin and vincristine-induced DNA fragmentation about 1.4- and 2.5-fold, indicating that P-gp is involved in the development of resistance to chemotherapy-induced apoptosis in this cell line. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 212-216 8875050-7 1996 Incubation of the cells with a modulator of MDR, PAK-104P, negated the observed drug efflux in Pgp and MRP expressing cells, which correlated with increased sensitivity of the MDR lines to doxorubicin. Doxorubicin 189-200 ATP binding cassette subfamily B member 1 Homo sapiens 95-98 8704189-4 1996 We have studied P-gp expression and function in childhood acute leukemias by developing a series of doxorubicin- and vincristine-selected CEM, T-cell lymphoblastoid cell lines that recapitulate the low levels of expression and resistance seen clinically. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 8911123-6 1996 Inhibition of Pgp activity by VER (6 mumol/l) enhanced DOX uptake and resulted in an intracellular nuclear compartmentalisation of DOX in LoVo-R cells. Doxorubicin 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 8911123-6 1996 Inhibition of Pgp activity by VER (6 mumol/l) enhanced DOX uptake and resulted in an intracellular nuclear compartmentalisation of DOX in LoVo-R cells. Doxorubicin 131-134 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 8911123-8 1996 However, similar increases in intracellular DOX uptake due to the inhibitory effect of VER on Pgp greatly potentiated DOX cytotoxicity in LoVo-R cells synchronised in the S or G2M phase compared with non-synchronised cycling cells. Doxorubicin 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 94-97 8911123-8 1996 However, similar increases in intracellular DOX uptake due to the inhibitory effect of VER on Pgp greatly potentiated DOX cytotoxicity in LoVo-R cells synchronised in the S or G2M phase compared with non-synchronised cycling cells. Doxorubicin 118-121 ATP binding cassette subfamily B member 1 Homo sapiens 94-97 8911123-11 1996 Finally, the combination of synchronisation by MTX and of inhibition of Pgp activity by VER produced a considerable reduction in DOX IC50 (approximately 50-fold) in LoVo-R cells compared with the cells not treated with MTX and VER. Doxorubicin 129-132 ATP binding cassette subfamily B member 1 Homo sapiens 72-75 8911123-12 1996 In conclusion, this study demonstrates that, in LoVo-R cells, the effect of Pgp inhibition on DOX cytotoxicity is dependent on cell cycle phase. Doxorubicin 94-97 ATP binding cassette subfamily B member 1 Homo sapiens 76-79 8911123-13 1996 DOX cytotoxicity is maximal when inhibition of Pgp activity occurs during the S/G2M phases. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 47-50 8635868-5 1996 In doxorubicin only-selected cells (8226/dox4), drug resistance was mediated by over-expression of the MDR1 gene and its cognate protein P-glycoprotein. Doxorubicin 3-14 ATP binding cassette subfamily B member 1 Homo sapiens 103-107 8870372-6 1996 However, despite the great increase caused by PSC in the toxicity of DOX and a more modest effect on the toxicity of the two DOX derivatives, this MDR reversal agent could only completely block the PGP mediated MMDOX resistance whereas DOX refractoriness was only decreased. Doxorubicin 125-128 ATP binding cassette subfamily B member 1 Homo sapiens 198-201 8870372-6 1996 However, despite the great increase caused by PSC in the toxicity of DOX and a more modest effect on the toxicity of the two DOX derivatives, this MDR reversal agent could only completely block the PGP mediated MMDOX resistance whereas DOX refractoriness was only decreased. Doxorubicin 125-128 ATP binding cassette subfamily B member 1 Homo sapiens 198-201 8870372-7 1996 CONCLUSIONS: The combination of MMDOX or IODODOX with PSC 1.6 microM is more efficient than the combination of DOX plus PSC for the full reversion of PGP-mediated drug resistance. Doxorubicin 34-37 ATP binding cassette subfamily B member 1 Homo sapiens 150-153 8648821-12 1996 Active P-gp functions were observed in the 2 doxorubicin-RLs but not in the 2 cisplatin-RLs. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 7-11 8648821-18 1996 CONCLUSIONS: Expression of mdr-1 was not commonly seen in TCC cell lines but can be significantly induced by chronic exposure to doxorubicin. Doxorubicin 129-140 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 8688320-5 1996 Furthermore, the expression of P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated. Doxorubicin 161-172 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 8688320-5 1996 Furthermore, the expression of P-glycoprotein (P-gp) and multidrug resistance-related protein (MRP), which both can contribute to resistance to daunorubicin and doxorubicin, were immunohistochemically investigated. Doxorubicin 161-172 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 8635868-5 1996 In doxorubicin only-selected cells (8226/dox4), drug resistance was mediated by over-expression of the MDR1 gene and its cognate protein P-glycoprotein. Doxorubicin 3-14 ATP binding cassette subfamily B member 1 Homo sapiens 137-151 8635868-9 1996 Our results indicate that the inclusion of verapamil during drug selection with doxorubicin influences the drug-resistant phenotype by preventing the selection of MDR1/P-glycoprotein-positive cells. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 163-167 8635868-9 1996 Our results indicate that the inclusion of verapamil during drug selection with doxorubicin influences the drug-resistant phenotype by preventing the selection of MDR1/P-glycoprotein-positive cells. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 168-182 8791998-1 1996 The P-glycoprotein (P-gp) molecules which are expressed on multidrug-resistant (MDR) tumor cells efflux a variety of anti-cancer drugs, such as doxorubicin. Doxorubicin 144-155 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 8791998-1 1996 The P-glycoprotein (P-gp) molecules which are expressed on multidrug-resistant (MDR) tumor cells efflux a variety of anti-cancer drugs, such as doxorubicin. Doxorubicin 144-155 ATP binding cassette subfamily B member 1 Homo sapiens 20-24 8605092-0 1996 Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Doxorubicin 10-21 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 8605092-9 1996 The persistence of brefeldin A-responsive phenotype on the background of variable MRP expression suggests this agent as a useful functional probe for non-P-gp-mediated resistance to plasma-achievable doxorubicin concentrations. Doxorubicin 200-211 ATP binding cassette subfamily B member 1 Homo sapiens 154-158 8605104-1 1996 Expression of the MRP gene has been demonstrated in vitro to be a casual factor in non-P-glycoprotein-mediated multidrug resistance, and is implicated in resistance to a number of the chemotherapeutic agents currently used in the treatment of high-grade transitional cell carcinoma (TCC) of the bladder (doxorubicin, epirubicin and vinblastine). Doxorubicin 304-315 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 8605092-8 1996 The P-gp-negative PSN1/ADR cells adapted to 510 nM doxorubicin retained brefeldin A-sensitive doxorubicin accumulation defects while MRP declined. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 8605092-8 1996 The P-gp-negative PSN1/ADR cells adapted to 510 nM doxorubicin retained brefeldin A-sensitive doxorubicin accumulation defects while MRP declined. Doxorubicin 94-105 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 9816200-9 1996 The effective DOX dose required for inhibiting MDR1(+) Hep3B and Hep G2 cell proliferation by 50% (DOX IC50) was 44.5 ng/ml and 43.5 microgram/ml, as compared with 10.7 ng/ml for Pgp-negative SK-HEP-1 cells. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 8640766-8 1996 Those with mdr1 activation demonstrated a broad cross-resistance to vinblastine, doxorubicin, and etoposide, whereas the other 6 mutants were cross-resistant only to the Vinca alkaloids. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 9206112-0 1996 The amplification and expression of MDR1 gene in adriamycine resistant cell line of colon cancer cell HR8348. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 9414394-8 1996 MDL 201,307 increased uptake and decreased efflux of doxorubicin suggesting that MDL 201,307 blocks the GP170-mediated efflux pump mechanism. Doxorubicin 53-64 ATP binding cassette subfamily B member 1 Homo sapiens 104-109 8637212-0 1996 Expression of MRP and mdr1 in human gastrointestinal cancer cell lines: a correlation with resistance against doxorubicin. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 21781664-7 1996 These studies demonstrated that immunoblastic B lymphoma cells selected for vincristine or adriamycin resistance preferentially develop P-glycoprotein-mediated vincristine efflux which plays a pivotal role in vincristine resistance. Doxorubicin 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 136-150 8928730-0 1996 Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 8928730-0 1996 Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K+ and Cl- currents in MES-SA cells. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 8643093-0 1996 Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Doxorubicin 112-123 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 8562335-0 1996 Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 14-36 8603335-11 1996 Thus, the selection of DOX resistance in two sublines of HL-60 cells which differ in their response to retinoic acid-induced myeloid differentiation is reproducibly associated with overexpression of mdr-1 versus MRP. Doxorubicin 23-26 ATP binding cassette subfamily B member 1 Homo sapiens 199-204 9816200-9 1996 The effective DOX dose required for inhibiting MDR1(+) Hep3B and Hep G2 cell proliferation by 50% (DOX IC50) was 44.5 ng/ml and 43.5 microgram/ml, as compared with 10.7 ng/ml for Pgp-negative SK-HEP-1 cells. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 179-182 9816200-9 1996 The effective DOX dose required for inhibiting MDR1(+) Hep3B and Hep G2 cell proliferation by 50% (DOX IC50) was 44.5 ng/ml and 43.5 microgram/ml, as compared with 10.7 ng/ml for Pgp-negative SK-HEP-1 cells. Doxorubicin 99-102 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 9816200-11 1996 Similarly, plasma from patients containing immunosuppressive levels of CsA lowered DOX IC50 of the MDR1(+) Hep G2 cells by up to 4-fold. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 9816200-15 1996 Pharmacological concentrations of cyclosporin analogues, including one nonimmunosuppressive form, enhance DOX cytotoxicity of MDR1(+) HCC cells by modulating drug retention. Doxorubicin 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 9816200-16 1996 CsA as found in posttransplant patient plasma enhanced DOX cytotoxicity to human MDR1(+) hepatoma cells in vitro, albeit at less than optimal chemosensitizing concentrations. Doxorubicin 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 9816200-18 1996 These findings support our hypothesis that in vivo immunosuppressive levels of CsA may enhance DOX chemotherapeutic efficacy on MDR1(+) HCC cells. Doxorubicin 95-98 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 8672855-0 1996 [Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil]. Doxorubicin 117-129 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 8605275-4 1996 By RT-PCR analysis of mdr1, mdr3, and mrp mRNA, these adriamycin-resistant cells showed a higher expression of the transcript of these genes than those of the parent cells. Doxorubicin 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 8605275-5 1996 By FACS analysis, both the adriamycin-resistant cells showed a higher expression of P-glycoprotein on their cell surfaces. Doxorubicin 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 84-98 8603451-8 1996 The current study suggests that in the early phase of Adriamycin treatment, GST and GPX are more important than P-glycoprotein for the development in HOB1 cells of resistance against Adriamycin. Doxorubicin 183-193 ATP binding cassette subfamily B member 1 Homo sapiens 112-126 8646794-1 1996 The morpholinyl analogues of doxorubicin (DOX) have previously been reported to be non-cross-resistant in multidrug resistant (MDR) cells due to a lower affinity for P-glycoprotein relative to the parent compound. Doxorubicin 29-40 ATP binding cassette subfamily B member 1 Homo sapiens 166-180 8612315-5 1996 The cells express high levels of the mdr1 gene product, P-glycoprotein, and are 25-to 60-fold resistant to doxorubicin (DOX), etoposide (VP-16), vinblastine (VBL), and taxol (TAX). Doxorubicin 120-123 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 8646794-1 1996 The morpholinyl analogues of doxorubicin (DOX) have previously been reported to be non-cross-resistant in multidrug resistant (MDR) cells due to a lower affinity for P-glycoprotein relative to the parent compound. Doxorubicin 42-45 ATP binding cassette subfamily B member 1 Homo sapiens 166-180 8845487-0 1995 Relationship between doxorubicin cell sensitivity, drug-induced DNA double-strand breaks, glutathione content and P-glycoprotein in mammalian tumor cells. Doxorubicin 21-32 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 8862007-1 1996 An mdr1 hammerhead was introduced into two adriamycin-selected multi-drug resistant human lung cell lines both of which over-express p-glycoprotein. Doxorubicin 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 3-7 8862007-1 1996 An mdr1 hammerhead was introduced into two adriamycin-selected multi-drug resistant human lung cell lines both of which over-express p-glycoprotein. Doxorubicin 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 133-147 8564974-7 1996 All three I3C acid-condensation products also increased the accumulation of the P-glycoprotein substrate, doxorubicin, in B16/hMDR-1 transfectants to levels comparable to parental B16 cells. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 126-132 8564974-11 1996 The resistance of B16/hMDR-1 transfectants to vinblastine and doxorubicin was preserved after i.p. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 22-28 8603335-1 1996 Tumor cell resistance to doxorubicin (DOX) is usually associated with the overexpression of P-glycoprotein (PGP) in model systems. Doxorubicin 25-36 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 8603335-1 1996 Tumor cell resistance to doxorubicin (DOX) is usually associated with the overexpression of P-glycoprotein (PGP) in model systems. Doxorubicin 25-36 ATP binding cassette subfamily B member 1 Homo sapiens 108-111 8603335-1 1996 Tumor cell resistance to doxorubicin (DOX) is usually associated with the overexpression of P-glycoprotein (PGP) in model systems. Doxorubicin 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 8603335-1 1996 Tumor cell resistance to doxorubicin (DOX) is usually associated with the overexpression of P-glycoprotein (PGP) in model systems. Doxorubicin 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 108-111 8603335-9 1996 The overexpression of phosphorylated PGP in immunoprecipitates with C-219 antibody was identified in both sublines of DOX-resistant HL-60 cells with 7q+ abnormalities, and this is consistent with the location of mdr-1 sequences to 7q21-21.1. Doxorubicin 118-121 ATP binding cassette subfamily B member 1 Homo sapiens 37-40 8603335-10 1996 Also, analysis of RNA from parental-sensitive and DOX-resistant sublines by reverse transcriptase-polymerase chain reaction revealed: a) comparable expression of multidrug resistance related protein (MPR) in sensitive and resistant sublines; and b) overexpression of mdr-1 only in the DOX-resistant sublines. Doxorubicin 50-53 ATP binding cassette subfamily B member 1 Homo sapiens 267-272 8603335-10 1996 Also, analysis of RNA from parental-sensitive and DOX-resistant sublines by reverse transcriptase-polymerase chain reaction revealed: a) comparable expression of multidrug resistance related protein (MPR) in sensitive and resistant sublines; and b) overexpression of mdr-1 only in the DOX-resistant sublines. Doxorubicin 285-288 ATP binding cassette subfamily B member 1 Homo sapiens 267-272 7589484-0 1995 Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression. Doxorubicin 32-42 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 7492789-4 1995 When anti-B4-bR was combined simultaneously with doxorubicin or etoposide, additive to supra-additive killing of Namalwa and Namalwa/mdr-1 cells was observed. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 133-138 8603675-0 1995 Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 8603675-3 1995 In this paper, the relationship between doxorubicin subcellular distribution and P-glycoprotein activity at different cell sites has been investigated by different techniques. Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 81-95 8603675-12 1995 These findings, suggesting the possible involvement of nuclear P-glycoprotein in the regulation of subcellular doxorubicin distribution in multidrug-resistant cells, open new insights on the mechanisms of P-glycoprotein-mediated resistance to anticancer drugs. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 8603675-12 1995 These findings, suggesting the possible involvement of nuclear P-glycoprotein in the regulation of subcellular doxorubicin distribution in multidrug-resistant cells, open new insights on the mechanisms of P-glycoprotein-mediated resistance to anticancer drugs. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 205-219 7589484-10 1995 These studies demonstrated that immunoblastic B lymphoma cells selected for adriamycin resistance preferentially developed P-glycoprotein-mediated vincristine efflux which plays an important role in vincristine resistance. Doxorubicin 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 123-137 7476894-5 1995 Despite some exceptions, we found that there was a good association between the ability of these analogues to induce mdr1 and P-gp expression and their ability to reverse vinblastine and doxorubicin resistance, revealing a structure-function relationship for this phenomenon. Doxorubicin 187-198 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 7488241-8 1995 The potentiation of DOX cytotoxicity was associated with an increase in DOX uptake in LoVo-R cells and with an increased [3H]azidopine P-gp photolabeling inhibition. Doxorubicin 20-23 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 8845477-5 1995 Nevertheless, the sensitivity of their mitogen-induced proliferation to cytostatics, including doxorubicin and CsA, could be increased by the Pgp blockers. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 142-145 8845478-2 1995 AD198 and doxorubicin showed comparable antitumor activity in the Pgp-negative breast cancer cell line MCF-7 and the Pgp-negative ovarian carcinoma cell line A2780. Doxorubicin 10-21 ATP binding cassette subfamily B member 1 Homo sapiens 66-69 8845478-2 1995 AD198 and doxorubicin showed comparable antitumor activity in the Pgp-negative breast cancer cell line MCF-7 and the Pgp-negative ovarian carcinoma cell line A2780. Doxorubicin 10-21 ATP binding cassette subfamily B member 1 Homo sapiens 117-120 7476894-5 1995 Despite some exceptions, we found that there was a good association between the ability of these analogues to induce mdr1 and P-gp expression and their ability to reverse vinblastine and doxorubicin resistance, revealing a structure-function relationship for this phenomenon. Doxorubicin 187-198 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 7622101-6 1995 Resistance to doxorubicin appears to be mediated by enhanced efflux from the cell by increased expression of membrane glycoproteins acting as a drug efflux pump, such as P-glycoprotein. Doxorubicin 14-25 ATP binding cassette subfamily B member 1 Homo sapiens 170-184 8572572-2 1995 In contrast to U-937/WT cells, the DOX-resistant U-937/RD cells have longer doubling time; are more differentiated along the monocytic lineage as determined by the presence of morphological features and mRNA coding for the monocyte colony-stimulating factor-1 receptor; synthesize the apoptosis-associated Bax protein; are less sensitive to apoptosis-inducing topoisomerase II-directed drugs, apparently because of increased synthesis of P-glycoprotein; and are practically non-tumorigenic when xenografted in nude mice. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 438-452 7562498-4 1995 Thaliblastine (TBL), a plant alkaloid and P-glycoprotein (P-gp) inhibitor, is presently shown to fully reverse 490-fold resistance to Adriamycin (AdR) in a multidrug-resistant (MDR) human breast cancer cell line (MCF/AdR) that overexpresses P-gp, whereas the same treatment had no effect on AdR cytotoxicity in the drug-sensitive parental MCF-7 cells. Doxorubicin 134-144 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 7555211-0 1995 Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox? Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 5-19 7555211-2 1995 K562/Dox displayed typical MDR features with respect to its cross-resistance to a variety of functionally and structurally unrelated compounds: vincristine (Vin), Dox, mitomycin C, reduced steady-state intracellular anthracycline accumulation, and elevated P-glycoprotein expression/mdr1 mRNA transcription/mdr1 gene amplification. Doxorubicin 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 257-271 7555211-2 1995 K562/Dox displayed typical MDR features with respect to its cross-resistance to a variety of functionally and structurally unrelated compounds: vincristine (Vin), Dox, mitomycin C, reduced steady-state intracellular anthracycline accumulation, and elevated P-glycoprotein expression/mdr1 mRNA transcription/mdr1 gene amplification. Doxorubicin 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 283-287 7555211-2 1995 K562/Dox displayed typical MDR features with respect to its cross-resistance to a variety of functionally and structurally unrelated compounds: vincristine (Vin), Dox, mitomycin C, reduced steady-state intracellular anthracycline accumulation, and elevated P-glycoprotein expression/mdr1 mRNA transcription/mdr1 gene amplification. Doxorubicin 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 307-311 7555211-4 1995 After 8 h incubation of cells with 50 ng/ml Dox (5 times higher than its IC50 to K562 cells), there were only slight differences (p > 0.05) in intracellular drug levels between K562/Dox and K562 cells, clearly indicating that K562/Dox, circumventing drug toxicity in this case, was irrelevant to reduced drug accumulation caused by P-glycoprotein. Doxorubicin 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 335-349 7756676-9 1995 In conclusion this MTC cell line exhibited over-expression of the MDR1 gene and its resistance to doxorubicin can be partially reversed by CSA, verapamil and S9788. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 7734314-5 1995 T24/VCR cells which had elevated levels of MDR1 mRNA and P-glycoprotein but not of MRP mRNA, showed cross-resistance to doxorubicin. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 7734314-5 1995 T24/VCR cells which had elevated levels of MDR1 mRNA and P-glycoprotein but not of MRP mRNA, showed cross-resistance to doxorubicin. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 7734315-2 1995 The induction of mdr1 RNA expression by three anthracyclines, (doxorubicin, daunorubicin, epirubicin), VP-16 and two vinca alkaloids (vincristine, vinblastine) was semiquantitatively assessed by scanning Northern blots on a phosphorimager. Doxorubicin 63-74 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 7887974-6 1995 The resistance modulating factors (RMF), i.e. IC50 drug/IC50 drug + modulator, were found to be proportional to the expression of MDR-1, ranging from 8 to 42 for Adriamycin and from 16 to 63 for vincristine. Doxorubicin 162-172 ATP binding cassette subfamily B member 1 Homo sapiens 130-135 7656812-0 1995 [Reduced intracellular drug accumulation related to overexpression of P-glycoprotein cannot explain the complete drug resistance in MDR cell variant K562/Dox]. Doxorubicin 154-157 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 7656812-1 1995 The purpose of this study was to determine what proportion of drug resistance of MDR cell variant K562/Dox was attributed to the reduced steady state intracellular drug accumulation related to overexpression of P-glycoprotein. Doxorubicin 103-106 ATP binding cassette subfamily B member 1 Homo sapiens 211-225 7656812-4 1995 K562/Dox cells were positively stained with anti-human p-glycoprotein monoclonal antibody JSB-1, indicating overexpression of P-gp. Doxorubicin 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 7656812-7 1995 However, the resistances of K562/Dox cells to epirubicin and daunorubicin still remained for about 5.6 and > 6.6 folds, respectively, even at verapamil concentration of 6 mumol/L, suggesting at least a relatively big fraction of drug resistance was not directly related to the altered cellular pharmacokinetics associated with overexpression of P-glycoprotein. Doxorubicin 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 348-362 7670142-3 1995 The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 7670142-3 1995 The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide. Doxorubicin 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 7645952-3 1995 Doxorubicin (DX) resistance is mostly related to the multidrug resistance gene product P-gp. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 7734315-8 1995 The rapid increase in mdr1 expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdr1 expression may have an important role in the development of drug-resistant tumours. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 7734315-8 1995 The rapid increase in mdr1 expression after a short period of exposure to doxorubicin, daunorubicin or epirubicin suggests that induction of mdr1 expression may have an important role in the development of drug-resistant tumours. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 7822320-3 1995 The cysteine-less P-glycoprotein-A52 retained the ability to confer resistance to vinblastine, colchicine, doxorubicin, and actinomycin D with only a small decrease in efficiency relative to wild-type enzyme. Doxorubicin 107-118 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 7829527-7 1995 Wild type p53 stimulation of MDRCAT expression also occurred in parental and doxorubicin-resistant SW620 colon and parental 2780 ovarian cancer cell lines, indicating that wild type p53-mediated simulation of the MDR1 promoter is not restricted to a single cell line. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 213-217 7848886-1 1994 BACKGROUND: To determine the expression of P-glycoprotein in pre- and post-chemotherapy tumor tissue samples from patients with transitional cell carcinomas treated with M-VAC (methotrexate, vinblastine, adriamycin and cisplatin). Doxorubicin 204-214 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 7733620-0 1995 Rhodamine 123: is it an appropriate dye to study P-glycoprotein activity in adriamycin-resistant K562 cells? Doxorubicin 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 7733620-1 1995 The ability of the P-glycoprotein to efflux rhodamine 123 and adriamycin was evaluated using adriamycin-sensitive and -resistant human leukemia K562 cells. Doxorubicin 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 7733620-1 1995 The ability of the P-glycoprotein to efflux rhodamine 123 and adriamycin was evaluated using adriamycin-sensitive and -resistant human leukemia K562 cells. Doxorubicin 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 7733620-2 1995 We observed that low temperature or verapamil (a P-glycoprotein blocker) inhibited adriamycin efflux in multidrug resistant cells. Doxorubicin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 7733620-5 1995 Thus, in adriamycin-resistant K562 cells, the rhodamine efflux may be due to P-glycoprotein activity and also to a nonspecific targeting of dye in resistant K562 cells. Doxorubicin 9-19 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 7634377-2 1995 Multidrug resistance (MDR) in this cell line which was selected for resistance to Adriamycin (ADR), is associated with increased expression of P-glycoprotein (P-gp). Doxorubicin 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 143-157 7634377-2 1995 Multidrug resistance (MDR) in this cell line which was selected for resistance to Adriamycin (ADR), is associated with increased expression of P-glycoprotein (P-gp). Doxorubicin 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 159-163 7799045-13 1995 The higher frequency of P-gp immunoreactivity in residual tumors after chemotherapy points to induction of P-gp in ovarian carcinomas by doxorubicin-containing combination chemotherapy. Doxorubicin 137-148 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 8704279-6 1995 Verapamil enhanced the sensitivity of SKOV3/CIS to doxorubicin (260-fold), in conformity with the proposed mechanism of Pgp in multidrug resistance (MDR), but it did not potentiate cisplatin cytotoxicity in SKOV3/CIS cells. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 120-123 7805856-1 1994 Hydroxyrubin (OH-Dox), a neutral doxorubicin derivative that is only slightly cross-resistant to doxorubicin (Dox), can be actively pumped out of resistant K562 cells by P-glycoprotein (P-gp). Doxorubicin 17-20 ATP binding cassette subfamily B member 1 Homo sapiens 170-184 7805856-1 1994 Hydroxyrubin (OH-Dox), a neutral doxorubicin derivative that is only slightly cross-resistant to doxorubicin (Dox), can be actively pumped out of resistant K562 cells by P-glycoprotein (P-gp). Doxorubicin 17-20 ATP binding cassette subfamily B member 1 Homo sapiens 186-190 7805856-4 1994 However, the efficiency of P-gp in pumping out the drugs is 2.5 times less for OH-Dox than for Dox. Doxorubicin 82-85 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 21559709-2 1994 Exposure of each cell line to 10 mu M DOX for 2 h resulted in an intracellular fluorescent level directly correlated to its sensitivity to the drug but inversely related to its cellular P-glycoprotein (P-gp) level. Doxorubicin 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 186-200 21559709-2 1994 Exposure of each cell line to 10 mu M DOX for 2 h resulted in an intracellular fluorescent level directly correlated to its sensitivity to the drug but inversely related to its cellular P-glycoprotein (P-gp) level. Doxorubicin 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 202-206 7996436-0 1994 Decreased intracellular compartmentalization of doxorubicin in cell lines expressing P-glycoprotein. Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 85-99 7996436-2 1994 In contrast, in P-glycoprotein-expressing drug-resistant HL-60R and SU-4R cells, doxorubicin distribution rapidly approaches equilibrium. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 16-30 7705462-3 1994 The binding of [3H]vinblastine to P-glycoprotein was not ATP-dependent, and was inhibited by cytotoxic drugs with the following potency order; vincristine > doxorubicin > etoposide. Doxorubicin 160-171 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 7706385-2 1994 A method using confocal microscopy was developed to measure the transport activity of P-gp from the rate of movement of doxorubicin, a fluorescent substrate of P-gp, across the membrane of a single cell. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 7706385-2 1994 A method using confocal microscopy was developed to measure the transport activity of P-gp from the rate of movement of doxorubicin, a fluorescent substrate of P-gp, across the membrane of a single cell. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 160-164 7982498-0 1994 The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. Doxorubicin 44-55 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 7982498-4 1994 RU 486 appeared to prevent the P-gp-mediated doxorubicin efflux out of RHC1 cells and was demonstrated to interfere directly with P-gp drug binding sites since it blocked P-gp labelling by the photoactivable P-gp ligand azidopine. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 7949184-0 1994 Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 62-76 7949184-3 1994 Prolonged passage of U-A10 cells in 10 ng/mL of doxorubicin had little effect on MRP RNA levels, but increased MDR1 expression. Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 7518859-1 1994 PURPOSE: In multiple myeloma (MM) refractory to doxorubicin (DXR) and/or vincristine (VCR), myeloma cells frequently express the multidrug resistance (MDR) phenotype, associated with overexpression of P-glycoprotein (Pgp), which acts as a drug efflux pump. Doxorubicin 61-64 ATP binding cassette subfamily B member 1 Homo sapiens 201-215 21559677-0 1994 Reversion of p-glycoprotein mediated multidrug-resistance to vincristine and adriamycin by psc-833, a cyclosporine derivative in human neuroblastoma cell-lines. Doxorubicin 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 21559677-3 1994 Resistance to vincristine and adriamycin was inverse to the degree of MDR1 expression. Doxorubicin 30-40 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 21559677-6 1994 These data suggest that MDR1 may play a protective role against vincristine and adriamycin in human neuroblastoma cells, and PSC-833 can reverse this protection. Doxorubicin 80-90 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 7915196-0 1994 Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 7915196-17 1994 Activation of the mdr1 gene is the predominant mechanism selected by DOX in these resistant clones. Doxorubicin 69-72 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 7915520-3 1994 Western blot analysis, using a newly generated monoclonal antibody F4 which recognizes specifically an extracellular epitope of human MDR1 P-glycoprotein, reveals that soluble P-glycoprotein is detected in the cultured media of viable adriamycin-resistant human ovarian carcinoma 2780AD cells, whereas those of the drug-sensitive parent A2780 cells contain no detectable level of soluble P-glycoprotein. Doxorubicin 235-245 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 7915520-3 1994 Western blot analysis, using a newly generated monoclonal antibody F4 which recognizes specifically an extracellular epitope of human MDR1 P-glycoprotein, reveals that soluble P-glycoprotein is detected in the cultured media of viable adriamycin-resistant human ovarian carcinoma 2780AD cells, whereas those of the drug-sensitive parent A2780 cells contain no detectable level of soluble P-glycoprotein. Doxorubicin 235-245 ATP binding cassette subfamily B member 1 Homo sapiens 139-153 7915520-3 1994 Western blot analysis, using a newly generated monoclonal antibody F4 which recognizes specifically an extracellular epitope of human MDR1 P-glycoprotein, reveals that soluble P-glycoprotein is detected in the cultured media of viable adriamycin-resistant human ovarian carcinoma 2780AD cells, whereas those of the drug-sensitive parent A2780 cells contain no detectable level of soluble P-glycoprotein. Doxorubicin 235-245 ATP binding cassette subfamily B member 1 Homo sapiens 176-190 7915520-3 1994 Western blot analysis, using a newly generated monoclonal antibody F4 which recognizes specifically an extracellular epitope of human MDR1 P-glycoprotein, reveals that soluble P-glycoprotein is detected in the cultured media of viable adriamycin-resistant human ovarian carcinoma 2780AD cells, whereas those of the drug-sensitive parent A2780 cells contain no detectable level of soluble P-glycoprotein. Doxorubicin 235-245 ATP binding cassette subfamily B member 1 Homo sapiens 176-190 7518859-1 1994 PURPOSE: In multiple myeloma (MM) refractory to doxorubicin (DXR) and/or vincristine (VCR), myeloma cells frequently express the multidrug resistance (MDR) phenotype, associated with overexpression of P-glycoprotein (Pgp), which acts as a drug efflux pump. Doxorubicin 61-64 ATP binding cassette subfamily B member 1 Homo sapiens 217-220 7911330-3 1994 Evidence suggesting involvement of P-Glycoprotein (P-Gp), included (1) comparable transport of P-Gp substrate doxorubicin, (2) transport stimulation by ATP and (3) transport suppression by the P-Gp inhibitor, verapamil. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 7910518-9 1994 IFN-alpha enhances the ability of VPL to modulate DOX cytotoxicity and accumulation, possibly by altering the accessibility of p-gp binding site(s) to VPL. Doxorubicin 50-53 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 7908989-0 1994 MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. Doxorubicin 55-66 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 7908215-1 1994 Overexpression of the multidrug resistance (mdr1) gene has been implicated in resistance to a number of the chemotherapeutic agents currently used in the treatment of bladder cancer (doxorubicin, vincristine and epirubicin). Doxorubicin 183-194 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 7908989-10 1994 When the IC50 values were compared among the cell lines, the results revealed a close association with the MDR1 gene expression only for doxorubicin resistance. Doxorubicin 137-148 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 7908989-11 1994 Verapamil and quinidine lowered the IC50 values of doxorubicin for MDR1-positive cell lines. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 7908989-13 1994 CONCLUSION: These results indicate that the MDR1 gene probably has a role in doxorubicin resistance in hepatocellular carcinoma and that the resistance can be overcome by some multidrug resistance-reversing agents. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 7915506-5 1994 Whereas the cytotoxic effect of Dox was considerably increased by verapamil, cyclosporin A and its non-immunosuppressive analogue SDZ PSC 833 in the Pgp-expressing Dox-resistant sublines, comparatively small effects on the Dox and Vcr sensitivity were observed in the patient samples, irrespective of their Pgp expression. Doxorubicin 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 149-152 7915506-5 1994 Whereas the cytotoxic effect of Dox was considerably increased by verapamil, cyclosporin A and its non-immunosuppressive analogue SDZ PSC 833 in the Pgp-expressing Dox-resistant sublines, comparatively small effects on the Dox and Vcr sensitivity were observed in the patient samples, irrespective of their Pgp expression. Doxorubicin 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 307-310 7915506-5 1994 Whereas the cytotoxic effect of Dox was considerably increased by verapamil, cyclosporin A and its non-immunosuppressive analogue SDZ PSC 833 in the Pgp-expressing Dox-resistant sublines, comparatively small effects on the Dox and Vcr sensitivity were observed in the patient samples, irrespective of their Pgp expression. Doxorubicin 164-167 ATP binding cassette subfamily B member 1 Homo sapiens 149-152 7915506-5 1994 Whereas the cytotoxic effect of Dox was considerably increased by verapamil, cyclosporin A and its non-immunosuppressive analogue SDZ PSC 833 in the Pgp-expressing Dox-resistant sublines, comparatively small effects on the Dox and Vcr sensitivity were observed in the patient samples, irrespective of their Pgp expression. Doxorubicin 164-167 ATP binding cassette subfamily B member 1 Homo sapiens 149-152 7508682-9 1994 Using JSB-1, the threshold for detection of elevated Pgp corresponded to less than two-fold relative resistance to doxorubicin. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 53-56 7914378-4 1994 The succinate dehydrogenase (SD) activity for each drug of P-gp positive and negative tumors was as follows: 81.8 +/- 15.2% vs. 66.3 +/- 16.1% for Adriamycin (ADM), 75.5 +/- 14.2% vs. 59.1 +/- 17.6% for aclacinomycin A (ACR), 71.7 +/- 15.0% vs. 61.1 +/- 14.0% for mitomycin C (MMC), and 57.5 +/- 18.4% vs. 47.0 +/- 16.7% for cisplatin (CDDP). Doxorubicin 147-157 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 7914378-4 1994 The succinate dehydrogenase (SD) activity for each drug of P-gp positive and negative tumors was as follows: 81.8 +/- 15.2% vs. 66.3 +/- 16.1% for Adriamycin (ADM), 75.5 +/- 14.2% vs. 59.1 +/- 17.6% for aclacinomycin A (ACR), 71.7 +/- 15.0% vs. 61.1 +/- 14.0% for mitomycin C (MMC), and 57.5 +/- 18.4% vs. 47.0 +/- 16.7% for cisplatin (CDDP). Doxorubicin 159-162 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 21566941-1 1994 Human colon carcinoma LoVo/DX cells, which have been selected from parental LoVo for resistance to doxorubicin, express a typical multidrug resistant (MDR-1) phenotype. Doxorubicin 99-110 ATP binding cassette subfamily B member 1 Homo sapiens 151-156 7906507-3 1994 We found that MRK-16, a monoclonal antibody against P-glycoprotein, and cyclosporine, synergistically enhanced the antitumor effects of vincristine and adriamycin in multidrug-resistant K562/ADM cells. Doxorubicin 152-162 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 7905787-0 1994 Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Doxorubicin 28-38 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 7905787-6 1994 Our data showed that the expression of the MDR1 gene in these cells resulted in a relative resistance of these cells to Adriamycin without affecting their susceptibility to TNF killing. Doxorubicin 120-130 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 7946563-0 1994 Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Doxorubicin 67-78 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 7914748-3 1994 Thereby, we observed that actinomycin D or adriamycin administered at sublethal concentrations induced increases of mdr1 mRNA levels and resistance within 72 h. Furthermore, on leukemia cell samples collected before and after chemotherapy we checked by a complementary DNA polymerase chain reaction (cDNA-PCR) approach for similar alterations in the relative expression levels of the MDR-associated genes (a) mdr1/P-gp (b) mrp (MDR related protein), and (c) the topoisomerase II isoforms alpha and beta. Doxorubicin 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 7914748-3 1994 Thereby, we observed that actinomycin D or adriamycin administered at sublethal concentrations induced increases of mdr1 mRNA levels and resistance within 72 h. Furthermore, on leukemia cell samples collected before and after chemotherapy we checked by a complementary DNA polymerase chain reaction (cDNA-PCR) approach for similar alterations in the relative expression levels of the MDR-associated genes (a) mdr1/P-gp (b) mrp (MDR related protein), and (c) the topoisomerase II isoforms alpha and beta. Doxorubicin 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 409-413 8142172-7 1994 This work shows that association of doxorubicin with nanoparticles could provide a useful tool for circumventing multidrug resistance, probably by a bypass of P-glycoprotein rather than by an inhibition of this pump. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 159-173 7904476-7 1994 [125I]NAPS photolabeling of P-gp was preferentially competed by MDR-related drugs, with vinblastine > VCR > colchicine > doxorubicin > actinomycin D. Many drugs that are known to reverse MDR were potent inhibitors of [125I]NAPS binding to P-gp. Doxorubicin 130-141 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 7923555-0 1994 Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Doxorubicin 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 109-123 7946563-3 1994 A significant association was observed in both tumour types between P-gp expression and in vitro resistance to doxorubicin. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 7946563-4 1994 We also observed a higher clinical response rate to doxorubicin +/- vincristine in patients with breast cancers not expressing P-gp. Doxorubicin 52-63 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 7946563-6 1994 Our results support the relevance of P-gp expression as a specific indicator of resistance to certain drugs, such as doxorubicin and vincristine, involved in the phenomenon of multidrug resistance in breast and ovarian cancer cells. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 8207045-5 1994 In those cell lines showing a decreased mdr1 expression after a long-term cytokine pretreatment we found a dramatic enhancement of cytotoxicity of the MDR relevant drugs vincristine and doxorubicin, whereas LS 174T cells remained resistant. Doxorubicin 186-197 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 8285174-1 1993 A bisbenzylisoquinoline alkaloid, cepharanthine, significantly enhanced vinblastine, adriamycin and etoposide sensitivities in P-glycoprotein positive renal cancer cells. Doxorubicin 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 7907333-3 1994 Thus, the Adriamycin(ADR)-selected, P-glycoprotein-positive MDR Friend leukemia cell line F4-6RADR was exposed to stepwise increased concentrations of CsA at a constant level of 0.05 microgram/ml ADR. Doxorubicin 10-20 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 7903690-0 1994 MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 7902877-4 1994 Furthermore, the strategy of circumvention of P-glycoprotein-mediated resistance using the combination of doxorubicin and verapamil intravesically was tested in 5 patients. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 46-60 7865904-3 1994 Here we show that cells that overexpress low levels of P-glycoprotein or are transfected with human MDR1 have approximately 10-fold greater resistance to bisantrene compared to vinblastine, doxorubicin, or colchicine. Doxorubicin 190-201 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 7865904-3 1994 Here we show that cells that overexpress low levels of P-glycoprotein or are transfected with human MDR1 have approximately 10-fold greater resistance to bisantrene compared to vinblastine, doxorubicin, or colchicine. Doxorubicin 190-201 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 7903198-2 1993 We previously showed that MDR cells derived from exposure to Adriamycin are cross-resistant to a chemical carcinogen, benzo(a)pyrene, due to its cellular efflux by the P-gp-mediated putative drug efflux pump. Doxorubicin 61-71 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 7902089-6 1993 Hence, 9-alkyl and morpholinyl substituted compounds appear to behave less favourably as substrates for energy-driven drug efflux by Pgp-positive MDR cells than do DOX or DNR. Doxorubicin 164-167 ATP binding cassette subfamily B member 1 Homo sapiens 133-136 7905253-1 1993 P-glycoprotein (P-gp) detection by FCM (flow cytometry) was correlated with P-gp detection by immunohistochemical staining or Western blotting in K562 cell lines variably resistant to doxorubicin (DOX). Doxorubicin 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 7905253-1 1993 P-glycoprotein (P-gp) detection by FCM (flow cytometry) was correlated with P-gp detection by immunohistochemical staining or Western blotting in K562 cell lines variably resistant to doxorubicin (DOX). Doxorubicin 197-200 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 7905253-1 1993 P-glycoprotein (P-gp) detection by FCM (flow cytometry) was correlated with P-gp detection by immunohistochemical staining or Western blotting in K562 cell lines variably resistant to doxorubicin (DOX). Doxorubicin 197-200 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 7905253-1 1993 P-glycoprotein (P-gp) detection by FCM (flow cytometry) was correlated with P-gp detection by immunohistochemical staining or Western blotting in K562 cell lines variably resistant to doxorubicin (DOX). Doxorubicin 197-200 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 7905253-5 1993 Thirteen of the 15 P-gp positive tumors were resistant to DOX and vincristine (VCR) on TIA. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 7905253-6 1993 Thus, P-gp detection by FCM correlates strongly with tumor sensitivity to DOX and VCR (p < 0.001). Doxorubicin 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 6-10 8105865-0 1993 Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Doxorubicin 23-34 ATP binding cassette subfamily B member 1 Homo sapiens 104-126 8105865-7 1993 N/C ratios in highly resistant P-glycoprotein-containing cells could be increased with the resistance modifier verapamil to values of 1.3-2.7, a process that was paralleled by a decrease of the cellular doxorubicin amounts present at IC50. Doxorubicin 203-214 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 21573380-8 1993 The expression of P-glycoprotein as determined by flow cytometric analysis of tumor cells harvested from lesions in different organs correlated inversely with their sensitivity to DOX. Doxorubicin 180-183 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 8101765-1 1993 HL60 cells isolated for resistance to Adriamycin (HL60/ADR) overexpress a 190-kDa ATP binding protein which has a minor sequence homology with P-glycoprotein. Doxorubicin 38-48 ATP binding cassette subfamily B member 1 Homo sapiens 143-157 7685615-2 1993 The anti-oestrogens significantly enhanced dox toxicity to multidrug resistant, P-glycoprotein-positive cell lines, but did not affect toxicity to intrinsically resistant, P-glycoprotein-negative cells. Doxorubicin 43-46 ATP binding cassette subfamily B member 1 Homo sapiens 80-94 8100862-10 1993 P-glycoprotein expression was roughly proportional to the degree of resistance to both doxorubicin and etoposide, but did not always correlate with the effect of verapamil on decreasing doxorubicin resistance. Doxorubicin 87-98 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8098658-7 1993 Mdr1/P-glycoprotein expression was mirrored by lowered sensitivities of the cultivated NK-cells towards actinomycin D or adriamycin. Doxorubicin 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 8097673-9 1993 Northern blot analysis revealed MDR1 gene expression in Adriamycin-resistant cells. Doxorubicin 56-66 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 8097673-11 1993 These results suggest that W-77 enhances the antitumor activity of Adriamycin by inhibiting both GST and P-glycoprotein. Doxorubicin 67-77 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 8098658-7 1993 Mdr1/P-glycoprotein expression was mirrored by lowered sensitivities of the cultivated NK-cells towards actinomycin D or adriamycin. Doxorubicin 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 5-19 8100351-2 1993 Transfection of P-glycoprotein-expressing doxorubicin-resistant MCF-7 cells with an expression vector containing the cDNA for protein kinase C alpha in the antisense orientation reduces protein kinase C alpha levels and decreases total protein kinase C activity by 75%. Doxorubicin 42-53 ATP binding cassette subfamily B member 1 Homo sapiens 16-30 8096520-4 1993 The regulation of mdr1 expression was examined in two MDR tumor cell lines selected for resistance to doxorubicin and their corresponding parental cell lines. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 8095491-0 1993 P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line. Doxorubicin 88-99 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8095499-1 1993 Basal transcription of the human multidrug resistance (mdr1) promoter was studied by chloramphenicol acetyltransferase (CAT) reporter fusion gene analysis in two parental and doxorubicin-resistant human tumor cell lines. Doxorubicin 175-186 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 8397460-8 1993 However tamoxifen reduced the IC50 of doxorubicin by a factor of 1.9 in the low MDR1 expressor (SK-Hep1) and 1.1 in the high MDR1 expressor line (p < 10(-5) respectively). Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 8397460-15 1993 In summary, the combination of tamoxifen and cyclosporin A at the concentrations normally seen after clinical administration of these modulators showed significant synergism on the sensitivity to doxorubicin in both low and high MDR1 expressor HCC lines. Doxorubicin 196-207 ATP binding cassette subfamily B member 1 Homo sapiens 229-233 8095141-0 1993 Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase pi gene expression. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 8094626-4 1993 Significant expression of MDR-1 mRNA and P-glycoprotein was not detected in 25 cases of multiple myeloma prior to chemotherapy and even after several courses of VAD (vincristine, adriamycin and dexamethasone) therapy by Northern blotting and immunostaining using monoclonal anti-P-glycoprotein antibody (MRK-16), respectively. Doxorubicin 179-189 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 8093668-6 1993 A substantially higher incidence of PGP expression (50%, 83%, respectively) occurred when the total vincristine dose exceeded 20 mg and when doxorubicin exceeded 340 mg. Doxorubicin 141-152 ATP binding cassette subfamily B member 1 Homo sapiens 36-39 8093668-7 1993 In the 11 patients who received both high vincristine and doxorubicin dosages (> 20 mg, > 340 mg total dose) there was 100% incidence of PGP expression in the tumor cells. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 143-146 8093668-11 1993 Our findings indicate a strong correlation between PGP expression in myeloma and past chemotherapy in myeloma, in particular, related to prior exposure to the natural product agents vincristine and doxorubicin. Doxorubicin 198-209 ATP binding cassette subfamily B member 1 Homo sapiens 51-54 8093668-12 1993 Additionally, the proportion of PGP-positive plasma cells was significantly higher in the doxorubicin-treated patients than the nondoxorubicin-treated patients (87.7% v 65.17%; P = .013). Doxorubicin 90-101 ATP binding cassette subfamily B member 1 Homo sapiens 32-35 8093668-13 1993 Combined high vincristine and doxorubicin total dosage appear highly predictive of PGP expression. Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 83-86 8103456-2 1993 In 17 of these, chemosensitivity to Adriamycin and vinblastine was also assessed by a microtiter succinate dehydrogenase inhibition test and the correlation between the expression of P-glycoprotein and intrinsic multidrug resistance was investigated. Doxorubicin 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 183-197 8098947-4 1993 The functional assays for Pgp expression were positive in 78 and 59% of patients using the fluo-3 and doxorubicin (dox) assays, respectively. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 26-29 8098947-4 1993 The functional assays for Pgp expression were positive in 78 and 59% of patients using the fluo-3 and doxorubicin (dox) assays, respectively. Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 26-29 8456189-9 1993 For example, resistance to adriamycin and vinblastine, two of the agents in the M-VAC regimen are mediated in part by the mdr1 gene. Doxorubicin 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 1356622-1 1992 Modulation of the expression of P-glycoprotein, a plasma membrane protein associated with multidrug resistance, was examined in drug-sensitive and drug-resistant tumor cells treated with leukoregulin, a M(r) 50,000 cytokine from human lymphocytes that rapidly permeabilizes the plasma membrane of many tumor cells facilitating the uptake of doxorubicin and other tumor-inhibitory antibiotics. Doxorubicin 341-352 ATP binding cassette subfamily B member 1 Homo sapiens 32-46 1361758-0 1992 Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 142-156 1358437-4 1992 Evidence supporting the involvement of P-gp included the inhibition of azidopine binding to P-gp benzo(alpha)pyrene and the inhibition of benzo(alpha)pyrene efflux by Adriamycin and verapamil. Doxorubicin 167-177 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 1360648-5 1992 In a CAT expression assay using the corresponding point-mutated MDR1 promoter fused to a CAT gene, binding inhibition of NF-R1 to the promoter resulted in 2- to 3-fold increases of CAT activity, as compared to the intact promoter in Adriamycin-resistant K562 cells. Doxorubicin 233-243 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 1360210-0 1992 Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Doxorubicin 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 113-127 8094615-6 1993 The mechanism of action of terfenadine appeared to be due to inhibition of the function of P-glycoprotein since it augmented the accumulation of doxorubicin and inhibited the efflux of rhodamine 123 from MDR lines but had no effect on drug accumulation or efflux in sensitive cells. Doxorubicin 145-156 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 1356622-7 1992 Leukoregulin enhancement of doxorubicin uptake and increased membrane permeability varied directly with the decrease in P-glycoprotein expression. Doxorubicin 28-39 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 1356622-8 1992 Leukoregulin in combination with doxorubicin enhanced the inhibition of cell proliferation in 8226/DOX40 multidrug-resistant cells over expressing P-glycoprotein. Doxorubicin 33-44 ATP binding cassette subfamily B member 1 Homo sapiens 147-161 1334113-4 1992 Twenty specimens were identified as MDR1 based upon test results showing resistance to adriamycin, vinca alkaloid, and etoposide. Doxorubicin 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 1356264-8 1992 Several other drugs that are known to be transported by P-glycoprotein enhanced the ATPase activity in a dose-dependent manner with relative potencies as follows: doxorubicin = vinblastine greater than daunomycin greater than actinomycin D greater than verapamil greater than colchicine. Doxorubicin 163-174 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 1359116-0 1992 Kinetic analysis of P-glycoprotein-mediated doxorubicin efflux. Doxorubicin 44-55 ATP binding cassette subfamily B member 1 Homo sapiens 20-34 1359116-1 1992 P-glycoprotein lowers the intracellular concentration of a variety of unrelated compounds including doxorubicin by actively removing them from the cell. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 1387586-3 1992 In contrast, two of the drug-resistant variants selected with DOX plus verapamil, an agent which inhibits P-glycoprotein-mediated multidrug resistance, displayed a collateral sensitivity to STZ and BCNU. Doxorubicin 62-65 ATP binding cassette subfamily B member 1 Homo sapiens 106-120 1356441-0 1992 In archaebacteria, there is a doxorubicin efflux pump similar to mammalian P-glycoprotein. Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 75-89 1444203-0 1992 An oligomer complementary to the 5" end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Doxorubicin 84-95 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 1444203-1 1992 Acquired resistance to doxorubicin and other anti-cancer drugs is generally dependent on gene amplification of a specific nucleotide sequence, the MDR1 gene. Doxorubicin 23-34 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 1379944-0 1992 Modulation of expression of multidrug resistance gene (mdr-1) by adriamycin. Doxorubicin 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 1361524-1 1992 Overexpression of P-glycoprotein (P-gp) in cancer cells can result in resistance to several chemotherapy agents (multidrug resistance) including doxorubicin and vincristine. Doxorubicin 145-156 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 1361524-1 1992 Overexpression of P-glycoprotein (P-gp) in cancer cells can result in resistance to several chemotherapy agents (multidrug resistance) including doxorubicin and vincristine. Doxorubicin 145-156 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 1352990-9 1992 These studies suggest that the specificity of Pgp transport can be modulated by phosphorylation and that vinblastine, adriamycin, or actinomycin D transport, but not that of colchicine, is diminished after dephosphorylation by sodium butyrate. Doxorubicin 118-128 ATP binding cassette subfamily B member 1 Homo sapiens 46-49 1353703-4 1992 Doxorubicin selection of the human squamous lung cancer cell line SW-1573 resulted in multidrug-resistant sublines in which a non-P-glycoprotein-mediated form of multidrug resistance precedes mdr1 expression. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 130-144 1353703-4 1992 Doxorubicin selection of the human squamous lung cancer cell line SW-1573 resulted in multidrug-resistant sublines in which a non-P-glycoprotein-mediated form of multidrug resistance precedes mdr1 expression. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 192-196 1511024-10 1992 Several mechanisms of doxorubicin resistance have been identified in cell lines and fresh tumors, including alterations in glutathione peroxidase activity and MDR-1 gene expression. Doxorubicin 22-33 ATP binding cassette subfamily B member 1 Homo sapiens 159-164 1354408-7 1992 These results indicate that a decreased activity of topoisomerase II is the major factor for the development of etoposide resistance, and that an overexpression of the MDR1 gene is responsible, in part, for the development of resistance to the drug and some structurally unrelated compounds such as adriamycin and vinca alkaloids. Doxorubicin 299-309 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 1357834-1 1992 We have studied the patterns of P-glycoprotein expression before and after 3 cycles of induction chemotherapy (5-fluorouracil, adriamycin and cyclophosphamide) using immunohistochemically stained paraffin-embedded specimen of 28 patients with locally advanced breast cancer. Doxorubicin 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 32-46 1348862-1 1992 A non-P-glycoprotein-mediated mechanism of multidrug resistance (non-Pgp MDR) has been identified in doxorubicin-selected sublines of the human non-small cell lung carcinoma cell line SW-1573. Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 6-20 1374585-6 1992 The least resistant cell line in which Pgp could be detected by IpS was fivefold resistant to doxorubicin, whereas Pgp was detected by WB in cells greater than twofold resistant. Doxorubicin 94-105 ATP binding cassette subfamily B member 1 Homo sapiens 39-42 1349796-3 1992 Our results showed that the Pgp-mediated AdR1.2 cells possessed an activated drug efflux pump and decreased nucleus binding of Adriamycin, while the non-Pgp-mediated SRA1.2 cells only held the second feature. Doxorubicin 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 28-31 1349797-0 1992 A single 24h contact time with adriamycin provokes the emergence of resistant cells expressing the Gp 170 protein. Doxorubicin 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 99-105 1537074-4 1992 Conversely, a direct relationship was found between the mdr1 EL of HCC cell lines and the number of drug-resistant (DR) colonies arising from each parent cell line treated in continuous culture with high DOX concentrations. Doxorubicin 204-207 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 1358894-3 1992 The binding pattern of Adriamycin in sensitive and in highly resistant cells was inversely related to the expression of P-glycoprotein. Doxorubicin 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 1358894-5 1992 The use of ABA in combination with the estimate of P-glycoprotein expression is recommended in clinical practice as an accurate means for predicting the sensitivity of osteosarcoma to Adriamycin. Doxorubicin 184-194 ATP binding cassette subfamily B member 1 Homo sapiens 51-65 1369463-5 1991 These sterols in yeast membrane probably inhibit the function of human P-glycoprotein as a multidrug transporter in yeast cells, because expression of P-glycoprotein in yeast cells did not confer resistance to doxorubicin. Doxorubicin 210-221 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 1682280-3 1991 In the first, including a series of Adriamycin-resistant SW620 and DLD-I sub-lines, and in parental HCT-15 cells, P-glycoprotein has a major role in Adriamycin resistance, as evidenced by a correlation between Adriamycin resistance, expression of the multidrug-resistance gene mdr-I and its product, P-glycoprotein (Pgp), decreased drug accumulation and reversibility by verapamil. Doxorubicin 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 1682280-3 1991 In the first, including a series of Adriamycin-resistant SW620 and DLD-I sub-lines, and in parental HCT-15 cells, P-glycoprotein has a major role in Adriamycin resistance, as evidenced by a correlation between Adriamycin resistance, expression of the multidrug-resistance gene mdr-I and its product, P-glycoprotein (Pgp), decreased drug accumulation and reversibility by verapamil. Doxorubicin 149-159 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 1682280-3 1991 In the first, including a series of Adriamycin-resistant SW620 and DLD-I sub-lines, and in parental HCT-15 cells, P-glycoprotein has a major role in Adriamycin resistance, as evidenced by a correlation between Adriamycin resistance, expression of the multidrug-resistance gene mdr-I and its product, P-glycoprotein (Pgp), decreased drug accumulation and reversibility by verapamil. Doxorubicin 149-159 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 1682280-7 1991 In the cell lines in which P-glycoprotein was a major determinant of Adriamycin resistance, the drug exposure (defined as the product of the concentration and the time of treatment) needed to achieve a given percent cell kill was reduced as much as 9-fold when cells were treated for 7 days as compared with 3 hr. Doxorubicin 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 1681887-7 1991 N/C ratio measurements may define a general Pgp-independent type of defense of mammalian cells against certain anticancer agents which may precede Pgp expression in early doxorubicin resistance. Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 44-47 1681887-7 1991 N/C ratio measurements may define a general Pgp-independent type of defense of mammalian cells against certain anticancer agents which may precede Pgp expression in early doxorubicin resistance. Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 147-150 1684906-9 1991 Selection for Dox resistance in SCLC may thus result in atypical multidrug-resistance characterised by absence of P-gp overexpression and atypical cross-resistance. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 1775975-11 1991 For example, resistance to Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) and vinblastine, two components in the MVAC regimen, are mediated in part by the MDR1 gene. Doxorubicin 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 1775975-11 1991 For example, resistance to Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) and vinblastine, two components in the MVAC regimen, are mediated in part by the MDR1 gene. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 1682280-9 1991 In some human colon carcinoma cell lines Pgp appears to play a significant role in resistance to Adriamycin, and this can be overcome by the use of competitive inhibitors of Pgp. Doxorubicin 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 41-44 1682280-9 1991 In some human colon carcinoma cell lines Pgp appears to play a significant role in resistance to Adriamycin, and this can be overcome by the use of competitive inhibitors of Pgp. Doxorubicin 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 174-177 1687601-2 1991 An overexpression of P-glycoprotein has been reported to correlate with the degree of resistance to anticancer agents, especially to adriamycin. Doxorubicin 133-143 ATP binding cassette subfamily B member 1 Homo sapiens 21-35 1687601-5 1991 Although six (75.0 per cent) of the 8 P-glycoprotein positive tumors were resistant to adriamycin, the other two tumors showed clinical responses. Doxorubicin 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 1676918-4 1991 Myeloma cells expressing MDR1 immunohistochemically tended to be more doxorubicin resistant in vitro than MDR1-negative cells. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 1673852-0 1991 Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 1675575-2 1991 When MCF-7 breast carcinoma cells were transfected with the human mdr1 gene (BC-19 cells), they expressed levels of P-glycoprotein equivalent to those of cells selected for resistance to doxorubicin (MCF-7/ADR) but exhibited 10- to 50-fold less resistance to doxorubicin and vinblastine. Doxorubicin 187-198 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 1675575-2 1991 When MCF-7 breast carcinoma cells were transfected with the human mdr1 gene (BC-19 cells), they expressed levels of P-glycoprotein equivalent to those of cells selected for resistance to doxorubicin (MCF-7/ADR) but exhibited 10- to 50-fold less resistance to doxorubicin and vinblastine. Doxorubicin 259-270 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 1676033-5 1991 Although it has been demonstrated that resistance to vinblastine, colchicine, doxorubicin and actinomycin D in human multidrug-resistant cells is associated with overexpression of P-glycoprotein, very little expression of P-glycoprotein was found in these human hepatoma cells. Doxorubicin 78-89 ATP binding cassette subfamily B member 1 Homo sapiens 180-194 1671383-4 1991 Multidrug resistance in human MCF-7 breast cancer cells selected for resistance to adriamycin (AdrR MCF-7) is associated with amplification and overexpression of the mdr1 gene which encodes P-glycoprotein. Doxorubicin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 166-170 1673331-1 1991 The molecular characteristics of two human doxorubicin-resistant cell lines were examined specifically for MDR1 gene amplification by Southern analysis and for overexpression of its messenger RNA. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 1673331-2 1991 The 285-fold doxorubicin-resistant colon adenocarcinoma subline, LoVo/DR5, was found to overexpress the mRNA for P-glycoprotein without the concomitant requirement of MDR1 gene amplification, suggesting that relatively high levels of P-glycoprotein mediated multiple drug resistance may occur by transcriptional activation of the gene. Doxorubicin 13-24 ATP binding cassette subfamily B member 1 Homo sapiens 113-127 1673331-2 1991 The 285-fold doxorubicin-resistant colon adenocarcinoma subline, LoVo/DR5, was found to overexpress the mRNA for P-glycoprotein without the concomitant requirement of MDR1 gene amplification, suggesting that relatively high levels of P-glycoprotein mediated multiple drug resistance may occur by transcriptional activation of the gene. Doxorubicin 13-24 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 1673331-2 1991 The 285-fold doxorubicin-resistant colon adenocarcinoma subline, LoVo/DR5, was found to overexpress the mRNA for P-glycoprotein without the concomitant requirement of MDR1 gene amplification, suggesting that relatively high levels of P-glycoprotein mediated multiple drug resistance may occur by transcriptional activation of the gene. Doxorubicin 13-24 ATP binding cassette subfamily B member 1 Homo sapiens 234-248 1710609-4 1991 Unlike the sensitive parental cell lines, all 4 sublines display MDR-patterns of resistance, with the P-glycoprotein pump (P-170) detected only in the doxorubicin-selected sublines. Doxorubicin 151-162 ATP binding cassette subfamily B member 1 Homo sapiens 102-116 1845955-13 1991 These results indicate that multidrug resistance due to P-glycoprotein-mediated drug efflux is not the only mechanism of doxorubicin resistance that occurs in sarcomas and that glutathione peroxidase-dependent detoxification of doxorubicin-induced oxygen radicals may contribute to clinical doxorubicin resistance. Doxorubicin 228-239 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 1845955-13 1991 These results indicate that multidrug resistance due to P-glycoprotein-mediated drug efflux is not the only mechanism of doxorubicin resistance that occurs in sarcomas and that glutathione peroxidase-dependent detoxification of doxorubicin-induced oxygen radicals may contribute to clinical doxorubicin resistance. Doxorubicin 228-239 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 1850221-0 1991 Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Doxorubicin 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 1850221-2 1991 MDR1 and GST-pi expression, which is known to be a marker for adriamycin resistance, was detected in six (66.7%) and seven (77.8%) of the nine clinically resistant tumors, respectively. Doxorubicin 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 1850221-3 1991 However, in four of the six adriamycin responsive tumors, MDR1 and/or GST-pi expression were detected. Doxorubicin 28-38 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 1988108-2 1991 Resistance to doxorubicin in the human multidrug resistant breast cancer cell line, MCF-7 AdrR, has been attributed to increased glutathione (GSH) S-transferase and GSH peroxidase activity, as well as to increased expression of the mdr1 gene product, P-glycoprotein. Doxorubicin 14-25 ATP binding cassette subfamily B member 1 Homo sapiens 232-236 1673852-5 1991 Moreover, there was a significant association between P-glycoprotein expression and in vitro resistance to doxorubicin and vincristine. Doxorubicin 107-118 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 1977668-3 1990 Five patients resistant to protocols including vincristine, melphalan and doxorubicin were found to express P-glycoprotein. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 1982999-2 1990 The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 1974823-0 1990 Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Doxorubicin 128-139 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 1974823-0 1990 Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Doxorubicin 128-139 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 1974823-3 1990 In three independent selections for doxorubicin resistance, MDR variants arose in which mdr1 P-glycoprotein mRNA and protein was not detectable. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 1974823-3 1990 In three independent selections for doxorubicin resistance, MDR variants arose in which mdr1 P-glycoprotein mRNA and protein was not detectable. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 93-107 1974823-4 1990 Selection on higher doxorubicin concentrations gave rise to variants containing high levels of mdr1 mRNA, due to transcriptional activation of the mdr1 gene. Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 1974823-4 1990 Selection on higher doxorubicin concentrations gave rise to variants containing high levels of mdr1 mRNA, due to transcriptional activation of the mdr1 gene. Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 1974823-5 1990 Upon continued selection for higher levels of doxorubicin resistance, the mdr1 gene became amplified, resulting in an additional increase in the level of mdr1 mRNA. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 1974823-5 1990 Upon continued selection for higher levels of doxorubicin resistance, the mdr1 gene became amplified, resulting in an additional increase in the level of mdr1 mRNA. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 154-158 1980915-1 1990 The expression of MDR1 gene was investigated in human solid tumors with respect to adriamycin resistance. Doxorubicin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 1980915-7 1990 However, two of five tumors which resisted adriamycin treatment were found to be negative in MDR1 transcript, but positive in immunohistological analysis. Doxorubicin 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 1978461-8 1990 Some cases reflected the prior administration of adriamycin, vincristine and VP-16, which are known to induce P-GP expression. Doxorubicin 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 1694250-5 1990 Taken together with earlier evidence that the resistance of MGH-U1R to doxorubicin can be reversed by a calcium-channel blocker verapamil, and the measured over-expression of the mdr1 gene in these cells, MGH-U1R has the characteristic multiple drug resistance properties similar to other established doxorubicin resistant carcinoma cell lines. Doxorubicin 301-312 ATP binding cassette subfamily B member 1 Homo sapiens 179-183 1970934-1 1990 Increased expression of the mdr1 gene, encoding the 175 kDa P-glycoprotein, and the gst-pi gene, encoding the anionic isozyme of glutathione S-transferase (GST), have previously been detected in continuous human breast cancer cell lines selected in vitro for resistance to doxorubicin. Doxorubicin 273-284 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 1970934-6 1990 Comparison of the dose of doxorubicin causing 50% inhibition of growth (ID50) with RNA levels showed that the tumours with high mdr1 expression had high ID50, while the more sensitive explants had low mdr1 expression. Doxorubicin 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 1980493-2 1990 After treatment with sodium butyrate a dose-dependent increase of P-glycoprotein mRNA expression was observed in the adriamycin-resistant K562 and vincristine-resistant K562 lines. Doxorubicin 117-127 ATP binding cassette subfamily B member 1 Homo sapiens 66-80 1980493-3 1990 With 10 mM sodium butyrate, the level of P-glycoprotein mRNA reached 20 times that of control adriamycin-resistant K562 and with 30 mM sodium butyrate, it exceeded 5 times that of control vincristine-resistant K562. Doxorubicin 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 1980915-8 1990 These results indicate that immunohistochemical analysis would be more sensitive for detecting P-glycoprotein-expression, and that resistance to adriamycin, being multifactorial, can be associated at least, in part with the increased amount of MDR1 gene product. Doxorubicin 145-155 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 1980915-8 1990 These results indicate that immunohistochemical analysis would be more sensitive for detecting P-glycoprotein-expression, and that resistance to adriamycin, being multifactorial, can be associated at least, in part with the increased amount of MDR1 gene product. Doxorubicin 145-155 ATP binding cassette subfamily B member 1 Homo sapiens 244-248 1972154-1 1990 Development of multidrug resistance due to overexpression of P-glycoprotein (Pgp), a cell membrane drug efflux pump, occurs commonly during in vitro selections with adriamycin (Adr). Doxorubicin 165-175 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 1972154-1 1990 Development of multidrug resistance due to overexpression of P-glycoprotein (Pgp), a cell membrane drug efflux pump, occurs commonly during in vitro selections with adriamycin (Adr). Doxorubicin 165-175 ATP binding cassette subfamily B member 1 Homo sapiens 77-80 1968359-2 1990 The drug resistance pattern of mdr1-transfected clones includes relatively high resistance to gramicidin D (about 300-fold), vincristine (about 100-fold), and actinomycin D (about 100-fold) and a lower degree of resistance to doxorubicin (about 10-fold), VP16-213 (about 10-fold), and colchicine (about 6-fold). Doxorubicin 226-237 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 2202383-3 1990 We have made attempts to inhibit the expression of the MDR1 gene in MCF-7 human breast cancer cells selected for resistance to Adriamycin using phosphorothioate analogs of oligodeoxynucleotides. Doxorubicin 127-137 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 2342238-1 1990 In order to predict natural resistance to Adriamycin (ADM), the amplification of multidrug resistance gene 1 (MDR1) was investigated in 50 human cancer specimens using Southern blot analysis. Doxorubicin 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 81-108 2342238-1 1990 In order to predict natural resistance to Adriamycin (ADM), the amplification of multidrug resistance gene 1 (MDR1) was investigated in 50 human cancer specimens using Southern blot analysis. Doxorubicin 42-52 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 2342238-1 1990 In order to predict natural resistance to Adriamycin (ADM), the amplification of multidrug resistance gene 1 (MDR1) was investigated in 50 human cancer specimens using Southern blot analysis. Doxorubicin 54-57 ATP binding cassette subfamily B member 1 Homo sapiens 81-108 2342238-1 1990 In order to predict natural resistance to Adriamycin (ADM), the amplification of multidrug resistance gene 1 (MDR1) was investigated in 50 human cancer specimens using Southern blot analysis. Doxorubicin 54-57 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 1967551-6 1990 LU-49888 labeling of Pgp was also inhibited by actinomycin D (45%), podophyllotoxin (47%), and amsacrine (82%), marginally by doxorubicin (25%), colchicine (22%), daunorubicin (18%), and etoposide (14%), but not by teniposide. Doxorubicin 126-137 ATP binding cassette subfamily B member 1 Homo sapiens 21-24 1706611-2 1990 P-glycoprotein is a molecule strongly associated with multi-drug resistance to certain cytostatic drugs, including adriamycin, vincristine, and daunorubicin. Doxorubicin 115-125 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 2308979-2 1990 MDR1 sublines with 6-fold (RPMI8226/DOX6) and 40-fold (RPMI 8226/DOX40) resistance to doxorubicin (DOX) were selected from the chemosensitive MM parent line RPMI 8226/S. Doxorubicin 86-97 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 2308979-2 1990 MDR1 sublines with 6-fold (RPMI8226/DOX6) and 40-fold (RPMI 8226/DOX40) resistance to doxorubicin (DOX) were selected from the chemosensitive MM parent line RPMI 8226/S. Doxorubicin 36-39 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 1979457-0 1990 Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 98-112 33775688-5 2021 Our results demonstrated that the DOX-resistant MCF-7 and MDA-MB-231 clones exhibit higher NF-kappaB (p65) function, which is linked to the upregulated expression of ABCB1 and ABCC1 transporter proteins. Doxorubicin 34-37 ATP binding cassette subfamily B member 1 Homo sapiens 166-171 33808505-11 2021 They were able to increase the accumulation of doxorubicin inside the human promyelocytic leukemia HL60/MDR cells overexpressing P-gp and potentiate the antiproliferative activity of this anti-cancer drug. Doxorubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 2202383-6 1990 The MDR1 inhibition with phosphorothioates was studied by measuring their effects on adriamycin toxicity and by immunocytochemical titration of P170. Doxorubicin 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 33762953-12 2021 Inhibition of LINC01116 suppressed cell viability, migration, and invasion, along with upregulating the expression of E-cadherin, downregulating vimentin, and attenuating doxorubicin resistance in MG-63/Dox cells. Doxorubicin 203-206 ATP binding cassette subfamily B member 1 Homo sapiens 171-193 34624510-0 2022 Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 32164732-12 2020 Mechanistically, ERK5-IN-1 increased intracellular accumulation of doxorubicin dose dependently by directly inhibiting the efflux function of ABCB1. Doxorubicin 67-78 ATP binding cassette subfamily B member 1 Homo sapiens 142-147 34624510-1 2022 P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 34624510-1 2022 P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 34624510-1 2022 P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. Doxorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 34624510-1 2022 P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. Doxorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 34624510-2 2022 In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2, HIF-1alpha, miRNAs, and long noncoding (lnc)RNAs, to reveal their participation in DOX resistance. Doxorubicin 165-168 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 34624510-4 2022 Furthermore, ATP depletion impairs P-gp activity to enhance the antitumor activity of DOX. Doxorubicin 86-89 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 34719826-0 2022 Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study. Doxorubicin 23-34 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 34896572-4 2022 Results showed that Tween 80 exhibited non-competitive inhibition on the doxorubicin efflux of P-gp and MRP1, with the inhibitory affinity 0.00195% (14.89 muM) and 0.00245% (18.7 muM), respectively. Doxorubicin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 34896572-4 2022 Results showed that Tween 80 exhibited non-competitive inhibition on the doxorubicin efflux of P-gp and MRP1, with the inhibitory affinity 0.00195% (14.89 muM) and 0.00245% (18.7 muM), respectively. Doxorubicin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 34856211-4 2022 VOA, a bisindole alkaloid extracted from Peschiera fuchsiaefolia, has already been shown to be effective in enhancing the effect of doxorubicin, because it interferes with the P-gp function. Doxorubicin 132-143 ATP binding cassette subfamily B member 1 Homo sapiens 176-180 34463270-8 2021 In contrast, ABCB1 C1236T C/C diplotype was significantly related to the occurrence of ADRs: one volunteer with this genotype suffered dizziness, somnolence and hand paresthesia, while no other volunteer suffered any of these ADRs (p < 0.045). Doxorubicin 87-91 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 34648615-6 2021 Transient overexpression of MDR1 increased drug tolerance of HCT-8 cells on paclitaxel, doxorubicin HCl and vincristine sulphate (2.11- to 2.27-fold increase), but not on cyclosporin A, daunorubicin HCl and nitazoxanide. Doxorubicin 88-103 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 34915026-8 2022 We demonstrated that chemoresistance to doxorubicin in ABCB1high cells was partially reversed by inhibitors of de novo ceramide synthesis (L-cycloserine) and CerS (fumonisin B1) in cell viability assays. Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 34751283-6 2021 Moreover, the elevated reactive oxygen species (ROS) in cancer cells triggered rapid NO release to reduce P-gp and thus synergistically increase the therapeutic effect of doxorubicin (DOX). Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 34751283-6 2021 Moreover, the elevated reactive oxygen species (ROS) in cancer cells triggered rapid NO release to reduce P-gp and thus synergistically increase the therapeutic effect of doxorubicin (DOX). Doxorubicin 184-187 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 34496281-7 2021 Through CD44-mediated targeting, DOX/siGCN5@HPMSNs increases drug internalization in CD44-overexpressing cancer cells, and markedly promotes DOX retention by down-regulating P-gp expression in drug-resistant cancers through silencing GCN5. Doxorubicin 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 174-178 34496281-7 2021 Through CD44-mediated targeting, DOX/siGCN5@HPMSNs increases drug internalization in CD44-overexpressing cancer cells, and markedly promotes DOX retention by down-regulating P-gp expression in drug-resistant cancers through silencing GCN5. Doxorubicin 141-144 ATP binding cassette subfamily B member 1 Homo sapiens 174-178 34496281-8 2021 Of note, in an MDR breast tumor model, DOX and siGCN5 co-delivered HPMSNs inhibits MDR tumor growth by 77%, abolishes P-gp-mediated drug resistance, and eliminates DOX"s systemic toxicity. Doxorubicin 39-42 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 34496281-11 2021 This nanosystem efficiently co-delivered DOX and siGCN5 into drug-resistant cancer cells and significantly inhibited the tumor growth through: (1) HA shell enhanced the cellular internalization of loaded DOX and siGCN5 via CD44-mediated targeting; (2) the pH/redox dual-responsive nanosystem released the cargos in response to the intracellular environment; (3) the released siGCN5 downregulated P-gp epigenetically. Doxorubicin 41-44 ATP binding cassette subfamily B member 1 Homo sapiens 396-400 34496281-12 2021 In an MDR breast tumor model (MCF7/ADR), DOX and siGCN5 loaded HPMSNs markedly inhibited tumor growth, almost completely abolished P-gp expression, and minimized systemic toxicity of DOX. Doxorubicin 41-44 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 34560519-14 2021 Moreover, asiatic acid also enhanced the sensitivity of doxorubicin-resistant MCF-7 cells to doxorubicin by improving P-glycoprotein (P-gp) function. Doxorubicin 56-67 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 34560519-14 2021 Moreover, asiatic acid also enhanced the sensitivity of doxorubicin-resistant MCF-7 cells to doxorubicin by improving P-glycoprotein (P-gp) function. Doxorubicin 56-67 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 34560519-14 2021 Moreover, asiatic acid also enhanced the sensitivity of doxorubicin-resistant MCF-7 cells to doxorubicin by improving P-glycoprotein (P-gp) function. Doxorubicin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 34560519-14 2021 Moreover, asiatic acid also enhanced the sensitivity of doxorubicin-resistant MCF-7 cells to doxorubicin by improving P-glycoprotein (P-gp) function. Doxorubicin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 34874967-7 2021 In conclusion, the combined therapy of DTX or DOX and TG1 increases drug efficacy via suppressing the p-glycoprotein efflux pump. Doxorubicin 46-49 ATP binding cassette subfamily B member 1 Homo sapiens 102-116 34848465-7 2021 EPI served as a substrate of P-glycoprotein and multidrug associated protein (MRP) 1 and MRP2 similarly to DOX, but the efflux efficiency of each transporter was markedly different between EPI and DOX. Doxorubicin 107-110 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 34848465-7 2021 EPI served as a substrate of P-glycoprotein and multidrug associated protein (MRP) 1 and MRP2 similarly to DOX, but the efflux efficiency of each transporter was markedly different between EPI and DOX. Doxorubicin 197-200 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 34931867-10 2021 ABCB1 expression was upregulated in HepG2/Dox cells. Doxorubicin 42-45 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 34931867-13 2021 Transfection with miR-183 partially reversed chemotherapeutic drug resistance by downregulating the expression of ABCB1 and CTNNB1 in HepG2/Dox cells. Doxorubicin 140-143 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 34844236-0 2022 Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Doxorubicin 53-64 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 34844236-9 2022 RESULTS: Using the PCR array, MDR1 was identified as the key gene that regulates DOX resistance in OCI-Ly3/DOX-A100, a non-GCB DLBCL cell line. Doxorubicin 81-84 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 34844236-9 2022 RESULTS: Using the PCR array, MDR1 was identified as the key gene that regulates DOX resistance in OCI-Ly3/DOX-A100, a non-GCB DLBCL cell line. Doxorubicin 107-110 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 34900540-6 2021 Concurrently, DOX-efflux-associated P-glycoprotein was also inhibited by O2, prolonging drug retention in cancer cells. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 34476509-6 2021 P-glycoprotein-mediated efflux of Pira was determined in GA-treated K562/Dox cancer cells. Doxorubicin 73-76 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 34476509-8 2021 GA inhibited P-glycoprotein-mediated efflux of Pira in GA-treated K562/Dox cancer cells. Doxorubicin 71-74 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 34564140-7 2021 Non-cytotoxic to human carcinoma cells, azachrysosporazies 1-5 were capable of reversing doxorubicin resistance in P-glycoprotein (P-gp)-overexpressing human colon carcinoma cells (SW620 Ad300), with optimum activity exhibited by the C-2" substituted analogues 3-5. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 34114067-6 2021 RESULTS: DOX-resistant OS cells exhibited high multidrug resistant 1 (MDR1) expression, which was suppressed by OBP-702 or MDR1 siRNA, resulting in enhanced DOX-induced apoptosis. Doxorubicin 9-12 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 34114067-6 2021 RESULTS: DOX-resistant OS cells exhibited high multidrug resistant 1 (MDR1) expression, which was suppressed by OBP-702 or MDR1 siRNA, resulting in enhanced DOX-induced apoptosis. Doxorubicin 9-12 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 34114067-6 2021 RESULTS: DOX-resistant OS cells exhibited high multidrug resistant 1 (MDR1) expression, which was suppressed by OBP-702 or MDR1 siRNA, resulting in enhanced DOX-induced apoptosis. Doxorubicin 157-160 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 34114067-6 2021 RESULTS: DOX-resistant OS cells exhibited high multidrug resistant 1 (MDR1) expression, which was suppressed by OBP-702 or MDR1 siRNA, resulting in enhanced DOX-induced apoptosis. Doxorubicin 157-160 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 34572790-5 2021 All of the oxoselenoesters, except K4, were potent ABCB1 inhibitors, and two of them, namely K5 and K6, enhanced the activity of doxorubicin in a synergistic manner. Doxorubicin 129-140 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 34174351-7 2021 Moreover, the P-glycoprotein mediated DOX efflux is also diminished by concomitantly producing NO intracellularly. Doxorubicin 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 34286569-6 2021 In addition to the cytotoxicity contributed by DOX, NO, and heat, TPGS and NO act as MDR reversal agents to inhibit P-glycoprotein (P-gp)-related efflux of DOX by HepG2/ADR cells. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 116-130 34354052-0 2021 Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase. Doxorubicin 22-32 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 34286569-6 2021 In addition to the cytotoxicity contributed by DOX, NO, and heat, TPGS and NO act as MDR reversal agents to inhibit P-glycoprotein (P-gp)-related efflux of DOX by HepG2/ADR cells. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 34286569-6 2021 In addition to the cytotoxicity contributed by DOX, NO, and heat, TPGS and NO act as MDR reversal agents to inhibit P-glycoprotein (P-gp)-related efflux of DOX by HepG2/ADR cells. Doxorubicin 156-159 ATP binding cassette subfamily B member 1 Homo sapiens 116-130 34286569-6 2021 In addition to the cytotoxicity contributed by DOX, NO, and heat, TPGS and NO act as MDR reversal agents to inhibit P-glycoprotein (P-gp)-related efflux of DOX by HepG2/ADR cells. Doxorubicin 156-159 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 34374660-0 2021 Algerian propolis: between protection of normal cells and potentialisation of the anticancer effects of doxorubicin against breast cancer cells via P-glycoprotein inhibition and cell cycle arrest in the S phase. Doxorubicin 104-115 ATP binding cassette subfamily B member 1 Homo sapiens 148-162 34405014-6 2021 Also, parthenolide (PTL), which is a specific NF-kappaB inhibitor, effectively eliminated drug-resistant LSCs and enhanced the sensitivity of K562/ADM cells to doxorubicin-induced apoptosis by down-regulating NF-kappaB pathway-mediated P-gp expression. Doxorubicin 160-171 ATP binding cassette subfamily B member 1 Homo sapiens 236-240 34336684-4 2021 First, we found that STAT5a and ABCB1 were expressed at higher levels in doxorubicin-resistant cell lines and chemoresistant patients, and their expression was positively correlated. Doxorubicin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 32-37 34069490-0 2021 Essential Oils, Pituranthos chloranthus and Teucrium ramosissimum, Chemosensitize Resistant Human Uterine Sarcoma MES-SA/Dx5 Cells to Doxorubicin by Inducing Apoptosis and Targeting P-Glycoprotein. Doxorubicin 134-145 ATP binding cassette subfamily B member 1 Homo sapiens 182-196 34094940-0 2021 Crizotinib and Doxorubicin Cooperatively Reduces Drug Resistance by Mitigating MDR1 to Increase Hepatocellular Carcinoma Cells Death. Doxorubicin 15-26 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 34094940-9 2021 Therefore, Crizo plus Dox sensitize HCC drug resistance by engaging PERK-p- eIF2alpha-MDR1, and kill HCC cells by engaging PERK-JNK- autophagic cell death pathways. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 34094940-10 2021 These newly discovered mechanisms of Crizo plus Dox not only provide a potential treatment for HCC but also point to an approach to overcome MDR1 related drug resistance in other cancers. Doxorubicin 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 34421363-6 2021 Overexpressions of STAT3 and P-glycoprotein (P-gp) were identified in T24/DOX and T24/CIS, which could be reversed by NTX. Doxorubicin 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 34421363-6 2021 Overexpressions of STAT3 and P-glycoprotein (P-gp) were identified in T24/DOX and T24/CIS, which could be reversed by NTX. Doxorubicin 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 34198967-8 2021 Additionally, the Hep3B/rho0 cells showed resistance to the anticancer drug doxorubicin because of the increased expression of ATP-binding cassette Subfamily B Member 1. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 127-168 35582915-0 2022 Epifriedelanol enhances adriamycin-induced cytotoxicity towards K562/ADM cells by down regulating of P-gp and MRP2. Doxorubicin 24-34 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 35330134-3 2022 In this study, we utilize homology modelling and molecular docking analysis to determine the binding affinity and the potential interaction sites of MRP1 with Carboplatin, Gemcitabine, Doxorubicin, Paclitaxel, and Topotecan. Doxorubicin 185-196 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 35614289-5 2022 Among non-cytotoxic synthetic analogs (1-14), several derivatives effectively and significantly sensitized MDR cells by interfering with the drug transport function of P-gp to three anticancer drugs, vincristine, paclitaxel, and doxorubicin. Doxorubicin 229-240 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 35235816-0 2022 miR-200c increases the sensitivity of breast cancer cells to Doxorubicin through downregulating MDR1 gene. Doxorubicin 61-72 ATP binding cassette subfamily B member 1 Homo sapiens 96-100 35235816-5 2022 The purpose of this paper is to examine the outcome of miR-200c restoring on enhancing the BC cells" sensitivity to Doxorubicin through downregulating the MDR1 expression. Doxorubicin 116-127 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 35235816-11 2022 Furthermore, miR-200c could increase the BC cells" sensitivity to Doxorubicin by reducing the MDR1 gene expression. Doxorubicin 66-77 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 35279218-0 2022 Correction to: MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). Doxorubicin 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 35450042-7 2022 The short-term and long-term intracellular accumulation of doxorubicin greatly increased in the KB-C2 cells co-cultured with ribociclib, indicating ribociclib inhibited the drug efflux activity of P-gp. Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 197-201 35450348-6 2022 Compounds 2-4 were found to be selective toward cancer cell lines and were able to inhibit P-glycoprotein (P-gp) activity in NCI-H460/R cells at longer exposure of 72 h and consequently revert doxorubicin (DOX) resistance in subsequent combined treatment. Doxorubicin 193-204 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 35450348-6 2022 Compounds 2-4 were found to be selective toward cancer cell lines and were able to inhibit P-glycoprotein (P-gp) activity in NCI-H460/R cells at longer exposure of 72 h and consequently revert doxorubicin (DOX) resistance in subsequent combined treatment. Doxorubicin 193-204 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 35450348-6 2022 Compounds 2-4 were found to be selective toward cancer cell lines and were able to inhibit P-glycoprotein (P-gp) activity in NCI-H460/R cells at longer exposure of 72 h and consequently revert doxorubicin (DOX) resistance in subsequent combined treatment. Doxorubicin 206-209 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 35450348-6 2022 Compounds 2-4 were found to be selective toward cancer cell lines and were able to inhibit P-glycoprotein (P-gp) activity in NCI-H460/R cells at longer exposure of 72 h and consequently revert doxorubicin (DOX) resistance in subsequent combined treatment. Doxorubicin 206-209 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 35330134-2 2022 The multidrug resistance protein 1 (MRP1) is a membrane-bound ABC transporter involved in cross resistance to many structurally and functionally diverse classes of anticancer drugs including doxorubicin, taxane, and platinum. Doxorubicin 191-202 ATP binding cassette subfamily B member 1 Homo sapiens 4-34 35330134-2 2022 The multidrug resistance protein 1 (MRP1) is a membrane-bound ABC transporter involved in cross resistance to many structurally and functionally diverse classes of anticancer drugs including doxorubicin, taxane, and platinum. Doxorubicin 191-202 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 35451580-0 2022 miR-205 Reverses MDR-1 Mediated Doxorubicin Resistance via PTEN in Human Liver Cancer HepG2 Cells. Doxorubicin 32-43 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 35327403-3 2022 Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox). Doxorubicin 218-229 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 35327403-3 2022 Here, we report that infigratinib (BGJ 398), a potent FGFR1-4 inhibitor, restores sensitivity of a broad spectrum of ABCB1-overexpressing cancer cells to certain chemotherapeutic agents, including paclitaxel (PTX) and doxorubicin (Dox). Doxorubicin 231-234 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 35327403-7 2022 As expected, no apoptosis was found in ABCB1-overexpressing cancer cells treated with PTX, Dox, or BGJ 398 alone. Doxorubicin 91-94 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 35451580-11 2022 Finally, we found that miR-205 was down-regulated in HepG2/DOX cells, and its overexpression led to enhancing apoptosis with re-sensitization of HepG2/DOX cell lines to DOX through PTEN/PI3K/ Akt/MDR1 pathway. Doxorubicin 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 196-200 35451580-11 2022 Finally, we found that miR-205 was down-regulated in HepG2/DOX cells, and its overexpression led to enhancing apoptosis with re-sensitization of HepG2/DOX cell lines to DOX through PTEN/PI3K/ Akt/MDR1 pathway. Doxorubicin 151-154 ATP binding cassette subfamily B member 1 Homo sapiens 196-200 35451580-11 2022 Finally, we found that miR-205 was down-regulated in HepG2/DOX cells, and its overexpression led to enhancing apoptosis with re-sensitization of HepG2/DOX cell lines to DOX through PTEN/PI3K/ Akt/MDR1 pathway. Doxorubicin 169-172 ATP binding cassette subfamily B member 1 Homo sapiens 196-200 35075112-0 2022 Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression. Doxorubicin 33-44 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 34978808-5 2022 Sal combined with DOX inhibited the growth of HeLa-ADR-luc cells in vivo and downregulated the DOX-induced high expression of MDR1. Doxorubicin 18-21 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 34978808-5 2022 Sal combined with DOX inhibited the growth of HeLa-ADR-luc cells in vivo and downregulated the DOX-induced high expression of MDR1. Doxorubicin 95-98 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 35075112-8 2022 High expression of GAL1 in HepG2 cells reduced intracellular accumulation of DOX likely by increasing P-gp protein expression rather than altering its membrane localization. Doxorubicin 77-80 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 35075112-10 2022 Moreover, "loss-of-function" experiments revealed that P-gp mediates GAL1-driven resistance to DOX, but not to sorafenib, in HepG2 cells. Doxorubicin 95-98 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 35047507-2 2021 In this study, we found the expression levels of Survivin protein (BIRC5) and P-glycoprotein (MDR1) in MCF-7/doxorubicin (DOX) cells (drug-resistant cells) were significantly higher than MCF-7 cells (wild-type cells). Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 35047507-2 2021 In this study, we found the expression levels of Survivin protein (BIRC5) and P-glycoprotein (MDR1) in MCF-7/doxorubicin (DOX) cells (drug-resistant cells) were significantly higher than MCF-7 cells (wild-type cells). Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 35047507-2 2021 In this study, we found the expression levels of Survivin protein (BIRC5) and P-glycoprotein (MDR1) in MCF-7/doxorubicin (DOX) cells (drug-resistant cells) were significantly higher than MCF-7 cells (wild-type cells). Doxorubicin 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 35047507-2 2021 In this study, we found the expression levels of Survivin protein (BIRC5) and P-glycoprotein (MDR1) in MCF-7/doxorubicin (DOX) cells (drug-resistant cells) were significantly higher than MCF-7 cells (wild-type cells). Doxorubicin 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 2582432-3 1989 Dx5 cells express high levels of the mdr1 gene product P-glycoprotein and are 25- to 30-fold resistant to doxorubicin (DOX), etoposide (VP-16), and vinblastine (VBL). Doxorubicin 119-122 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 35126877-3 2022 Using doxorubicin (Dox) as a model chemotherapeutic drug, the Ca2+ nano-inhibitors efficiently deprived intracellular excessive free Ca2+, suppressed P-glycoprotein (P-gp) expression and significantly enhanced intracellular drug accumulation in Dox-resistant tumor cells. Doxorubicin 6-17 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 35126877-3 2022 Using doxorubicin (Dox) as a model chemotherapeutic drug, the Ca2+ nano-inhibitors efficiently deprived intracellular excessive free Ca2+, suppressed P-glycoprotein (P-gp) expression and significantly enhanced intracellular drug accumulation in Dox-resistant tumor cells. Doxorubicin 6-17 ATP binding cassette subfamily B member 1 Homo sapiens 166-170 35126877-3 2022 Using doxorubicin (Dox) as a model chemotherapeutic drug, the Ca2+ nano-inhibitors efficiently deprived intracellular excessive free Ca2+, suppressed P-glycoprotein (P-gp) expression and significantly enhanced intracellular drug accumulation in Dox-resistant tumor cells. Doxorubicin 19-22 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 35126877-3 2022 Using doxorubicin (Dox) as a model chemotherapeutic drug, the Ca2+ nano-inhibitors efficiently deprived intracellular excessive free Ca2+, suppressed P-glycoprotein (P-gp) expression and significantly enhanced intracellular drug accumulation in Dox-resistant tumor cells. Doxorubicin 19-22 ATP binding cassette subfamily B member 1 Homo sapiens 166-170 2575381-3 1989 We found that MDR1 promoter could be activated directly on the addition of anticancer agents including vincristine, daunomycin, adriamycin and colchicine. Doxorubicin 128-138 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 2569930-7 1989 In addition, the photolabeling was partially blocked by Adriamycin, vincristine, and colchicine, suggesting that the specific binding sites for verapamil on P-glycoprotein are closely related to the binding sites for these calcium channel blockers and antitumor agents. Doxorubicin 56-66 ATP binding cassette subfamily B member 1 Homo sapiens 157-171 2575610-1 1989 We have isolated a cDNA clone, pCA12-2, from a lambda gt11 cDNA library of an adriamycin-resistant subline of human myelogenous leukemia K562 (K562/ADM) by plaque hybridization with the 2.6 kb genomic probe of P-glycoprotein reported previously. Doxorubicin 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 210-224 2571333-9 1989 Furthermore, a radiolabeled N-hydroxysuccinimide ester derivative of doxorubicin, which inhibited VCR binding to EHR2/DNR+ membranes to an even greater extent than doxorubicin, labeled plasma membrane proteins from EHR2 and EHR2/DNR+ identically and did not demonstrate any binding to P-glycoprotein. Doxorubicin 69-80 ATP binding cassette subfamily B member 1 Homo sapiens 285-299 2572588-10 1989 The levels of P-glycoprotein returned to normal with a half-life of about 24 h. In spite of a 20-25-fold increase in the level of mdr-1/Pgp mRNA and P-glycoprotein, the SW-620 cell line did not demonstrate increased resistance to doxorubicin and vinblastine or decreased accumulation of vinblastine. Doxorubicin 230-241 ATP binding cassette subfamily B member 1 Homo sapiens 130-135 2766278-7 1989 MDR1 transcripts (4.5 kilobases) were observed in the RNA preparations obtained from 3 of 10 patients who were treated with doxorubicin or vincristine, 2 drugs known to select the MDR phenotype in vitro. Doxorubicin 124-135 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 2766278-11 1989 Our study suggests that, in spite of the weak occurrence of the MDR process in patients with ovarian cancers, MDR1 expression can be related to previous treatment with doxorubicin or vincristine. Doxorubicin 168-179 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 2724349-0 1989 MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 2566379-1 1989 P-glycoprotein is a plasma membrane protein believed to mediate resistance to natural product drugs such as vincristine, Adriamycin, and actinomycin D. Doxorubicin 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 2724349-5 1989 To clarify the association of the MDR1 protein product P-glycoprotein with natural resistance to doxorubicin (ADR) in RCCs, we evaluated the effects of quinidine on in vitro sensitivity to ADR in 16 RCC samples, using a [3H]thymidine incorporation assay. Doxorubicin 97-108 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 2899456-1 1988 A monoclonal antibody (MAb), MRK 16, specific to Adriamycin-resistant human myelogenous leukemia cell line K562, was used to examine whether the antigen molecules (P-glycoprotein) recognized by the MAb are present in the adrenals. Doxorubicin 49-59 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 2565403-0 1989 Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. Doxorubicin 14-25 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 2565403-8 1989 The difference in frequency of intrinsic doxorubicin resistance between P-glycoprotein-negative and -positive tumors was highly significant (P less than .001). Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 2565403-12 1989 Our findings indicate that positive staining for P-glycoprotein associated with multidrug resistance predicts intrinsic cellular resistance of human cancers to doxorubicin. Doxorubicin 160-171 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 2564428-11 1989 Verapamil increased the intracellular accumulation of doxorubicin and vincristine in vitro for both a P-gly-positive myeloma cell line and tumor cells from two patients with end-stage myeloma which over-expressed P-gly. Doxorubicin 54-65 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 2564428-11 1989 Verapamil increased the intracellular accumulation of doxorubicin and vincristine in vitro for both a P-gly-positive myeloma cell line and tumor cells from two patients with end-stage myeloma which over-expressed P-gly. Doxorubicin 54-65 ATP binding cassette subfamily B member 1 Homo sapiens 213-218 2903793-8 1988 In contrast, the expression of P-glycoprotein remained constant whether in the presence or absence of Adriamycin during these experiments. Doxorubicin 102-112 ATP binding cassette subfamily B member 1 Homo sapiens 31-45 2563664-4 1989 Analysis of cell lines with gradually increasing levels of multidrug resistance (8226/S, 8226/Dox6 and 8226/Dox40) demonstrated a close association between the level of resistance to doxorubicin, defined by the mean lethal dose (D0) and the amount of P-glycoprotein on individual cells determined by the optical density (r = 0.82, P less than 0.0005). Doxorubicin 183-194 ATP binding cassette subfamily B member 1 Homo sapiens 251-265 2891711-5 1988 In this study, we have purified the P-glycoprotein from the human myelogenous leukemia K562 cell line resistant to adriamycin (K562/ADM) by means of one-step immunoaffinity chromatography using a monoclonal antibody against P-glycoprotein. Doxorubicin 115-125 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 2898143-5 1988 Infected cells became resistant to colchicine, vinblastine, doxorubicin, VP16 (etoposide), and puromycin, but not cisplatin, indicating that the presence of the human MDR1 gene is sufficient to cause multidrug resistance. Doxorubicin 60-71 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 2896069-8 1988 Third, intracellular DOX accumulation (as measured by [14C]DOX at 1-h and high-performance liquid chromatography analysis) was decreased approximately 2.7-fold in LoVo DOXR cells and approximately 2.0-fold in HT1080/DR4 cells. Doxorubicin 21-24 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 3308067-3 1987 Doxorubicin-resistant cell lines developed in vitro by exposure of a sensitive cell line to increasing concentrations of doxorubicin develop resistance on the basis of a decrease in drug accumulation and have increased expression of the mdr-1 gene. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 237-242 3481435-1 1987 Amplification and increased expression of the mdr1 gene associated with multidrug resistance in human tumors were found in multidrug-resistant sublines of human myelogenous leukemia K562 selected with vincristine (K562/VCR) or adriamycin (K562/ADM). Doxorubicin 227-237 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 3308067-3 1987 Doxorubicin-resistant cell lines developed in vitro by exposure of a sensitive cell line to increasing concentrations of doxorubicin develop resistance on the basis of a decrease in drug accumulation and have increased expression of the mdr-1 gene. Doxorubicin 121-132 ATP binding cassette subfamily B member 1 Homo sapiens 237-242 2886122-5 1987 These studies thus demonstrate adriamycin resistance in P-glycoprotein negative HL60 cells. Doxorubicin 31-41 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 2886122-6 1987 Furthermore adriamycin and vincristine are found to have distinct effects in inducing overexpression of P-glycoprotein in the HL60 cell line. Doxorubicin 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 3457471-2 1986 Multidrug resistance in human KB carcinoma cells selected in colchicine, vinblastine, or Adriamycin is associated with amplification of specific DNA sequences (the multidrug resistance locus, mdr1). Doxorubicin 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 192-196 3027054-2 1987 Multidrug resistance in human KB carcinoma cells selected for resistance to colchicine, vinblastine, or adriamycin results from overexpression, and frequently amplification, of a specific gene (mdr1). Doxorubicin 104-114 ATP binding cassette subfamily B member 1 Homo sapiens 194-198 33948366-7 2021 This phenomeon was further confirmed by the strong association of IGF2BP3 and ABCB1 expression with DOX sensitivity. Doxorubicin 100-103 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 34000577-2 2021 However, the development of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in tumor chemotherapy has seriously reduced the therapeutic efficacy of Dox. Doxorubicin 158-161 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 34000577-2 2021 However, the development of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in tumor chemotherapy has seriously reduced the therapeutic efficacy of Dox. Doxorubicin 158-161 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 34000577-5 2021 It was found that Cur reversed P-gp-mediated resistance in SW620/Ad300 cells by enhancing the Dox-induced cytotoxicity and apoptosis. Doxorubicin 94-97 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 34000577-6 2021 Further mechanistic studies indicated that Cur inhibited the ATP-dependent transport activity of P-gp, thereby increasing the intra-celluar accumulation of Dox in drug-resistant cells. Doxorubicin 156-159 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 33598946-9 2021 miR-21 suppression dramatically downregulated P-gp expression and activity in DOX-resistance cells and abolished MDR by an increment of intracellular accumulation of DOX in PC3/DOX cells (p < 0.05). Doxorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 32229058-7 2021 The function of P-gp and BCRP was tested using a doxorubicin uptake assay and an ATPase assay. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 32229058-16 2021 Then, we found that the two compounds increased doxorubicin accumulation in P-gp overexpressing CEM/ADR5000 by three-fold compared to cells without inhibitor. Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 34031441-0 2021 The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 18-23 34031441-0 2021 The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 34031441-3 2021 Here we explored the role of inhibition of MDR1 or ABCG2 in sensitizing liver cancer stem cells to doxorubicin, the most frequently used chemotherapeutic agent in treating liver cancer. Doxorubicin 99-110 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 34031441-4 2021 We show that the inhibition of MDR1 or ABCG2 in Huh7 and PLC/PRF/5 cells using either pharmacological inhibitors or RNAi resulted in the elevated level of intracellular concentration of doxorubicin and the accompanied increased apoptosis as determined by confocal microscopy, high-performance liquid chromatography, flow cytometry, and annexin V assay. Doxorubicin 186-197 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 34031441-6 2021 Thus, the elevation of effective intracellular concentration of doxorubicin via the inhibition of MDR1 or ABCG2 represents a promising future strategy that transforms doxorubicin from a traditional chemotherapy agent into a robust killer of liver cancer stem cells for patients undergoing transarterial chemoembolization. Doxorubicin 64-75 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 34031441-6 2021 Thus, the elevation of effective intracellular concentration of doxorubicin via the inhibition of MDR1 or ABCG2 represents a promising future strategy that transforms doxorubicin from a traditional chemotherapy agent into a robust killer of liver cancer stem cells for patients undergoing transarterial chemoembolization. Doxorubicin 167-178 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 34023560-5 2021 MCF-7/DOX and MDA-MB-468/DOX cells also exhibited an up-regulation of drug resistance-related protein MDR1. Doxorubicin 6-9 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 34023560-5 2021 MCF-7/DOX and MDA-MB-468/DOX cells also exhibited an up-regulation of drug resistance-related protein MDR1. Doxorubicin 25-28 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 34048174-19 2021 Further study was needed to determine significance of P-glycoprotein expression in IVR after single intravesical adriamycin instillation. Doxorubicin 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 33735724-4 2021 METHODS: Calcein-AM, rhodamine 123, and doxorubicin were fluorescent substrates for the evaluation of P-gp inhibitory function and detailed drug binding modes. Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 33725657-5 2021 Compound 16 containing isopropoxy possessed good potency against P-gp mediated MDR in MCF-7/ADR (IC50 (doxorubicin) = 0.73 muM, RF = 69.6 with 5 muM 16 treated). Doxorubicin 103-114 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 33927626-0 2021 A New Chalcone Derivative C49 Reverses Doxorubicin Resistance in MCF-7/DOX Cells by Inhibiting P-Glycoprotein Expression. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 33917090-5 2021 In particular, their feature stronger influence on the activity of P-glycoprotein of cell cultures resistant to doxorubicin than doxorubicin. Doxorubicin 112-123 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 33917090-5 2021 In particular, their feature stronger influence on the activity of P-glycoprotein of cell cultures resistant to doxorubicin than doxorubicin. Doxorubicin 129-140 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 33691545-4 2022 Ganoderiol F could increase the intracellular accumulation of doxorubicin in KBv200 cells through inhibiting P-glycoprotein transport function. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 109-123 33753859-0 2021 Nongenotoxic ABCB1 activator tetraphenylphosphonium can contribute to doxorubicin resistance in MX-1 breast cancer cell line. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 33753859-2 2021 This study describes possible mechanisms, that might contribute to upregulation of ABCB1 and synergistically boost the acquisition of doxorubicin (DOX) resistance in breast cancer MX-1 cell line. Doxorubicin 134-145 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 33753859-2 2021 This study describes possible mechanisms, that might contribute to upregulation of ABCB1 and synergistically boost the acquisition of doxorubicin (DOX) resistance in breast cancer MX-1 cell line. Doxorubicin 147-150 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 33753859-3 2021 DOX resistance in MX-1 cell line was induced by a stepwise increase of drug concentration or by pretreatment of cells with an ABCB1 transporter activator tetraphenylphosphonium (TPP+) followed by DOX exposure. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 126-131 33753859-6 2021 Gradual activation of canonical EMT transcription factors with later activation of ABCB1 at the transcript level was observed in DOX-only treated cells, while TPP+ exposure induced considerable activation of ABCB1 at both, mRNA and protein level. Doxorubicin 129-132 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 33753859-8 2021 ABCB1-active cells were highly resistant to DOX and showed morphological and molecular features of EMT. Doxorubicin 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 33753859-9 2021 The study suggests that nongenotoxic ABCB1 inducer can possibly accelerate development of DOX resistance. Doxorubicin 90-93 ATP binding cassette subfamily B member 1 Homo sapiens 37-42 33476826-3 2021 Under near-infrared (NIR) irradiation, the released high-concentration of NO gas inhibited the P-gp expression to sensitize the chemotherapeutic medicine DOX and assisted photothermal therapy (PTT) to eradicate cancer cells without skin scarring. Doxorubicin 154-157 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 33432521-2 2022 In this study, folate-targeted polymeric micellar carrier was successfully constructed to co-delivery of doxorubicin (DOX) and SIS3 (FA/DOX/SIS3 micelles), a specific Smad3 inhibitor which sensitizes ABCB1- and ABCG2-overexpressing cancer cells to chemotherapeutic agents. Doxorubicin 105-116 ATP binding cassette subfamily B member 1 Homo sapiens 200-205 33995950-2 2021 However, in most cases, efflux pumps like P-glycoprotein (P-gp), expel the taken drugs out of the cell and decrease the Dox bioavailability. Doxorubicin 120-123 ATP binding cassette subfamily B member 1 Homo sapiens 42-56 33995950-2 2021 However, in most cases, efflux pumps like P-glycoprotein (P-gp), expel the taken drugs out of the cell and decrease the Dox bioavailability. Doxorubicin 120-123 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 33189788-4 2021 With the help of CSCs-specific targeting and P-gp inhibitor Tar, the accumulation of DOX delivered by the mSiO2-dPG nanocarriers could be greatly increased in drug resistant three-dimensional mammosphere of breast CSCs, and the chemotherapeutic efficacy against breast CSCs was enhanced. Doxorubicin 85-88 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 33009882-7 2021 Furthermore, overexpression of MDR1 rescued the effects of UA on Adriamycin resistance and sensitivity. Doxorubicin 65-75 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 33009882-8 2021 This work reveals a novel HuR/MDR1 axis responsible for UA-mediated attenuation on Adriamycin resistance in OC cells. Doxorubicin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 32712543-11 2020 The combination of the FUC and DOX decreased ABCC1, ABCG2, and ABCB1 expression. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 63-68 33411349-7 2021 CONCLUSIONS: CD44 might be involved in adriamycin resistance via regulation of P-gp, MMP-2, MMP-9, and Bcl-2/Bax. Doxorubicin 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 33365267-0 2020 Thrombospondin-1 Receptor CD47 Overexpression Contributes to P-Glycoprotein-Mediated Multidrug Resistance Against Doxorubicin in Thyroid Carcinoma FTC-133 Cells. Doxorubicin 114-125 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 32253945-3 2020 Two amide derivatives, displaying the best P-gp activity, were tested in co-administration with the antineoplastic drug doxorubicin in different cancer cell lines, showing a significant sensitising activity towards doxorubicin. Doxorubicin 215-226 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 32584473-6 2020 To study the mechanism of doxorubicin resistance, we generated a doxorubicin-resistant PCa cell line C4-2B (C4-2B DoxR) in this study, by culturing cells in an increasing doxorubicin concentration. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 26-48 33305727-0 2020 Reduced cytotoxicity in doxorubicin-exposed HepG2 cells pretreated with menthol due to upregulation of P-glycoprotein. Doxorubicin 24-35 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 33305727-1 2020 The aim of the present study was to examine changes in the expression and activity of P-glycoprotein (P-gp) in human hepatocellular carcinoma HepG2 cells after exposure to menthol, and their relationship to the cytotoxicity of and apoptotic responses to doxorubicin (DOX), a substrate of P-gp, in the cells. Doxorubicin 254-265 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 33351694-10 2020 The interactions among circ_0002060, miR-198, and ABCB1 in DOX-resistant OS cells were confirmed by dual-luciferase reporter assay, RNA immunoprecipitation assay, or RNA pull-down assay. Doxorubicin 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 50-55 33351694-14 2020 Besides, miR-198 decreased DOX resistance by binding to ABCB1. Doxorubicin 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 33351694-16 2020 Conclusions: circ_0002060 promoted DOX resistance and OS progression by regulating the miR-198/ABCB1 axis, suggesting that circ_0002060 might be a promising biomarker for OS therapy. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 95-100 33052979-0 2020 Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1alpha and MDR1. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 33163405-3 2020 Sapitinib significantly increased the efficacy of paclitaxel and doxorubicin in ABCB1 overexpressing cells without altering the expression or the subcellular location of the ABCB1 transporter. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 32545695-7 2020 Finally, we evaluated the effect of SR59230A plus doxorubicin on K562 and K562/DOX cell lines; K562/DOX cells are resistant to doxorubicin and show P-glycoprotein (P-gp) overexpression. Doxorubicin 100-103 ATP binding cassette subfamily B member 1 Homo sapiens 148-162 33305727-1 2020 The aim of the present study was to examine changes in the expression and activity of P-glycoprotein (P-gp) in human hepatocellular carcinoma HepG2 cells after exposure to menthol, and their relationship to the cytotoxicity of and apoptotic responses to doxorubicin (DOX), a substrate of P-gp, in the cells. Doxorubicin 254-265 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 33305727-1 2020 The aim of the present study was to examine changes in the expression and activity of P-glycoprotein (P-gp) in human hepatocellular carcinoma HepG2 cells after exposure to menthol, and their relationship to the cytotoxicity of and apoptotic responses to doxorubicin (DOX), a substrate of P-gp, in the cells. Doxorubicin 267-270 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 33305727-1 2020 The aim of the present study was to examine changes in the expression and activity of P-glycoprotein (P-gp) in human hepatocellular carcinoma HepG2 cells after exposure to menthol, and their relationship to the cytotoxicity of and apoptotic responses to doxorubicin (DOX), a substrate of P-gp, in the cells. Doxorubicin 267-270 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 33305727-5 2020 These results demonstrate that menthol causes hepatocellular carcinoma cells to acquire resistance to DOX by increasing its efflux through the upregulation of P-gp. Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 159-163 32320704-5 2020 In addition, cofilin-1 elevated the expression and drug efflux activity of multidrug resistance protein 1 (MDR1) by P38 MAPK signaling pathway, resulting in decrease of the adriamycin-induced apoptosis as well as the lytic cell death, and the subsequent resistance against adriamycin. Doxorubicin 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 75-105 32320704-5 2020 In addition, cofilin-1 elevated the expression and drug efflux activity of multidrug resistance protein 1 (MDR1) by P38 MAPK signaling pathway, resulting in decrease of the adriamycin-induced apoptosis as well as the lytic cell death, and the subsequent resistance against adriamycin. Doxorubicin 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 32320704-5 2020 In addition, cofilin-1 elevated the expression and drug efflux activity of multidrug resistance protein 1 (MDR1) by P38 MAPK signaling pathway, resulting in decrease of the adriamycin-induced apoptosis as well as the lytic cell death, and the subsequent resistance against adriamycin. Doxorubicin 273-283 ATP binding cassette subfamily B member 1 Homo sapiens 75-105 32320704-5 2020 In addition, cofilin-1 elevated the expression and drug efflux activity of multidrug resistance protein 1 (MDR1) by P38 MAPK signaling pathway, resulting in decrease of the adriamycin-induced apoptosis as well as the lytic cell death, and the subsequent resistance against adriamycin. Doxorubicin 273-283 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 31967866-6 2020 DOX and Rh123 accumulation and efflux results further confirmed that the reversal of MDR activity happens its reversal mechanism is by virtue of inhibition of the P-gp efflux ability and increase in the intracellular drug accumulation. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 163-167 32707710-4 2020 In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1. Doxorubicin 167-178 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 32707710-4 2020 In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1. Doxorubicin 167-178 ATP binding cassette subfamily B member 1 Homo sapiens 205-210 32872293-5 2020 We found that HL156A inhibited the expression of MDR1 by inhibiting the HOXC6-mediated ERK1/2 signaling pathway and increased the sensitivity to paclitaxel or doxorubicin in MDR cells. Doxorubicin 159-170 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 32984343-5 2020 We found that RN486 significantly increased the efficacy of paclitaxel and doxorubicin in both drug-selected carcinoma cells and transfected cells overexpressing ABCB1. Doxorubicin 75-86 ATP binding cassette subfamily B member 1 Homo sapiens 162-167 32830792-9 2020 RESULTS The mRNA and protein expressions of ETS1 and ABCB1 were up-regulated in Dox-resistant leukemia cell line K562/ADR. Doxorubicin 80-83 ATP binding cassette subfamily B member 1 Homo sapiens 53-58 32422185-5 2020 Our present results showed that 33 muM of Que significantly improved the cytotoxicity of doxorubicin (Dox) to P-gp-overexpressed SW620/Ad300 cells by proliferation and apoptpsis assay. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 32422185-5 2020 Our present results showed that 33 muM of Que significantly improved the cytotoxicity of doxorubicin (Dox) to P-gp-overexpressed SW620/Ad300 cells by proliferation and apoptpsis assay. Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 32422185-6 2020 Further mechanism studies demonstrated that Que inhibited the ATP-driven transport activity of P-gp, which in turn increased the intracellular accumulation of Dox. Doxorubicin 159-162 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 32416187-11 2020 miR-29a significantly down-regulated P-gp expression and activity in HT29/DOX cells and declined drug resistance through elevation of intracellular DOX. Doxorubicin 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 32416187-14 2020 As a result, miR-29a overexpression is led to enhance the sensitivity of HT29/DOX cells to DOX-treatment by targeting P-gp. Doxorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 32416187-14 2020 As a result, miR-29a overexpression is led to enhance the sensitivity of HT29/DOX cells to DOX-treatment by targeting P-gp. Doxorubicin 91-94 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 32393026-5 2020 Mechanistically, intracellular NO can downregulate the drug efflux-related P-glycoprotein and adenosine 5"-triphosphate-binding cassette transporters, thereby increasing the DOX accumulation in the cell nuclei. Doxorubicin 174-177 ATP binding cassette subfamily B member 1 Homo sapiens 75-89 32711421-10 2020 In contrast, crocin increased doxorubicin cytotoxicity in drug-resistant cells, which might be induced by reduced MDR1 activity. Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 32566390-10 2020 Our results suggest SECO as a novel P-gp inhibitor that can re-sensitize cancer cells during DOX chemotherapy. Doxorubicin 93-96 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 32061787-0 2020 A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 75-80 32061787-4 2020 METHODS: Ovarian (A2780) and pancreatic (MiaPaca2) cancer cells were used to generate DOX-resistant clones by overexpressing ABCB1 or stepwise treatment of DOX. Doxorubicin 86-89 ATP binding cassette subfamily B member 1 Homo sapiens 125-130 32061787-9 2020 CONCLUSIONS: These results suggest that BEZ is a non-substrate inhibitor of ABCB1 and is able to effectively re-sensitize cells overexpressing ABCB1 to the effects of DOX. Doxorubicin 167-170 ATP binding cassette subfamily B member 1 Homo sapiens 143-148 32457290-3 2020 Paclitaxel- and doxorubicin-resistant cancer cells showed higher expression of MDR1 and HSF1. Doxorubicin 16-27 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 32545695-9 2020 Finally, we observed that SR59230A plus doxorubicin increased doxorubicin resistance reversion mainly in hypoxia, probably acting on P-gp. Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 32545695-9 2020 Finally, we observed that SR59230A plus doxorubicin increased doxorubicin resistance reversion mainly in hypoxia, probably acting on P-gp. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 32391276-6 2020 Here we report the MACC1 dependent treatment resistance of colorectal cancer (CRC) cells to standard therapeutics like doxorubicin by upregulating ATP-binding cassette subfamily B member 1 (ABCB1) protein. Doxorubicin 119-130 ATP binding cassette subfamily B member 1 Homo sapiens 147-188 32142738-1 2020 Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 32142738-1 2020 Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 52-55 32142738-1 2020 Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. Doxorubicin 113-116 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 32142738-1 2020 Disulfiram (DSF) is an inhibitor of P-glycoprotein (Pgp), the main obstacle limiting the success of doxorubicin (DOX), but it has poor solubility and stability. Doxorubicin 113-116 ATP binding cassette subfamily B member 1 Homo sapiens 52-55 32142738-5 2020 LipoDSF-DOX increased DOX intracellular accumulation and cytotoxicity in Pgp-expressing breast cancer cells, with an efficacy superior to the mixture of free DSF and DOX, thanks to a differential kinetics of release of DSF and DOX when carried by liposomes. Doxorubicin 8-11 ATP binding cassette subfamily B member 1 Homo sapiens 73-76 32142738-5 2020 LipoDSF-DOX increased DOX intracellular accumulation and cytotoxicity in Pgp-expressing breast cancer cells, with an efficacy superior to the mixture of free DSF and DOX, thanks to a differential kinetics of release of DSF and DOX when carried by liposomes. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 73-76 32340269-5 2020 A KCR cell line (doxorubicin-resistant, expressing ABCB1) was used to induce loss of resistance by withdrawing doxorubicin in culture medium. Doxorubicin 17-28 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 32340269-5 2020 A KCR cell line (doxorubicin-resistant, expressing ABCB1) was used to induce loss of resistance by withdrawing doxorubicin in culture medium. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 32340269-8 2020 After 16 weeks of doxorubicin withdrawal, a decrease of ABCB1 activity and expression occurred. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 32331368-2 2020 Indeed, Pgp effluxes doxorubicin and impairs the immunesensitizing functions of calreticulin (CRT), an "eat-me" signal mediating ICD. Doxorubicin 21-32 ATP binding cassette subfamily B member 1 Homo sapiens 8-11 32331368-8 2020 Pgp knock-out restores doxorubicin-induced ICD in MDA-MB-231/DX cells that recapitulated the phenotype of R-3-treated cells. Doxorubicin 23-34 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 32391276-6 2020 Here we report the MACC1 dependent treatment resistance of colorectal cancer (CRC) cells to standard therapeutics like doxorubicin by upregulating ATP-binding cassette subfamily B member 1 (ABCB1) protein. Doxorubicin 119-130 ATP binding cassette subfamily B member 1 Homo sapiens 190-195 32290047-12 2020 The results suggest that GQDs nanoparticles would be suitable for the delivery of other multidrug resistance protein 1 (MRP1) substrate drugs that bind to the transporter at the same binding pocket, while MSN can strongly inhibit doxorubicin efflux by MRP1. Doxorubicin 230-241 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 32290047-12 2020 The results suggest that GQDs nanoparticles would be suitable for the delivery of other multidrug resistance protein 1 (MRP1) substrate drugs that bind to the transporter at the same binding pocket, while MSN can strongly inhibit doxorubicin efflux by MRP1. Doxorubicin 230-241 ATP binding cassette subfamily B member 1 Homo sapiens 252-256 32290281-6 2020 Many compounds displayed a dual activity against P-gp and CA XII being active in the Rhd 123 uptake test on K562/DOX cells and in the hCA XII inhibition test. Doxorubicin 113-116 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 32290281-7 2020 On LoVo/DOX cells, that overexpress both P-gp and CA XII, some coumarin derivatives showed a high MDR reversal effect in Rhd 123 uptake and doxorubicin cytotoxicity enhancement tests. Doxorubicin 8-11 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 32290047-13 2020 On the other hand, PLA showed moderate inhibition of doxorubicin efflux by MRP1 suggesting that this nanomaterial can also be useful to treat MDR (Multidrug resistance) due to MRP1 overexpression. Doxorubicin 53-64 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 32290281-7 2020 On LoVo/DOX cells, that overexpress both P-gp and CA XII, some coumarin derivatives showed a high MDR reversal effect in Rhd 123 uptake and doxorubicin cytotoxicity enhancement tests. Doxorubicin 140-151 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 31883144-8 2020 Interestingly, expressions of both miRNAs were suppressed during treatment with Cd2+ and doxorubicin, which induced the expression of P-gp, indicating the universality of these miRNAs-related mechanisms. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 32309708-6 2020 In earlier reports on kidney cancer, several mechanisms were discussed, including the metabolism of DOX to its less toxic derivative, doxorubicinol, overexpression of ATP binding cassette subfamily B member 1 (ABCB1) transporters, that remove DOX from the inside of cells; however, there was no focus on the simple but very important contribution of drug protonation described in the present study. Doxorubicin 100-103 ATP binding cassette subfamily B member 1 Homo sapiens 167-208 32309708-6 2020 In earlier reports on kidney cancer, several mechanisms were discussed, including the metabolism of DOX to its less toxic derivative, doxorubicinol, overexpression of ATP binding cassette subfamily B member 1 (ABCB1) transporters, that remove DOX from the inside of cells; however, there was no focus on the simple but very important contribution of drug protonation described in the present study. Doxorubicin 100-103 ATP binding cassette subfamily B member 1 Homo sapiens 210-215 32309708-6 2020 In earlier reports on kidney cancer, several mechanisms were discussed, including the metabolism of DOX to its less toxic derivative, doxorubicinol, overexpression of ATP binding cassette subfamily B member 1 (ABCB1) transporters, that remove DOX from the inside of cells; however, there was no focus on the simple but very important contribution of drug protonation described in the present study. Doxorubicin 243-246 ATP binding cassette subfamily B member 1 Homo sapiens 167-208 32309708-6 2020 In earlier reports on kidney cancer, several mechanisms were discussed, including the metabolism of DOX to its less toxic derivative, doxorubicinol, overexpression of ATP binding cassette subfamily B member 1 (ABCB1) transporters, that remove DOX from the inside of cells; however, there was no focus on the simple but very important contribution of drug protonation described in the present study. Doxorubicin 243-246 ATP binding cassette subfamily B member 1 Homo sapiens 210-215 32273806-5 2020 In this study, we encapsulated the Ver and Dox in PLGA nanoparticles to inhibit the P-gp drug efflux in breast cancer. Doxorubicin 43-46 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 32155954-1 2020 The ATP Binding Cassette transporter B1 (ABCB1) induces chemoresistance in osteosarcoma, because it effluxes doxorubicin, reducing the intracellular accumulation, toxicity, and immunogenic cell death induced by the drug. Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 4-39 32142738-5 2020 LipoDSF-DOX increased DOX intracellular accumulation and cytotoxicity in Pgp-expressing breast cancer cells, with an efficacy superior to the mixture of free DSF and DOX, thanks to a differential kinetics of release of DSF and DOX when carried by liposomes. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 73-76 32142738-5 2020 LipoDSF-DOX increased DOX intracellular accumulation and cytotoxicity in Pgp-expressing breast cancer cells, with an efficacy superior to the mixture of free DSF and DOX, thanks to a differential kinetics of release of DSF and DOX when carried by liposomes. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 73-76 32142738-6 2020 The mechanism of the increased DOX retention relied on the DSF-induced sulfhydraton of Pgp and followed by its ubiquitination. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 87-90 32142738-7 2020 These events reduced Pgp expression and catalytic activity in LipoDSF-DOX-treated cells. Doxorubicin 70-73 ATP binding cassette subfamily B member 1 Homo sapiens 21-24 32142738-8 2020 Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. Doxorubicin 29-33 ATP binding cassette subfamily B member 1 Homo sapiens 73-76 32142738-8 2020 Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. Doxorubicin 29-33 ATP binding cassette subfamily B member 1 Homo sapiens 230-233 32142738-8 2020 Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. Doxorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 73-76 32142738-8 2020 Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. Doxorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 230-233 32142738-8 2020 Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. Doxorubicin 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 73-76 32142738-8 2020 Our results show that LipoDSF-DOX effectively reversed DOX resistance in Pgp-expressing breast cancer cells, exploiting the temporally different kinetics of release of DSF and DOX, optimized to decrease expression and activity of Pgp. Doxorubicin 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 230-233 32028187-4 2020 The over-expressed P-gp MCF-7 cells (MCF-7/DOX) were developed from wildtype (WT) MCF-7 cells by a stepwise continuous exposure of the WT cells to different concentrations of Doxorubicin (DOX) (0.1 - 1 muM) over a period of 4 months. Doxorubicin 43-46 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 32028187-4 2020 The over-expressed P-gp MCF-7 cells (MCF-7/DOX) were developed from wildtype (WT) MCF-7 cells by a stepwise continuous exposure of the WT cells to different concentrations of Doxorubicin (DOX) (0.1 - 1 muM) over a period of 4 months. Doxorubicin 175-186 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 32028187-4 2020 The over-expressed P-gp MCF-7 cells (MCF-7/DOX) were developed from wildtype (WT) MCF-7 cells by a stepwise continuous exposure of the WT cells to different concentrations of Doxorubicin (DOX) (0.1 - 1 muM) over a period of 4 months. Doxorubicin 188-191 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 32028187-7 2020 The flow cytometry result showed two distinct peaks of P-gp positive and negative expression in MCF-7/DOX cell population, which correlates with the ELISA-based assay (p 0.001). Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 32028187-12 2020 The ZnPcS4-induced PDT was less effective for MCF-7/DOX cells which could be attributed to decreased retention of ZnPcS4 in major cellular organelles due to the presence of increased drug efflux P-gp. Doxorubicin 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 195-199 32028187-13 2020 The current findings suggest that, increased P-gp expression, a characteristic of multidrug resistance together with other related intrinsic mechanisms might contribute to render MCF-7/DOX cells less sensitive to ZnPcS4-induced phototoxicity. Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 31912555-0 2020 Doxorubicin Encapsulated in P-glycoprotein-Modified 2D-Nanodisks Overcomes Multidrug Resistance. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 31420991-0 2020 NRF2/ABCB1-mediated efflux and PARP1-mediated dampening of DNA damage contribute to doxorubicin resistance in chronic hypoxic HepG2 cells. Doxorubicin 84-95 ATP binding cassette subfamily B member 1 Homo sapiens 5-10 31420991-7 2020 On the basis of these findings, we concluded that NRF2/ABCB1-mediated efflux and PARP1-mediated DNA repair contribute to doxorubicin resistance in chronic hypoxic HepG2 cells. Doxorubicin 121-132 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 31991669-5 2020 Both CURC-loaded SLNs were 5-10-fold more effective than free CURC in increasing the intracellular retention and toxicity of doxorubicin in Pgp-expressing triple negative breast cancer (TNBC). Doxorubicin 125-136 ATP binding cassette subfamily B member 1 Homo sapiens 140-143 31991669-8 2020 These results suggest that the combination therapy, based on CURC-loaded SLNs and doxorubicin, is an effective and safe approach to overcome the Pgp-mediated chemoresistance in TNBC. Doxorubicin 82-93 ATP binding cassette subfamily B member 1 Homo sapiens 145-148 32160712-0 2020 The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/beta-Catenin Signaling Pathway. Doxorubicin 62-72 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 31975579-6 2020 Structure-activity relationship studies determined that selected chrysosporazines were promising noncytotoxic inhibitors of the multidrug resistance efflux pump P-glycoprotein (P-gp), capable of reversing doxorubicin resistance in P-gp-overexpressing human colon carcinoma cells (SW620 Ad300). Doxorubicin 205-216 ATP binding cassette subfamily B member 1 Homo sapiens 161-175 31975579-6 2020 Structure-activity relationship studies determined that selected chrysosporazines were promising noncytotoxic inhibitors of the multidrug resistance efflux pump P-glycoprotein (P-gp), capable of reversing doxorubicin resistance in P-gp-overexpressing human colon carcinoma cells (SW620 Ad300). Doxorubicin 205-216 ATP binding cassette subfamily B member 1 Homo sapiens 177-181 31975579-6 2020 Structure-activity relationship studies determined that selected chrysosporazines were promising noncytotoxic inhibitors of the multidrug resistance efflux pump P-glycoprotein (P-gp), capable of reversing doxorubicin resistance in P-gp-overexpressing human colon carcinoma cells (SW620 Ad300). Doxorubicin 205-216 ATP binding cassette subfamily B member 1 Homo sapiens 231-235 32155954-1 2020 The ATP Binding Cassette transporter B1 (ABCB1) induces chemoresistance in osteosarcoma, because it effluxes doxorubicin, reducing the intracellular accumulation, toxicity, and immunogenic cell death induced by the drug. Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 41-46 32155954-3 2020 Recruiting this population may represent an alternative strategy to rescue doxorubicin efficacy in ABCB1-expressing osteosarcoma. Doxorubicin 75-86 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 31963614-0 2020 Potentiation of Low-Dose Doxorubicin Cytotoxicity by Affecting P-Glycoprotein through Caryophyllane Sesquiterpenes in HepG2 Cells: an in Vitro and in Silico Study. Doxorubicin 25-36 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 31963614-3 2020 The involvement of P-glycoprotein (P-gp) in the HepG2-chemosensitization to doxorubicin was evaluated. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 31963614-3 2020 The involvement of P-glycoprotein (P-gp) in the HepG2-chemosensitization to doxorubicin was evaluated. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 31963614-6 2020 Also, an increased intracellular accumulation of doxorubicin and rhodamine 123 induced by caryophyllane sesquiterpenes was found, thus suggesting their interference with P-gp function. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 170-174 31963614-7 2020 A lowered expression of P-gp induced by the combinations, with respect to doxorubicin alone, was observed too. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 31679697-4 2020 Mechanism study showed that veliparib could significantly enhance the accumulation of doxorubicin in ABCB1-overexpression liver cancer cells, without down-regulating the expression level of ABCB1. Doxorubicin 86-97 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 31897118-0 2020 Curcumin increases the sensitivity of K562/DOX cells to doxorubicin by targeting S100 calcium-binding protein A8 and P-glycoprotein. Doxorubicin 43-46 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 31897118-0 2020 Curcumin increases the sensitivity of K562/DOX cells to doxorubicin by targeting S100 calcium-binding protein A8 and P-glycoprotein. Doxorubicin 56-67 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 31593704-0 2019 7-O-geranylquercetin contributes to reverse P-gp-mediated adriamycin resistance in breast cancer. Doxorubicin 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 31639417-8 2019 Microdevices were shown to inhibit P-gp mediated transport of calcein AM, doxorubicin, and rhodamine 123 (R123) and BCRP mediated transport of BODIPY-FL-prazosin. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 31801248-4 2019 In this study, tetrandrine showed synergistic cytotoxic activity in combinational use with chemotherapeutic drugs, such as Doxorubicin, Vincristine, and Paclitaxel, in both drug-induced and MDR1 gene-transfected cancer cells that over-expressed ABCB1/P-glycoprotein. Doxorubicin 123-134 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 31466437-1 2019 Nitric oxide (NO) molecular messenger can reverse the multidrug resistance (MDR) effect of cancer cells through reducing P-glycoprotein (P-gp) expression, beneficial for creating a favorable microenvironment for the treatment of doxorubicin (Dox)-resistant cancer cells. Doxorubicin 229-240 ATP binding cassette subfamily B member 1 Homo sapiens 121-135 31705398-5 2019 It was proved that miR495 could significantly decrease the expression of P-gp which elevated intracellular drug accumulation in A549/DOX. Doxorubicin 133-136 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 31623608-3 2019 Celecoxib (CXB), a selective COX-2 inhibitor, can dramatically enhance the cytotoxicity of doxorubicin (DOX) in breast cancer cells overexpressing P-gp. Doxorubicin 91-102 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 31623608-3 2019 Celecoxib (CXB), a selective COX-2 inhibitor, can dramatically enhance the cytotoxicity of doxorubicin (DOX) in breast cancer cells overexpressing P-gp. Doxorubicin 104-107 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 31466437-1 2019 Nitric oxide (NO) molecular messenger can reverse the multidrug resistance (MDR) effect of cancer cells through reducing P-glycoprotein (P-gp) expression, beneficial for creating a favorable microenvironment for the treatment of doxorubicin (Dox)-resistant cancer cells. Doxorubicin 229-240 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 31466437-1 2019 Nitric oxide (NO) molecular messenger can reverse the multidrug resistance (MDR) effect of cancer cells through reducing P-glycoprotein (P-gp) expression, beneficial for creating a favorable microenvironment for the treatment of doxorubicin (Dox)-resistant cancer cells. Doxorubicin 242-245 ATP binding cassette subfamily B member 1 Homo sapiens 121-135 31466437-1 2019 Nitric oxide (NO) molecular messenger can reverse the multidrug resistance (MDR) effect of cancer cells through reducing P-glycoprotein (P-gp) expression, beneficial for creating a favorable microenvironment for the treatment of doxorubicin (Dox)-resistant cancer cells. Doxorubicin 242-245 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 31466437-8 2019 This NO and Dox sequential release of ADLAu@CuS YSNPs could significantly inhibit P-gp expression and enhance Dox accumulation in Dox-resistant MCF-7/ADR cells, leading to promising in vitro and in vivo therapeutic effects and presenting their great potential for MDR cancer therapy. Doxorubicin 12-15 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 31466437-8 2019 This NO and Dox sequential release of ADLAu@CuS YSNPs could significantly inhibit P-gp expression and enhance Dox accumulation in Dox-resistant MCF-7/ADR cells, leading to promising in vitro and in vivo therapeutic effects and presenting their great potential for MDR cancer therapy. Doxorubicin 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 31466437-8 2019 This NO and Dox sequential release of ADLAu@CuS YSNPs could significantly inhibit P-gp expression and enhance Dox accumulation in Dox-resistant MCF-7/ADR cells, leading to promising in vitro and in vivo therapeutic effects and presenting their great potential for MDR cancer therapy. Doxorubicin 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 31545293-6 2019 P-gp mRNA expression was quantified in 143B human osteosarcoma cells treated with DOX with/without PIO. Doxorubicin 82-85 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 31545293-9 2019 DOX significantly induced P-gp mRNA in a dose-dependent manner in 143B cells. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 31545293-10 2019 PIO inhibited the increase of P-gp mRNA induced by DOX treatment when co-administrated with DOX. Doxorubicin 51-54 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 31545293-10 2019 PIO inhibited the increase of P-gp mRNA induced by DOX treatment when co-administrated with DOX. Doxorubicin 92-95 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 31209929-9 2019 The ABCB1 concentrations in the plasma membrane of drug selected K562/Dox and K562/HHT cells containing the highest amount of transporter reached millimolar levels. Doxorubicin 70-73 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 31880526-10 2019 The accumulation of ADM in drug-resistant cells was increased significantly after treatment with 1 and 5 mu-M SAS, while the efflux of Rh123 was significantly inhibited, suggesting that SAS reversed MDR by inhibiting p-gp function. Doxorubicin 20-23 ATP binding cassette subfamily B member 1 Homo sapiens 217-221 31403276-5 2019 The removed QDs-Ela could specifically combine with P-gp in the cancer cell membrane and inhibit their active sites, which prevents the efflux of intracellular DOX and increases the retention of DOX. Doxorubicin 160-163 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 31381334-0 2019 Molecular Energetics of Doxorubicin Pumping by Human P-Glycoprotein. Doxorubicin 24-35 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 31381334-3 2019 Herein, the transport of a typical antitumor drug, doxorubicin, by P-gp is investigated using targeted molecular dynamics (MD) simulations and molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) analysis. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 31403276-5 2019 The removed QDs-Ela could specifically combine with P-gp in the cancer cell membrane and inhibit their active sites, which prevents the efflux of intracellular DOX and increases the retention of DOX. Doxorubicin 195-198 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 31207578-0 2019 Teratogenic jervine increases the activity of doxorubicin in MCF-7/ADR cells by inhibiting ABCB1. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 91-96 31207578-3 2019 We demonstrated that the synergistic mechanism was related to the intracellular accumulation of DOX via modulating ABCB1 transportation. Doxorubicin 96-99 ATP binding cassette subfamily B member 1 Homo sapiens 115-120 30940690-7 2019 In MCF-7/Adr cells, transfection with anti-ABCB1 siRNA effectively downregulated its target efflux protein, ABCB1; increased cellular uptake of DOX; and enhanced its cytotoxic effect. Doxorubicin 144-147 ATP binding cassette subfamily B member 1 Homo sapiens 43-48 31087712-8 2019 In addition, ciglitazone considerably decreased the expression levels and activity of P-gp in DOX-resistant K562 cells. Doxorubicin 94-97 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 31416138-6 2019 The inhibition of P-glycoprotein (P-gp) was determined in vitro, and the respective sensitization of doxorubicin-resistant ovarian carcinoma overproducing P-gp was detected. Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 31501742-6 2019 ABCB1 inhibition using zosuquidar resulted in similar effects like nanoparticle incorporation, indicating that doxorubicin-loaded nanoparticles successfully circumvent ABCB1-mediated drug efflux. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 31501742-2 2019 Here, we tested doxorubicin-loaded human serum albumin (HSA) nanoparticles in the neuroblastoma cell line UKF-NB-3 and its ABCB1-expressing sublines adapted to vincristine (UKF-NB-3rVCR1) and doxorubicin (UKF-NB-3rDOX20). Doxorubicin 16-27 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 31501742-6 2019 ABCB1 inhibition using zosuquidar resulted in similar effects like nanoparticle incorporation, indicating that doxorubicin-loaded nanoparticles successfully circumvent ABCB1-mediated drug efflux. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 168-173 31501742-7 2019 The limited re-sensitisation of UKF-NB-3rDOX20 cells to doxorubicin by circumvention of ABCB1-mediated efflux is probably due to the presence of multiple doxorubicin resistance mechanisms. Doxorubicin 56-67 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 31501742-7 2019 The limited re-sensitisation of UKF-NB-3rDOX20 cells to doxorubicin by circumvention of ABCB1-mediated efflux is probably due to the presence of multiple doxorubicin resistance mechanisms. Doxorubicin 154-165 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 31265310-5 2019 At 10 nM, the compounds were not cytotoxic for the brain microvascular endothelial hCMEC/D3 cell line, but they markedly enhanced the permeability of the Pgp-substrate doxorubicin through the BBB. Doxorubicin 168-179 ATP binding cassette subfamily B member 1 Homo sapiens 154-157 31382390-6 2019 Furthermore, Res was observed to synergistically improve the cytotoxicity of Dox by down-regulating the P-glycoprotein (P-gp) expression, decreasing the membrane potential of the mitochondrial and ATP level, as well as inducing cell apoptosis mediated by mitochondria. Doxorubicin 77-80 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 31382390-6 2019 Furthermore, Res was observed to synergistically improve the cytotoxicity of Dox by down-regulating the P-glycoprotein (P-gp) expression, decreasing the membrane potential of the mitochondrial and ATP level, as well as inducing cell apoptosis mediated by mitochondria. Doxorubicin 77-80 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 31047947-0 2019 Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 31202598-0 2019 Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells. Doxorubicin 85-96 ATP binding cassette subfamily B member 1 Homo sapiens 9-23 31047947-1 2019 Doxorubicin (dox) is one of the first-line drug in osteosarcoma treatment but its effectiveness is limited by the efflux pump P-glycoprotein (Pgp) and by the onset of cardiotoxicity. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 31047947-1 2019 Doxorubicin (dox) is one of the first-line drug in osteosarcoma treatment but its effectiveness is limited by the efflux pump P-glycoprotein (Pgp) and by the onset of cardiotoxicity. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 142-145 31047947-1 2019 Doxorubicin (dox) is one of the first-line drug in osteosarcoma treatment but its effectiveness is limited by the efflux pump P-glycoprotein (Pgp) and by the onset of cardiotoxicity. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 31047947-1 2019 Doxorubicin (dox) is one of the first-line drug in osteosarcoma treatment but its effectiveness is limited by the efflux pump P-glycoprotein (Pgp) and by the onset of cardiotoxicity. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 142-145 31047947-2 2019 We previously demonstrated that synthetic doxs conjugated with a H2S-releasing moiety (Sdox) were less cardiotoxic and more effective than dox against Pgp-overexpressing osteosarcoma cells. Doxorubicin 42-46 ATP binding cassette subfamily B member 1 Homo sapiens 151-154 31047947-2 2019 We previously demonstrated that synthetic doxs conjugated with a H2S-releasing moiety (Sdox) were less cardiotoxic and more effective than dox against Pgp-overexpressing osteosarcoma cells. Doxorubicin 42-45 ATP binding cassette subfamily B member 1 Homo sapiens 151-154 31047947-4 2019 HA-Lsdox showed favorable drug-release profile and higher toxicity in vitro and in vivo than dox or the FDA-approved liposomal dox Caelyx against Pgp-overexpressing osteosarcoma, displaying the same cardiotoxicity profile of Caelyx . Doxorubicin 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 147-150 31180580-0 2019 LncRNA FENDRR attenuates adriamycin resistance via suppressing MDR1 expression through sponging HuR and miR-184 in chronic myelogenous leukaemia cells. Doxorubicin 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 31290351-9 2019 These studies suggest that GPx-mediated detoxification of peroxides can modulate the antitumor activity of doxorubicin in the presence of high levels of Pgp. Doxorubicin 107-118 ATP binding cassette subfamily B member 1 Homo sapiens 153-156 31538529-0 2019 3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 31538529-4 2019 Conclusion: Nanomolar P-gp inhibitors, such as 23 (IC50 = 4.2 nM), restored the antiproliferative activity of doxorubicin in multidrug-resistant cells. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 31103263-9 2019 Increased drug sensitivity was observed with Pgp silencing or inhibition as determined by drug IC50s of paclitaxel-response of silenced Pgp and doxorubicin-response of inhibited Pgp, respectively. Doxorubicin 144-155 ATP binding cassette subfamily B member 1 Homo sapiens 45-48 31048454-5 2019 B1/G2 cells were also cross-resistant to the ABCB1 substrate doxorubicin, the ABCG2 substrate topotecan, as well as mitoxantrone and the cell cycle checkpoint kinase 1 inhibitor prexasertib, both of which were found to be substrates of both ABCB1 and ABCG2. Doxorubicin 61-72 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 31047947-7 2019 We propose HA-Lsdox as an innovative tool noteworthy to be tested in Pgp-overexpressing patients, who are frequently less responsive to standard treatments in which dox is one of the most important drugs. Doxorubicin 16-19 ATP binding cassette subfamily B member 1 Homo sapiens 69-72 31262904-5 2019 RESULTS: Selenoanhydride exerted a selective activity towards the doxorubicin-resistant KCR cell line overexpressing ABCB1. Doxorubicin 66-77 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 30959046-8 2019 On the other hand, GBD can downregulate the activity of P-gp ATPase when cotreated with DOX or verapamil, revealing that GBD was a substrate of P-gp. Doxorubicin 88-91 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 31293428-16 2019 Conclusions: The results indicate that DT-010 overcomes Dox resistance in human breast cancer cells through a dual action via simultaneously inhibiting P-gp-mediated drug efflux and influencing metabolic process. Doxorubicin 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 31235998-18 2019 Western blotting showed that upregulation of miR-34a combined with treatment with doxorubicin caused significant changes in the expression levels of p-p53, SIRT1, cyclin D1, CDK4, CDK6, BCL-2, MDR1/P-gp and AXL proteins (P < 0.01). Doxorubicin 82-93 ATP binding cassette subfamily B member 1 Homo sapiens 193-197 31235998-19 2019 CONCLUSION: MiR-34a may enhance the inhibitory effect of doxorubicin by downregulating MDR1/P-gp and AXL, which may be related to p53 expression. Doxorubicin 57-68 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 31249297-5 2019 Inhibition of ABCB1 triggers an accumulation of doxorubicin, DNA damage, and cell death. Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 30959046-8 2019 On the other hand, GBD can downregulate the activity of P-gp ATPase when cotreated with DOX or verapamil, revealing that GBD was a substrate of P-gp. Doxorubicin 88-91 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 30959046-9 2019 Moreover, the obtained kinetic inhibition parameters proved that GBD was a competitive inhibitor of P-gp, and in molecular docking simulation modeling, GBD exhibited stronger binding affinity with P-gp than DOX. Doxorubicin 207-210 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 30959046-9 2019 Moreover, the obtained kinetic inhibition parameters proved that GBD was a competitive inhibitor of P-gp, and in molecular docking simulation modeling, GBD exhibited stronger binding affinity with P-gp than DOX. Doxorubicin 207-210 ATP binding cassette subfamily B member 1 Homo sapiens 197-201 30959046-10 2019 In conclusion, GBD can increase the accumulation of DOX in MDA-MB-231/MDR1 cells by suppressing the expression of P-gp and competitively inhibiting the P-gp efflux pump and enhance the apoptosis of MDA-MB-231/MDR1 cells induced by DOX, and thus realize reversal effects on MDR. Doxorubicin 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 30959046-10 2019 In conclusion, GBD can increase the accumulation of DOX in MDA-MB-231/MDR1 cells by suppressing the expression of P-gp and competitively inhibiting the P-gp efflux pump and enhance the apoptosis of MDA-MB-231/MDR1 cells induced by DOX, and thus realize reversal effects on MDR. Doxorubicin 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 30998372-1 2019 Intracellular doxorubicin (DOX) pumping out of cells through the P-glycoprotein (P-gp) transporter leads to the reduction of intracellular DOX levels and induces multidrug resistance (MDR). Doxorubicin 14-25 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 30998372-1 2019 Intracellular doxorubicin (DOX) pumping out of cells through the P-glycoprotein (P-gp) transporter leads to the reduction of intracellular DOX levels and induces multidrug resistance (MDR). Doxorubicin 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 30998372-1 2019 Intracellular doxorubicin (DOX) pumping out of cells through the P-glycoprotein (P-gp) transporter leads to the reduction of intracellular DOX levels and induces multidrug resistance (MDR). Doxorubicin 139-142 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 30998372-4 2019 Importantly, superior antitumor activity of DOX/HA-DOCA-His-PF micelles was presented on the growth inhibition of MCF-7/Adr tumor cells, by further inhibiting the P-gp activity on intracellular DOX efflux through the depletion of intracellular adenosine triphosphate content. Doxorubicin 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 163-167 30998372-4 2019 Importantly, superior antitumor activity of DOX/HA-DOCA-His-PF micelles was presented on the growth inhibition of MCF-7/Adr tumor cells, by further inhibiting the P-gp activity on intracellular DOX efflux through the depletion of intracellular adenosine triphosphate content. Doxorubicin 194-197 ATP binding cassette subfamily B member 1 Homo sapiens 163-167 31258739-0 2019 Co-delivery of Cyclopamine and Doxorubicin Mediated by Bovine Serum Albumin Nanoparticles Reverses Doxorubicin Resistance in Breast Cancer by Down-regulating P-glycoprotein Expression. Doxorubicin 31-42 ATP binding cassette subfamily B member 1 Homo sapiens 99-121 30924055-11 2019 Similarly, the results showed significant differences in P-glycoprotein function of K562/Dox cancer cells after treatment with IRCM when compared to the non-treated K562/Dox cancer cells, with iohexol and iodixanol being the notable exceptions once again. Doxorubicin 89-92 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 30937974-5 2019 Costunolide dramatically enhanced doxorubicin-induced antiproliferative activity against K562/ADR cells through inhibition of PI3K/Akt pathway, activation of caspases 3, cleavage of poly (ADP-ribose) polymerase, and downregulation of p-glycoprotein expression. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 234-248 31258739-0 2019 Co-delivery of Cyclopamine and Doxorubicin Mediated by Bovine Serum Albumin Nanoparticles Reverses Doxorubicin Resistance in Breast Cancer by Down-regulating P-glycoprotein Expression. Doxorubicin 31-42 ATP binding cassette subfamily B member 1 Homo sapiens 158-172 31258739-4 2019 Rather than simple combination of two different chemotherapeutics, the CYC also increased the intracellular DOX accumulation by decreasing the expression of P-glycoprotein (P-gp), which could thus reverse the DOX resistance. Doxorubicin 108-111 ATP binding cassette subfamily B member 1 Homo sapiens 157-171 31258739-4 2019 Rather than simple combination of two different chemotherapeutics, the CYC also increased the intracellular DOX accumulation by decreasing the expression of P-glycoprotein (P-gp), which could thus reverse the DOX resistance. Doxorubicin 108-111 ATP binding cassette subfamily B member 1 Homo sapiens 173-177 31258739-4 2019 Rather than simple combination of two different chemotherapeutics, the CYC also increased the intracellular DOX accumulation by decreasing the expression of P-glycoprotein (P-gp), which could thus reverse the DOX resistance. Doxorubicin 209-212 ATP binding cassette subfamily B member 1 Homo sapiens 157-171 31258739-4 2019 Rather than simple combination of two different chemotherapeutics, the CYC also increased the intracellular DOX accumulation by decreasing the expression of P-glycoprotein (P-gp), which could thus reverse the DOX resistance. Doxorubicin 209-212 ATP binding cassette subfamily B member 1 Homo sapiens 173-177 30982500-0 2019 C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells. Doxorubicin 33-44 ATP binding cassette subfamily B member 1 Homo sapiens 62-67 31190812-8 2019 Further, biological functionality tests of the synthesized co-delivery nanocarriers show high inhibition of P-gp protein encoded by MDR-1 gene in MCF-7/MDR cells (a variant of human breast cancer cell line with drug resistance) after transfection of these nanocarriers carrying MDR-1 siRNA and doxorubicin simultaneously, which sensitize the MCF-7/MDR cells to doxorubicin, overall leading to improved cell suppression. Doxorubicin 294-305 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 31190812-8 2019 Further, biological functionality tests of the synthesized co-delivery nanocarriers show high inhibition of P-gp protein encoded by MDR-1 gene in MCF-7/MDR cells (a variant of human breast cancer cell line with drug resistance) after transfection of these nanocarriers carrying MDR-1 siRNA and doxorubicin simultaneously, which sensitize the MCF-7/MDR cells to doxorubicin, overall leading to improved cell suppression. Doxorubicin 294-305 ATP binding cassette subfamily B member 1 Homo sapiens 278-283 31190812-8 2019 Further, biological functionality tests of the synthesized co-delivery nanocarriers show high inhibition of P-gp protein encoded by MDR-1 gene in MCF-7/MDR cells (a variant of human breast cancer cell line with drug resistance) after transfection of these nanocarriers carrying MDR-1 siRNA and doxorubicin simultaneously, which sensitize the MCF-7/MDR cells to doxorubicin, overall leading to improved cell suppression. Doxorubicin 361-372 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 31190812-8 2019 Further, biological functionality tests of the synthesized co-delivery nanocarriers show high inhibition of P-gp protein encoded by MDR-1 gene in MCF-7/MDR cells (a variant of human breast cancer cell line with drug resistance) after transfection of these nanocarriers carrying MDR-1 siRNA and doxorubicin simultaneously, which sensitize the MCF-7/MDR cells to doxorubicin, overall leading to improved cell suppression. Doxorubicin 361-372 ATP binding cassette subfamily B member 1 Homo sapiens 278-283 30997984-2 2019 Herein, a dual-responsive polyplex with effective endo-lysosomal escape based on methoxypoly(ethylene glycol)-polylactide-polyhistidine-ss-oligoethylenimine (mPEG- b-PLA-PHis-ssOEI) was developed for codelivering MDR1 siRNA and doxorubicin (DOX). Doxorubicin 228-239 ATP binding cassette subfamily B member 1 Homo sapiens 213-217 30997984-2 2019 Herein, a dual-responsive polyplex with effective endo-lysosomal escape based on methoxypoly(ethylene glycol)-polylactide-polyhistidine-ss-oligoethylenimine (mPEG- b-PLA-PHis-ssOEI) was developed for codelivering MDR1 siRNA and doxorubicin (DOX). Doxorubicin 241-244 ATP binding cassette subfamily B member 1 Homo sapiens 213-217 30967374-5 2019 With DOX, the RI and P-gp expression increased slightly, and the MDR1 mRNA expression level gradually increased to the BIU-87/DOX level. Doxorubicin 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 30967374-5 2019 With DOX, the RI and P-gp expression increased slightly, and the MDR1 mRNA expression level gradually increased to the BIU-87/DOX level. Doxorubicin 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 30967374-5 2019 With DOX, the RI and P-gp expression increased slightly, and the MDR1 mRNA expression level gradually increased to the BIU-87/DOX level. Doxorubicin 126-129 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 30982500-6 2019 The doxorubicin resistance of cells expressing C-terminal truncated HBx correlated with upregulation of the ATP binding cassette subfamily B member 1(ABCB1) transporter, resulting in the enhanced efflux of doxorubicin. Doxorubicin 4-15 ATP binding cassette subfamily B member 1 Homo sapiens 108-149 30982500-6 2019 The doxorubicin resistance of cells expressing C-terminal truncated HBx correlated with upregulation of the ATP binding cassette subfamily B member 1(ABCB1) transporter, resulting in the enhanced efflux of doxorubicin. Doxorubicin 4-15 ATP binding cassette subfamily B member 1 Homo sapiens 150-155 30982500-6 2019 The doxorubicin resistance of cells expressing C-terminal truncated HBx correlated with upregulation of the ATP binding cassette subfamily B member 1(ABCB1) transporter, resulting in the enhanced efflux of doxorubicin. Doxorubicin 206-217 ATP binding cassette subfamily B member 1 Homo sapiens 108-149 30982500-6 2019 The doxorubicin resistance of cells expressing C-terminal truncated HBx correlated with upregulation of the ATP binding cassette subfamily B member 1(ABCB1) transporter, resulting in the enhanced efflux of doxorubicin. Doxorubicin 206-217 ATP binding cassette subfamily B member 1 Homo sapiens 150-155 30982500-7 2019 Inhibiting the activity of ABCB1 and silencing ABCB1 expression by small interfering ribonucleic acid (siRNA) increased the cytotoxicity of doxorubicin. Doxorubicin 140-151 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 30982500-7 2019 Inhibiting the activity of ABCB1 and silencing ABCB1 expression by small interfering ribonucleic acid (siRNA) increased the cytotoxicity of doxorubicin. Doxorubicin 140-151 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 30982500-8 2019 These results indicate that elevated ABCB1 expression induced by C-terminal truncation of HBx was responsible for doxorubicin resistance in HCC. Doxorubicin 114-125 ATP binding cassette subfamily B member 1 Homo sapiens 37-42 30964927-0 2019 Retraction: Sinomenine Sensitizes Multidrug-Resistant Colon Cancer Cells (Caco-2) to Doxorubicin by Downregulation of MDR-1 Expression. Doxorubicin 85-96 ATP binding cassette subfamily B member 1 Homo sapiens 118-123 30742940-5 2019 ABCB1 inhibitor PSC833/valspodar or PITX2 siRNA reversed doxorubicin resistance. Doxorubicin 57-68 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 30977678-0 2019 ABCB1 (C1236T) Polymorphism Affects P-Glycoprotein-Mediated Transport of Methotrexate, Doxorubicin, Actinomycin D, and Etoposide. Doxorubicin 87-98 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 30977678-0 2019 ABCB1 (C1236T) Polymorphism Affects P-Glycoprotein-Mediated Transport of Methotrexate, Doxorubicin, Actinomycin D, and Etoposide. Doxorubicin 87-98 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 30977678-1 2019 P-glycoprotein (P-gp), encoded by the ABCB1 (ATP-binding cassette transporter superfamily B member 1) gene, is a transport protein involved in the efflux and distribution of the osteosarcoma drugs methotrexate, doxorubicin, actinomycin D, and etoposide. Doxorubicin 211-222 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 30977678-1 2019 P-glycoprotein (P-gp), encoded by the ABCB1 (ATP-binding cassette transporter superfamily B member 1) gene, is a transport protein involved in the efflux and distribution of the osteosarcoma drugs methotrexate, doxorubicin, actinomycin D, and etoposide. Doxorubicin 211-222 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 30977678-1 2019 P-glycoprotein (P-gp), encoded by the ABCB1 (ATP-binding cassette transporter superfamily B member 1) gene, is a transport protein involved in the efflux and distribution of the osteosarcoma drugs methotrexate, doxorubicin, actinomycin D, and etoposide. Doxorubicin 211-222 ATP binding cassette subfamily B member 1 Homo sapiens 38-43 30977678-6 2019 Accumulation of methotrexate, doxorubicin, actinomycin D, and etoposide was significantly lower in cells overexpressing wild-type P-gp than in untransfected control cells, indicating that these drugs are substrates of P-gp. Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 30977678-6 2019 Accumulation of methotrexate, doxorubicin, actinomycin D, and etoposide was significantly lower in cells overexpressing wild-type P-gp than in untransfected control cells, indicating that these drugs are substrates of P-gp. Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 218-222 30977678-9 2019 Conversely, doxorubicin was transported to a greater extent by wild-type P-gp. Doxorubicin 12-23 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 30926883-2 2019 Here, we investigated cross-talk between the miR-221 network and P-glycoprotein (P-gp) in doxorubicin-induced drug resistance of leukemia cells. Doxorubicin 90-101 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 30171603-0 2019 Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P-glycoprotein. Doxorubicin 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 178-192 30926883-2 2019 Here, we investigated cross-talk between the miR-221 network and P-glycoprotein (P-gp) in doxorubicin-induced drug resistance of leukemia cells. Doxorubicin 90-101 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 30668405-8 2019 The P-gp inhibition kinetics of tenulin and isotenulin were evaluated by rhodamine123 and doxorubicin efflux assays. Doxorubicin 90-101 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 30904920-13 2019 CONCLUSIONS Taken together, our results showed that miR-222-3p induced DOX resistance via suppressing FOXP2, upregulating P-gp, and inhibiting the caspase pathway. Doxorubicin 71-74 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 30039475-2 2019 Herein, the mRNA-cleaving DNAzyme that targets the mRNA of MDR1 gene in doxorubicin-resistant breast cancer cell line (MCF-7/DR) loaded on the chitosan beta-cyclodextrin complexes was used as a tropical agent. Doxorubicin 72-83 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 30039475-7 2019 The rationale usage of this platform is to sensitize MCF-7/DR to doxorubicin by downregulating the drug-resistance gene MDR1. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 30032164-5 2019 Furthermore, miR-140 mimics could enhance the sensitivity of BCSCs to doxorubicin (Dox) through the Wnt1/ABCB1 pathway both in vitro and vivo. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 105-110 30032164-5 2019 Furthermore, miR-140 mimics could enhance the sensitivity of BCSCs to doxorubicin (Dox) through the Wnt1/ABCB1 pathway both in vitro and vivo. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 105-110 30650062-0 2019 MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 30650062-14 2019 P-gp inhibition increases sensitivity to doxorubicin and etoposide, suggesting that MDR1 is involved in sensitivity to these drugs and could be a potential target for cytotoxic treatment improvement in ACC. Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 30650062-14 2019 P-gp inhibition increases sensitivity to doxorubicin and etoposide, suggesting that MDR1 is involved in sensitivity to these drugs and could be a potential target for cytotoxic treatment improvement in ACC. Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 30623608-10 2019 MDR1 overexpression enhanced the viability and doxorubicin resistance of CC cells. Doxorubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 30623608-11 2019 Besides, MDR1 overexpression plasmid significantly abrogated the decrease in cell proliferation and resistance of HCT116 cells to doxorubicin caused by FOXO3 knockout. Doxorubicin 130-141 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 30623608-12 2019 CONCLUSION: Forkhead box O3 exhibited promotive effects on the proliferation and doxorubicin resistance in CC cells via targeting MDR1. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 30572191-5 2019 The synergistic effects were yielded by the combination of UA and Dox based on the investigation of the intracellular accumulation, the P-glycoprotein (P-gp) mediated transport, the energy metabolism including glycolysis, tricarboxylic acid (TCA) cycle, and glutamine metabolism as well as related amino acid metabolism. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 136-150 30572191-5 2019 The synergistic effects were yielded by the combination of UA and Dox based on the investigation of the intracellular accumulation, the P-glycoprotein (P-gp) mediated transport, the energy metabolism including glycolysis, tricarboxylic acid (TCA) cycle, and glutamine metabolism as well as related amino acid metabolism. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 30430199-2 2019 Several studies have demonstrated that the major cause for doxorubicin resistance in osteosarcoma is the increased expression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 157-162 30430199-2 2019 Several studies have demonstrated that the major cause for doxorubicin resistance in osteosarcoma is the increased expression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 163-177 30483812-0 2019 Levistolide A synergistically enhances doxorubicin-induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 30483812-12 2019 Furthermore, multidrug resistance protein 1 (MDR1) expression in k562/dox cells was downregulated by levistolide A in a dose-dependent manner, thus suggesting that levistolide A may modulate MDR1 during cancer therapy. Doxorubicin 70-73 ATP binding cassette subfamily B member 1 Homo sapiens 13-43 30483812-12 2019 Furthermore, multidrug resistance protein 1 (MDR1) expression in k562/dox cells was downregulated by levistolide A in a dose-dependent manner, thus suggesting that levistolide A may modulate MDR1 during cancer therapy. Doxorubicin 70-73 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 30483812-12 2019 Furthermore, multidrug resistance protein 1 (MDR1) expression in k562/dox cells was downregulated by levistolide A in a dose-dependent manner, thus suggesting that levistolide A may modulate MDR1 during cancer therapy. Doxorubicin 70-73 ATP binding cassette subfamily B member 1 Homo sapiens 191-195 30342318-2 2019 We observed that ferulic acid enhanced the cytotoxicity of doxorubicin and vincristine in the P-gp overexpressing KB ChR8-5 cells. Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 30471372-4 2019 As expected, tumors treated by free doxorubicin hydrochloride (DOX HCl) showed obvious increase of P-glycoprotein, while for tumors treated by nanocarrier encapsulated doxorubicin, the P-glycoprotein level stayed low as untreated group. Doxorubicin 36-61 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 30471372-4 2019 As expected, tumors treated by free doxorubicin hydrochloride (DOX HCl) showed obvious increase of P-glycoprotein, while for tumors treated by nanocarrier encapsulated doxorubicin, the P-glycoprotein level stayed low as untreated group. Doxorubicin 36-61 ATP binding cassette subfamily B member 1 Homo sapiens 185-199 30471372-4 2019 As expected, tumors treated by free doxorubicin hydrochloride (DOX HCl) showed obvious increase of P-glycoprotein, while for tumors treated by nanocarrier encapsulated doxorubicin, the P-glycoprotein level stayed low as untreated group. Doxorubicin 63-70 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 30471372-4 2019 As expected, tumors treated by free doxorubicin hydrochloride (DOX HCl) showed obvious increase of P-glycoprotein, while for tumors treated by nanocarrier encapsulated doxorubicin, the P-glycoprotein level stayed low as untreated group. Doxorubicin 63-70 ATP binding cassette subfamily B member 1 Homo sapiens 185-199 30471372-4 2019 As expected, tumors treated by free doxorubicin hydrochloride (DOX HCl) showed obvious increase of P-glycoprotein, while for tumors treated by nanocarrier encapsulated doxorubicin, the P-glycoprotein level stayed low as untreated group. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 30471372-4 2019 As expected, tumors treated by free doxorubicin hydrochloride (DOX HCl) showed obvious increase of P-glycoprotein, while for tumors treated by nanocarrier encapsulated doxorubicin, the P-glycoprotein level stayed low as untreated group. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 185-199 30471372-5 2019 Further exploration found that MDR1 gene transcription got involved in the resistance induction mechanism as its mRNA levels in DOX HCl stimulated cells were thousands of times of those in parent cell. Doxorubicin 128-135 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 30745853-9 2019 In addition, RA synergistically increased doxorubicin toxicity by increasing its cellular uptake, ablating efflux and downregulating MDR1 in drug-resistant cells with attenuation of STAT3 Phosphorylation. Doxorubicin 42-53 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 30609135-7 2019 The results of the present study demonstrated that treatment of SKOV3 with 55 muM of RES and 250 nM of DOX simultaneously increased cell viability in CSCs to DOX after 24 and 48 hours by increasing the expression of Bcl-2-associated X protein (BAX) and caspase-3 genes, and decreased the expression and function of multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 1 (MRP1) genes indicated by intracellular the rhodamine 123 content. Doxorubicin 103-106 ATP binding cassette subfamily B member 1 Homo sapiens 315-345 30609135-7 2019 The results of the present study demonstrated that treatment of SKOV3 with 55 muM of RES and 250 nM of DOX simultaneously increased cell viability in CSCs to DOX after 24 and 48 hours by increasing the expression of Bcl-2-associated X protein (BAX) and caspase-3 genes, and decreased the expression and function of multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 1 (MRP1) genes indicated by intracellular the rhodamine 123 content. Doxorubicin 103-106 ATP binding cassette subfamily B member 1 Homo sapiens 347-351 30318192-1 2019 In this study, quercetin-chitosan conjugate (QT-CS) was synthesized for oral delivery of doxorubicin (DOX) to improve its oral bioavailability by increasing its water solubility, opening tight junction and bypassing the P-glycoprotein (P-gp). Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 220-234 30318192-1 2019 In this study, quercetin-chitosan conjugate (QT-CS) was synthesized for oral delivery of doxorubicin (DOX) to improve its oral bioavailability by increasing its water solubility, opening tight junction and bypassing the P-glycoprotein (P-gp). Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 236-240 30318192-1 2019 In this study, quercetin-chitosan conjugate (QT-CS) was synthesized for oral delivery of doxorubicin (DOX) to improve its oral bioavailability by increasing its water solubility, opening tight junction and bypassing the P-glycoprotein (P-gp). Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 220-234 30318192-1 2019 In this study, quercetin-chitosan conjugate (QT-CS) was synthesized for oral delivery of doxorubicin (DOX) to improve its oral bioavailability by increasing its water solubility, opening tight junction and bypassing the P-glycoprotein (P-gp). Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 236-240 30066239-5 2019 The two most potent inhibitors (R)-3 and (S)-3 displayed the ability to increase intracellular accumulation of doxorubicin, thereby sensitizing P-gp-overexpressing tumor cells to chemotherapy by decreasing doxorubicin IC50 value up to 15-fold. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 30538042-7 2019 Meanwhile, it was also increased the retention of P-gp substrates DOX and Rhodamine 123 (Rho-123) while did not affect the ATPase activity. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 30760665-7 2019 Besides, ABCB1 overexpression plasmid enhanced the viability of SKOV3 and OVCA433 cells compared to empty vector under treatment with the same concentration of doxorubicin, whereas ABCB1 shRNA inhibited doxorubicin resistance of SKOV3 DR cells compared to control. Doxorubicin 160-171 ATP binding cassette subfamily B member 1 Homo sapiens 9-14 30760665-7 2019 Besides, ABCB1 overexpression plasmid enhanced the viability of SKOV3 and OVCA433 cells compared to empty vector under treatment with the same concentration of doxorubicin, whereas ABCB1 shRNA inhibited doxorubicin resistance of SKOV3 DR cells compared to control. Doxorubicin 203-214 ATP binding cassette subfamily B member 1 Homo sapiens 9-14 30760665-7 2019 Besides, ABCB1 overexpression plasmid enhanced the viability of SKOV3 and OVCA433 cells compared to empty vector under treatment with the same concentration of doxorubicin, whereas ABCB1 shRNA inhibited doxorubicin resistance of SKOV3 DR cells compared to control. Doxorubicin 203-214 ATP binding cassette subfamily B member 1 Homo sapiens 181-186 30676767-7 2019 Furthermore, it was found that cells exposed to the mixture presented a significantly reduced expression level of genes associated with MDR, including ABCB1, which encodes for glycoprotein P. In vitro data showed that MIX2 effectively sensitizes tumor cells to doxorubicin. Doxorubicin 261-272 ATP binding cassette subfamily B member 1 Homo sapiens 151-156 30465789-5 2019 Mechanistically studies revealed that HDAC2 can regulate the transcription of ABCB1 via directly binding with its promoter and increasing its expression in Dox resistant HCC cells. Doxorubicin 156-159 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 30465789-7 2019 Co-immunoprecipitation revealed that HDAC2 can bind with c-fos, an important transcription factor of ABCB1, in HCC/Dox cells. Doxorubicin 115-118 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 30465789-8 2019 Knockdown of c-Fos decreased the binding between HDAC2 and promoter of ABCB1 in HCC/Dox cells. Doxorubicin 84-87 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 30544754-7 2018 In this connection, LS-2-3j significantly enhanced the activity of chemotherapeutic drugs in MDR cells and could significantly increase the intracellular accumulation of doxorubicin (DOX) and mitoxantrone (MITX) by inhibiting the function of the efflux pumps in ABCB1- or ABCG2-overexpressing cells. Doxorubicin 170-181 ATP binding cassette subfamily B member 1 Homo sapiens 262-267 31223218-11 2018 Our results demonstrate that the development of MDR in K562/Dox is underlined by a genomic amplification of the chromosome 7 region harboring the ABCB1 gene. Doxorubicin 60-63 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 30672437-5 2018 At the same time, it markedly inhibited MDR1 gene expression and P-GLP protein to sensitize the cytotoxic effect of DOX. Doxorubicin 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 30544754-7 2018 In this connection, LS-2-3j significantly enhanced the activity of chemotherapeutic drugs in MDR cells and could significantly increase the intracellular accumulation of doxorubicin (DOX) and mitoxantrone (MITX) by inhibiting the function of the efflux pumps in ABCB1- or ABCG2-overexpressing cells. Doxorubicin 183-186 ATP binding cassette subfamily B member 1 Homo sapiens 262-267 30273544-11 2018 Collectively, our data showed that HDAC6 mediated upregulation of IL-8 can regulate the Dox sensitivity of OS cells via transcriptionally regulating the expression of ABCB1. Doxorubicin 88-91 ATP binding cassette subfamily B member 1 Homo sapiens 167-172 32254754-5 2018 In vitro studies demonstrated that the DOX and Ela co-delivered nanovesicles showed superior cytotoxicity and enhanced anti-tumor properties as compared to single DOX-delivery nanosystems in MCF-7/ADR cancer, which was attributed to the P-gp bioactivity inhibition as investigated by a cell immunofluorescence assay. Doxorubicin 39-42 ATP binding cassette subfamily B member 1 Homo sapiens 237-241 30401501-6 2018 The cellular thermal shift assay (CETSA) showed that WS-10 was able to bind to ABCB1, which could be responsible for the reversal effect of WS-10 toward paclitaxel and doxorubicin in SW620/Ad300 cells. Doxorubicin 168-179 ATP binding cassette subfamily B member 1 Homo sapiens 79-84 30477461-14 2018 CONCLUSION: The present findings illustrate that the studied flavonoids significantly enhances doxorubicin-mediated cell death through modulating P-gp expression pattern by targeting Wnt/beta-catenin signaling in drug-resistant KBCHR8-5 cells. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 30469543-6 2018 The kinetics study for P-gp inhibition was evaluated by doxorubicin and rhodamine123 efflux assays. Doxorubicin 56-67 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 30469543-10 2018 The function of P-gp was inhibited by taxifolin through uncompetitive inhibition of rhodamine 123 and doxorubicin efflux. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 30613324-3 2018 The P-gp inhibition study showed that compounds 7, 8, and 9 successfully increased intracellular doxorubicin (DOX) accumulation in the P-gp overexpressed Lucena 1 cells from 25, 12.5, and 6.25 muM, respectively. Doxorubicin 97-108 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 30613324-3 2018 The P-gp inhibition study showed that compounds 7, 8, and 9 successfully increased intracellular doxorubicin (DOX) accumulation in the P-gp overexpressed Lucena 1 cells from 25, 12.5, and 6.25 muM, respectively. Doxorubicin 97-108 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 30613324-3 2018 The P-gp inhibition study showed that compounds 7, 8, and 9 successfully increased intracellular doxorubicin (DOX) accumulation in the P-gp overexpressed Lucena 1 cells from 25, 12.5, and 6.25 muM, respectively. Doxorubicin 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 30613324-3 2018 The P-gp inhibition study showed that compounds 7, 8, and 9 successfully increased intracellular doxorubicin (DOX) accumulation in the P-gp overexpressed Lucena 1 cells from 25, 12.5, and 6.25 muM, respectively. Doxorubicin 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 30217766-5 2018 This can be explained by the ability of RES to reduce the P-glycoprotein (P-gp)-mediated efflux of DOX. Doxorubicin 99-102 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 30217766-5 2018 This can be explained by the ability of RES to reduce the P-glycoprotein (P-gp)-mediated efflux of DOX. Doxorubicin 99-102 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 30137985-4 2018 Further evaluation for the multidrug resistance (MDR) reversal activity of compound 5 revealed it enhanced the sensitivity of MCF-7/ADR cells toward adriamycin 39-fold at 10 muM through modulating P-glycoprotein-mediated drug exclusion. Doxorubicin 149-159 ATP binding cassette subfamily B member 1 Homo sapiens 197-211 30273544-0 2018 Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 136-141 30273544-0 2018 Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 136-141 30037815-11 2018 ABCB1 and ABCC1 RNA expression levels decreased by 58.47-fold and 1.47-fold, respectively, on day 5 of the cycle.Conclusions: Combination of MRP-1/P-gp inhibitor, nilotinib, as coadjuvant with doxorubicin is feasible; it appears not to add substantial toxicity compared with doxorubicin alone. Doxorubicin 193-204 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 30037815-11 2018 ABCB1 and ABCC1 RNA expression levels decreased by 58.47-fold and 1.47-fold, respectively, on day 5 of the cycle.Conclusions: Combination of MRP-1/P-gp inhibitor, nilotinib, as coadjuvant with doxorubicin is feasible; it appears not to add substantial toxicity compared with doxorubicin alone. Doxorubicin 275-286 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 30266241-9 2018 These findings suggest that the combined treatment of metformin with DOX potentiates the anticancer efficacy of DOX in DU145 cells via inhibiting ABCB1 function, cell cycle arrest at G1/S transition and apoptosis induction. Doxorubicin 69-72 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 30266241-9 2018 These findings suggest that the combined treatment of metformin with DOX potentiates the anticancer efficacy of DOX in DU145 cells via inhibiting ABCB1 function, cell cycle arrest at G1/S transition and apoptosis induction. Doxorubicin 112-115 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 30254169-4 2018 Here, we describe that lysosomal sequestration of Pgp substrates, including doxorubicin, also occurs in human and porcine brain endothelial cells that form the blood-brain barrier. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 50-53 29990852-4 2018 Since phenothiazines are known as multidrug resistance modulators the sensitive human colorectal adenocarcinoma cell line (LoVo) and its doxorubicin-resistant, ABCB1 overexpressing, subline (LoVo/Dx) have been employed as a model system. Doxorubicin 137-148 ATP binding cassette subfamily B member 1 Homo sapiens 160-165 30150104-6 2018 The cellular thermal shift assay (CETSA) showed that WS-10 was able to bind to ABCB1, which could be responsible for the reversal effect of WS-10 toward paclitaxel and doxorubicin in SW620/Ad300 cells. Doxorubicin 168-179 ATP binding cassette subfamily B member 1 Homo sapiens 79-84 30066890-0 2018 Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 30066890-8 2018 Knockdown of TWIST increased the sensitivity of R-HepG2 cells to 5-fluroracil, cisplatin and doxorubicin through a reduction in MDR1 expression and drug efflux ability. Doxorubicin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 30122894-0 2018 Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 111-116 30210283-8 2018 Moreover, ectopic expression of miR-298 downregulated P-gp expression at the mRNA and protein levels, thereby increasing the intracellular accumulation of AEDs in drug-resistant HBMEC/PHT and U87-MG/DOX cells. Doxorubicin 199-202 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 30040100-3 2018 Here, we report a novel nanosystem of charge-reversal-functionalized PLGA nanobubbles (denoted as Dox-NBs/PPP/P-gp shRNA) for the co-delivery of Dox and P-gp shRNA for the reversal of drug resistance and for ultrasonic-imaging-guided tumor therapy. Doxorubicin 98-101 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 30040100-6 2018 The in vitro experiments showed that Dox-NBs/PPP/P-gp shRNA nanobubbles could co-deliver Dox and P-gp shRNA into tumor cells and could effectively suppress P-gp expression, leading to enhanced overall therapeutic effects against MCF-7/MDR cells by restraining the drug efflux. Doxorubicin 37-40 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 30040100-6 2018 The in vitro experiments showed that Dox-NBs/PPP/P-gp shRNA nanobubbles could co-deliver Dox and P-gp shRNA into tumor cells and could effectively suppress P-gp expression, leading to enhanced overall therapeutic effects against MCF-7/MDR cells by restraining the drug efflux. Doxorubicin 37-40 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 30040100-6 2018 The in vitro experiments showed that Dox-NBs/PPP/P-gp shRNA nanobubbles could co-deliver Dox and P-gp shRNA into tumor cells and could effectively suppress P-gp expression, leading to enhanced overall therapeutic effects against MCF-7/MDR cells by restraining the drug efflux. Doxorubicin 37-40 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 29635751-6 2018 In addition, combined treatment of Dox, Pac, or Vcr with Que significantly downregulated P-gp expression and eliminated BCSCs. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 29484528-6 2018 For example, the death rate in the parental line under low-dose doxorubicin treatment is increased from 0.64 (+- 0.22) x 10-2 to 1.46 (+- 0.58) x 10-2 h-1 with increasing fractions of MDR1-overexpressing cells. Doxorubicin 64-75 ATP binding cassette subfamily B member 1 Homo sapiens 184-188 29768014-8 2018 More importantly, the preferentially released CUR inhibited the drug efflux function of the membrane P-glycoprotein (P-gp), which subsequently facilitated the nuclear transportation of DOX released from the PDA-MSN core, and, in turn, the synergistic effects on killing MDR cancer cells. Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 29768014-8 2018 More importantly, the preferentially released CUR inhibited the drug efflux function of the membrane P-glycoprotein (P-gp), which subsequently facilitated the nuclear transportation of DOX released from the PDA-MSN core, and, in turn, the synergistic effects on killing MDR cancer cells. Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 29798663-4 2018 The resulting carrier EphA10 antibody-conjugated pH-sensitive doxorubicin (DOX), MDR1-siRNA coloading lipoplexes (shortened as DOX + siRNA/ePL) with high serum stability had favorable physicochemical properties. Doxorubicin 127-130 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 29798663-5 2018 DOX + siRNA/ePL exhibited an incremental cellular uptake, enhanced P-gp downregulation efficacy, as well as a better cell cytotoxicity in human breast cancer cell line/adriamycin drug-resistant (MCF-7/ADR) cells. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 29798663-8 2018 The histological study further demonstrated that DOX + siRNA/ePL could inhibit the proliferation, induce apoptosis effect, and downregulate the P-gp expression in vivo. Doxorubicin 49-52 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 29771490-4 2018 In our design, the cationic poly[2-( N, N-dimethylaminoethyl)methacrylate] is introduced onto the PMSN surface through a light-sensitive coumarin ester derivative linker to adsorb P-gp shRNA, whereas the photocleavable o-nitrobenzyl ester derivative-caged DOX is loaded into the inner pores of the PMSN. Doxorubicin 256-259 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 29766327-13 2018 The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin. Doxorubicin 150-161 ATP binding cassette subfamily B member 1 Homo sapiens 120-123 29890725-5 2018 Three compounds used at 1 nM increased the delivery of doxorubicin, a typical substrate of Pgp, across BBB monolayer, without altering the expression and activity of other transporters. Doxorubicin 55-66 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 29655913-0 2018 Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression. Doxorubicin 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 29772519-2 2018 The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 29772519-2 2018 The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 29693201-0 2018 IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Doxorubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 87-109 29693201-0 2018 IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1). Doxorubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 29693201-10 2018 These results suggested that IL-8 regulates the Dox resistance of CRC cells via modulation of MDR1 through IKK-beta/p65 signals. Doxorubicin 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 29655913-0 2018 Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression. Doxorubicin 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 29655913-8 2018 Germacrone decreased adriamycin-induced expression of MDR1 mRNA and P-gp protein. Doxorubicin 21-31 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 29655913-8 2018 Germacrone decreased adriamycin-induced expression of MDR1 mRNA and P-gp protein. Doxorubicin 21-31 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 29655913-9 2018 Overexpression of P-glycoprotein (P-gp) reversed the effect of germacrone on adriamycin resistance in K562/ADM cells. Doxorubicin 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 29655913-9 2018 Overexpression of P-glycoprotein (P-gp) reversed the effect of germacrone on adriamycin resistance in K562/ADM cells. Doxorubicin 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 29671072-3 2018 We reported in our previous study that Met inhibits P-gp in DOX resistant breast cancer (MCF-7/DOX) cells. Doxorubicin 60-63 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 29656198-0 2018 Synthesis and biological evaluation of 2,5-disubstituted furan derivatives as P-glycoprotein inhibitors for Doxorubicin resistance in MCF-7/ADR cell. Doxorubicin 108-119 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 29656198-9 2018 This study provides highlighted P-gp inhibitor for withstanding malignant tumor cell with multidrug resistance especially doxorubicin resistance setting the basis for further studies. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 29701706-5 2018 In addition, mansorin-B, mansorin-C, mansorin-II and mansorin-III significantly increased cellular entrapment of the P-glycoprotein (P-gp) substrate, doxorubicin, in colorectal cancer cells expressing the P-gp pump. Doxorubicin 150-161 ATP binding cassette subfamily B member 1 Homo sapiens 117-131 29663807-4 2018 The intracellular multidrug resistance 1 (MDR1) mRNA and upstream erythroblastosis virus E26 oncogene homolog 1 (ETS1) mRNA can be silenced by MBs, which can effectively inhibit the expression of P-gp and further prevent the efflux of Dox and reverse MDR. Doxorubicin 235-238 ATP binding cassette subfamily B member 1 Homo sapiens 18-40 29663807-4 2018 The intracellular multidrug resistance 1 (MDR1) mRNA and upstream erythroblastosis virus E26 oncogene homolog 1 (ETS1) mRNA can be silenced by MBs, which can effectively inhibit the expression of P-gp and further prevent the efflux of Dox and reverse MDR. Doxorubicin 235-238 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 29663807-4 2018 The intracellular multidrug resistance 1 (MDR1) mRNA and upstream erythroblastosis virus E26 oncogene homolog 1 (ETS1) mRNA can be silenced by MBs, which can effectively inhibit the expression of P-gp and further prevent the efflux of Dox and reverse MDR. Doxorubicin 235-238 ATP binding cassette subfamily B member 1 Homo sapiens 196-200 29671072-3 2018 We reported in our previous study that Met inhibits P-gp in DOX resistant breast cancer (MCF-7/DOX) cells. Doxorubicin 95-98 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 29541235-9 2018 As a potential explanation for this doxorubicin resistance, significantly increased mRNA expression levels of ATP-binding cassette ABCB1 (multidrug resistance protein 1) and ABCC1 (multidrug resistance-associated protein 1) were observed by reverse transcription-quantitative polymerase chain reaction. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 131-136 29541235-9 2018 As a potential explanation for this doxorubicin resistance, significantly increased mRNA expression levels of ATP-binding cassette ABCB1 (multidrug resistance protein 1) and ABCC1 (multidrug resistance-associated protein 1) were observed by reverse transcription-quantitative polymerase chain reaction. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 138-168 29368443-3 2018 In this paper, we evaluated effects of BA on reversing P-gp mediated MDR of adriamycin (ADR)-resistant human breast carcinoma (MCF-7/ADR) cells. Doxorubicin 76-86 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 29181822-10 2018 In addition, Sch A enhanced DOX-induced cleavage of Caspase-9 and PARP levels by increasing intracellular DOX accumulation and inhibiting P-gp function. Doxorubicin 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 29459273-6 2018 Importantly, the new derivatives were similarly potent against wild type cells and their variants resistant to doxorubicin due to P-glycoprotein (Pgp) expression or p53 inactivation. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 130-144 29407947-8 2018 Lineweaver-Burk and Dixon plots implied that 1 was a competitive inhibitor to DOX in the binding site of P-gp with a Ki of 0.49-0.50 muM. Doxorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 29407947-9 2018 Our data suggested that 1 had a high binding affinity toward the DOX recognition site of P-gp. Doxorubicin 65-68 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 29747752-6 2018 RESULTS: Our data found that the intracellular accumulation of rhodamine-123 (Rh123) and doxorubicin (ADR) were increased, the sensitivity of BEL/5-FU cells to chemotherapeutic drugs were increased, and the expressions of ABCB1, ABCC1 and ABCC2 were all down-regulated, which indicated that the functions and expressions of ABCB1, ABCC1 and ABCC2 efflux pump were inhibited by quercetin treatment. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 222-227 29747752-6 2018 RESULTS: Our data found that the intracellular accumulation of rhodamine-123 (Rh123) and doxorubicin (ADR) were increased, the sensitivity of BEL/5-FU cells to chemotherapeutic drugs were increased, and the expressions of ABCB1, ABCC1 and ABCC2 were all down-regulated, which indicated that the functions and expressions of ABCB1, ABCC1 and ABCC2 efflux pump were inhibited by quercetin treatment. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 324-329 29305422-7 2018 These two mechanisms increased lysosomal Pgp and facilitated lysosomal accumulation of the Pgp substrate, doxorubicin, resulting in resistance. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 41-44 29305422-7 2018 These two mechanisms increased lysosomal Pgp and facilitated lysosomal accumulation of the Pgp substrate, doxorubicin, resulting in resistance. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 29333658-5 2018 Core-shell PLA@poly-shRNA structures that codeliver a high payload of doxorubicin (Dox) and multidrug resistance protein 1 (MDR1) targeted shRNA for MDR breast cancer (BC) therapy are developed. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 29181822-11 2018 Furthermore, Sch A selectively suppressed P-gp at gene and protein levels in MCF-7/DOX cells which express high level of MDR1 but not MRP1, MRP3, or BCRP. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 29181822-11 2018 Furthermore, Sch A selectively suppressed P-gp at gene and protein levels in MCF-7/DOX cells which express high level of MDR1 but not MRP1, MRP3, or BCRP. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 29181822-16 2018 CONCLUSION: Sch A specifically reverses P-gp-mediated DOX resistance in MCF-7/DOX cells by blocking P-gp, NF-kappaB, and Stat3 signaling. Doxorubicin 54-57 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 29181822-16 2018 CONCLUSION: Sch A specifically reverses P-gp-mediated DOX resistance in MCF-7/DOX cells by blocking P-gp, NF-kappaB, and Stat3 signaling. Doxorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 29318976-0 2018 Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition. Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 169-183 29445446-9 2018 Meanwhile, ABCC1 and MDR-1 were significantly increased in Caki-2/VBL and Caki-2/DOX cells. Doxorubicin 81-84 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 29019073-6 2018 Cellular accumulation studies confirmed that PEGCCF was able to concentration-dependently enhance the cellular accumulation of DOX and rhodamine 123 in MDA-MB-231 cells through its P-glycoprotein (P-gp) inhibition activity. Doxorubicin 127-130 ATP binding cassette subfamily B member 1 Homo sapiens 181-195 29019073-6 2018 Cellular accumulation studies confirmed that PEGCCF was able to concentration-dependently enhance the cellular accumulation of DOX and rhodamine 123 in MDA-MB-231 cells through its P-glycoprotein (P-gp) inhibition activity. Doxorubicin 127-130 ATP binding cassette subfamily B member 1 Homo sapiens 197-201 29559849-6 2018 In addition, functional assays revealed that circPVT1 knockdown by siRNA could weaken the resistance to doxorubicin and cisplatin of OS cells through decreasing the expression of classical drug resistance-related gene ABCB1. Doxorubicin 104-115 ATP binding cassette subfamily B member 1 Homo sapiens 218-223 29568367-4 2018 Sensitivity was completely restored with specific inhibitors cyclosporine (ABCB1) and Ko143 (ABCG2): K562-Dox LD50asciminib+cyclosporine = 13 nM, K562-ABCG2 LD50asciminib+Ko143 = 15 nM (p < 0.001). Doxorubicin 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 75-80 29568367-7 2018 K562-Dox asciminib-resistant cells had increased ABCB1 expression (2.1-fold vs control cells p = 0.0033). Doxorubicin 5-8 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 29456815-3 2018 The aim of this study was to investigate the efficiency and ability of CRISPR/Cas9 genome editing technology to knockdown ABCB1 gene expression in adriamycin resistant (A2780/ADR) ovarian cancer cell line and evaluate the sensitivity changes to doxorubicin. Doxorubicin 147-157 ATP binding cassette subfamily B member 1 Homo sapiens 122-127 29456815-8 2018 The dramatic decline in ABCB1 gene expression was associated with increased sensitivity of cells transfected with sgRNAs to doxorubicin. Doxorubicin 124-135 ATP binding cassette subfamily B member 1 Homo sapiens 24-29 29133241-8 2018 In conclusion, both in silico and in vitro studies confirm that PIP is an inhibitor of P-gp mediated DOX efflux, suggesting PIP as a promising adjuvant to DOX cancer chemotherapy. Doxorubicin 101-104 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 29133241-8 2018 In conclusion, both in silico and in vitro studies confirm that PIP is an inhibitor of P-gp mediated DOX efflux, suggesting PIP as a promising adjuvant to DOX cancer chemotherapy. Doxorubicin 155-158 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 30497065-0 2018 Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. Doxorubicin 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 30761958-0 2018 Erratum to Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition. Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 180-194 30761958-1 2018 Due to an oversight one of the author"s name was published wrong in the article entitled "Algerian Propolis Potentiates Doxorubicin Mediated Anticancer Effect Against Human Pancreatic PANC-1 Cancer Cell Line through Cell Cycle Arrest, Apoptosis Induction and P-Glycoprotein Inhibition" in "Anti-Cancer Agents in Medicinal Chemistry, 2018, Vol. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 259-273 30439718-6 2018 DOX sensitivity was assessed by detecting IC50 value of DOX, the protein levels of P-glycoprotein (P-gp) and glutathione S-transferase-pi (GST-pi) and apoptosis. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 83-97 30439718-6 2018 DOX sensitivity was assessed by detecting IC50 value of DOX, the protein levels of P-glycoprotein (P-gp) and glutathione S-transferase-pi (GST-pi) and apoptosis. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 30439718-10 2018 Knockdown of XIST inhibited DOX resistance of CRC cells, as evidenced by the reduced IC50 value of DOX, decreased P-gp and GST-pi levels and enhanced apoptosis in XIST-silenced DOX-resistant CRC cells. Doxorubicin 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 29371766-6 2018 Our results revealed that, the over expression of miR-122 in HepG2 cells treated or untreated with doxorubicin could modulate the sensitivity of cells to chemotherapeutic drug through downregulation of MDR-related genes, ABCB1 and ABCF2. Doxorubicin 99-110 ATP binding cassette subfamily B member 1 Homo sapiens 221-226 29486476-8 2018 RESULTS: Voruciclib significantly potentiated the effect of paclitaxel and doxorubicin in ABCB1-overexpressing cells, as well as mitoxantrone and SN-38 in ABCG2-overexpressing cells. Doxorubicin 75-86 ATP binding cassette subfamily B member 1 Homo sapiens 90-95 29343957-11 2018 In the aggregate, newly synthesized MSNP-PEI-DOX/MDR1-siRNA improves cancer chemotherapy effect in terms of treating multidrug-resistant cancer compared to DOX only, clearly demonstrating that MSNP-PEI-DOX/MDR1-siRNA has potential therapeutic application for multidrug-resistant cancer in the future. Doxorubicin 45-48 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 28881205-4 2018 The main cause of multidrug resistance (MDR) of DOX is the overexpression of P-glycoprotein (P-gp), which can be inhibited by QUR. Doxorubicin 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 28881205-4 2018 The main cause of multidrug resistance (MDR) of DOX is the overexpression of P-glycoprotein (P-gp), which can be inhibited by QUR. Doxorubicin 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 29343957-11 2018 In the aggregate, newly synthesized MSNP-PEI-DOX/MDR1-siRNA improves cancer chemotherapy effect in terms of treating multidrug-resistant cancer compared to DOX only, clearly demonstrating that MSNP-PEI-DOX/MDR1-siRNA has potential therapeutic application for multidrug-resistant cancer in the future. Doxorubicin 45-48 ATP binding cassette subfamily B member 1 Homo sapiens 206-210 28987325-3 2017 In this study, P-glycoprotein (P-gp), which is reported to mediate MDR to anti-cancer drugs, was proved to be overexpressed in the adriamycin (ADR)-resistant human breast cancer cells, namely MCF-7/ADR cells. Doxorubicin 131-141 ATP binding cassette subfamily B member 1 Homo sapiens 15-29 28987325-3 2017 In this study, P-glycoprotein (P-gp), which is reported to mediate MDR to anti-cancer drugs, was proved to be overexpressed in the adriamycin (ADR)-resistant human breast cancer cells, namely MCF-7/ADR cells. Doxorubicin 131-141 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 29051118-7 2017 Sequentially, DOX formulation (CSO-ss-SA/DOX or DOX HCl) was delivered when P-gp was reduced to the lowest level. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 28762597-11 2017 LY294002 can decrease the expression of multidrug resistance protein-1 (MRP1) in NSCLC Dox-resistant cells. Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 40-70 29416762-6 2018 Metformin increased nuclear doxorubicin accumulation and overcame drug resistance by down-regulating drug-resistant genes such as P-glycoprotein (Pgp). Doxorubicin 28-39 ATP binding cassette subfamily B member 1 Homo sapiens 130-144 29416762-6 2018 Metformin increased nuclear doxorubicin accumulation and overcame drug resistance by down-regulating drug-resistant genes such as P-glycoprotein (Pgp). Doxorubicin 28-39 ATP binding cassette subfamily B member 1 Homo sapiens 146-149 29061050-7 2017 Cold shock treatment triggered rapid intracellular release of doxorubicin against P-glycoprotein (Pgp)-mediated drug efflux, showing significantly improved anticancer efficacy as compared with free DOX. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 82-96 29061050-7 2017 Cold shock treatment triggered rapid intracellular release of doxorubicin against P-glycoprotein (Pgp)-mediated drug efflux, showing significantly improved anticancer efficacy as compared with free DOX. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 98-101 28825695-0 2017 Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma. Doxorubicin 44-55 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 28825695-5 2017 This implies the intracellular retention of doxorubicin in tumor cells, which is at least partly attributable to the effective inhibition of ABCB1 and ABCG2 transporter expression in ALR-expressing cells. Doxorubicin 44-55 ATP binding cassette subfamily B member 1 Homo sapiens 141-146 29238192-7 2017 Notably, free Dox induced much higher expression of ABCB1 and significantly enhanced the cell migration behavior in comparison with HSPC Doxlipo under a similar level of cytotoxicity. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 52-57 29061787-0 2017 (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 84-98 29061787-2 2017 P-gp expression is induced by doxorubicin (DOX). Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 29061787-2 2017 P-gp expression is induced by doxorubicin (DOX). Doxorubicin 43-46 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 29061787-3 2017 We aimed to clarify the mechanisms and inhibitory effects of EGCG on DOX-induced P-gp expression in HepG2 cells. Doxorubicin 69-72 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 29061787-7 2017 DOX induced the overexpression of MDR1 mRNA and increased the phosphorylation of Akt, ERK1/2, p38 MAPK and JNK. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 29061787-9 2017 The DOX-induced P-gp overexpression was partially suppressed by an inhibitor of MEK1/2 (U0126), but not by a PI3K inhibitor (LY294002). Doxorubicin 4-7 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 29061787-11 2017 CONCLUSION: EGCG inhibited DOX-induced overexpression of P-gp through the coordinate inhibitory action on MEK/ERK and PI3K/Akt signaling pathways. Doxorubicin 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 28776672-8 2017 Propolis but not Caf may act as a P-gp inhibitor by modulating P-gp activity and inhibiting DOX efflux. Doxorubicin 92-95 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 28818459-6 2017 This conjugate selectively improves adriamycin uptake and toxicity through reducing MDR1 mRNA and Pgp protein expression. Doxorubicin 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 28818459-6 2017 This conjugate selectively improves adriamycin uptake and toxicity through reducing MDR1 mRNA and Pgp protein expression. Doxorubicin 36-46 ATP binding cassette subfamily B member 1 Homo sapiens 98-101 29133241-0 2018 In silico comparisons between natural inhibitors of ABCB1/P-glycoprotein to overcome doxorubicin-resistance in the NCI/ADR-RES cell line. Doxorubicin 85-96 ATP binding cassette subfamily B member 1 Homo sapiens 52-57 29133241-0 2018 In silico comparisons between natural inhibitors of ABCB1/P-glycoprotein to overcome doxorubicin-resistance in the NCI/ADR-RES cell line. Doxorubicin 85-96 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 29133241-3 2018 In vitro studies on doxorubicin (DOX)-resistant NCI/ADR-RES cells, known to express P-gp, showed that, dose-dependently, PIP significantly increased intracellular accumulation of rhodamine-123 and had cytotoxic effects accessed by MTT assay. Doxorubicin 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 29133241-5 2018 P-gp ATPase assay showed that both DOX and PIP had dose-dependent inhibition of orthovandate-sensitive ATPase activity, indicating they are both P-gp inhibitors, with IC50 of 84+-1 and 37+-2muM, respectively. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 29133241-5 2018 P-gp ATPase assay showed that both DOX and PIP had dose-dependent inhibition of orthovandate-sensitive ATPase activity, indicating they are both P-gp inhibitors, with IC50 of 84+-1 and 37+-2muM, respectively. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 29133241-6 2018 PIP did not show any activation of ATPase activity, while DOX did, indicating that P-gp does not accept PIP as a substrate. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 29133241-7 2018 Using DOX at concentration 33.33muM together with PIP (100muM), DOX-mediated P-gp ATPase activity was decreased to levels 4-folds lower than DOX alone. Doxorubicin 6-9 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 29133241-7 2018 Using DOX at concentration 33.33muM together with PIP (100muM), DOX-mediated P-gp ATPase activity was decreased to levels 4-folds lower than DOX alone. Doxorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 29133241-7 2018 Using DOX at concentration 33.33muM together with PIP (100muM), DOX-mediated P-gp ATPase activity was decreased to levels 4-folds lower than DOX alone. Doxorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 29121121-4 2017 Emodin reversed adriamycin resistance in K562/ADM cells accompanied with the decrease of P-gp protein expression, further increasing the uptake of rhodamine123 in both K562/ADM and Caco-2 cells, indicating the inhibition of P-gp efflux function. Doxorubicin 16-26 ATP binding cassette subfamily B member 1 Homo sapiens 224-228 28901962-2 2017 Here, we present the effect of the N-(2-hydroxypropyl) methacrylamide-based polymer conjugate with P-gp inhibitor ritonavir (RIT) on the increase of free doxorubicin (DOX) and polymer-bound DOX cytotoxicity in the human neuroblastoma 4 cell line and its resistant clones to different cytostatics. Doxorubicin 154-165 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 28901962-2 2017 Here, we present the effect of the N-(2-hydroxypropyl) methacrylamide-based polymer conjugate with P-gp inhibitor ritonavir (RIT) on the increase of free doxorubicin (DOX) and polymer-bound DOX cytotoxicity in the human neuroblastoma 4 cell line and its resistant clones to different cytostatics. Doxorubicin 167-170 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 28901962-2 2017 Here, we present the effect of the N-(2-hydroxypropyl) methacrylamide-based polymer conjugate with P-gp inhibitor ritonavir (RIT) on the increase of free doxorubicin (DOX) and polymer-bound DOX cytotoxicity in the human neuroblastoma 4 cell line and its resistant clones to different cytostatics. Doxorubicin 190-193 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 28901484-6 2017 These DOX-resistant cells also showed increases in p21, Bcl-2 and MDR-1 expression. Doxorubicin 6-9 ATP binding cassette subfamily B member 1 Homo sapiens 66-71 28901484-8 2017 The inhibition by I2 + DOX was also accompanied by impaired MDR-1 induction as well as by a significant increase in PPARgamma expression. Doxorubicin 23-26 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 28762597-11 2017 LY294002 can decrease the expression of multidrug resistance protein-1 (MRP1) in NSCLC Dox-resistant cells. Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 29077148-11 2017 Furthermore, the combination of Dox and SSd had a stronger anticancer effect than Dox alone or SSd alone by inhibiting tumor growth and P-gp expression. Doxorubicin 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 29077148-11 2017 Furthermore, the combination of Dox and SSd had a stronger anticancer effect than Dox alone or SSd alone by inhibiting tumor growth and P-gp expression. Doxorubicin 82-85 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 27405391-6 2017 siRNA-micelle micelles could enhance the knockdown efficacy of siRNA by improving the transfection efficiency, downregulating P-gp expression, and passing the drug efflux transporters, thereby improving the therapeutic effects of Dox-micelle. Doxorubicin 230-233 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 28411377-0 2017 miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 29085470-3 2017 The SHG44/DOX cells grew continually in 0.1 microg/ml DOX and expressed increased levels of mRNA of multidrug resistance genes [multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1) and lung resistance protein (LRP)] compared with the parental SHG44 cells. Doxorubicin 10-13 ATP binding cassette subfamily B member 1 Homo sapiens 128-150 29085470-3 2017 The SHG44/DOX cells grew continually in 0.1 microg/ml DOX and expressed increased levels of mRNA of multidrug resistance genes [multidrug resistance 1 (MDR1), multidrug resistance-associated protein 1 (MRP1) and lung resistance protein (LRP)] compared with the parental SHG44 cells. Doxorubicin 10-13 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 29085470-5 2017 In addition, the levels of MDR1, MRP1 and LRP were downregulated by this traditional Chinese medicine, coupled with increased intracellular DOX concentrations. Doxorubicin 140-143 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 29190892-8 2017 Using genetic and pharmacological approaches, we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down. Doxorubicin 119-122 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 29190892-8 2017 Using genetic and pharmacological approaches, we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down. Doxorubicin 119-122 ATP binding cassette subfamily B member 1 Homo sapiens 160-164 29190892-8 2017 Using genetic and pharmacological approaches, we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down. Doxorubicin 210-213 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 29190892-8 2017 Using genetic and pharmacological approaches, we demonstrated that MDR1 and MRP4 were major effectors of H19-regulated Dox resistance in breast cancer cells as MDR1 and MRP4 expression was markedly elevated in Dox-resistant cells while dramatically reduced when H19 was knocked down. Doxorubicin 210-213 ATP binding cassette subfamily B member 1 Homo sapiens 160-164 29104509-3 2017 In a previous study, we have reported that a novel antisense lncRNA FOXF1-AS1, also known as FENDRR, could sensitize doxorubicin-resistance of OS cells through down-regulating ABCB1 and ABCC1. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 176-181 28411377-5 2017 The results indicated that the expression of MDR1 in the above cells or tumours was suppressed and that subsequently the drug accumulation in the MDR cells was decreased, cell death was increased, and tumour growth was inhibited after treatment with taxol-doxorubicin, demonstrating increased drug sensitivity. Doxorubicin 256-267 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 29056886-4 2017 One of Pgp-transportable agents, doxorubicin (DOX), was encapsulated in the hydrophobic core of the micelle and in the stem sequence of MB. Doxorubicin 33-44 ATP binding cassette subfamily B member 1 Homo sapiens 7-10 28405849-6 2017 However, accumulation of adriamycin and rhodamine 123 were increased which suggested the depression of P-gp activity. Doxorubicin 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 103-107 29056886-4 2017 One of Pgp-transportable agents, doxorubicin (DOX), was encapsulated in the hydrophobic core of the micelle and in the stem sequence of MB. Doxorubicin 46-49 ATP binding cassette subfamily B member 1 Homo sapiens 7-10 29056886-6 2017 With its relatively high enzymatic stability, a-MBM-DOX initially facilitated intracellular MDR1 mRNA imaging to distinguish multidrug-resistant and non-multidrug-resistant cells and subsequently downregulated the MDR1 gene expression owing to an antisense effect. Doxorubicin 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 29056886-6 2017 With its relatively high enzymatic stability, a-MBM-DOX initially facilitated intracellular MDR1 mRNA imaging to distinguish multidrug-resistant and non-multidrug-resistant cells and subsequently downregulated the MDR1 gene expression owing to an antisense effect. Doxorubicin 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 214-218 28667355-0 2017 Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1). Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 28323030-4 2017 In addition, transcription factor FOXC2 also contributes to doxorubicin resistance through inducing the expression of the classical multi-drug resistance-related ABCB1 gene similar to FOXC2-AS1. Doxorubicin 60-71 ATP binding cassette subfamily B member 1 Homo sapiens 162-167 28667355-6 2017 In addition, si-visfatin can significantly down regulate the expression of multidrug resistance 1 (MDR1), while not multidrug resistance-associated protein 1 or lung resistance-related protein, in both HCT-116 Dox/R and SW480 Dox/R cells. Doxorubicin 210-213 ATP binding cassette subfamily B member 1 Homo sapiens 75-97 28667355-6 2017 In addition, si-visfatin can significantly down regulate the expression of multidrug resistance 1 (MDR1), while not multidrug resistance-associated protein 1 or lung resistance-related protein, in both HCT-116 Dox/R and SW480 Dox/R cells. Doxorubicin 210-213 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 28667355-6 2017 In addition, si-visfatin can significantly down regulate the expression of multidrug resistance 1 (MDR1), while not multidrug resistance-associated protein 1 or lung resistance-related protein, in both HCT-116 Dox/R and SW480 Dox/R cells. Doxorubicin 226-229 ATP binding cassette subfamily B member 1 Homo sapiens 75-97 28667355-10 2017 Collectively, our present study revealed that visfatin mediates the Dox resistance of CRC cells via up regulation of MDR1. Doxorubicin 68-71 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 29151072-0 2017 The lactate receptor (HCAR1/GPR81) contributes to doxorubicin chemoresistance via ABCB1 transporter up-regulation in human cervical cancer HeLa cells. Doxorubicin 50-61 ATP binding cassette subfamily B member 1 Homo sapiens 82-87 29151072-3 2017 This study showed, for the first time, the mechanism of HCAR1-mediated chemoresistance to doxorubicin through regulation of ABCB1 transporter. Doxorubicin 90-101 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 28536971-0 2017 Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells. Doxorubicin 126-129 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 28536971-1 2017 PURPOSE: To select P-glycoprotein (P-gp) inhibitor from natural source for reversal of DOX resistance in K562 cells and to develop selected one in to nanoformulation in combination with DOX. Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 28536971-1 2017 PURPOSE: To select P-glycoprotein (P-gp) inhibitor from natural source for reversal of DOX resistance in K562 cells and to develop selected one in to nanoformulation in combination with DOX. Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 28536971-1 2017 PURPOSE: To select P-glycoprotein (P-gp) inhibitor from natural source for reversal of DOX resistance in K562 cells and to develop selected one in to nanoformulation in combination with DOX. Doxorubicin 186-189 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 28536971-1 2017 PURPOSE: To select P-glycoprotein (P-gp) inhibitor from natural source for reversal of DOX resistance in K562 cells and to develop selected one in to nanoformulation in combination with DOX. Doxorubicin 186-189 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 28536971-2 2017 METHODS: DOX resistant K562 (K562R) cells were developed and reversal of resistance by P-gp inhibitor was validated by co-treatment with verapamil. Doxorubicin 9-12 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 28536971-6 2017 RESULTS: P-gp inhibitors such as biochanin-A and curcumin were marked suitable for combination with DOX. Doxorubicin 100-103 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 28611294-7 2017 The expression levels of three genes, ABCB1, ABCB4 and IFI16, were upregulated in the Dox-resistant cell lines. Doxorubicin 86-89 ATP binding cassette subfamily B member 1 Homo sapiens 38-43 27878697-12 2017 It was speculated that the NFkappaB pathway directly acts on doxorubicin-induced MDR1 and MRP1 expression in MCF-7/Dox cells. Doxorubicin 61-72 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 27878697-12 2017 It was speculated that the NFkappaB pathway directly acts on doxorubicin-induced MDR1 and MRP1 expression in MCF-7/Dox cells. Doxorubicin 115-118 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 28106284-9 2017 Thus, we concluded that Pgp and BCRP expression can be regulated via cross-talk between doxorubicin and hypoxia, promoting drug resistance in HT-29 WT, and HT-29DxR cells and that this process may be ROS dependent. Doxorubicin 88-99 ATP binding cassette subfamily B member 1 Homo sapiens 24-27 28665335-8 2017 The present studies demonstrated that isoxanthohumol was a competitive ABCB1 inhibitor which reversed ABCB1-mediated doxorubicin resistance in MCF-7/ADR cells; and therefore could be further developed to help with overcoming ABCB1-mediated drug resistance. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 28665335-8 2017 The present studies demonstrated that isoxanthohumol was a competitive ABCB1 inhibitor which reversed ABCB1-mediated doxorubicin resistance in MCF-7/ADR cells; and therefore could be further developed to help with overcoming ABCB1-mediated drug resistance. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 28665335-8 2017 The present studies demonstrated that isoxanthohumol was a competitive ABCB1 inhibitor which reversed ABCB1-mediated doxorubicin resistance in MCF-7/ADR cells; and therefore could be further developed to help with overcoming ABCB1-mediated drug resistance. Doxorubicin 117-128 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 28788434-9 2017 In the ICC studies, it was demonstrated that certain concentrations of MLT and DOX cause an increase in the percentage of cells expressing P-gp, which correlates positively with ABCB1 expression (RT-PCR). Doxorubicin 79-82 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 28788434-9 2017 In the ICC studies, it was demonstrated that certain concentrations of MLT and DOX cause an increase in the percentage of cells expressing P-gp, which correlates positively with ABCB1 expression (RT-PCR). Doxorubicin 79-82 ATP binding cassette subfamily B member 1 Homo sapiens 178-183 28624793-9 2017 Importantly, BU remarkable increased the effect of DOX against the ABCB1 resistant HCT8/ADR colorectal cell xenografts in nude mice, without inducing any obvious toxicity. Doxorubicin 51-54 ATP binding cassette subfamily B member 1 Homo sapiens 67-72 28534954-4 2017 Among them, Icory significantly sensitized ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells to vincristine, doxorubicin and paclitaxel, but not to the non-ABCB1 substrate cisplatin. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 43-48 28534954-6 2017 Further mechanistic study revealed that Icory increased the intracellular accumulation of doxorubicin in ABCB1-overexpressing cells by blocking the efflux function of ABCB1. Doxorubicin 90-101 ATP binding cassette subfamily B member 1 Homo sapiens 105-110 28534954-6 2017 Further mechanistic study revealed that Icory increased the intracellular accumulation of doxorubicin in ABCB1-overexpressing cells by blocking the efflux function of ABCB1. Doxorubicin 90-101 ATP binding cassette subfamily B member 1 Homo sapiens 167-172 28106284-0 2017 Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions. Doxorubicin 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 46-49 28106284-2 2017 In this study, we investigated whether doxorubicin promotes Pgp and/or BCRP expression to induce drug resistance in colon cancer cells under hypoxic conditions. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 60-63 28106284-5 2017 We found that the combination of chemically induced hypoxia and doxorubicin promoted Pgp mRNA expression within 24 h in HT-29WT and HT-29DxR cells. Doxorubicin 64-75 ATP binding cassette subfamily B member 1 Homo sapiens 85-88 28106284-6 2017 Both doxorubicin and CoCl2 alone or in combination induced Pgp and BCRP expression, as demonstrated via confocal microscopy in each of the above two cell lines. Doxorubicin 5-16 ATP binding cassette subfamily B member 1 Homo sapiens 59-62 28106284-7 2017 Thus, we surmised that Pgp and BCRP expression may result from synergistic effects exerted by the combination of doxorubicin-induced ROS production and HIF-1alpha activity under hypoxic conditions. Doxorubicin 113-124 ATP binding cassette subfamily B member 1 Homo sapiens 23-26 28106284-8 2017 However, HIF-1alpha activity disruption via the administration of E3330, an APE-1 inhibitor, downregulated Pgp expression and increased doxorubicin delivery to HT-29 cells, where it served as a substrate for Pgp, indicating the existence of an indirect relationship between Pgp expression and doxorubicin accumulation. Doxorubicin 293-304 ATP binding cassette subfamily B member 1 Homo sapiens 208-211 28106284-8 2017 However, HIF-1alpha activity disruption via the administration of E3330, an APE-1 inhibitor, downregulated Pgp expression and increased doxorubicin delivery to HT-29 cells, where it served as a substrate for Pgp, indicating the existence of an indirect relationship between Pgp expression and doxorubicin accumulation. Doxorubicin 293-304 ATP binding cassette subfamily B member 1 Homo sapiens 208-211 28380403-6 2017 3p-siRNA-MDR1 transfection also enhanced the anti-leukaemia efficacy of doxorubicin. Doxorubicin 72-83 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 28693150-5 2017 Additionally, methotrexate and doxorubicin are the most widely used anticancer agents against osteosarcoma, and the observed enhanced chemoresistance of OS-TICs to these two agents could be associated with the upregulation of DHFR and MDR1. Doxorubicin 31-42 ATP binding cassette subfamily B member 1 Homo sapiens 235-239 28554760-0 2017 Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells. Doxorubicin 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 28323030-5 2017 Thus, we concluded that the lncRNA FOXC2-AS1 may promote doxorubicin resistance in OS by increasing the expression of transcription factor FOXC2, further facilitating ABCB1 expression. Doxorubicin 57-68 ATP binding cassette subfamily B member 1 Homo sapiens 167-172 28630426-1 2017 Adriamycin (ADR) induces the over-expression of P-glycoprotein (P-gp) and multiple drug resistance in breast cancer cells. Doxorubicin 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 28630426-1 2017 Adriamycin (ADR) induces the over-expression of P-glycoprotein (P-gp) and multiple drug resistance in breast cancer cells. Doxorubicin 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 28530401-4 2017 Here, zeolitic imidazolate framework ZIF-8, as one of the biocompatible metal organic frameworks (MOFs), is reported for the first time as the multidrug carrier to realizing the efficient codelivery of verapamil hydrochloride (VER) as the P-glycoprotein inhibitor as well as doxorubicin hydrochloride (DOX) as an anticancer drug to overcome the MDR in addition to realize the active targeted ability for an efficient anticancer effect. Doxorubicin 275-300 ATP binding cassette subfamily B member 1 Homo sapiens 239-253 28530401-4 2017 Here, zeolitic imidazolate framework ZIF-8, as one of the biocompatible metal organic frameworks (MOFs), is reported for the first time as the multidrug carrier to realizing the efficient codelivery of verapamil hydrochloride (VER) as the P-glycoprotein inhibitor as well as doxorubicin hydrochloride (DOX) as an anticancer drug to overcome the MDR in addition to realize the active targeted ability for an efficient anticancer effect. Doxorubicin 302-305 ATP binding cassette subfamily B member 1 Homo sapiens 239-253 28478351-3 2017 Present study focused on a novel porphyrin-based photosensitizer DTP (meso-5-[p-diethylene triamine pentaacetic acid-aminophenyl]-10,15,20-triphenyl-porphyrin)-mediated photocytotoxicity on MDR1 highly expressing human breast cancer cell line MCF-7/ADR (adriamycin resistant) and the parental MCF-7 cell line. Doxorubicin 254-264 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 28409628-2 2017 Poly(N-(2-hydroxypropyl) methacrylamide) (PHPMA)-based carriers that are able to release the anticancer drug doxorubicin in the lysosomes have shown promise to reduce P-gp mediated resistance. Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 28409628-4 2017 This work presents a strategy to maximize P-gp inhibition and enhance doxorubicin cytotoxicity in cancer cells by using a dual functional PHPMA conjugate carrying both the anticancer drug doxorubicin and the P-glycoprotein inhibitor zosuquidar (Zos). Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 208-222 28409628-4 2017 This work presents a strategy to maximize P-gp inhibition and enhance doxorubicin cytotoxicity in cancer cells by using a dual functional PHPMA conjugate carrying both the anticancer drug doxorubicin and the P-glycoprotein inhibitor zosuquidar (Zos). Doxorubicin 188-199 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 28409628-7 2017 Finally, the incorporation of both Dox and Zos in a single polymer carrier enhanced P-gp inhibition as compared to a control PHPMA conjugate containing only Dox. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 27250110-6 2017 The cellular uptake of DOX increased upon addition of free CQ, indicating that CQ may interact with P-gp and MRP1; however, the expressions of P-gp and MRP1 remained unchanged. Doxorubicin 23-26 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 29069754-0 2017 LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1. Doxorubicin 25-36 ATP binding cassette subfamily B member 1 Homo sapiens 94-99 28334432-6 2017 RESULT: The Adriamycin-resistant human breast cancer cells (MCF7/ADM) secreted exosomes carrying UCH-L1 and P-gp proteins into the extracellular microenvironment then integrated into Adriamycin-sensitive human breast cancer cells (MCF7/WT) in a time-dependent manner, transferring the chemoresistance phenotype. Doxorubicin 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 28463476-3 2017 A novel nanomicellar drug-delivery system as a carrier for doxorubicin (DOX) was developed, in which d-alpha-tocopheryl polyethylene glycol 1000 succinate was used as a P-gp inhibitor, alpha-tocopheryl succinate was introduced as a mitochondrial disrupting agent, and d-alpha-tocopheryl polyethylene glycol 2000 succinate was used as the main building block of micelles. Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 28463476-3 2017 A novel nanomicellar drug-delivery system as a carrier for doxorubicin (DOX) was developed, in which d-alpha-tocopheryl polyethylene glycol 1000 succinate was used as a P-gp inhibitor, alpha-tocopheryl succinate was introduced as a mitochondrial disrupting agent, and d-alpha-tocopheryl polyethylene glycol 2000 succinate was used as the main building block of micelles. Doxorubicin 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 29069754-6 2017 Together, our study demonstrated that lncRNA FENDRR may act as an inhibitory molecule of doxorubicin-resistance through down-regulating the expression of ABCB1 and ABCC1 genes in osteosarcoma cells. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 154-159 28342979-0 2017 Guggulsterone sensitized drug-resistant human hepatocarcinoma cells to doxorubicin through a Cox-2/P-gp dependent pathway. Doxorubicin 71-82 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 28342979-13 2017 The present study suggested that guggulsterone might enhance the cytotoxic effect of doxorubicin to PLC/PRF/5R cells through a Cox-2/P-gp dependent pathway. Doxorubicin 85-96 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 28223126-10 2017 Collectively, our data revealed that targeted inhibition of HDAC8 can suppress the growth of NB cells and increase Dox sensitivity via up regulation of miR-137 and suppression of MDR1. Doxorubicin 115-118 ATP binding cassette subfamily B member 1 Homo sapiens 179-183 28423656-7 2017 Further analysis revealed that the expressions of hypoxia-inducible factor-1alpha and multidrug resistance 1/P-glycoprotein decreased at both messenger RNA and protein levels by treatments with combined drugs compared to doxorubicin alone. Doxorubicin 221-232 ATP binding cassette subfamily B member 1 Homo sapiens 86-108 28423656-7 2017 Further analysis revealed that the expressions of hypoxia-inducible factor-1alpha and multidrug resistance 1/P-glycoprotein decreased at both messenger RNA and protein levels by treatments with combined drugs compared to doxorubicin alone. Doxorubicin 221-232 ATP binding cassette subfamily B member 1 Homo sapiens 109-123 28000875-6 2017 Furthermore, fulvestrant not only restored the intracellular accumulation of doxorubicin but also relocalized it to the nuclei in Bats-72 and Bads-200 cells, which may be another potential mechanism of reversal of P-gp mediated doxorubicin resistance. Doxorubicin 228-239 ATP binding cassette subfamily B member 1 Homo sapiens 214-218 29145976-3 2017 Upon repeated or even single dose treatment of cultured tumor cells or tumors in vivo with anti-tumor agents such as paclitaxel and doxorubicin, increased ABCB1 copy number has been demonstrated, resulting from chromosomal amplification events at 7q11.2-21 locus, leading to marked P-glycoprotein overexpression, and multidrug resistance (MDR). Doxorubicin 132-143 ATP binding cassette subfamily B member 1 Homo sapiens 155-160 29145976-3 2017 Upon repeated or even single dose treatment of cultured tumor cells or tumors in vivo with anti-tumor agents such as paclitaxel and doxorubicin, increased ABCB1 copy number has been demonstrated, resulting from chromosomal amplification events at 7q11.2-21 locus, leading to marked P-glycoprotein overexpression, and multidrug resistance (MDR). Doxorubicin 132-143 ATP binding cassette subfamily B member 1 Homo sapiens 282-296 28358418-6 2017 We respectively knocked down the expression of Apollon and MDR1 using short hairpin RNA (shRNA) in adriamycin (ADM) resistant human CML K562 cells and examined the drug sensitivity, the consequences with regard to ADM accumulation and the alterations in the expression of Apollon and MDR1. Doxorubicin 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 28487651-3 2017 Among these, the non-cytotoxic lignan (+-) pinoresinol successfully restored sensitivity to doxorubicin from 7 muM in the P-gp overexpressed human myelogenous leukemia cells, Lucena 1. Doxorubicin 92-103 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 28070974-4 2017 In this work, we successfully developed a smart stimulus-responsive short peptide-assembled system, termed as PD/VER nanogels, which synergistically combined the acid-activatable antitumor prodrug doxorubicin (Dox) with the P-gp inhibitor verapamil (VER) for reversing MDR. Doxorubicin 197-208 ATP binding cassette subfamily B member 1 Homo sapiens 224-228 28070974-4 2017 In this work, we successfully developed a smart stimulus-responsive short peptide-assembled system, termed as PD/VER nanogels, which synergistically combined the acid-activatable antitumor prodrug doxorubicin (Dox) with the P-gp inhibitor verapamil (VER) for reversing MDR. Doxorubicin 210-213 ATP binding cassette subfamily B member 1 Homo sapiens 224-228 27989702-7 2017 Confocal laser scanning microscope (CLSM) images confirmed that the amount of DOX-EPNs internalized by Caco-2 cells was higher than that of DOX-Sol showing that P-glycoprotein-mediated drug efflux was reduced by the introduction of EPNs. Doxorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 161-175 27989702-7 2017 Confocal laser scanning microscope (CLSM) images confirmed that the amount of DOX-EPNs internalized by Caco-2 cells was higher than that of DOX-Sol showing that P-glycoprotein-mediated drug efflux was reduced by the introduction of EPNs. Doxorubicin 140-143 ATP binding cassette subfamily B member 1 Homo sapiens 161-175 32263875-6 2017 More significantly, Dox/Mito-DGL was successfully applied to improve the efficacy towards multi-drug resistant cancer cells by altering the mitochondrial membrane potential and bypassing the P-glycoprotein-mediated drug efflux. Doxorubicin 20-23 ATP binding cassette subfamily B member 1 Homo sapiens 191-205 27885740-4 2017 Furthermore, ASP5878 inhibited cell proliferation of adriamycin-resistant UM-UC-14 cell line harboring MDR1 overexpression and gemcitabine-resistant RT-112 cell line. Doxorubicin 53-63 ATP binding cassette subfamily B member 1 Homo sapiens 103-107 28665335-0 2017 Prenylflavonoid Isoxanthohumol Sensitizes MCF-7/ADR Cells to Doxorubicin Cytotoxicity via Acting as a Substrate of ABCB1. Doxorubicin 61-72 ATP binding cassette subfamily B member 1 Homo sapiens 115-120 28665335-6 2017 Molecular mechanism studies further demonstrated that isoxanthohumol inhibited ABCB1-mediated doxorubicin efflux; stimulated the ATPase activity of ABCB1 (ATP-binding cassette sub-family B member 1); and acted as an ABCB1 substrate. Doxorubicin 94-105 ATP binding cassette subfamily B member 1 Homo sapiens 79-84 28665335-7 2017 Molecular docking results suggested that isoxanthohumol bound to the central transmembrane domain of ABCB1 and its binding site overlapped with the doxorubicin binding site. Doxorubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 28303028-4 2017 Mechanistically, alectinib increased the intracellular accumulation of ABCB1/ABCG2 substrates such as doxorubicin (DOX) and Rhodamine 123 (Rho 123) by inhibiting the efflux function of the transporters in ABCB1- or ABCG2-overexpressing cells but not in their parental sensitive cells. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 28303028-4 2017 Mechanistically, alectinib increased the intracellular accumulation of ABCB1/ABCG2 substrates such as doxorubicin (DOX) and Rhodamine 123 (Rho 123) by inhibiting the efflux function of the transporters in ABCB1- or ABCG2-overexpressing cells but not in their parental sensitive cells. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 205-210 28303028-4 2017 Mechanistically, alectinib increased the intracellular accumulation of ABCB1/ABCG2 substrates such as doxorubicin (DOX) and Rhodamine 123 (Rho 123) by inhibiting the efflux function of the transporters in ABCB1- or ABCG2-overexpressing cells but not in their parental sensitive cells. Doxorubicin 115-118 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 28184922-4 2017 Apoptosis of anti-cancer drugs and accumulation of doxorubicin (DOX) and Rhodamine 123 (Rho123) in P-gp overexpressing cells were evaluated by flow cytometry. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 28184922-6 2017 CBF enhanced the effect of DOX against P-gp-overexpressing LoVo/ADR cell xenografts in nude mice. Doxorubicin 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 27123551-10 2017 Our results demonstrate SSA could increase the chemosensitivity of P-gp overexpressing HepG2/ADM and MCF-7/ADR cells to doxorubicin (DOX), vincristine (VCR) and paclitaxel. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 27123551-10 2017 Our results demonstrate SSA could increase the chemosensitivity of P-gp overexpressing HepG2/ADM and MCF-7/ADR cells to doxorubicin (DOX), vincristine (VCR) and paclitaxel. Doxorubicin 133-136 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 27123551-12 2017 Moreover, it could also increase the retention of P-gp substrates DOX and rhodamine 123 in MCF-7/ADR cells, and decrease digoxin efflux ratio in Caco-2 cell monolayer. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 28052008-0 2017 Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Doxorubicin 149-152 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 28052008-0 2017 Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Doxorubicin 162-173 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 28125071-0 2017 Backstabbing P-gp: Side-Chain Cleaved Ecdysteroid 2,3-Dioxolanes Hyper-Sensitize MDR Cancer Cells to Doxorubicin without Efflux Inhibition. Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 27816545-5 2017 Furthermore, LY2835219 significantly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 141-146 28421447-3 2017 P-gp blocker verapamil suppressed doxorubicin accumulation leading to cell death induction. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 27816545-5 2017 Furthermore, LY2835219 significantly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells. Doxorubicin 94-97 ATP binding cassette subfamily B member 1 Homo sapiens 141-146 27835872-6 2016 Inhibition of ABCB1 was associated with reversing drug resistance in osteosarcoma MDR cell lines (KHOSR2 and U-2OSR2) to doxorubicin. Doxorubicin 121-132 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 28036387-0 2016 Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients. Doxorubicin 71-82 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 28036387-3 2016 The ABCB1 and SLC22A16 genes encode proteins that are essential for doxorubicin transport. Doxorubicin 68-79 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 27825801-5 2016 Our findings showed that DHA-E3 significantly potentiated the cytotoxicity of vincristine(VCR) and adriamycin(ADR) in the P-gp over-expressing KB/VCR and A02 cells. Doxorubicin 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 27780727-5 2016 Taken together, our findings demonstrated that hypermethylation of Notch3 causes activation of P-glycoprotein in adriamycin-resistant cells. Doxorubicin 113-123 ATP binding cassette subfamily B member 1 Homo sapiens 95-109 27753480-3 2016 These compounds were able to decrease efficiently Pgp mediated influx and efflux of rhodamine-123 (Rho) and to restore the cytotoxicity of vinorelbine 3 (VLN) and doxorubicin (Dox) on K562R (dox-resistant) cell lines. Doxorubicin 163-174 ATP binding cassette subfamily B member 1 Homo sapiens 50-53 27753480-3 2016 These compounds were able to decrease efficiently Pgp mediated influx and efflux of rhodamine-123 (Rho) and to restore the cytotoxicity of vinorelbine 3 (VLN) and doxorubicin (Dox) on K562R (dox-resistant) cell lines. Doxorubicin 176-179 ATP binding cassette subfamily B member 1 Homo sapiens 50-53 27841296-0 2016 Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity. Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 113-127 27906178-0 2016 A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 27906178-3 2016 Both Dp44mT and DpC potently target and kill Pgp-expressing tumors, while DOX effectively kills non-Pgp-expressing cancers. Doxorubicin 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 100-103 27906178-7 2016 Notably, the combination of Dp44mT or DpC with DOX showed a very high level of synergism in multiple Pgp-expressing cell types, for example, cervical, breast and colorectal cancer cells. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 101-104 27906178-12 2016 The synergistic and potent anti-tumor efficacy observed between DOX and thiosemicarbazones represents a promising treatment combination for advanced cancers, which are heterogeneous and composed of non-Pgp- and Pgp-expressing tumor cells. Doxorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 202-205 27906178-12 2016 The synergistic and potent anti-tumor efficacy observed between DOX and thiosemicarbazones represents a promising treatment combination for advanced cancers, which are heterogeneous and composed of non-Pgp- and Pgp-expressing tumor cells. Doxorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 211-214 27697501-3 2016 The potency of these compounds to modulate Pgp-mediated MDR was evaluated through daunorubicin accumulation and potentiation of doxorubicin cytotoxicity in K562/R7 multidrug resistant cells overexpressing Pgp. Doxorubicin 128-139 ATP binding cassette subfamily B member 1 Homo sapiens 43-46 27466354-2 2016 A total of 40% to 45% of high-grade osteosarcoma patients are unresponsive, or only partially responsive, to doxorubicin (Dox), due to the overexpression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 185-190 27466354-2 2016 A total of 40% to 45% of high-grade osteosarcoma patients are unresponsive, or only partially responsive, to doxorubicin (Dox), due to the overexpression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). Doxorubicin 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 185-190 27466354-2 2016 A total of 40% to 45% of high-grade osteosarcoma patients are unresponsive, or only partially responsive, to doxorubicin (Dox), due to the overexpression of the drug efflux transporter ABCB1/P-glycoprotein (Pgp). Doxorubicin 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 191-205 27588398-8 2016 Inhibition of ABCB1 partially restored paclitaxel and doxorubicin sensitivity. Doxorubicin 54-65 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 27664577-12 2016 Silencing of ABCB1 expression using specific siRNA increased significantly, but did not completely restore full sensitivity to both paclitaxel and doxorubicin. Doxorubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 27754360-11 2016 We showed that Rack1 regulated P-gp activity, which was necessary for adriamycin-induced P-gp-mediated phosphorylation of Anxa2 and Erk1/2. Doxorubicin 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 27683125-8 2016 DISCUSSION: These results indicate that the reduced ASS1 expression in Dox-resistant sarcomas may contribute to drug resistance in association with the expression of P-gp. Doxorubicin 71-74 ATP binding cassette subfamily B member 1 Homo sapiens 166-170 27683125-11 2016 METHODS: We assessed the expressions of ASS1 and P-glycoprotein (P-gp) in clinical specimens and cell lines of osteosarcoma (KHOS), doxorubicin (Dox)-resistant osteosarcoma (KHOSR2), epithelioid sarcomas (ES-X and VAESBJ) and alveolar soft part sarcoma (ASPS-KY). Doxorubicin 132-143 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 27683125-11 2016 METHODS: We assessed the expressions of ASS1 and P-glycoprotein (P-gp) in clinical specimens and cell lines of osteosarcoma (KHOS), doxorubicin (Dox)-resistant osteosarcoma (KHOSR2), epithelioid sarcomas (ES-X and VAESBJ) and alveolar soft part sarcoma (ASPS-KY). Doxorubicin 145-148 ATP binding cassette subfamily B member 1 Homo sapiens 49-63 27754360-11 2016 We showed that Rack1 regulated P-gp activity, which was necessary for adriamycin-induced P-gp-mediated phosphorylation of Anxa2 and Erk1/2. Doxorubicin 70-80 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 27785023-7 2016 These results implied that the polymeric micelles displayed great potentials as P-gp modulators to reverse DOX resistance in MCF-7/ADR breast carcinoma. Doxorubicin 107-110 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 27503929-4 2016 Doxorubicin resistance conferred by loss of the SMARCB1 subunit of the SWI/SNF complex was caused by transcriptional upregulation of a single gene, encoding the multidrug resistance pump ABCB1. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 187-192 27306525-0 2016 Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Doxorubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 27306525-0 2016 Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Doxorubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 27306525-0 2016 Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Doxorubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 27306525-0 2016 Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers. Doxorubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 171-175 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 44-74 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 128-131 ATP binding cassette subfamily B member 1 Homo sapiens 44-74 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 128-131 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 128-131 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 128-131 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 234-237 ATP binding cassette subfamily B member 1 Homo sapiens 44-74 27306525-2 2016 Here, we set out to assess the roles of the multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-gp) in the doxorubicin (DOX) resistance of NSCLC cells, as well as the putative therapeutic efficacy of MRP1 and P-gp blockers on DOX-treated NSCLC cells. Doxorubicin 234-237 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 27306525-4 2016 RESULTS: We found that in response to DOX treatment, NSCLC cells that express high levels of MRP1 and P-gp (such as CH27) showed a better DOX efflux and a higher DOX resistance. Doxorubicin 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 27306525-4 2016 RESULTS: We found that in response to DOX treatment, NSCLC cells that express high levels of MRP1 and P-gp (such as CH27) showed a better DOX efflux and a higher DOX resistance. Doxorubicin 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 27306525-4 2016 RESULTS: We found that in response to DOX treatment, NSCLC cells that express high levels of MRP1 and P-gp (such as CH27) showed a better DOX efflux and a higher DOX resistance. Doxorubicin 138-141 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 27306525-4 2016 RESULTS: We found that in response to DOX treatment, NSCLC cells that express high levels of MRP1 and P-gp (such as CH27) showed a better DOX efflux and a higher DOX resistance. Doxorubicin 138-141 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 27306525-4 2016 RESULTS: We found that in response to DOX treatment, NSCLC cells that express high levels of MRP1 and P-gp (such as CH27) showed a better DOX efflux and a higher DOX resistance. Doxorubicin 138-141 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 27306525-4 2016 RESULTS: We found that in response to DOX treatment, NSCLC cells that express high levels of MRP1 and P-gp (such as CH27) showed a better DOX efflux and a higher DOX resistance. Doxorubicin 138-141 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 27306525-6 2016 We also found that hypoxia could inhibit MRP1 and P-gp expression in a HIF-1alpha-dependent manner, abolish DOX resistance and boost the chemosensitizer effect of MK571 and Verapamil on DOX treatment of all the NSCLC cells tested, except the DOX-resistant CH27 cells. Doxorubicin 186-189 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 27306525-6 2016 We also found that hypoxia could inhibit MRP1 and P-gp expression in a HIF-1alpha-dependent manner, abolish DOX resistance and boost the chemosensitizer effect of MK571 and Verapamil on DOX treatment of all the NSCLC cells tested, except the DOX-resistant CH27 cells. Doxorubicin 186-189 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 27306525-7 2016 CONCLUSIONS: From our data we conclude that MRP1 and P-gp play critical roles in the DOX resistance of the NSCLC cells tested. Doxorubicin 85-88 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 27306525-7 2016 CONCLUSIONS: From our data we conclude that MRP1 and P-gp play critical roles in the DOX resistance of the NSCLC cells tested. Doxorubicin 85-88 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 27306525-8 2016 MRP1 and P-gp targeted therapy using MK571, Verapamil, CoCl2 or ambient hypoxia appeared to be promising in abolishing the DOX efflux and DOX resistance of the NSCLC cells. Doxorubicin 123-126 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 27306525-8 2016 MRP1 and P-gp targeted therapy using MK571, Verapamil, CoCl2 or ambient hypoxia appeared to be promising in abolishing the DOX efflux and DOX resistance of the NSCLC cells. Doxorubicin 123-126 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 27306525-8 2016 MRP1 and P-gp targeted therapy using MK571, Verapamil, CoCl2 or ambient hypoxia appeared to be promising in abolishing the DOX efflux and DOX resistance of the NSCLC cells. Doxorubicin 138-141 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 27306525-8 2016 MRP1 and P-gp targeted therapy using MK571, Verapamil, CoCl2 or ambient hypoxia appeared to be promising in abolishing the DOX efflux and DOX resistance of the NSCLC cells. Doxorubicin 138-141 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 27444552-5 2016 Also, HSPCs encapsulating siMDR1 knockdowned 99.4% MDR1 gene with up to ~6 times of enhancement compared to naked siMDR1, increased the doxorubicin accumulation, down-regulated P-glycoprotein (P-gp) expression and suppressed cellular migration in breast cancer MCF-7/ADR cells. Doxorubicin 136-147 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 27841296-10 2016 Both RES and DID significantly enhanced the intracellular entrapment of DOX due to blocking the efflux activity of p-glycoprotein pump. Doxorubicin 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 27566564-3 2016 We considered the typical acidic extracellular pH (pHe) of sarcomas, and found that doxorubicin (DXR) cytotoxicity is reduced in P-gp negative OS cells cultured at pHe 6.5 compared to standard 7.4. Doxorubicin 84-95 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 27725879-4 2016 Knockout of ABCB1 by CRISPR/Cas9 system significantly enhances the sensitivity of ABCB1 substrate chemotherapeutic agents and the intracellular accumulation of rhodamine 123 and doxorubicin in MDR cancer cells. Doxorubicin 178-189 ATP binding cassette subfamily B member 1 Homo sapiens 12-17 27295567-9 2016 Collectively, our data establish a hitherto unknown liaison among MDR1, BMI1 and TIP60 and provide mechanistic insights into cisplatin-induced MDR1 expression resulting in acquired cross-resistance against paclitaxel, doxorubicin and likely other drugs. Doxorubicin 218-229 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 27621764-2 2016 METHODS: Expression of P-glycoprotein (P-gp) and NF-kappaB in human HepG2 or HepG2/adriamycin (ADM) cells treated with pCMV-NF-kappaB-small interference RNA (siRNA) with or without metformin, was analyzed by Western blot or fluorescence quantitative PCR. Doxorubicin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 23-37 27621764-2 2016 METHODS: Expression of P-glycoprotein (P-gp) and NF-kappaB in human HepG2 or HepG2/adriamycin (ADM) cells treated with pCMV-NF-kappaB-small interference RNA (siRNA) with or without metformin, was analyzed by Western blot or fluorescence quantitative PCR. Doxorubicin 83-93 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 27318188-13 2016 The control P-gp inhibitor, verapamil, partially increased doxorubicin uptake in CEM/ADR5000 cells. Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 27415012-8 2016 Active efflux of paclitaxel, olaparib, doxorubicin and rucaparib was confirmed in drug-resistant cells and in ABCB1-expressing bacterial membranes. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 27131064-6 2016 In particular, the compound 5a sensitized ABCB1/Flp-In -293 cells toward paclitaxel, vincristine, and doxorubicin by 16.1, 21.0, and 1.6-fold at 10 muM, respectively. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 42-47 27683125-15 2016 Moreover, we assessed the expression of P-gp after suppressing ASS1 in Dox-sensitive cells (MCF-7 and KHOS) and after transfecting ASS1 into Dox-resistant cells (ES-X, VAESBJ, ASPS-KY and KHOSR2). Doxorubicin 71-74 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 27486760-0 2016 Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma. Doxorubicin 72-83 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 27486760-3 2016 DOX induced P-gp expression, which was associated with increased GRP78 levels and Akt activation in vitro and in vivo. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 27486760-4 2016 Functional analysis showed that Akt induces P-gp and GRP78 expression, which contributes to the DOX-induced Akt activation. Doxorubicin 96-99 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 27286705-7 2016 Uptake experiments with doxorubicin (DOX), a P-gp substrate, revealed that DOX accumulation was significantly decreased in Ad vector-infected A549 cells. Doxorubicin 24-35 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 27286705-7 2016 Uptake experiments with doxorubicin (DOX), a P-gp substrate, revealed that DOX accumulation was significantly decreased in Ad vector-infected A549 cells. Doxorubicin 37-40 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 27286705-7 2016 Uptake experiments with doxorubicin (DOX), a P-gp substrate, revealed that DOX accumulation was significantly decreased in Ad vector-infected A549 cells. Doxorubicin 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 27286705-8 2016 The decrease of DOX uptake was blocked by verapamil, a P-gp inhibitor. Doxorubicin 16-19 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 27088190-2 2016 In this study, we designed micellar vectors for doxorubicin based on amphiphilic copolymers sequentially linking beta-cyclodextrin (beta-CD), polylacticacid (PLA) or polycaprolactone (PCL) block, and polyethylene glycol (PEG) block to overcome drug resistance in human acute myeloid leukemia cells (HL60/ADR) overexpressing multidrug resistance protein 1 (MRP1). Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 324-354 27088190-2 2016 In this study, we designed micellar vectors for doxorubicin based on amphiphilic copolymers sequentially linking beta-cyclodextrin (beta-CD), polylacticacid (PLA) or polycaprolactone (PCL) block, and polyethylene glycol (PEG) block to overcome drug resistance in human acute myeloid leukemia cells (HL60/ADR) overexpressing multidrug resistance protein 1 (MRP1). Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 356-360 27196753-3 2016 Mechanistically, osimertinib increased the intracellular accumulations of doxorubicin (DOX) and Rhodamine 123 (Rho 123) by inhibiting the efflux function of the transporters in ABCB1- or ABCG2-overexpressing cells but not in their parental sensitive cells. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 177-182 27196753-3 2016 Mechanistically, osimertinib increased the intracellular accumulations of doxorubicin (DOX) and Rhodamine 123 (Rho 123) by inhibiting the efflux function of the transporters in ABCB1- or ABCG2-overexpressing cells but not in their parental sensitive cells. Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 177-182 27058921-4 2016 Tangeretin profoundly inhibited the ABCB1 transporter activity since it significantly increased the intracellular accumulation of doxorubicin, and flutax-2 in A2780/T cells and decreased the efflux of ABCB1 substrates in Caco2 cells without altering the expression of ABCB1. Doxorubicin 130-141 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 27405085-5 2016 ABCB1 overexpression increased the resistance of cells to doxorubicin, vinblastine and TKIs. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 27784426-6 2016 Results: After being treated by adriamycin, hepatoma cells showed increased expression of P-gp and an increased level of NF-kappaB phosphorylation. Doxorubicin 32-42 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 27154979-7 2016 In this way, classical Pgp substrates, such as doxorubicin (DOX), can be actively transported into this organelle. Doxorubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 23-26 27154979-7 2016 In this way, classical Pgp substrates, such as doxorubicin (DOX), can be actively transported into this organelle. Doxorubicin 60-63 ATP binding cassette subfamily B member 1 Homo sapiens 23-26 27272776-10 2016 DOX treatment (Group 4) resulted in significant reduction in tumor size in the Bel-7402/ADMsi tumor model (p<0.05), indicating reversal of multidrug resistance in tumor by MDR1 siRNA. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 175-179 27176642-10 2016 Our findings suggest that multidrug resistant osteosarcoma cells are able to spread their ability to resist the effects of doxorubicin treatment on sensitive cells by transferring exosomes carrying MDR-1 mRNA and its product P-glycoprotein. Doxorubicin 123-134 ATP binding cassette subfamily B member 1 Homo sapiens 198-203 26733176-0 2016 Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Doxorubicin 157-160 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 26733176-0 2016 Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin. Doxorubicin 170-181 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 26733176-4 2016 Metformin was not a substrate of P-gp but suppressed the elevated level of P-gp in K562/Dox cells. Doxorubicin 88-91 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 26733176-8 2016 Above all, P-gp substrate selectively aggravated this ATP depletion effect and increased cell apoptosis in K562/Dox cells. Doxorubicin 112-115 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 26733176-9 2016 In conclusion, metformin decreases P-gp expression in K562/Dox cells via blocking phosphorylation of extracellular signal-regulated kinase. Doxorubicin 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 26733176-10 2016 P-gp substrate increases K562/Dox cell apoptosis via aggravating ATP depletion induced by combination of metformin and 2-deoxyglucose. Doxorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 27272776-13 2016 CONCLUSION: In vitro transfection of siRNAs" vectors targeting the MDR1 gene can effectively silence MDR1 mRNA and P-gp expression in DOX-resistant human hepatocellular carcinoma Bel-7402/ADM cells that resulted in reversal of multidrug resistance to DOX in the xenograft tumor model. Doxorubicin 134-137 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 27272776-13 2016 CONCLUSION: In vitro transfection of siRNAs" vectors targeting the MDR1 gene can effectively silence MDR1 mRNA and P-gp expression in DOX-resistant human hepatocellular carcinoma Bel-7402/ADM cells that resulted in reversal of multidrug resistance to DOX in the xenograft tumor model. Doxorubicin 134-137 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 27272776-13 2016 CONCLUSION: In vitro transfection of siRNAs" vectors targeting the MDR1 gene can effectively silence MDR1 mRNA and P-gp expression in DOX-resistant human hepatocellular carcinoma Bel-7402/ADM cells that resulted in reversal of multidrug resistance to DOX in the xenograft tumor model. Doxorubicin 134-137 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 27272776-13 2016 CONCLUSION: In vitro transfection of siRNAs" vectors targeting the MDR1 gene can effectively silence MDR1 mRNA and P-gp expression in DOX-resistant human hepatocellular carcinoma Bel-7402/ADM cells that resulted in reversal of multidrug resistance to DOX in the xenograft tumor model. Doxorubicin 251-254 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 27272776-13 2016 CONCLUSION: In vitro transfection of siRNAs" vectors targeting the MDR1 gene can effectively silence MDR1 mRNA and P-gp expression in DOX-resistant human hepatocellular carcinoma Bel-7402/ADM cells that resulted in reversal of multidrug resistance to DOX in the xenograft tumor model. Doxorubicin 251-254 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 27272776-13 2016 CONCLUSION: In vitro transfection of siRNAs" vectors targeting the MDR1 gene can effectively silence MDR1 mRNA and P-gp expression in DOX-resistant human hepatocellular carcinoma Bel-7402/ADM cells that resulted in reversal of multidrug resistance to DOX in the xenograft tumor model. Doxorubicin 251-254 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 27029378-4 2016 The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells. Doxorubicin 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 193-207 27082231-6 2016 The ability of psoralen to modulate the transport activity of P-gp in MCF-7/ADR cells was evaluated by measuring the accumulation and efflux of rhodamine 123 (Rh 123) and adriamycin with flow cytometry. Doxorubicin 171-181 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 27029378-4 2016 The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells. Doxorubicin 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 209-213 27029378-4 2016 The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells. Doxorubicin 249-252 ATP binding cassette subfamily B member 1 Homo sapiens 193-207 27029378-4 2016 The codelivery of miR-129-5p and DOX with LCss (DLCss/miR) significantly increased miR-129-5p expression over 100-fold in MCF-7/ADR cells, which effectively overcame MDR by directly inhibiting P-glycoprotein (P-gp), thereby increasing intracellular DOX accumulation and cytotoxicity in MCF-7/ADR cells. Doxorubicin 249-252 ATP binding cassette subfamily B member 1 Homo sapiens 209-213 27035504-3 2016 The present study aimed to investigate the reversal of MDR by silencing homeobox A10 (HOXA10) in adriamycin (ADR)-resistant human chronic myelogenous leukemia (CML) K562/ADM cells by modulating the expression of P-gp and MRP-1. Doxorubicin 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 212-216 26844637-8 2016 Interestingly, although single exposure to NFV transiently induced P-glycoprotein (P-gp) levels, multiple treatments with NFV inhibited both P-gp expression and efflux function, which increased intracellular DOX concentrations. Doxorubicin 208-211 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 27035504-3 2016 The present study aimed to investigate the reversal of MDR by silencing homeobox A10 (HOXA10) in adriamycin (ADR)-resistant human chronic myelogenous leukemia (CML) K562/ADM cells by modulating the expression of P-gp and MRP-1. Doxorubicin 97-107 ATP binding cassette subfamily B member 1 Homo sapiens 221-226 26821347-8 2016 Meanwhile, the detection cycle could be shortened from 12 to 2 h. Furthermore, this hDAuNP beacon can serve as an antisense agent to down-regulate P-gp expression and to reverse drug resistance of MCF-7/Adr cells to doxorubicin. Doxorubicin 216-227 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 26596829-0 2016 Differential effects of c-myc and ABCB1 silencing on reversing drug resistance in HepG2/Dox cells. Doxorubicin 88-91 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 26596829-7 2016 Results obtained, with regard to ABCB1 silencing on HepG2/Dox cells, have shown that ABCB1-deficient cells exhibited a significant reduction in ABCC1 expression as compared to ABCB1-sufficient cells. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 33-38 26596829-7 2016 Results obtained, with regard to ABCB1 silencing on HepG2/Dox cells, have shown that ABCB1-deficient cells exhibited a significant reduction in ABCC1 expression as compared to ABCB1-sufficient cells. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 26596829-7 2016 Results obtained, with regard to ABCB1 silencing on HepG2/Dox cells, have shown that ABCB1-deficient cells exhibited a significant reduction in ABCC1 expression as compared to ABCB1-sufficient cells. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 26764104-5 2016 Interestingly the equivalent dose of free DOX was more toxic to 3T3 than to Caco2 cells, reducing the 3T3 viability to 72% and the Caco2 viability to 80%, which is likely due to the presence of the p-glycoprotein pumps in Caco2 cells. Doxorubicin 42-45 ATP binding cassette subfamily B member 1 Homo sapiens 198-212 26969380-9 2016 CONCLUSIONS: Our findings indicated that sinapine played an important role in the downregulation of MDR1 expression through suppression of fibroblast growth factor receptor (FGFR)4/FRS2alpha-ERK1/2 mediated NF-kappaB activation in MCF-7/dox cancer cells. Doxorubicin 237-240 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 26887049-5 2016 LP117, the compound that exerted the strongest effect on ABCB1, interfered in the investigated concentrations of up to 2muM with the ABCB1-mediated transport of vincristine, vinorelbine, actinomycin D, paclitaxel, and calcein-AM but not of doxorubicin, rhodamine 123, or JC-1. Doxorubicin 240-251 ATP binding cassette subfamily B member 1 Homo sapiens 133-138 26874277-0 2016 Prolyl isomerase Pin1 regulates doxorubicin-inducible P-glycoprotein level by reducing Foxo3 stability. Doxorubicin 32-43 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 26891792-2 2016 To understand the molecular mechanisms regulating chemotherapeutic responses to doxorubicin, we previously carried out a genomewide search of doxorubicin-resistance genes in Schizosaccharomyces pombe fission yeast and showed that these genes are organized into networks that counteract doxorubicin cytotoxicity. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 142-164 26846508-0 2016 Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription. Doxorubicin 32-43 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 26846508-0 2016 Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription. Doxorubicin 45-48 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 26846508-10 2016 CONCLUSIONS: Our data revealed that HDAC2 can regulate Dox sensitivity of CRC cells by targeting ABCB1 transcription. Doxorubicin 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 97-102 26842910-0 2016 MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). Doxorubicin 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 90-104 26998164-5 2016 Subsequently, the expression of two multidrug resistance proteins, P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1), was analyzed in K562/DOX cells. Doxorubicin 153-156 ATP binding cassette subfamily B member 1 Homo sapiens 93-123 26998164-5 2016 Subsequently, the expression of two multidrug resistance proteins, P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP1), was analyzed in K562/DOX cells. Doxorubicin 153-156 ATP binding cassette subfamily B member 1 Homo sapiens 125-129 27152241-2 2016 In addition, morphine seems to mediate the uptake of Dox into the brain by its reduced efflux mediated by P-glycoprotein (P-gp). Doxorubicin 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 106-120 27152241-2 2016 In addition, morphine seems to mediate the uptake of Dox into the brain by its reduced efflux mediated by P-glycoprotein (P-gp). Doxorubicin 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 27152241-6 2016 Additionally, we investigated the role of morphine on the uptake of Dox by MDCKII cells transfected with human MDR1 gene encoding for P-gp. Doxorubicin 68-71 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 27152241-6 2016 Additionally, we investigated the role of morphine on the uptake of Dox by MDCKII cells transfected with human MDR1 gene encoding for P-gp. Doxorubicin 68-71 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 27152241-10 2016 Additionally, Dox increased in MDCKII-P-gp transfected cells only in the presence of morphine with a significantly higher level comparing control group (3.84) vs Dox plus morphine group (12.29, P<0.05). Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 26601947-2 2016 Lysosomal-Pgp can pump substrates into the organelle, thereby trapping certain chemotherapeutics (e.g. doxorubicin; DOX). Doxorubicin 103-114 ATP binding cassette subfamily B member 1 Homo sapiens 10-13 26601947-2 2016 Lysosomal-Pgp can pump substrates into the organelle, thereby trapping certain chemotherapeutics (e.g. doxorubicin; DOX). Doxorubicin 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 10-13 26601947-12 2016 This lysosomal-Pgp actively transported the Pgp substrate, DOX, into the lysosome where it became trapped as a result of protonation at pH 5. Doxorubicin 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 15-18 26601947-12 2016 This lysosomal-Pgp actively transported the Pgp substrate, DOX, into the lysosome where it became trapped as a result of protonation at pH 5. Doxorubicin 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 44-47 26601947-13 2016 Due to increased lysosomal DOX trapping, Pgp-expressing cells became more resistant to DOX. Doxorubicin 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 41-44 26601947-13 2016 Due to increased lysosomal DOX trapping, Pgp-expressing cells became more resistant to DOX. Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 41-44 26842910-0 2016 MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). Doxorubicin 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 26842910-18 2016 CONCLUSION: Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. Doxorubicin 94-104 ATP binding cassette subfamily B member 1 Homo sapiens 121-135 26408180-9 2016 Thus, we concluded that lncRNA ODRUL may act as a pro-doxorubicin-resistant molecule through inducing the expression of the classical multidrug resistance-related ABCB1 gene in osteosarcoma cells .These findings may provide a novel target for reversing doxorubicin resistance in OS. Doxorubicin 54-65 ATP binding cassette subfamily B member 1 Homo sapiens 163-168 26655793-5 2016 Driven by the "core-shell" structure and the electrostatic interaction, this triblock copolymer could efficiently encapsulate P-glycoprotein (P-gp) siRNA and doxorubicin (DOX). Doxorubicin 171-174 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 26655793-7 2016 Compared to the non-specific delivery, these FA functionalized nanomicelles could efficiently deliver P-gp siRNA to reducing both P-gp expression levels and IC50 value of the DOX in DOX-resistant breast cancer cells (MCF-7/ADR). Doxorubicin 175-178 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 26655793-7 2016 Compared to the non-specific delivery, these FA functionalized nanomicelles could efficiently deliver P-gp siRNA to reducing both P-gp expression levels and IC50 value of the DOX in DOX-resistant breast cancer cells (MCF-7/ADR). Doxorubicin 182-185 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 26404133-7 2016 Moreover, the interference of CIP2A could decrease the P-gp protein activity elucidated by Rhodamine 123 (Rh123) efflux assay in HeLa and HeLa/Dox cells. Doxorubicin 143-146 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 26330294-5 2016 We further demonstrated that the synergistic mechanism was related to the increased intracellular accumulation of doxorubicin in the cells and the downregulation of the cancer stem-like cells via modulation on both ABCB1 and ABCG2 transporters with independence of Smoothened. Doxorubicin 114-125 ATP binding cassette subfamily B member 1 Homo sapiens 215-220 26319048-2 2016 We have previously shown that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin directly inhibits ABCB1, alters the glycosylation of the transporter, and enhances the intracellular accumulation of doxorubicin with subsequent anti-cancer action. Doxorubicin 231-242 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 26548759-5 2016 We found that in our OS cell lines this agent was able to revert the ABCB1/ABCC1-mediated resistance against doxorubicin, as well as against the drugs used in second-line OS treatments that are substrates of these transporters (taxotere, etoposide, vinorelbine). Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 26572087-7 2016 The MCF-7/del p53 cells acquired resistance to doxorubicin with increased P-gp efflux function. Doxorubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 26506420-4 2015 Furthermore, cetuximab markedly increased intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) in ABCB1-overexpressing MDR cancer cells in a concentration-dependent manner. Doxorubicin 72-83 ATP binding cassette subfamily B member 1 Homo sapiens 121-126 30695594-4 2016 However removal of these drugs out of cells MCF-7 and MCF-7/MDR1 was significantly different: in the latter case all free Dox was excluded from the cells for 24 hours while Dox, accumulated in composition with dendrimers, still remained in the cells. Doxorubicin 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 30695594-4 2016 However removal of these drugs out of cells MCF-7 and MCF-7/MDR1 was significantly different: in the latter case all free Dox was excluded from the cells for 24 hours while Dox, accumulated in composition with dendrimers, still remained in the cells. Doxorubicin 173-176 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 26718439-9 2015 Troglitazone and aleglitazar significantly down regulated P-gp expression in K562/DOX cells; in addition, the present study revealed that aleglitazar elevated intracellular accumulation of Rh123in K562/DOX cells as short-term effects, which also contribute to the reversal of MDR. Doxorubicin 82-85 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 26718439-10 2015 These findings show that troglitazone and especially aleglitazar exhibited potent effects in the reversal of P-gp-mediated MDR, suggesting that these compounds may be effective for combination therapy strategies and circumventing MDR in K562/DOX cells to other conventional chemotherapeutic drugs. Doxorubicin 242-245 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 26556876-5 2015 Ceritinib significantly increased the intracellular accumulation of chemotherapeutic agents such as doxorubicin (DOX) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 26556876-5 2015 Ceritinib significantly increased the intracellular accumulation of chemotherapeutic agents such as doxorubicin (DOX) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells. Doxorubicin 113-116 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 26689156-3 2015 Nobiletin profoundly inhibited ABCB1 transporter activity since it significantly increased the intracellular accumulation of DOX and Flutax-2 in A2780/T cells and decreased the efflux of ABCB1 substrates in Caco2 cells without altering the mRNA and protein expression of ABCB1. Doxorubicin 125-128 ATP binding cassette subfamily B member 1 Homo sapiens 31-36 26668505-8 2015 After treatment of HepG2 cells with different doses of doxorubicin, the expression of NF-kappaB/p65, P-p65, and especially P-gp were dose-dependently upregulated. Doxorubicin 55-66 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 26510307-3 2015 In this work, a new co-delivery system, DOX-PLGA/PEI/P-gp shRNA nanobubbles (NBs) around 327 nm, to overcome doxorubicin (DOX) resistance in MCF-7 human breast cancer was designed and developed. Doxorubicin 40-43 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 26510307-3 2015 In this work, a new co-delivery system, DOX-PLGA/PEI/P-gp shRNA nanobubbles (NBs) around 327 nm, to overcome doxorubicin (DOX) resistance in MCF-7 human breast cancer was designed and developed. Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 26510307-3 2015 In this work, a new co-delivery system, DOX-PLGA/PEI/P-gp shRNA nanobubbles (NBs) around 327 nm, to overcome doxorubicin (DOX) resistance in MCF-7 human breast cancer was designed and developed. Doxorubicin 122-125 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 26510307-4 2015 Positively charged polyethylenimine (PEI) were modified onto the surface of DOX-PLGA NBs through DCC/NHS crosslinking, and could efficiently condense P-gp shRNA into DOX-PLGA/PEI NBs at vector/shRNA weight ratios of 70:1 and above. Doxorubicin 76-79 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 26510307-4 2015 Positively charged polyethylenimine (PEI) were modified onto the surface of DOX-PLGA NBs through DCC/NHS crosslinking, and could efficiently condense P-gp shRNA into DOX-PLGA/PEI NBs at vector/shRNA weight ratios of 70:1 and above. Doxorubicin 166-169 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 26510307-6 2015 Cellular experimental results further showed that DOX-PLGA/PEI/P-gp shRNA NBs could facilitate cellular uptake of DOX into cells and increase the cell proliferation suppression effect of DOX against MCF-7/ADR cells (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). Doxorubicin 50-53 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 26510307-6 2015 Cellular experimental results further showed that DOX-PLGA/PEI/P-gp shRNA NBs could facilitate cellular uptake of DOX into cells and increase the cell proliferation suppression effect of DOX against MCF-7/ADR cells (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). Doxorubicin 50-53 ATP binding cassette subfamily B member 1 Homo sapiens 236-250 26510307-6 2015 Cellular experimental results further showed that DOX-PLGA/PEI/P-gp shRNA NBs could facilitate cellular uptake of DOX into cells and increase the cell proliferation suppression effect of DOX against MCF-7/ADR cells (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). Doxorubicin 50-53 ATP binding cassette subfamily B member 1 Homo sapiens 252-256 26510307-6 2015 Cellular experimental results further showed that DOX-PLGA/PEI/P-gp shRNA NBs could facilitate cellular uptake of DOX into cells and increase the cell proliferation suppression effect of DOX against MCF-7/ADR cells (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). Doxorubicin 114-117 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 26510307-6 2015 Cellular experimental results further showed that DOX-PLGA/PEI/P-gp shRNA NBs could facilitate cellular uptake of DOX into cells and increase the cell proliferation suppression effect of DOX against MCF-7/ADR cells (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). Doxorubicin 114-117 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 26510307-6 2015 Cellular experimental results further showed that DOX-PLGA/PEI/P-gp shRNA NBs could facilitate cellular uptake of DOX into cells and increase the cell proliferation suppression effect of DOX against MCF-7/ADR cells (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). Doxorubicin 114-117 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 26510307-8 2015 The increased cellular uptake and nuclear accumulation of DOX delivered by DOX-PLGA/PEI/P-gp shRNA NBs in MCF-7/ADR cells was confirmed by fluorescence microscopy and fluorescence spectrophotometry, and might be owning to the down-regulation of P-gp and reduced the efflux of DOX. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 26510307-8 2015 The increased cellular uptake and nuclear accumulation of DOX delivered by DOX-PLGA/PEI/P-gp shRNA NBs in MCF-7/ADR cells was confirmed by fluorescence microscopy and fluorescence spectrophotometry, and might be owning to the down-regulation of P-gp and reduced the efflux of DOX. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 245-249 26510307-8 2015 The increased cellular uptake and nuclear accumulation of DOX delivered by DOX-PLGA/PEI/P-gp shRNA NBs in MCF-7/ADR cells was confirmed by fluorescence microscopy and fluorescence spectrophotometry, and might be owning to the down-regulation of P-gp and reduced the efflux of DOX. Doxorubicin 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 245-249 26510307-8 2015 The increased cellular uptake and nuclear accumulation of DOX delivered by DOX-PLGA/PEI/P-gp shRNA NBs in MCF-7/ADR cells was confirmed by fluorescence microscopy and fluorescence spectrophotometry, and might be owning to the down-regulation of P-gp and reduced the efflux of DOX. Doxorubicin 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 245-249 26510307-10 2015 Furthermore, the in vitro cellular ultrasound imaging suggested that the employment of the DOX-PLGA/PEI/P-gp shRNA NBs could efficiently enhance ultrasound imaging of cancer cells. Doxorubicin 91-94 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 26510307-11 2015 These results demonstrated that the developed DOX-PLGA/PEI/P-gp shRNA NBs is a potential, safe and efficient theranotic agent for cancer therapy and diagnostics. Doxorubicin 46-49 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 26506420-4 2015 Furthermore, cetuximab markedly increased intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) in ABCB1-overexpressing MDR cancer cells in a concentration-dependent manner. Doxorubicin 85-88 ATP binding cassette subfamily B member 1 Homo sapiens 121-126 26339922-2 2015 Results of the current study suggest a dual effect of miltirone on P-gp inhibition and apoptotic induction in a human hepatoma HepG2 cell line and its P-gp-overexpressing doxorubicin-resistant counterpart (R-HepG2). Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 26459009-0 2015 Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 26291333-7 2015 FD18 inhibited P-gp-mediated doxorubicin efflux and has no effect on influx. Doxorubicin 29-40 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 26153782-12 2015 Inhibition and knock down of P-gp by CsA and siRNA, respectively, enhanced etoposide- and doxorubicin-induced cell death in the EBV-positive T-cell lines. Doxorubicin 90-101 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 25861751-10 2015 miR-124 targeted to FZD5 and miR-124 mimics as well as FZD5 siRNA showed significant inhibitory effects on P-gp expression in Caki-2/DOX cells. Doxorubicin 133-136 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 26194248-1 2015 We previously elucidated that ATP-binding cassette subfamily B member 1 (ABCB1) mediates the efflux of doxorubicin-conjugated block copolymers from HeLa cells. Doxorubicin 103-114 ATP binding cassette subfamily B member 1 Homo sapiens 30-71 26194248-1 2015 We previously elucidated that ATP-binding cassette subfamily B member 1 (ABCB1) mediates the efflux of doxorubicin-conjugated block copolymers from HeLa cells. Doxorubicin 103-114 ATP binding cassette subfamily B member 1 Homo sapiens 73-78 26169035-0 2015 BME, a novel compound of anthraquinone, down regulated P-glycoprotein expression in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells via generation of reactive oxygen species. Doxorubicin 84-95 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 26169035-0 2015 BME, a novel compound of anthraquinone, down regulated P-glycoprotein expression in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells via generation of reactive oxygen species. Doxorubicin 139-142 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 26169035-3 2015 The present study revealed that BME, a novel compound of anthraquinone, elevated intracellular accumulation of the P-gp substrates and reduced concentration resulting in 50% inhibition of cell growth (IC50) values for doxorubicin (DOX) in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 218-229 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 26169035-3 2015 The present study revealed that BME, a novel compound of anthraquinone, elevated intracellular accumulation of the P-gp substrates and reduced concentration resulting in 50% inhibition of cell growth (IC50) values for doxorubicin (DOX) in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 231-234 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 26169035-3 2015 The present study revealed that BME, a novel compound of anthraquinone, elevated intracellular accumulation of the P-gp substrates and reduced concentration resulting in 50% inhibition of cell growth (IC50) values for doxorubicin (DOX) in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 239-250 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 26169035-3 2015 The present study revealed that BME, a novel compound of anthraquinone, elevated intracellular accumulation of the P-gp substrates and reduced concentration resulting in 50% inhibition of cell growth (IC50) values for doxorubicin (DOX) in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 294-297 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 26464619-6 2015 A lncRNA-mRNA co-expression network identified lncRNAs, including ENST00000563280 and NR-036444, may play a critical role in doxorubicin-resistance of OS by interacting with important genes such as ABCB1, HIF1A and FOXC2. Doxorubicin 125-136 ATP binding cassette subfamily B member 1 Homo sapiens 198-203 25323158-9 2015 In addition, resistant K562/Dox cells exhibited significantly higher ABCB1 mRNA expression than resistant K562/HHT cells. Doxorubicin 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 26158764-7 2015 Furthermore Gal-3 antagonist suppresses this interaction and results in a decrease of the phosphorylation and the ATPase activity of P-gp, leading to an increased sensitivity to doxorubicin-mediated cell death. Doxorubicin 178-189 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 25824409-0 2015 Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 26295136-0 2015 Mixed Micelles of Doxorubicin Overcome Multidrug Resistance by Inhibiting the Expression of P-Glycoprotein. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 26295136-4 2015 Western blot results showed that the expression level of P-gp significantly decreased as H460/TaxR cells were incubated with Dox/DSPE-PEG/TPGS mixed micelles. Doxorubicin 125-128 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 26036634-5 2015 Lapatinib was shown to increase the accumulation of doxorubicin in ABCB1-overexpressing hepatocellular cancer cells and normal liver tissues without altering the protein level of ABCB1. Doxorubicin 52-63 ATP binding cassette subfamily B member 1 Homo sapiens 67-72 25824409-6 2015 GA increased the intracellular accumulation of DOX by inhibiting both P-gp expression and activity. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 26026084-7 2015 CONCLUSION: It can be concluded that these derivatives show synergism in the presence of doxorubicin and could have potential as ABCB1 inhibitors. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 129-134 25909227-8 2015 Moreover, miR-21 inhibitor suppressed the expression and activity of MDR1, thereby sensitizing DLBCL cells to doxorubicin. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 25714087-4 2015 In this study, the molecular mechanism underlying the cytotoxicity and downregulation of P-gp expression by chabamide in adriamycin-resistant human leukemia cells (K562/ADR) was clarified. Doxorubicin 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 26054673-3 2015 We found that tumorspheres generated from MCF-7 human breast cancer cells exhibited high proportions of quiescent cells and expressed MDR-1 at elevated levels, leading to resistance to 5-fluorouracil, paclitaxel, and doxorubicin. Doxorubicin 217-228 ATP binding cassette subfamily B member 1 Homo sapiens 134-139 25596698-8 2015 The combination of PGRMC1 knockdown and the P-glycoprotein inhibitor verapamil significantly decreased the viability of P-glycoprotein-overexpressing MES-SA/DxR-8 muM cells after doxorubicin treatment. Doxorubicin 179-190 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 25596698-8 2015 The combination of PGRMC1 knockdown and the P-glycoprotein inhibitor verapamil significantly decreased the viability of P-glycoprotein-overexpressing MES-SA/DxR-8 muM cells after doxorubicin treatment. Doxorubicin 179-190 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 26902021-1 2015 BACKGROUND/AIMS: To detect the cellular sensitivity to adriamycin (ADR) by assessing autophagy, apoptosis, and multidrug resistance gene 1 (mdr1) expression in LoVo/Adr cells. Doxorubicin 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 25586174-9 2015 The effect of glucose-induced stress on Pgp-mediated drug resistance was examined after incubating cells with the chemotherapeutic and Pgp substrate, doxorubicin (DOX), and performing MTT assays validated by viable cell counts. Doxorubicin 150-161 ATP binding cassette subfamily B member 1 Homo sapiens 40-43 25586174-9 2015 The effect of glucose-induced stress on Pgp-mediated drug resistance was examined after incubating cells with the chemotherapeutic and Pgp substrate, doxorubicin (DOX), and performing MTT assays validated by viable cell counts. Doxorubicin 163-166 ATP binding cassette subfamily B member 1 Homo sapiens 40-43 25586174-13 2015 The HIF-1alpha target, Pgp, was up-regulated at low and high glucose levels, which led to lower cellular accumulation of Pgp substrate, rhodamine123, and greater resistance to DOX. Doxorubicin 176-179 ATP binding cassette subfamily B member 1 Homo sapiens 23-26 25681670-0 2015 Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. Doxorubicin 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 111-125 25681670-2 2015 We compared the effects of two consecutive low doses versus a single high dose of doxorubicin in drug-sensitive Pgp-negative and drug-resistant Pgp-positive human and murine cancer cells. Doxorubicin 82-93 ATP binding cassette subfamily B member 1 Homo sapiens 112-115 25809558-5 2015 Additionally, benzo[b]tryptanthrin reversed adriamycin resistance by down-regulation of multidrug resistance protein 1 (MDR1) in adriamycin-resistant MCF7 breast cancer cells (MCF7adr) with more potent inhibitory activity than tryptanthrin. Doxorubicin 44-54 ATP binding cassette subfamily B member 1 Homo sapiens 88-118 25681670-2 2015 We compared the effects of two consecutive low doses versus a single high dose of doxorubicin in drug-sensitive Pgp-negative and drug-resistant Pgp-positive human and murine cancer cells. Doxorubicin 82-93 ATP binding cassette subfamily B member 1 Homo sapiens 144-147 25681670-7 2015 Our work shows that the "apparent" ineffectiveness of doxorubicin against drug-resistant tumors overexpressing Pgp can be overcome by changing the timing of its administration and its doses. Doxorubicin 54-65 ATP binding cassette subfamily B member 1 Homo sapiens 111-114 25809558-5 2015 Additionally, benzo[b]tryptanthrin reversed adriamycin resistance by down-regulation of multidrug resistance protein 1 (MDR1) in adriamycin-resistant MCF7 breast cancer cells (MCF7adr) with more potent inhibitory activity than tryptanthrin. Doxorubicin 44-54 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 25809558-5 2015 Additionally, benzo[b]tryptanthrin reversed adriamycin resistance by down-regulation of multidrug resistance protein 1 (MDR1) in adriamycin-resistant MCF7 breast cancer cells (MCF7adr) with more potent inhibitory activity than tryptanthrin. Doxorubicin 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 88-118 25809558-5 2015 Additionally, benzo[b]tryptanthrin reversed adriamycin resistance by down-regulation of multidrug resistance protein 1 (MDR1) in adriamycin-resistant MCF7 breast cancer cells (MCF7adr) with more potent inhibitory activity than tryptanthrin. Doxorubicin 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 25779097-5 2015 Similarly, ganoderenic acid B could also significantly reverse the resistance of ABCB1-overexpressing MCF-7/ADR cells to doxorubicin. Doxorubicin 121-132 ATP binding cassette subfamily B member 1 Homo sapiens 81-86 25989890-0 2015 Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Doxorubicin 113-124 ATP binding cassette subfamily B member 1 Homo sapiens 21-26 25779097-4 2015 Ganoderenic acid B, a lanostane-type triterpene isolated from Ganoderma lucidum, exhibited potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to doxorubicin, vincristine and paclitaxel. Doxorubicin 175-186 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 25862866-4 2015 MATERIALS AND METHODS: Steroid derivatives were studied for their growth-inhibitory effect, cytotoxicity, reversal of multidrug resistance, apoptosis induction, and interaction with doxorubicin on multidrug resistant human ATP-binding cassette, sub-family B, member 1 (ABCB1) gene-transfected mouse T-lymphoma cell line, and human PC-3 and LNCaP prostate cancer cell lines in vitro. Doxorubicin 182-193 ATP binding cassette subfamily B member 1 Homo sapiens 223-267 25862866-6 2015 RESULTS: Both the activity of steroid derivatives on inhibition of the ABCB1 pump and their interaction with doxorubicin are dependent on the substituent groups of the investigated steroidal structures. Doxorubicin 109-120 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 25989890-2 2015 Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 34-94 25989890-2 2015 Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 96-101 25989890-2 2015 Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 128-133 25989890-2 2015 Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. Doxorubicin 158-169 ATP binding cassette subfamily B member 1 Homo sapiens 34-94 25989890-2 2015 Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. Doxorubicin 158-169 ATP binding cassette subfamily B member 1 Homo sapiens 96-101 25989890-2 2015 Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. Doxorubicin 158-169 ATP binding cassette subfamily B member 1 Homo sapiens 128-133 26122223-5 2015 The human doxorubicin (doxo) resistant uterine sarcoma cells (MES-SA/Dx5) that overexpress Pgp (100-fold), were treated with the antipsychotic alone (1, 10 and 20 muM) or in combination with different concentrations of doxo (2, 4 and 8 muM). Doxorubicin 23-27 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 26019802-0 2015 Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Doxorubicin 55-66 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 26019802-6 2015 RESULTS: Our results showed a significant decrease in P-gp expression and subsequent enhancement of chemosensitivity to doxorubicin in vitro. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 25662500-8 2015 The nanocomplexes loaded with pDNA-iMDR1-shRNA against P-gp could reverse MDR accompanied by the suppression of MDR1/P-gp expression at the mRNA and protein levels and improve the internalization and cytotoxicity of Adriamycin (ADR) in the MCF-7/ADR multidrug-resistant cell line. Doxorubicin 216-226 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 25788263-3 2015 In the present study, we showed that c-Src dependent Caveolin-1 phosphorylation promoted the translocation of P-gp into caveolae, resulting in multidrug resistance in adriamycin resistant gastric cancer SGC7901/Adr and breast cancer MCF-7/Adr cells. Doxorubicin 167-177 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 26122223-5 2015 The human doxorubicin (doxo) resistant uterine sarcoma cells (MES-SA/Dx5) that overexpress Pgp (100-fold), were treated with the antipsychotic alone (1, 10 and 20 muM) or in combination with different concentrations of doxo (2, 4 and 8 muM). Doxorubicin 10-21 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 25664052-0 2014 Adenovirus-delivered PDCD5 counteracts adriamycin resistance of osteosarcoma cells through enhancing apoptosis and inhibiting Pgp. Doxorubicin 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 126-129 24621440-14 2015 Significantly, cabozantinib increased the inhibitory efficacy of doxorubicin in P-gp-overexpressing HepG2/adr cell xenografts in nude mice. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 25687049-0 2015 [Effect of quercetin on doxorubicin-induced expression of MDR1 gene in HL-60 cells]. Doxorubicin 24-35 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 25687049-3 2015 Recent studies showed Dox-induced coexpression of COX2 and MDR1 genes in human leukaemia cells, and whether Dox-induced MDR1 up-regulation in acute leukaemia cells is dependent on COX2-transcriptional activity and thus might be overcome or prevented with COX2-promotor inhibitor quercetin interfering with COX2 expression and activity. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 25687049-3 2015 Recent studies showed Dox-induced coexpression of COX2 and MDR1 genes in human leukaemia cells, and whether Dox-induced MDR1 up-regulation in acute leukaemia cells is dependent on COX2-transcriptional activity and thus might be overcome or prevented with COX2-promotor inhibitor quercetin interfering with COX2 expression and activity. Doxorubicin 108-111 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 25687049-4 2015 This study was purposed to investigate the impacts of quercetin on Dox-induced mRNA expression of MDR1 and COX2 genes in HL-60 leukemia cells. Doxorubicin 67-70 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 25687049-6 2015 RESULTS: The incubation of HL-60 cells with Dox not only up-regulated MDR1 mRNA, but also COX2 mRNA expression, and after co-incubation with quercetin or celecoxib, Dox-induced overexpression of MDR1 and COX2 mRNA were reduced by quercetin, not by celecoxib, whereas PGE2 release was significantly decreased with subsequent enhancement of Dox cytotoxic efficacy by both of them. Doxorubicin 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 25687049-6 2015 RESULTS: The incubation of HL-60 cells with Dox not only up-regulated MDR1 mRNA, but also COX2 mRNA expression, and after co-incubation with quercetin or celecoxib, Dox-induced overexpression of MDR1 and COX2 mRNA were reduced by quercetin, not by celecoxib, whereas PGE2 release was significantly decreased with subsequent enhancement of Dox cytotoxic efficacy by both of them. Doxorubicin 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 195-199 25437111-0 2015 Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin. Doxorubicin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 26558272-6 2015 The proteins of multidrug gene (the MDR-related protein, MRP1) and P-glycoprotein (P-gp) in MCF-7/MDR cells were downregulated after exposure to 2DG, accompanied with the suppression of the activity of ATP-dependent drug-efflux pump and transmembrane transporter, increasing the intracellular accumulation of DOX to reverse the chemoresistance in multidrug cancer cells. Doxorubicin 309-312 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 26558272-6 2015 The proteins of multidrug gene (the MDR-related protein, MRP1) and P-glycoprotein (P-gp) in MCF-7/MDR cells were downregulated after exposure to 2DG, accompanied with the suppression of the activity of ATP-dependent drug-efflux pump and transmembrane transporter, increasing the intracellular accumulation of DOX to reverse the chemoresistance in multidrug cancer cells. Doxorubicin 309-312 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 26075272-2 2015 Previously, we reported that less-polar ecdysteroids can modulate the doxorubicin resistance of a multidrug resistant (MDR) mouse lymphoma cell line expressing the human ABCB1 transporter. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 170-175 25482933-0 2015 Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 25482933-3 2015 Our results showed that dasatinib significantly increased the sensitivity of P-gp-overexpressing MCF-7/Adr cells to doxorubicin in MTT assays; thus lead to an enhanced cytotoxicity of doxorubicin in MCF-7/Adr cells. Doxorubicin 116-127 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 25482933-3 2015 Our results showed that dasatinib significantly increased the sensitivity of P-gp-overexpressing MCF-7/Adr cells to doxorubicin in MTT assays; thus lead to an enhanced cytotoxicity of doxorubicin in MCF-7/Adr cells. Doxorubicin 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 26235354-5 2015 The intracellular accumulation with P-gp substrates of doxorubicin was determined by flow cytometry. Doxorubicin 55-66 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 26235354-9 2015 W6 significantly and dose-dependently increased intracellular accumulation of P-gp substrate doxorubicin (DOX) in P-gp overexpressing KBv200 cells, and also inhibited the ATPase activity of P-gp. Doxorubicin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 26235354-9 2015 W6 significantly and dose-dependently increased intracellular accumulation of P-gp substrate doxorubicin (DOX) in P-gp overexpressing KBv200 cells, and also inhibited the ATPase activity of P-gp. Doxorubicin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 26235354-9 2015 W6 significantly and dose-dependently increased intracellular accumulation of P-gp substrate doxorubicin (DOX) in P-gp overexpressing KBv200 cells, and also inhibited the ATPase activity of P-gp. Doxorubicin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 26235354-9 2015 W6 significantly and dose-dependently increased intracellular accumulation of P-gp substrate doxorubicin (DOX) in P-gp overexpressing KBv200 cells, and also inhibited the ATPase activity of P-gp. Doxorubicin 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 26235354-9 2015 W6 significantly and dose-dependently increased intracellular accumulation of P-gp substrate doxorubicin (DOX) in P-gp overexpressing KBv200 cells, and also inhibited the ATPase activity of P-gp. Doxorubicin 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 26235354-9 2015 W6 significantly and dose-dependently increased intracellular accumulation of P-gp substrate doxorubicin (DOX) in P-gp overexpressing KBv200 cells, and also inhibited the ATPase activity of P-gp. Doxorubicin 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 25738311-8 2015 In addition, HepG2/IR cells were resistant to the chemotherapy agent Adriamycin, which was accompanied by the upregulation of multidrug resistance gene 1/ P-glycoprotein (P-gp; an endoplasmic reticulum chaperone that plays a role in ER stress), and enhanced drug efflux. Doxorubicin 69-79 ATP binding cassette subfamily B member 1 Homo sapiens 155-169 25837780-4 2015 Multidrug-resistant P-glycoprotein-expressing CEM/ADR5000 leukemia cells were hypersensitive (collaterally sensitive) toward this extract compared to drug-sensitive CCRF-CEM cells, whereas CEM/ADR5000 cells were 2586-fold resistant to doxorubicin as control drug. Doxorubicin 235-246 ATP binding cassette subfamily B member 1 Homo sapiens 20-34 25550688-9 2014 The current study provides useful insight into the distinct ability of DOX and PTX to induce P-gp mediated MDR in breast cancer. Doxorubicin 71-74 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 25401518-9 2014 Taken together, the Wnt5A signaling pathway was shown to contribute to regulating the drug-resistance protein ABCB1 and beta-catenin-related genes in antagonizing the toxic effects of doxorubicin in the MDR cell lines and in clinical breast cancer samples. Doxorubicin 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 25457413-0 2015 Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling. Doxorubicin 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 25603048-0 2015 ABCB1, ABCC1, and LRP gene expressions are altered by LDL, HDL, and serum deprivation in a human doxorubicin-resistant uterine sarcoma cell line. Doxorubicin 97-108 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 25661387-3 2015 In vitro, Soluplus( ) micelles could significantly enhance the cellular accumulation of DOX in MCF-7/DOX cells, meanwhile, P-glycoprotein (P-gp)-mediated drug efflux was inhibited which was also verified in the membrane fluidity study. Doxorubicin 88-91 ATP binding cassette subfamily B member 1 Homo sapiens 123-137 25661387-3 2015 In vitro, Soluplus( ) micelles could significantly enhance the cellular accumulation of DOX in MCF-7/DOX cells, meanwhile, P-glycoprotein (P-gp)-mediated drug efflux was inhibited which was also verified in the membrane fluidity study. Doxorubicin 88-91 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 25661387-3 2015 In vitro, Soluplus( ) micelles could significantly enhance the cellular accumulation of DOX in MCF-7/DOX cells, meanwhile, P-glycoprotein (P-gp)-mediated drug efflux was inhibited which was also verified in the membrane fluidity study. Doxorubicin 101-104 ATP binding cassette subfamily B member 1 Homo sapiens 123-137 25661387-3 2015 In vitro, Soluplus( ) micelles could significantly enhance the cellular accumulation of DOX in MCF-7/DOX cells, meanwhile, P-glycoprotein (P-gp)-mediated drug efflux was inhibited which was also verified in the membrane fluidity study. Doxorubicin 101-104 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 25661387-6 2015 Furthermore, the excellent antitumor efficacy of DOX-M by intravenous injection was also observed, which indicated that the P-gp inhibition effect of Soluplus( ) could enhance the susceptibility of resistant tumor to DOX in vivo. Doxorubicin 49-52 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 25661387-6 2015 Furthermore, the excellent antitumor efficacy of DOX-M by intravenous injection was also observed, which indicated that the P-gp inhibition effect of Soluplus( ) could enhance the susceptibility of resistant tumor to DOX in vivo. Doxorubicin 217-220 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 25687049-7 2015 CONCLUSIONS: Dox-induced MDR1 up-regulation may be dependent on COX2-transcriptional activity, not PGE2, suggesting that the existence of causal link between COX2 and MDR1 expression induced by Dox, and modulation of COX2 transcriptional expression by quercetin would not only sensitize leukemia cells to Dox, but also prevent the acquisition of MDR during chemotherapy. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 25687049-7 2015 CONCLUSIONS: Dox-induced MDR1 up-regulation may be dependent on COX2-transcriptional activity, not PGE2, suggesting that the existence of causal link between COX2 and MDR1 expression induced by Dox, and modulation of COX2 transcriptional expression by quercetin would not only sensitize leukemia cells to Dox, but also prevent the acquisition of MDR during chemotherapy. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 25687049-7 2015 CONCLUSIONS: Dox-induced MDR1 up-regulation may be dependent on COX2-transcriptional activity, not PGE2, suggesting that the existence of causal link between COX2 and MDR1 expression induced by Dox, and modulation of COX2 transcriptional expression by quercetin would not only sensitize leukemia cells to Dox, but also prevent the acquisition of MDR during chemotherapy. Doxorubicin 194-197 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 25687049-7 2015 CONCLUSIONS: Dox-induced MDR1 up-regulation may be dependent on COX2-transcriptional activity, not PGE2, suggesting that the existence of causal link between COX2 and MDR1 expression induced by Dox, and modulation of COX2 transcriptional expression by quercetin would not only sensitize leukemia cells to Dox, but also prevent the acquisition of MDR during chemotherapy. Doxorubicin 194-197 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 25687049-7 2015 CONCLUSIONS: Dox-induced MDR1 up-regulation may be dependent on COX2-transcriptional activity, not PGE2, suggesting that the existence of causal link between COX2 and MDR1 expression induced by Dox, and modulation of COX2 transcriptional expression by quercetin would not only sensitize leukemia cells to Dox, but also prevent the acquisition of MDR during chemotherapy. Doxorubicin 194-197 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 25687049-7 2015 CONCLUSIONS: Dox-induced MDR1 up-regulation may be dependent on COX2-transcriptional activity, not PGE2, suggesting that the existence of causal link between COX2 and MDR1 expression induced by Dox, and modulation of COX2 transcriptional expression by quercetin would not only sensitize leukemia cells to Dox, but also prevent the acquisition of MDR during chemotherapy. Doxorubicin 194-197 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 25481438-5 2015 The psi-Pgp-tGC NPs could release functional siRNA molecules after cellular delivery, and they were able to facilitate siRNA delivery to Adriamycin-resistant breast cancer cells (MCF-7/ADR). Doxorubicin 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 8-11 25445037-4 2015 Effect of these compounds on P-gp mediated MDR was assessed in P-gp over-expressing MES-SA/DX5 doxorubicin resistant cells by flow cytometric detection of rhodamine 123 efflux. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 25445037-4 2015 Effect of these compounds on P-gp mediated MDR was assessed in P-gp over-expressing MES-SA/DX5 doxorubicin resistant cells by flow cytometric detection of rhodamine 123 efflux. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 25747987-0 2015 Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway. Doxorubicin 33-44 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 25747987-7 2015 In addition, an increase in Rh123 accumulation and a decrease in Rh123 efflux were observed in MG-63/DOX cells treated with icariin, indicating a blockage of the activity of MDR1. Doxorubicin 101-104 ATP binding cassette subfamily B member 1 Homo sapiens 174-178 25866761-4 2015 Covalently bound to a nanoparticle, tetrac as nanotetrac acts at the integrin to increase intracellular residence time of chemotherapeutic agents such as doxorubicin and etoposide that are substrates of P-gp. Doxorubicin 154-165 ATP binding cassette subfamily B member 1 Homo sapiens 203-207 25410489-0 2015 ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Doxorubicin 93-104 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 25096913-0 2014 Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 25525333-7 2014 In the same MDR tumor cells the new strategy of a co-loaded reversal agent and chemotherapeutic drug with CNTs could inhibit the function of P-glycoprotein in real-time by Ver as reversal agent, significantly increase the uptake of Dox, enhance the sensitivity of the MDR cancer cells to the chemotherapeutic agent, and induce apoptosis. Doxorubicin 232-235 ATP binding cassette subfamily B member 1 Homo sapiens 141-155 25410120-0 2014 Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 97-111 25410120-0 2014 Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin. Doxorubicin 186-197 ATP binding cassette subfamily B member 1 Homo sapiens 97-111 25410120-4 2014 Here, we set out to investigate whether P-glycoprotein (P-gp) expression may affect DOX-TRF conjugate-induced cellular drug accumulation and cytotoxicity. Doxorubicin 84-87 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 25410120-4 2014 Here, we set out to investigate whether P-glycoprotein (P-gp) expression may affect DOX-TRF conjugate-induced cellular drug accumulation and cytotoxicity. Doxorubicin 84-87 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 25410120-7 2014 CONCLUSION: Our data suggest that the newly developed DOX-TRF conjugate is a less P-gp dependent substrate than free DOX and, consequently, may be used in a clinical setting to increase treatment efficacy in resistant human tumors. Doxorubicin 54-57 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 25096913-8 2014 We found that very low mitotane concentrations sensitize ACC cells to the cytotoxic effects of doxorubicin, depending on P-gp expression. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 25096913-9 2014 In addition, mitotane directly inhibits P-gp detoxifying function, allowing doxorubicin cytotoxic activity. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 25002258-2 2014 In the synergistic treatment of siRNA and anti-cancer drug doxorubicin, it is crucial that both the siRNA and doxorubicin are simultaneously delivered to the tumor cells and the siRNA can fleetly down-regulate P-g before doxorubicin inactivates the P-gp and is pumped out. Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 249-253 25155545-6 2014 Human breast cancer MCF-7/ADR cells can be vulnerable to doxorubicin treatment after the strong downregulation of P-gp through siRNA tranfection. Doxorubicin 57-68 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 25985578-4 2014 In addition, Z01 and Z02 increased the accumulation of other P-gp substrates, rhodamine 123 and doxorubicin, in PR-HepG2 cells in a concentration-dependent manner. Doxorubicin 96-107 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 25302569-3 2014 P-Glycoprotein inhibition was quantified using a doxorubicin accumulation assay in human promyelotic leukemia HL60/MDR cells overexpressing P-glycoprotein. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 25442273-7 2014 P-glycoprotein-expressing and multidrug-resistant CEM/ADR5000 cells were much more sensitive toward compound 1 than toward doxorubicin and low cross-resistance or even collateral sensitivity was observed in other drug-resistent cell lines to this compound. Doxorubicin 123-134 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 25378226-3 2014 The conjugate limited the effects of P-glycoprotein (Pgp) efflux pumps of multidrug-resistant cells on DOX, indicating that diverting drugs to mitochondria is a potential promising method for treatment of drug-resistant cancers. Doxorubicin 103-106 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 25378226-3 2014 The conjugate limited the effects of P-glycoprotein (Pgp) efflux pumps of multidrug-resistant cells on DOX, indicating that diverting drugs to mitochondria is a potential promising method for treatment of drug-resistant cancers. Doxorubicin 103-106 ATP binding cassette subfamily B member 1 Homo sapiens 53-56 24687250-8 2014 The cellular heterogeneity in DOX uptake was found to be negatively correlated with drug cytotoxicity and surface P-gp expression, with r = -0.7680 to ~ -0.9587. Doxorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 114-118 24687250-9 2014 VER reduces the cellular variation in DOX uptake, suggesting that surface P-gp may be one of the causes of the cellular heterogeneity in DOX uptake. Doxorubicin 38-41 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 24687250-9 2014 VER reduces the cellular variation in DOX uptake, suggesting that surface P-gp may be one of the causes of the cellular heterogeneity in DOX uptake. Doxorubicin 137-140 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 25002258-2 2014 In the synergistic treatment of siRNA and anti-cancer drug doxorubicin, it is crucial that both the siRNA and doxorubicin are simultaneously delivered to the tumor cells and the siRNA can fleetly down-regulate P-g before doxorubicin inactivates the P-gp and is pumped out. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 249-253 25002258-2 2014 In the synergistic treatment of siRNA and anti-cancer drug doxorubicin, it is crucial that both the siRNA and doxorubicin are simultaneously delivered to the tumor cells and the siRNA can fleetly down-regulate P-g before doxorubicin inactivates the P-gp and is pumped out. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 249-253 25002258-6 2014 Release of siRNA down-regulates the mRNA and protein levels of P-gp in the MCF-7/ADR cell lines effectively and the accumulated doxorubicin facilitates apoptosis of the cells to reverse MDR. Doxorubicin 128-139 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 25002258-8 2014 The western blotting and RT-PCR results illustrate that the synergistic treatment of siRNA and doxorubicin leads to efficient reduction of the P-gp expression as well as cell apoptotic induction in MDR tumors at a small dosage of 0.5 mg/kg. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 25338578-2 2014 The growth inhibitory rate, half inhibitory concentration (IC50), reversing multiples to adriamycin- resistance were detected by MTT, and the curve of growth inhibitory rate was drawn; the MDR-1 and MRP-1 gene transcription was determined by RT-PCR; the expressions of P-gp and MRP-1 proteins were assayed by Western blot and flow cytometry. Doxorubicin 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 189-194 25150001-10 2014 CONCLUSIONS: rhIL-24 circumvented the drug-resistance of MCF-7/ADM cells via activation of the transcription factor Stat 3. rhIl24 has potential to act as a P-gp inhibitor to reverse Adriamycin resistance in breast cancer. Doxorubicin 183-193 ATP binding cassette subfamily B member 1 Homo sapiens 157-161 25238617-4 2014 The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells. Doxorubicin 172-183 ATP binding cassette subfamily B member 1 Homo sapiens 98-101 25238617-4 2014 The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells. Doxorubicin 172-183 ATP binding cassette subfamily B member 1 Homo sapiens 200-203 25238617-4 2014 The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells. Doxorubicin 172-183 ATP binding cassette subfamily B member 1 Homo sapiens 200-203 25238617-4 2014 The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells. Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 98-101 25238617-4 2014 The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells. Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 200-203 25238617-4 2014 The combined addition of UIC2 and 10 times lower concentrations of CsA than what is necessary for Pgp inhibition when the modulator is applied alone, decreased the EC50 of doxorubicin (DOX) in KB-V1 (Pgp+) cells in vitro almost to the level of KB-3-1 (Pgp-) cells. Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 200-203 25058526-4 2014 CEP-33779 significantly increased intracellular accumulation and decreased the efflux of doxorubicin by inhibiting the ABCB1 transport function. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 119-124 24877693-6 2014 MV-mediated transfer of P-gp led to redistribution of the chemotherapeutic drug adriamycin in recipient cells (A2780/WT), which displayed 5- and 5-fold higher resistance to adriamycin and paclitaxel, respectively. Doxorubicin 80-90 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 24877693-6 2014 MV-mediated transfer of P-gp led to redistribution of the chemotherapeutic drug adriamycin in recipient cells (A2780/WT), which displayed 5- and 5-fold higher resistance to adriamycin and paclitaxel, respectively. Doxorubicin 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 25043687-4 2014 We found that the P-glycoprotein expression was down-regulated by the intracellular acidification through inhibition of p38 mitogen-activated protein kinase (MAPK) and the activation of c-Jun N-terminal kinase (JNK) in the resisitant K562/DOX cells. Doxorubicin 239-242 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 25057799-5 2014 This event was accompanied in parallel by a higher release of NO, which caused nitration of P-glycoprotein (Pgp) and multidrug resistance related protein 1 (MRP1), two transporters involved in Dox efflux, and impaired their pump activity. Doxorubicin 193-196 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 25057799-5 2014 This event was accompanied in parallel by a higher release of NO, which caused nitration of P-glycoprotein (Pgp) and multidrug resistance related protein 1 (MRP1), two transporters involved in Dox efflux, and impaired their pump activity. Doxorubicin 193-196 ATP binding cassette subfamily B member 1 Homo sapiens 108-111 24289107-4 2014 This exploratory study was designed to correlate the mRNA expression levels of candidate genes mainly involved in the doxorubicin pathway (ABCB1, GSTP1, TOPO2alpha, BCL2, PKCbetaII) with the outcome of 54 patients with DLBCL undergoing a dose-dense R-CHOP regimen. Doxorubicin 118-129 ATP binding cassette subfamily B member 1 Homo sapiens 139-144 25338578-4 2014 The reversing multiples to adriamycin-resistance were 255.7 multiples, the transcription of mdr-1 and mrp-1 genes and the expression of P-gp and MRP-1 proteins significantly decreased (P < 0.05) in Raji/ADR cells after the treatment with cinobufotalin. Doxorubicin 27-37 ATP binding cassette subfamily B member 1 Homo sapiens 92-97 25092974-0 2014 The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression. Doxorubicin 60-71 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 24882106-6 2014 A quantitative time-course analysis of both HSP27 and P-gp in doxorubicin (DOX)-treated MCF-7/WT cells also implied that HSP27 may participate in the P-gp modulation. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 24882106-6 2014 A quantitative time-course analysis of both HSP27 and P-gp in doxorubicin (DOX)-treated MCF-7/WT cells also implied that HSP27 may participate in the P-gp modulation. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 24882106-6 2014 A quantitative time-course analysis of both HSP27 and P-gp in doxorubicin (DOX)-treated MCF-7/WT cells also implied that HSP27 may participate in the P-gp modulation. Doxorubicin 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 24882106-6 2014 A quantitative time-course analysis of both HSP27 and P-gp in doxorubicin (DOX)-treated MCF-7/WT cells also implied that HSP27 may participate in the P-gp modulation. Doxorubicin 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 24896565-4 2014 The RhoAK inhibition increased the delivery of Pgp substrates like doxorubicin across the BBB and improved the doxorubicin efficacy against glioblastoma cells co-cultured under a BBB monolayer. Doxorubicin 67-78 ATP binding cassette subfamily B member 1 Homo sapiens 47-50 25092974-0 2014 The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression. Doxorubicin 60-71 ATP binding cassette subfamily B member 1 Homo sapiens 135-149 25092974-5 2014 We designed a novel doxorubicin (DOX) sterically stabilized liposome system co-loaded with the low-dose P-gp inhibitor cyclosporine A (CsA) (DOX/CsA/SSL). Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 25092974-5 2014 We designed a novel doxorubicin (DOX) sterically stabilized liposome system co-loaded with the low-dose P-gp inhibitor cyclosporine A (CsA) (DOX/CsA/SSL). Doxorubicin 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 25092974-5 2014 We designed a novel doxorubicin (DOX) sterically stabilized liposome system co-loaded with the low-dose P-gp inhibitor cyclosporine A (CsA) (DOX/CsA/SSL). Doxorubicin 141-144 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 25092974-10 2014 CONCLUSION: This study demonstrated that the co-delivery of a low-dose P-gp inhibitor and liposomal DOX could improve the therapy of low-P-gp-expressing cancer, which is of significance in clinical tumor therapy. Doxorubicin 100-103 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 24818584-0 2014 Paris saponin VII from trillium tschonoskii reverses multidrug resistance of adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition and apoptosis augmentation. Doxorubicin 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 23934188-10 2014 Hypermethylation of the miR-137 promoter and negative regulation of miR-137 by CAR contribute in part to reduced miR-137 expression and increased CAR and MDR1 expression in doxorubicin-resistant neuroblastoma cells. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 154-158 24840054-7 2014 Our data showed that this transcription factor promoted the outward transport of intracellular doxorubicin by activating the P-glycoprotein (P-gp) expression in osteosarcoma cells maintained in normoxic conditions. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 125-139 24840054-7 2014 Our data showed that this transcription factor promoted the outward transport of intracellular doxorubicin by activating the P-glycoprotein (P-gp) expression in osteosarcoma cells maintained in normoxic conditions. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 24704556-6 2014 Furthermore, it could also increase the retention of ABCB1 substrates doxorubicin and rhodamine 123 in HepG2/ADM and MCF-7/ADR cells. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 53-58 24647772-0 2014 Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 24704556-9 2014 In addition, acerinol s action was reversible, suggesting that acerinol may act as a competitive inhibitor of ABCB1 by competing with other drug substrates like doxorubicin. Doxorubicin 161-172 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 24901713-0 2014 Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression. Doxorubicin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 24901713-6 2014 Importantly, we found that sinomenine enhances the sensitivity of MDR-Caco-2 cells towards doxorubicin by downregulating MDR-1 and COX-2 expression through inhibition of the NF-kappaB signaling pathway. Doxorubicin 91-102 ATP binding cassette subfamily B member 1 Homo sapiens 121-126 24694948-7 2014 In addition, TAI-95 increased the potency of cytotoxic Pgp substrates, including doxorubicin and topotecan. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 55-58 24652302-0 2014 Drug promiscuity of P-glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin. Doxorubicin 88-99 ATP binding cassette subfamily B member 1 Homo sapiens 20-34 24830744-5 2014 Furthermore, our results indicated that EVO enhanced the apoptotic action of DOX by inhibiting the Ras/MEK/ERK cascade and the expression of IAPs without inhibiting the expression and activity of P-glycoprotein (P-gp). Doxorubicin 77-80 ATP binding cassette subfamily B member 1 Homo sapiens 212-216 24595806-9 2014 Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression. Doxorubicin 124-135 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 24595806-9 2014 Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression. Doxorubicin 124-135 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 24595806-9 2014 Folate deprivation markedly increased growth inhibitory effects of the established MRP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MRP1-overexpressing cells, proportional to MRP1 expression. Doxorubicin 124-135 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 24549588-7 2014 In brief, this study demonstrated that extracellular HMGB1 may promote drug resistance to adriamycin and vincristine by upregulating P-gp in human gastric adenocarcinoma cells. Doxorubicin 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 24582564-0 2014 Tumor endothelial expression of P-glycoprotein upon microvesicular transfer of TrpC5 derived from adriamycin-resistant breast cancer cells. Doxorubicin 98-108 ATP binding cassette subfamily B member 1 Homo sapiens 32-46 24817930-8 2014 Our data show that drug resistance in the human breast cancer cell line MCF-7/MDR1 can be overcome by treatment with DOX encapsulated within mesoporous silica nanoparticles. Doxorubicin 117-120 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 25182442-1 2014 OBJECTIVE: To evaluate of hesperidin to overcome resistance of doxorubicin in MCF-7 resistant doxorubicin cells (MCF-7/Dox) in cytotoxicity apoptosis and P-glycoprotein (Pgp) expression in combination with doxorubicin. Doxorubicin 63-74 ATP binding cassette subfamily B member 1 Homo sapiens 154-168 25182442-1 2014 OBJECTIVE: To evaluate of hesperidin to overcome resistance of doxorubicin in MCF-7 resistant doxorubicin cells (MCF-7/Dox) in cytotoxicity apoptosis and P-glycoprotein (Pgp) expression in combination with doxorubicin. Doxorubicin 63-74 ATP binding cassette subfamily B member 1 Homo sapiens 170-173 25182442-10 2014 Co-chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect through inhibition of Pgp expression. Doxorubicin 31-42 ATP binding cassette subfamily B member 1 Homo sapiens 123-126 25182442-10 2014 Co-chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect through inhibition of Pgp expression. Doxorubicin 67-70 ATP binding cassette subfamily B member 1 Homo sapiens 123-126 24447463-10 2014 Moreover, the NP-based Dox formulation could bypass the drug efflux function of MRP1, thereby partially reversing the resistance to free Dox in 3D cultures. Doxorubicin 23-26 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 24370495-2 2014 Doxorubicin (DOX) and reactive oxygen species have also been implicated in the overexpression of P-glycoprotein (P-gp), which is encoded by the MDR1 gene and causes antitumor multidrug resistance. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 24370495-2 2014 Doxorubicin (DOX) and reactive oxygen species have also been implicated in the overexpression of P-glycoprotein (P-gp), which is encoded by the MDR1 gene and causes antitumor multidrug resistance. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 24370495-3 2014 In the present study, we assessed the effects of UDCA on the expression of MDR1 mRNA, P-gp, and intracellular reactive oxygen species levels in DOX-treated HepG2 cells and compared them to those of other bile acids. Doxorubicin 144-147 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 237-241 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 251-255 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 148-151 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 148-151 ATP binding cassette subfamily B member 1 Homo sapiens 237-241 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 148-151 ATP binding cassette subfamily B member 1 Homo sapiens 251-255 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 148-151 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 148-151 ATP binding cassette subfamily B member 1 Homo sapiens 237-241 24370495-4 2014 DOX-induced increases in reactive oxygen species levels and the expression of MDR1 mRNA were inhibited by N-acetylcysteine, an antioxidant, and the DOX-induced increase in reactive oxygen species levels and DOX-induced overexpression of MDR1 mRNA and P-gp were inhibited by UDCA. Doxorubicin 148-151 ATP binding cassette subfamily B member 1 Homo sapiens 251-255 24370495-7 2014 Thus, UDCA may have inhibited the overexpression of P-gp by suppressing DOX-induced reactive oxygen species production. Doxorubicin 72-75 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 24370495-9 2014 In conclusion, UDCA and CDCA had an inhibitory effect on the induction of P-gp expression and reactive oxygen species by DOX in HepG2 cells. Doxorubicin 121-124 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 24140176-0 2014 Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 24140176-11 2014 In a doxorubicin-resistant variant of the LoVo cell line (LoVoDx), MDR3 was expressed at higher levels than MDR1. Doxorubicin 5-16 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 24621983-5 2014 The impact of the 1199G>A SNP on ABCB1 activity towards rhodamine (Rh123), doxorubicin, vinblastine, tacrolimus and cyclosporine A was assessed by accumulation, cytotoxicity and/or kinetic experiments. Doxorubicin 78-89 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 24621983-8 2014 Unlike tacrolimus, our results also indicate that cyclosporine A, Rh123 and doxorubicin are transported in a similar extent by the wild-type and variant ABCB1 proteins while the variant protein seems to be more efficient for the transport of vinblastine. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 153-158 24660104-8 2014 Additionally, UMMS-4 profoundly inhibited the transport of rhodamine 123 (Rho 123) and doxorubicin (Dox) by the ABCB1 transporter. Doxorubicin 87-98 ATP binding cassette subfamily B member 1 Homo sapiens 112-117 24660104-8 2014 Additionally, UMMS-4 profoundly inhibited the transport of rhodamine 123 (Rho 123) and doxorubicin (Dox) by the ABCB1 transporter. Doxorubicin 100-103 ATP binding cassette subfamily B member 1 Homo sapiens 112-117 24758085-10 2014 Results of immunoblotting indicated that reduction of P-glycoprotein expression was detected in MCF-7/DOX cells after exposure to YI. Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 24370495-0 2014 Ursodeoxycholic acid inhibits overexpression of P-glycoprotein induced by doxorubicin in HepG2 cells. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 24370495-2 2014 Doxorubicin (DOX) and reactive oxygen species have also been implicated in the overexpression of P-glycoprotein (P-gp), which is encoded by the MDR1 gene and causes antitumor multidrug resistance. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 97-111 24370495-2 2014 Doxorubicin (DOX) and reactive oxygen species have also been implicated in the overexpression of P-glycoprotein (P-gp), which is encoded by the MDR1 gene and causes antitumor multidrug resistance. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 24370495-2 2014 Doxorubicin (DOX) and reactive oxygen species have also been implicated in the overexpression of P-glycoprotein (P-gp), which is encoded by the MDR1 gene and causes antitumor multidrug resistance. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 24370495-2 2014 Doxorubicin (DOX) and reactive oxygen species have also been implicated in the overexpression of P-glycoprotein (P-gp), which is encoded by the MDR1 gene and causes antitumor multidrug resistance. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 97-111 24652302-5 2014 Results indicate that different drugs like paclitaxel and doxorubicin approach the putative binding site of P-gp, and the inner residues are found to be important in this process. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 24239898-6 2014 In addition, exposure to adriamycin significantly enhanced motility in breast cancer cells and increased levels of P-gp and Anxa2. Doxorubicin 25-35 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 24239898-8 2014 However, suppression of P-gp pump activity and knockdown of MDR1 expression both disrupted adriamycin-induced Anxa2 phosphorylation. Doxorubicin 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 24229050-1 2014 To overcome the P-glycoprotein (P-gp)-induced multidrug resistance (MDR) of cancer cells, a novel copolymer, chitosan-graft-D-alpha-tocopheryl polyethylene glycol 1000 (TPGS) (CT) was synthesized for doxorubicin (DOX) delivery by the P-gp inhibiting virtue of TPGS. Doxorubicin 200-211 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 24239898-8 2014 However, suppression of P-gp pump activity and knockdown of MDR1 expression both disrupted adriamycin-induced Anxa2 phosphorylation. Doxorubicin 91-101 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 24321342-6 2014 This study revealed that HZ08 was capable of reversing adriamycin resistance mediated by P-glycoprotein as a result of intracellular enhancement of adriamycin accumulation, which was found to be superior to verapamil. Doxorubicin 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 24229050-1 2014 To overcome the P-glycoprotein (P-gp)-induced multidrug resistance (MDR) of cancer cells, a novel copolymer, chitosan-graft-D-alpha-tocopheryl polyethylene glycol 1000 (TPGS) (CT) was synthesized for doxorubicin (DOX) delivery by the P-gp inhibiting virtue of TPGS. Doxorubicin 213-216 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 24161697-6 2014 Treatment with a combination of RSV and Dox significantly increased the cellular accumulation of Dox by down-regulating the expression levels of ATP-binding cassette (ABC) transporter genes, MDR1, and MRP1. Doxorubicin 40-43 ATP binding cassette subfamily B member 1 Homo sapiens 191-195 24161697-6 2014 Treatment with a combination of RSV and Dox significantly increased the cellular accumulation of Dox by down-regulating the expression levels of ATP-binding cassette (ABC) transporter genes, MDR1, and MRP1. Doxorubicin 97-100 ATP binding cassette subfamily B member 1 Homo sapiens 191-195 24245692-7 2014 The combined use of GA and ADM decreased the expression of P-glycoprotein and increased the accumulation of ADM in lung cancer cells. Doxorubicin 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 59-73 25451842-7 2014 P-gp plays an active role in mediating MDR of cancer cells where a correlation between the sensitivities of cells and the accumulated DOX exists. Doxorubicin 134-137 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 24245692-10 2014 Importantly, our results indicated that the combination of GA and ADM exerted enhanced anti-tumor effects on A549 xenograft models through inhibiting NF-kappaB and P-glycoprotein, and attenuated ADM-induced cardiotoxicity. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 24190517-0 2014 A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression. Doxorubicin 60-71 ATP binding cassette subfamily B member 1 Homo sapiens 166-180 24438524-5 2014 Compound 6 inhibited P-glycoprotein by increasing doxorubicin accumulation and reducing expression of P-glycoprotein in CEM/ADR5000 cells. Doxorubicin 50-61 ATP binding cassette subfamily B member 1 Homo sapiens 21-35 23850894-1 2014 UNLABELLED: In this work we investigated how the surface charge and the presence of polyethylene glycol (PEG) on liposome carriers affect the delivery of the encapsulated doxorubicin in P-glycoprotein (Pgp)-overexpressing cells. Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 186-200 24326457-4 2014 The Dox-encapsulated NCs can effectively bypass the P-glycoprotein (Pgp)-mediated multidrug resistance of MCF7/ADR cancer cells, thereby resulting in increased intracellular drug concentration and reduced cell viability. Doxorubicin 4-7 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 24326457-4 2014 The Dox-encapsulated NCs can effectively bypass the P-glycoprotein (Pgp)-mediated multidrug resistance of MCF7/ADR cancer cells, thereby resulting in increased intracellular drug concentration and reduced cell viability. Doxorubicin 4-7 ATP binding cassette subfamily B member 1 Homo sapiens 68-71 23850894-1 2014 UNLABELLED: In this work we investigated how the surface charge and the presence of polyethylene glycol (PEG) on liposome carriers affect the delivery of the encapsulated doxorubicin in P-glycoprotein (Pgp)-overexpressing cells. Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 202-205 23850894-3 2014 PEG-coating was necessary to increase the Km of doxorubicin for Pgp. Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 64-67 23850894-4 2014 In particular the PEGylated phospholipid present in neutral liposomes, i.e. PEGylated distearoyl-phosphatidylethanolamine (DSPE-PEG), was a Pgp allosteric inhibitor, increased doxorubicin Km and inhibited Pgp ATPase activity. Doxorubicin 176-187 ATP binding cassette subfamily B member 1 Homo sapiens 140-143 23850894-8 2014 FROM THE CLINICAL EDITOR: These authors investigated how surface charge and PEGylation of liposome carriers affect the delivery of encapsulated doxorubicin to Pgp-overexpressing cells, concluding that both factors need to be considered in order to optimize doxorubicin delivery to chemoresistant cells. Doxorubicin 144-155 ATP binding cassette subfamily B member 1 Homo sapiens 159-162 24405590-8 2014 Western blotting and RT-PCR analysis indicated the higher levels of P-glycoprotein and FGFR2IIIc in 253J/DOX cells (P<0.05). Doxorubicin 105-108 ATP binding cassette subfamily B member 1 Homo sapiens 68-82 24601223-3 2014 In the present study, we reported a novel P-glycoprotein-mediated multidrug resistant cell model 253J/DOX, which was generated from human bladder cancer 253J cell line. Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 42-56 24326092-5 2013 Gastric cancer cells with Pgp expression were resistant to ADM and HCPT (p = 0.008 and p = 0.011, respectively). Doxorubicin 59-62 ATP binding cassette subfamily B member 1 Homo sapiens 26-29 24106081-4 2013 All of the compounds showed interaction with P-glycoprotein (P-gp), and 15 and 25, with the greatest activity, were able to revert P-gp-mediated resistance and reestablish the antitumor effect of doxorubicin in MCF7adr cells. Doxorubicin 196-207 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 24129234-5 2013 A decreased drug sensitivity was observed in doxorubicin-resistant cell lines, most probably related to ABCB1/MDR1 overexpression. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 104-109 24144228-3 2013 By generating the siRNA-loaded film atop a doxorubicin-loaded liposome, we identified an effective combination therapy with siRNA targeting multidrug resistance protein 1, which significantly enhanced doxorubicin efficacy by 4 fold in vitro and led to up to an 8-fold decrease in tumor volume compared to the control treatments with no observed toxicity. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 140-170 24144228-3 2013 By generating the siRNA-loaded film atop a doxorubicin-loaded liposome, we identified an effective combination therapy with siRNA targeting multidrug resistance protein 1, which significantly enhanced doxorubicin efficacy by 4 fold in vitro and led to up to an 8-fold decrease in tumor volume compared to the control treatments with no observed toxicity. Doxorubicin 201-212 ATP binding cassette subfamily B member 1 Homo sapiens 140-170 24129234-5 2013 A decreased drug sensitivity was observed in doxorubicin-resistant cell lines, most probably related to ABCB1/MDR1 overexpression. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 24382184-0 2013 Modulation of multidrug resistance P-glycoprotein activity by antiemetic compounds in human doxorubicin-resistant sarcoma cells (MES-SA/Dx-5): implications on cancer therapy. Doxorubicin 92-103 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 24062304-7 2013 Moreover, lysosomal Pgp was demonstrated to be functional because DOX accumulation in this organelle was prevented upon incubation with the established Pgp inhibitors valspodar or elacridar or by silencing Pgp expression with siRNA. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 152-155 24062304-7 2013 Moreover, lysosomal Pgp was demonstrated to be functional because DOX accumulation in this organelle was prevented upon incubation with the established Pgp inhibitors valspodar or elacridar or by silencing Pgp expression with siRNA. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 152-155 24062304-8 2013 Importantly, to elicit drug resistance via lysosomes, the cytotoxic chemotherapeutics (e.g. DOX, daunorubicin, or vinblastine) were required to be Pgp substrates and also ionized at lysosomal pH (pH 5), resulting in them being sequestered and trapped in lysosomes. Doxorubicin 92-95 ATP binding cassette subfamily B member 1 Homo sapiens 147-150 23418897-2 2013 The purposeof this study was to investigate the mechanism of reversal of P-glycoprotein (P-gp)-mediated MDR by BrTet and the involvement of the c-Jun N-terminal kinase (JNK)/c-Jun signaling pathway in both adriamycin-sensitive K562 and adriamycin-resistant K562 (KA) leukemia cells in hypoxia. Doxorubicin 206-216 ATP binding cassette subfamily B member 1 Homo sapiens 73-87 23418897-2 2013 The purposeof this study was to investigate the mechanism of reversal of P-glycoprotein (P-gp)-mediated MDR by BrTet and the involvement of the c-Jun N-terminal kinase (JNK)/c-Jun signaling pathway in both adriamycin-sensitive K562 and adriamycin-resistant K562 (KA) leukemia cells in hypoxia. Doxorubicin 206-216 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 23418897-2 2013 The purposeof this study was to investigate the mechanism of reversal of P-glycoprotein (P-gp)-mediated MDR by BrTet and the involvement of the c-Jun N-terminal kinase (JNK)/c-Jun signaling pathway in both adriamycin-sensitive K562 and adriamycin-resistant K562 (KA) leukemia cells in hypoxia. Doxorubicin 236-246 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 23418897-6 2013 It is concluded that using BrTet in combination with other chemotherapeutic agents and pharmacological inhibitors of JNK can abrogate the P-gp-induced MDR in adriamycin-resistant K562 cells, which has potential clinical relevance in cancer therapy for chemotherapeutic-resistant human leukemia. Doxorubicin 158-168 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 23674129-4 2013 Cytotoxicity was tested on 4 human cancer cell lines, while MDR reversal capacity was examined on P-glycoprotein overexpressing doxorubicin resistant MES-SA-DX5 and compared with non-resistant MES-SA cells. Doxorubicin 128-139 ATP binding cassette subfamily B member 1 Homo sapiens 98-112 24382184-5 2013 The human doxorubicin (doxo) resistant uterine sarcoma cells (MES-SA/Dx5) that overexpress Pgp, were treated with each antiemetic alone (1, 10 and 20 microM) or in combination with different doxo concentrations (2, 4, and 8 microM). Doxorubicin 10-21 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 24382184-5 2013 The human doxorubicin (doxo) resistant uterine sarcoma cells (MES-SA/Dx5) that overexpress Pgp, were treated with each antiemetic alone (1, 10 and 20 microM) or in combination with different doxo concentrations (2, 4, and 8 microM). Doxorubicin 23-27 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 23354914-0 2013 Pituitary homeobox 2 (PITX2) protects renal cancer cell lines against doxorubicin toxicity by transcriptional activation of the multidrug transporter ABCB1. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 150-155 24062304-6 2013 In Pgp-expressing cells, the Pgp substrate doxorubicin (DOX) became sequestered in LAMP2-stained lysosomes, but this was not observed in non-Pgp-expressing cells. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 3-6 24062304-6 2013 In Pgp-expressing cells, the Pgp substrate doxorubicin (DOX) became sequestered in LAMP2-stained lysosomes, but this was not observed in non-Pgp-expressing cells. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 29-32 24062304-6 2013 In Pgp-expressing cells, the Pgp substrate doxorubicin (DOX) became sequestered in LAMP2-stained lysosomes, but this was not observed in non-Pgp-expressing cells. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 29-32 24062304-6 2013 In Pgp-expressing cells, the Pgp substrate doxorubicin (DOX) became sequestered in LAMP2-stained lysosomes, but this was not observed in non-Pgp-expressing cells. Doxorubicin 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 3-6 24062304-6 2013 In Pgp-expressing cells, the Pgp substrate doxorubicin (DOX) became sequestered in LAMP2-stained lysosomes, but this was not observed in non-Pgp-expressing cells. Doxorubicin 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 29-32 24062304-6 2013 In Pgp-expressing cells, the Pgp substrate doxorubicin (DOX) became sequestered in LAMP2-stained lysosomes, but this was not observed in non-Pgp-expressing cells. Doxorubicin 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 29-32 24062304-7 2013 Moreover, lysosomal Pgp was demonstrated to be functional because DOX accumulation in this organelle was prevented upon incubation with the established Pgp inhibitors valspodar or elacridar or by silencing Pgp expression with siRNA. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 20-23 23925649-4 2013 We found that the expression of ABCB1 was correlated with the doxorubicin IC50 dose in eight hepatocellular carcinoma (HCC) cell lines: Hep3B, HCC3, LM-6, SMMC7721, Huh-7, SK-Hep-1, HepG2 and BEL-7402. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 32-37 23792120-4 2013 At a subtoxic concentration, 48-h exposure to 7-KC reduced the intracellular accumulation and cytotoxicity of P-gp substrate doxorubicin in hepatoma cells, but not in HuS-E/2 cells. Doxorubicin 125-136 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 23792430-6 2013 PN also exhibited inhibitory effect on NF-kappaB activation in A549/DOX cells, suggesting that inhibition of NF-kappaB was involved in attenuating P-gp expression by PN. Doxorubicin 68-71 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 23792430-9 2013 Overexpression of HSP70 upregulated P-gp expression independently of NF-kappaB activation in A549 cells, and knockdown of HSP70 caused a reduced expression of P-gp in A549/DOX cells. Doxorubicin 172-175 ATP binding cassette subfamily B member 1 Homo sapiens 159-163 23792430-11 2013 Taken together, PN can reverse DOX resistance through suppressing P-gp expression by mechanisms involving attenuation of NF-kappaB activation and HSP70 up-regulation. Doxorubicin 31-34 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 23720244-0 2013 Interaction of CJY, an isoflavone, with ATPase of P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 68-79 ATP binding cassette subfamily B member 1 Homo sapiens 50-64 23720244-0 2013 Interaction of CJY, an isoflavone, with ATPase of P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 123-126 ATP binding cassette subfamily B member 1 Homo sapiens 50-64 23720244-1 2013 OBJECTIVES: The previous study reported CJY, an isoflavone, can reverse P-glycoprotein (P-gp)-mediated multidrug-resistance (MDR) in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 133-144 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 23720244-1 2013 OBJECTIVES: The previous study reported CJY, an isoflavone, can reverse P-glycoprotein (P-gp)-mediated multidrug-resistance (MDR) in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 133-144 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 23720244-1 2013 OBJECTIVES: The previous study reported CJY, an isoflavone, can reverse P-glycoprotein (P-gp)-mediated multidrug-resistance (MDR) in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 188-191 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 23720244-1 2013 OBJECTIVES: The previous study reported CJY, an isoflavone, can reverse P-glycoprotein (P-gp)-mediated multidrug-resistance (MDR) in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 188-191 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 23494858-0 2013 Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation. Doxorubicin 45-55 ATP binding cassette subfamily B member 1 Homo sapiens 113-127 23354914-6 2013 In A498 cells, doxorubicin toxicity is augmented by the ABCB1 inhibitor, PSC833. Doxorubicin 15-26 ATP binding cassette subfamily B member 1 Homo sapiens 56-61 23602050-0 2013 Nuclear localization of P-glycoprotein is responsible for protection of the nucleus from doxorubicin in the resistant LoVo cell line. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 24-38 23735077-0 2013 ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo. Doxorubicin 26-29 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 23735077-3 2013 OBJECTIVE: We sought to establish an MG63/DOX cell xenografts model that maintained the MDR phenotype and molecular properties in vivo in order to screen for new P-gp inhibitors. Doxorubicin 42-45 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 23735077-6 2013 P-gp expression in MG63/DOX cells and tumor tissues was detected by western blotting and immunohistochemistry. Doxorubicin 24-27 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 23735077-8 2013 Furthermore, the ABCB1 inhibitor verapamil (10 muM) effectively reversed doxorubicin and paclitaxel resistance by 90- and 200-fold, respectively. Doxorubicin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 17-22 23683834-2 2013 Structure-activity relationship analysis showed that aromatic substituted aliphatic amine at the 24-positions (groups V) effectively and significantly sensitized P-gp overexpressing multidrug resistant (MDR) cells to anticancer drugs, such as docetaxel (DOC), vincristine (VCR), and adriamycin (ADM). Doxorubicin 283-293 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 23683834-2 2013 Structure-activity relationship analysis showed that aromatic substituted aliphatic amine at the 24-positions (groups V) effectively and significantly sensitized P-gp overexpressing multidrug resistant (MDR) cells to anticancer drugs, such as docetaxel (DOC), vincristine (VCR), and adriamycin (ADM). Doxorubicin 295-298 ATP binding cassette subfamily B member 1 Homo sapiens 162-166 23602050-4 2013 Here, we confirmed nuclear localization of P-gp in resistant LoVo cells and demonstrated its impact on doxorubicin efflux from the nucleus to cytoplasm. Doxorubicin 103-114 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 23252722-9 2013 Taken together, the present study demonstrated that the limited and paracellular intestinal absorption of doxorubicin was a major factor responsible for its low oral bioavailability, restricting the role of CYP3A4-mediated first-pass metabolism and P-gp-mediated efflux. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 249-253 23564041-3 2013 Doxorubicin is a substrate for ABC transporters like P-glycoprotein (ABCB1) which is present in human RD rhabdomyosarcoma cells. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 23674072-6 2013 Furthermore, knockdown of BMP6 in MCF7 cells enhanced the chemoresistance to doxorubicin by upregulation of mdr-1/P-gp expression and activation of the ERK signaling pathway. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 108-113 23434829-11 2013 Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 23466342-0 2013 Reversal of P-glycoprotein-mediated multidrug resistance is induced by mollugin in MCF-7/adriamycin cells. Doxorubicin 89-99 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 23466650-3 2013 Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 23466650-3 2013 Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 23466650-3 2013 Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 146-151 23466650-4 2013 The ABCB1 substrate accumulation and efflux assay showed that DABB and DHBB not only enhanced the retention of doxorubicin and rhodamine123 but also inhibited the efflux of rhodamine123. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 4-9 23116553-3 2013 METHODS: We sequenced AKR1C3 exon 5 and genotyped seven functional single nucleotide polymorphisms in CBR3, ABCB1 and SLC22A16 involved in doxorubicin pharmacology in 151 Asian breast cancer patients treated with doxorubicin-containing chemotherapy, and correlated these genotypes with doxorubicin pharmacokinetics and pharmacodynamics. Doxorubicin 139-150 ATP binding cassette subfamily B member 1 Homo sapiens 108-113 23621869-0 2013 Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistant human leukemia K562/adriamycin cells by down-regulating MDR1 via a mechanism involving NF-kappaB signaling inhibition. Doxorubicin 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 23473805-7 2013 Rp1 treatment resulted in an accumulation of doxorubicin or rhodamine 123 by decreasing MDR-1 activity in doxorubicin-resistant cells. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 23473805-7 2013 Rp1 treatment resulted in an accumulation of doxorubicin or rhodamine 123 by decreasing MDR-1 activity in doxorubicin-resistant cells. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 23983799-3 2013 In this study, we demonstrate that JNK1/2 activation by an extract from the root of Morus alba L. (White mulberry) reduces doxorubicin-resistant MCF-7/Dox cell viability by inhibiting YB-1 regulation of MDR1 gene expression. Doxorubicin 123-134 ATP binding cassette subfamily B member 1 Homo sapiens 203-207 23630447-11 2013 Further, women who developed low EFs had a 2-fold lower level of ABCB1 transcript, encoding the multidrug resistance protein 1 (MDR1), which is an efflux pump for doxorubicin, potentially leading to higher cardiac levels of drug. Doxorubicin 163-174 ATP binding cassette subfamily B member 1 Homo sapiens 65-70 23630447-11 2013 Further, women who developed low EFs had a 2-fold lower level of ABCB1 transcript, encoding the multidrug resistance protein 1 (MDR1), which is an efflux pump for doxorubicin, potentially leading to higher cardiac levels of drug. Doxorubicin 163-174 ATP binding cassette subfamily B member 1 Homo sapiens 96-126 23630447-11 2013 Further, women who developed low EFs had a 2-fold lower level of ABCB1 transcript, encoding the multidrug resistance protein 1 (MDR1), which is an efflux pump for doxorubicin, potentially leading to higher cardiac levels of drug. Doxorubicin 163-174 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 23630447-13 2013 CONCLUSIONS: It is proposed that chemo-induced cardiomyopathy may be due to a reduction in TCL1A levels, thereby causing increased apoptotic sensitivity, and leading to reduced cardiac MDR1 levels, causing higher cardiac levels of doxorubicin and intracellular free radicals. Doxorubicin 231-242 ATP binding cassette subfamily B member 1 Homo sapiens 185-189 23352909-4 2013 The copolymer unimers inhibited P-gp ATPase activity in a similar way as Pluronic P85, favoring DOXO accumulation in the resistant cell line, but not in the sensitive cell line. Doxorubicin 96-100 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 23352909-5 2013 DOXO loaded in the micelles accumulated more slowly inside the cells, but caused greater cytotoxicity than free drug solutions in the NCI-ADR-RES cell line, which overexpressed P-gp. Doxorubicin 0-4 ATP binding cassette subfamily B member 1 Homo sapiens 177-181 23449477-7 2013 Prolonged exposure of wild-type cells to doxorubicin (DOX) resulted in upregulation of P-gp, breast cancer resistance protein, survivin and Mcl-1. Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 23449477-7 2013 Prolonged exposure of wild-type cells to doxorubicin (DOX) resulted in upregulation of P-gp, breast cancer resistance protein, survivin and Mcl-1. Doxorubicin 54-57 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 23289892-6 2013 Analysis of multiple xenograft biopsies demonstrated significant Pgp knockdown at heterogeneous tumor sites that correspond to the regions where Dox was released intracellularly and induced apoptosis. Doxorubicin 145-148 ATP binding cassette subfamily B member 1 Homo sapiens 65-68 23220037-4 2013 The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario. Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 23220037-4 2013 The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario. Doxorubicin 114-117 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 23220037-10 2013 In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications. Doxorubicin 39-42 ATP binding cassette subfamily B member 1 Homo sapiens 96-100 22721393-7 2013 Compared to treatment with doxorubicin alone, combined treatment with doxorubicin and quercetin (0.7 muM) significantly inhibited cell proliferation and invasion and suppressed the expression of HIF-1alpha and P-gp. Doxorubicin 27-38 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 22721393-7 2013 Compared to treatment with doxorubicin alone, combined treatment with doxorubicin and quercetin (0.7 muM) significantly inhibited cell proliferation and invasion and suppressed the expression of HIF-1alpha and P-gp. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 23044041-2 2013 To overcome the drug efflux mediated by P-glycoprotein (P-gp) transporters, we developed pH-responsive poly(D,L-lactic-co-glycolic acid) hollow particles (PLGA HPs), capable of delivering doxorubicin (DOX) into MDR cells (MCF-7/ADR). Doxorubicin 188-199 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 23044041-2 2013 To overcome the drug efflux mediated by P-glycoprotein (P-gp) transporters, we developed pH-responsive poly(D,L-lactic-co-glycolic acid) hollow particles (PLGA HPs), capable of delivering doxorubicin (DOX) into MDR cells (MCF-7/ADR). Doxorubicin 188-199 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 23044041-2 2013 To overcome the drug efflux mediated by P-glycoprotein (P-gp) transporters, we developed pH-responsive poly(D,L-lactic-co-glycolic acid) hollow particles (PLGA HPs), capable of delivering doxorubicin (DOX) into MDR cells (MCF-7/ADR). Doxorubicin 201-204 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 23044041-2 2013 To overcome the drug efflux mediated by P-glycoprotein (P-gp) transporters, we developed pH-responsive poly(D,L-lactic-co-glycolic acid) hollow particles (PLGA HPs), capable of delivering doxorubicin (DOX) into MDR cells (MCF-7/ADR). Doxorubicin 201-204 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 23380628-10 2013 In addition, the cytotoxicity of DOXO-loaded micelles was higher than that observed for free drug solutions in a MDR ovarian NCI-ADR-RES cell line which overexpressed P-gp. Doxorubicin 33-37 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 23380628-11 2013 The inhibition of the P-gp efflux pump by some BOnEOmBOn copolymers, similar to that measured for the common P-gp inhibitor verapamil, favored the retention of DOXO inside the cell increasing its cytotoxic activity. Doxorubicin 160-164 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 23380628-11 2013 The inhibition of the P-gp efflux pump by some BOnEOmBOn copolymers, similar to that measured for the common P-gp inhibitor verapamil, favored the retention of DOXO inside the cell increasing its cytotoxic activity. Doxorubicin 160-164 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 23011844-4 2013 QUESTIONS/PURPOSES: We asked whether (1) Dox-loaded lipid-functionalized dextran-based biocompatible nanoparticles (Dox/NP) can reverse MDR, (2) Dox/NP has more potent cytotoxic effect on MDR tumors than poly(ethylene glycol)-modified liposomal Dox (PLD), and (3) multidrug resistance protein 1 (MDR1) small interfering RNA loaded in these nanoparticles (siMDR1/NP) can modulate MDR. Doxorubicin 41-44 ATP binding cassette subfamily B member 1 Homo sapiens 264-294 23011844-4 2013 QUESTIONS/PURPOSES: We asked whether (1) Dox-loaded lipid-functionalized dextran-based biocompatible nanoparticles (Dox/NP) can reverse MDR, (2) Dox/NP has more potent cytotoxic effect on MDR tumors than poly(ethylene glycol)-modified liposomal Dox (PLD), and (3) multidrug resistance protein 1 (MDR1) small interfering RNA loaded in these nanoparticles (siMDR1/NP) can modulate MDR. Doxorubicin 41-44 ATP binding cassette subfamily B member 1 Homo sapiens 296-300 22882382-4 2013 RESULTS: Our results showed that R-HepG2 cells, a doxorubicin-resistant sub-line of HepG2, exhibited decreased intracellular accumulation of doxorubicin and increased expression of P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 when compared with HepG2 cells. Doxorubicin 52-63 ATP binding cassette subfamily B member 1 Homo sapiens 183-197 22845311-4 2013 High levels of ABCB1 protein in K562-Dox cells resulted in a significantly increased 50% inhibitory concentration (IC(50)) compared with parental K562 cells for imatinib (IC(50)(IM); 9 microM to 19 microM, p = 0.002) and nilotinib (IC(50)(NIL); 345 nM to 620 nM, p = 0.013). Doxorubicin 37-40 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 32260752-7 2013 Interestingly, taken up by cells via endocytosis, PEG-DOX bypassed the P-glycoprotein (P-gp)-mediated efflux of DOX, leading to drug accumulation in DOX-resistant human breast cancer cells (MCF-7/ADR). Doxorubicin 54-57 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 32260752-7 2013 Interestingly, taken up by cells via endocytosis, PEG-DOX bypassed the P-glycoprotein (P-gp)-mediated efflux of DOX, leading to drug accumulation in DOX-resistant human breast cancer cells (MCF-7/ADR). Doxorubicin 54-57 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 32260752-7 2013 Interestingly, taken up by cells via endocytosis, PEG-DOX bypassed the P-glycoprotein (P-gp)-mediated efflux of DOX, leading to drug accumulation in DOX-resistant human breast cancer cells (MCF-7/ADR). Doxorubicin 112-115 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 32260752-7 2013 Interestingly, taken up by cells via endocytosis, PEG-DOX bypassed the P-glycoprotein (P-gp)-mediated efflux of DOX, leading to drug accumulation in DOX-resistant human breast cancer cells (MCF-7/ADR). Doxorubicin 112-115 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 24377601-0 2013 Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells. Doxorubicin 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 22759348-4 2013 GA dose dependently inhibited ABCB1 activity levels in the in vitro Pgp-Glo assay system and increased the cellular accumulation of ABCB1 substrate adriamycin. Doxorubicin 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 23983799-3 2013 In this study, we demonstrate that JNK1/2 activation by an extract from the root of Morus alba L. (White mulberry) reduces doxorubicin-resistant MCF-7/Dox cell viability by inhibiting YB-1 regulation of MDR1 gene expression. Doxorubicin 151-154 ATP binding cassette subfamily B member 1 Homo sapiens 203-207 23983799-6 2013 Moreover, REM promoted phosphorylation of c-Jun NH2-terminal kinase 1/2 (JNK1/2) and JNK1/2 inhibitor, SP600125 and rescued REM inhibition of both MDR1 expression and viabilities in MCF-7/Dox cells. Doxorubicin 188-191 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 23983799-7 2013 Consistently, overexpression of JNK1, c-Jun, or c-Fos inhibited YB-1-dependent MDR1 expression and reduced viabilities in MCF-7/Dox cells. Doxorubicin 128-131 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 23983799-8 2013 In conclusion, our data indicate that REM-activated JNK-cJun/c-Fos pathway decreases the viability of MCF-7/Dox cells by inhibiting YB-1-dependent MDR1 gene expression. Doxorubicin 108-111 ATP binding cassette subfamily B member 1 Homo sapiens 147-151 23023936-7 2013 Short- and long-term exposure of native K562 cells to adriamycin led to upregulation of P-gp and formation of acquired drug resistance. Doxorubicin 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 23023936-12 2013 This study reveals that curcuminoids have the potency to block the upregulation of P-gp and its mRNA induced by short- and long-term exposure to adriamycin. Doxorubicin 145-155 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 23383209-0 2013 Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 139-144 23103446-2 2013 We used K562/Dox cells overexpressing P-gp and their variants (subclones) with a gradually decreased P-gp expression. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 23103446-2 2013 We used K562/Dox cells overexpressing P-gp and their variants (subclones) with a gradually decreased P-gp expression. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 23103446-5 2013 We observed that K562/Dox cells overexpressing P-gp contained a significantly reduced intracellular level of nilotinib when compared to their counter partner K562 cells, which do not express P-gp. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 23103446-5 2013 We observed that K562/Dox cells overexpressing P-gp contained a significantly reduced intracellular level of nilotinib when compared to their counter partner K562 cells, which do not express P-gp. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 191-195 24008321-0 2013 Effect of phorbol 12-myristate 13-acetate on function and gene expression of P-glycoprotein in adriamycin-resistant K562/ADM cells. Doxorubicin 95-105 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 22757751-6 2012 1416 significantly enhanced cytotoxicity of VBL (vinblastine) in P-gp-overexpressed human multidrug-resistant K562/ADM (adriamycin) and KBV cells, but had no such effect on the parent K562 and KB cells. Doxorubicin 120-130 ATP binding cassette subfamily B member 1 Homo sapiens 65-69 23349819-4 2013 Furthermore, BIRB796 increased the intracellular accumulation of the ABCB1 substrates, such as rhodamine 123 and doxorubicin. Doxorubicin 113-124 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 22788770-2 2012 For instance, the anticancer drug doxorubicin, which is effective against glioblastoma in vitro, has poor efficacy in vivo, because it is extruded by P-glycoprotein (Pgp/ABCB1), multidrug resistance-related proteins and breast cancer resistance protein (BCRP/ABCG2) in BBB cells. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 170-175 22770799-5 2012 Facilitated by the cytotoxicity and uncompetitive P-gp ATPase inhibition by PLV(2K), PLV(2K)-DOX showed greater cytotoxicity compared with DOX solution with increased intracellular accumulation in resistant MCF-7/Adr cells. Doxorubicin 93-96 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 22900779-9 2012 In in vitro cytotoxicity test, THP enantiomers showed the potential of increasing the cytotoxicity of doxorubicin in P-gp-mediated multidrug resistant tumour cells. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 23257429-2 2012 The mRNA and protein expression of P-glycoprotein (Pgp) and the drug accumulation were assayed after acidifying the primary leukemia cells of patients or K562/DOX and K562/G01 cells. Doxorubicin 159-162 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 23257429-7 2012 It is concluded that the inhibiton of NHE1 can significantly decrease the protein expression of Pgp in K562/DOX and K562/G01 cells, increase the accumulation of Rhodamine123 and doxorubicin in the cells of advanced patients and enhance the sensitivity of cells to imatinib in which the p38 MAPK signal transduction pathways involves. Doxorubicin 108-111 ATP binding cassette subfamily B member 1 Homo sapiens 96-99 23046348-3 2012 Our study results showed that BBA enhanced the cytotoxicity of ABCB1 substrates and increased the accumulation of doxorubicin or rhodamine123 in ABCB1 overexpressing cells, but had no effect on non ABCB1 substrate, such as cisplatin; what"s more, BBA slightly reversed ABCG2-mediated resistance to SN-38, but did not affect the ABCC1-mediated MDR. Doxorubicin 114-125 ATP binding cassette subfamily B member 1 Homo sapiens 145-150 23046348-3 2012 Our study results showed that BBA enhanced the cytotoxicity of ABCB1 substrates and increased the accumulation of doxorubicin or rhodamine123 in ABCB1 overexpressing cells, but had no effect on non ABCB1 substrate, such as cisplatin; what"s more, BBA slightly reversed ABCG2-mediated resistance to SN-38, but did not affect the ABCC1-mediated MDR. Doxorubicin 114-125 ATP binding cassette subfamily B member 1 Homo sapiens 145-150 22995704-6 2012 The Dox-NPs were taken up by the cancer cells in vitro and significantly enhanced the cytotoxicity of Dox against human MDR1 cells with up to a 20-fold decrease in the IC50 values. Doxorubicin 4-7 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 22995704-6 2012 The Dox-NPs were taken up by the cancer cells in vitro and significantly enhanced the cytotoxicity of Dox against human MDR1 cells with up to a 20-fold decrease in the IC50 values. Doxorubicin 102-105 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 22988121-2 2012 In the present study, a Ca(2+)-permeable channel TRPC5 was found to be overproduced together with P-gp in adriamycin-resistant breast cancer cell line MCF-7/ADM. Doxorubicin 106-116 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 22770799-6 2012 PLV(2K)-DOX nanomicelles were uptaken into MCF-7/Adr cells via macropinocytosis and caveolae-mediated endocytosis, which further facilitate escapement of P-gp efflux. Doxorubicin 8-11 ATP binding cassette subfamily B member 1 Homo sapiens 154-158 22745335-2 2012 The present studies were conducted to elucidate the key factors that influenced ABCB1 expression, which could further alter adriamycin cellular pharmacokinetics. Doxorubicin 124-134 ATP binding cassette subfamily B member 1 Homo sapiens 80-85 22745335-4 2012 The results indicated that 20(S)-Rh2 inhibited adriamycin-induced ABCB1 expression in MCF-7/Adr cells. Doxorubicin 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 66-71 22745335-6 2012 Furthermore, 20(S)-Rh2 repressed the Adriamycin-enhanced ability of NF-kappaB to bind to the human multidrug resistance (MDR1) promoter, and MAPK/NF-kappaB inhibitors and NF-kappaB small interfering RNA reversed the adriamycin-induced expression of ABCB1. Doxorubicin 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 22745335-8 2012 In conclusion, the MAPK/NF-kappaB pathway mediates adriamycin-induced ABCB1 expression and subsequently alters the cellular pharmacokinetics of adriamycin. Doxorubicin 51-61 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 22745335-6 2012 Furthermore, 20(S)-Rh2 repressed the Adriamycin-enhanced ability of NF-kappaB to bind to the human multidrug resistance (MDR1) promoter, and MAPK/NF-kappaB inhibitors and NF-kappaB small interfering RNA reversed the adriamycin-induced expression of ABCB1. Doxorubicin 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 249-254 22745335-9 2012 It was speculated that 20(S)-Rh2 acted on this pathway to lower adriamycin-induced ABCB1 expression in MCF-7/Adr cells, which provided mechanism-based support to the development of 20(S)-Rh2 as a MDR reversal agent. Doxorubicin 64-74 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 22838646-9 2012 In drug-resistant MCF-7 cells, specific gene silencing effectively reduced expression of MDR1, the gene encoding the drug exporter P-gp, and consequently promoted the uptake of doxorubicin. Doxorubicin 177-188 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 23018344-0 2012 Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 23018344-8 2012 RESULTS: A doxorubicin-induced PGP overexpression cell line, K562/Dox, was generated. Doxorubicin 11-22 ATP binding cassette subfamily B member 1 Homo sapiens 31-34 23018344-8 2012 RESULTS: A doxorubicin-induced PGP overexpression cell line, K562/Dox, was generated. Doxorubicin 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 31-34 23018344-9 2012 The p38 inhibitor SB202190 significantly decreased MDR1 mRNA expression, as well as PGP, in K562/Dox cells. Doxorubicin 97-100 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 22946104-6 2012 ABCB1 expression and P-glycoprotein function were upregulated under cycling hypoxia in glioblastoma cells concomitant with decreased responses to doxorubicin and BCNU. Doxorubicin 146-157 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 22632055-3 2012 CCT129202 of more than 90% cell survival concentration significantly enhanced the cytotoxicity of substrate drugs and increased the intracellular accumulations of doxorubicin and rhodamine 123 in ABCB1 and ABCG2 overexpressing cells, while no effect was found on parental sensitive cells. Doxorubicin 163-174 ATP binding cassette subfamily B member 1 Homo sapiens 196-201 22683740-5 2012 The K562 cell, human myeloma cell, and its multidrug-resistance string, adriamycin-selected P-glycoprotein-overexpressed K562/A02, were analyzed by using an established procedure to validate feasibility. Doxorubicin 72-82 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 22521303-3 2012 We found that doxorubicin localized exclusively to the cytoplasm and was unable to reach the nuclei of resistant tumor cells because of the increased nuclear expression of MDR1/P-glycoprotein (P-gp). Doxorubicin 14-25 ATP binding cassette subfamily B member 1 Homo sapiens 172-176 23034269-5 2012 Human doxorubicin (doxo) resistant uterine sarcoma cells (MES-SA/Dx5) expressing high levels of Pgp were treated with two hepatoprotectors at various concentrations (1, 5 and 10 microM) that are clinically achievable, in the presence or absence of three different concentrations of doxo (2, 4 and 8 microM). Doxorubicin 19-23 ATP binding cassette subfamily B member 1 Homo sapiens 96-99 22639047-4 2012 Exclusively expressed P-gp cells from the human colon cancer HCT15/DOX line showed resistance to doxorubicin while parental HCT15 cells treated with doxorubicin displayed typical signs of apoptosis. Doxorubicin 67-70 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 22639047-4 2012 Exclusively expressed P-gp cells from the human colon cancer HCT15/DOX line showed resistance to doxorubicin while parental HCT15 cells treated with doxorubicin displayed typical signs of apoptosis. Doxorubicin 97-108 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 22578055-0 2012 Significant activity of ecdysteroids on the resistance to doxorubicin in mammalian cancer cells expressing the human ABCB1 transporter. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 22521303-3 2012 We found that doxorubicin localized exclusively to the cytoplasm and was unable to reach the nuclei of resistant tumor cells because of the increased nuclear expression of MDR1/P-glycoprotein (P-gp). Doxorubicin 14-25 ATP binding cassette subfamily B member 1 Homo sapiens 177-191 21562851-4 2012 MCF-7 cells and the derived P-glycoprotein (Pgp) overexpressing MCF-7/dox cells were treated with TMP, and their growth was examined by MTT assay. Doxorubicin 70-73 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 21562851-4 2012 MCF-7 cells and the derived P-glycoprotein (Pgp) overexpressing MCF-7/dox cells were treated with TMP, and their growth was examined by MTT assay. Doxorubicin 70-73 ATP binding cassette subfamily B member 1 Homo sapiens 44-47 21562851-6 2012 The results showed that TMP increased the intracellular concentration of doxorubicin and inhibited Pgp-mediated efflux of doxorubicin in a dose-dependent manner. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 99-102 21562851-7 2012 Moreover, TMP inhibited the ATPase activity of P-gp and suppressed the expression of Pgp in MCF-7/dox cells. Doxorubicin 98-101 ATP binding cassette subfamily B member 1 Homo sapiens 85-88 22593250-0 2012 Modulation of apoptosis protein profiles--role of P-gp in HeLa cells exposed to doxorubicin. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 22593250-1 2012 As shown previously doxorubicin (1 muM) plus sulindac (50 muM) reduced the expression of ABCB1 (ATP-binding cassette, sub-family B (MDR/TAP), member 1) mRNA in HeLa cells and this effect was accompanied by increased apoptosis. Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 89-94 22593250-1 2012 As shown previously doxorubicin (1 muM) plus sulindac (50 muM) reduced the expression of ABCB1 (ATP-binding cassette, sub-family B (MDR/TAP), member 1) mRNA in HeLa cells and this effect was accompanied by increased apoptosis. Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 96-150 22365753-2 2012 Of the 30 analogs synthesized, N(alpha),N(epsilon)-[(CH(3))(2)Mle-Tic](2)Lys-NH(2) and its D-Lys analog were found to exhibit potent P-gp inhibitory activity, twice that of verapamil, in doxorubicin-resistant K562 cells. Doxorubicin 187-198 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 22353810-10 2012 Treatment with a non-lethal concentration of doxorubicin (0.85 nM, 8 h) increased mitochondrial and plasma membrane MRP-1, increasing resistance to MRP-1 substrates. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 116-121 22353810-10 2012 Treatment with a non-lethal concentration of doxorubicin (0.85 nM, 8 h) increased mitochondrial and plasma membrane MRP-1, increasing resistance to MRP-1 substrates. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 148-153 22258826-4 2012 As CuNG increased cellular accumulation of doxorubicin in P-gp-expressing cells, we presumed that of CuNG may be potential to reverse P-gp-mediated drug resistance probably by lowering the P-gp expression at the protein as well as mRNA level. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 22258826-4 2012 As CuNG increased cellular accumulation of doxorubicin in P-gp-expressing cells, we presumed that of CuNG may be potential to reverse P-gp-mediated drug resistance probably by lowering the P-gp expression at the protein as well as mRNA level. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 22258826-4 2012 As CuNG increased cellular accumulation of doxorubicin in P-gp-expressing cells, we presumed that of CuNG may be potential to reverse P-gp-mediated drug resistance probably by lowering the P-gp expression at the protein as well as mRNA level. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 22307172-3 2012 In this study, we sought to investigate the localization and functional characterization of P-gp in mitochondria isolated from MCF-7 and doxorubicin-resistant MCF-7 (MCF-7/ADM) cells. Doxorubicin 161-172 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 22307172-12 2012 P-gp is expressed in the mitochondria of doxorubicin-resistant MCF-7 cells and has an efflux function. Doxorubicin 41-52 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 22226881-5 2012 Lys-P restored the cytotoxicity of Dox toward the resistant MDR1-transfected HEK293 and MCF-7 TX400 cells without affecting their corresponding parental cells. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 22226881-7 2012 Further mechanistic studies demonstrated that in the Caco-2 cell monolayer model, Lys-P abolished the P-gp-mediated efflux of Dox due to uncompetitive inhibition of P-gp ATPase without altering P-gp expression. Doxorubicin 126-129 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 22320402-5 2012 Lineweaver-Burk and Dixon plots suggest that 18 is a competitive inhibitor to DOX in binding to P-gp with a K(i) of 0.28-0.34 muM and a Hill coefficient of 1.17. Doxorubicin 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 96-100 22250587-0 2012 Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. Doxorubicin 146-157 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 22243797-4 2012 In this co-delivery system, Dox was firstly encapsulated into the hydrophobic cavities of beta-CD, resulting in bypass of P-glycoprotein (P-gp)-mediated drug efflux. Doxorubicin 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 122-136 22243797-4 2012 In this co-delivery system, Dox was firstly encapsulated into the hydrophobic cavities of beta-CD, resulting in bypass of P-glycoprotein (P-gp)-mediated drug efflux. Doxorubicin 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 22243797-5 2012 After complex formation of the mdr1 siRNA with Dox-loaded QDs via electrostatic interaction, significant down-regulation of mdr1 mRNA levels and P-gp expression was achieved as shown by RT-PCR and Western blotting experiments, respectively. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 22243797-5 2012 After complex formation of the mdr1 siRNA with Dox-loaded QDs via electrostatic interaction, significant down-regulation of mdr1 mRNA levels and P-gp expression was achieved as shown by RT-PCR and Western blotting experiments, respectively. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 22243797-5 2012 After complex formation of the mdr1 siRNA with Dox-loaded QDs via electrostatic interaction, significant down-regulation of mdr1 mRNA levels and P-gp expression was achieved as shown by RT-PCR and Western blotting experiments, respectively. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 22118813-8 2012 Flow cytometric analyses showed that IPH-926 but not ABCB1-negative breast cancer cells extruded the anticancer agent doxorubicin, a classical substrate of the ABCB1 drug transporter. Doxorubicin 118-129 ATP binding cassette subfamily B member 1 Homo sapiens 160-165 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 291-305 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 307-311 20641916-0 2004 4-[(18)F]Fluoropaclitaxel One of the mechanisms that tumor cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel (PAC), is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 361-366 20641759-0 2004 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 210-220 ATP binding cassette subfamily B member 1 Homo sapiens 365-379 20641759-0 2004 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 210-220 ATP binding cassette subfamily B member 1 Homo sapiens 381-385 20641759-0 2004 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-[(11)C]methyl-amino]-2-propan-2-yl-pentanenitrile One of the mechanisms by which cells mitigate the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Paclitaxel, is to limit their presence inside the cells via the transmembrane protein P-glycoprotein (P-gp), which is encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 210-220 ATP binding cassette subfamily B member 1 Homo sapiens 434-439 22158944-5 2012 Upon its release, doxorubicin traversed the intracellular milieu and entered the cell nucleus by a route that evaded pgp-mediated drug export. Doxorubicin 18-29 ATP binding cassette subfamily B member 1 Homo sapiens 117-120 22158944-8 2012 Together, our findings show that DNCs not only provide an alternative route of delivery of doxorubicin to pgp-overexpressing cancer cells but also may boost the uptake of transferrin-tagged therapeutic agents. Doxorubicin 91-102 ATP binding cassette subfamily B member 1 Homo sapiens 106-109 20641391-0 2004 1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 178-188 ATP binding cassette subfamily B member 1 Homo sapiens 321-335 20641391-0 2004 1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 178-188 ATP binding cassette subfamily B member 1 Homo sapiens 337-341 20641391-0 2004 1-(9H-Carbazol-4-yloxy)-3-(2-(2-[(11)C]methoxyphenoxy)ethylamino)-propan-2-ol One of the mechanisms cells use to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and Taxol, is to limit their presence inside the cells through the actions of P-glycoprotein (P-gp), a protein encoded by the multidrug resistance (MDR-1) gene (1, 2). Doxorubicin 178-188 ATP binding cassette subfamily B member 1 Homo sapiens 391-396 22250587-3 2012 MCF-7/MDR1 cells express high level of MDR1 and are resistant to doxorubicin. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 6-10 22250587-4 2012 We found that loperamide significantly enhanced the cytotoxicity of doxorubicin to MCF-7/MDR1 cells in a dose-dependent manner. Doxorubicin 68-79 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 22250587-5 2012 In conclusion, loperamide reversed the resistance of MCF-7/MDR1 cells to doxorubicin, suggesting that chemotherapy in combination with loperamide may benefit patients with MDR tumors once applied in clinic. Doxorubicin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 21520073-6 2012 Similarly, valspodar (PSC-833), a specific inhibitor of P-gp, restored sensitivity of the K562/Dox cell line to Cl-IB-MECA with concomitant increase of intracellular level of Cl-IB-MECA in the resistant cell line, while it affected cytotoxicity of Cl-IB-MECA in the sensitive cell line only marginally. Doxorubicin 95-98 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 22740937-0 2012 Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells. Doxorubicin 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 22740937-3 2012 The aim of the present study was to investigate the modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells. Doxorubicin 109-119 ATP binding cassette subfamily B member 1 Homo sapiens 66-80 22740937-6 2012 The effects of triptolide on P-glycoprotein activity were evaluated by measuring intracellular adriamycin accumulation. Doxorubicin 95-105 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 22740937-11 2012 Triptolide may effectively reverse the adriamycin resistance in K562/A02 cells via modulation of the P-glycoprotein expression and by increasing intracellular adriamycin accumulation. Doxorubicin 39-49 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 22044878-9 2012 From the overall results, the aminated thioxanthones represent a new class of P-gp inhibitors with improved efficacy in sensitizing a resistant P-gp overexpressing cell line (K562Dox) to doxorubicin. Doxorubicin 187-198 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 22217342-0 2012 HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. Doxorubicin 25-36 ATP binding cassette subfamily B member 1 Homo sapiens 74-88 22044878-9 2012 From the overall results, the aminated thioxanthones represent a new class of P-gp inhibitors with improved efficacy in sensitizing a resistant P-gp overexpressing cell line (K562Dox) to doxorubicin. Doxorubicin 187-198 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 22489175-2 2012 The clinical use of DOX, however, is limited by the dose-dependant P-glycoprotein (P-gp)-mediated resistance. Doxorubicin 20-23 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 21615726-8 2012 20(S)-Rh2 increased the rate and amount of adriamycin entering cellular/subcellular compartments in MCF-7/Adr cells through inhibition of P-glycoprotein (P-gp) activity, in turn augmenting adriamycin-induced apoptosis. Doxorubicin 43-53 ATP binding cassette subfamily B member 1 Homo sapiens 154-158 21615726-10 2012 CONCLUSIONS AND IMPLICATIONS: P-gp, which is overexpressed and functionally active at cellular/subcellular membranes, influences the cellular pharmacokinetic and pharmacological properties of adriamycin in MCF-7/Adr cells. Doxorubicin 192-202 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 21615726-11 2012 Inhibition of P-gp activity represents a key mechanism by which 20(S)-Rh2 attenuates adriamycin resistance. Doxorubicin 85-95 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 22275834-3 2012 METHODS: Doxorubicin (DOX), a chemotherapy drug that is a P-gp substrate, was conjugated to PLGA and encapsulated in the self-assembled LNP structure. Doxorubicin 9-20 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 22275834-3 2012 METHODS: Doxorubicin (DOX), a chemotherapy drug that is a P-gp substrate, was conjugated to PLGA and encapsulated in the self-assembled LNP structure. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 23493035-5 2012 Immonofluorescent technique was used to show MDR-1 protein in MDA-MB-231 and MCF-7 cells after treatment with DOX or DOCT. Doxorubicin 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 23493035-8 2012 Immonofluorescent results confirmed the expression of MDR-1 in these two cell lines after DOX or DOCT treatment. Doxorubicin 90-93 ATP binding cassette subfamily B member 1 Homo sapiens 54-59 22191778-0 2012 P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 22191778-3 2012 METHOD: We have synthesized a novel conjugate between a phospholipid (dioleoylphosphatidylethanolamine) and polyethylenimine (PEI) for siRNA delivery, for the purpose of silencing P-gp to overcome doxorubicin resistance in MCF-7 human breast cancer cells. Doxorubicin 197-208 ATP binding cassette subfamily B member 1 Homo sapiens 180-184 22191778-7 2012 DISCUSSION: The combination of doxorubicin and P-gp silencing formulations led to a twofold increase of doxorubicin uptake and a significant improvement of the therapeutic effect of doxorubicin in resistant cells. Doxorubicin 104-115 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 22191778-7 2012 DISCUSSION: The combination of doxorubicin and P-gp silencing formulations led to a twofold increase of doxorubicin uptake and a significant improvement of the therapeutic effect of doxorubicin in resistant cells. Doxorubicin 104-115 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 22573000-5 2012 In addition, the mechanisms of -elemene in reversing P-glycoprotein (Pgp)-mediated MDR demonstrated that -elemene significantly increases the intracellular accumulations of doxorubicin and Rh123 via inhibition of the P-gp transport function in MCF-7/DOX cells. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 22573000-5 2012 In addition, the mechanisms of -elemene in reversing P-glycoprotein (Pgp)-mediated MDR demonstrated that -elemene significantly increases the intracellular accumulations of doxorubicin and Rh123 via inhibition of the P-gp transport function in MCF-7/DOX cells. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 69-72 22573000-5 2012 In addition, the mechanisms of -elemene in reversing P-glycoprotein (Pgp)-mediated MDR demonstrated that -elemene significantly increases the intracellular accumulations of doxorubicin and Rh123 via inhibition of the P-gp transport function in MCF-7/DOX cells. Doxorubicin 250-253 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 22573000-5 2012 In addition, the mechanisms of -elemene in reversing P-glycoprotein (Pgp)-mediated MDR demonstrated that -elemene significantly increases the intracellular accumulations of doxorubicin and Rh123 via inhibition of the P-gp transport function in MCF-7/DOX cells. Doxorubicin 250-253 ATP binding cassette subfamily B member 1 Homo sapiens 69-72 22701315-4 2012 METHODS AND RESULTS: We report that carbonate apatite-mediated delivery of the siRNAs targeting ABCG2 and ABCB1 gene transcripts in human breast cancer cells which constitutively express both of the transporter genes dose-dependently enhanced chemosensitivity to doxorubicin, paclitaxel and cisplatin, the traditionally used chemotherapeutic agents. Doxorubicin 263-274 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 22489175-2 2012 The clinical use of DOX, however, is limited by the dose-dependant P-glycoprotein (P-gp)-mediated resistance. Doxorubicin 20-23 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 22489175-6 2012 The cytotoxicity experiments of ADOX or DOX against K562/DOX, with or without P-gp inhibitor, indicated that ADOX circumvents resistance by abolishing the P-gp recognition. Doxorubicin 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 22489175-6 2012 The cytotoxicity experiments of ADOX or DOX against K562/DOX, with or without P-gp inhibitor, indicated that ADOX circumvents resistance by abolishing the P-gp recognition. Doxorubicin 40-43 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 21400240-12 2011 CONCLUSIONS: In TS, the accumulation and distribution of doxorubicin was influenced by both the expression of P-glycoprotein and hypoxia-induced acidity. Doxorubicin 57-68 ATP binding cassette subfamily B member 1 Homo sapiens 110-124 21872924-3 2011 Conjugating the anticancer drug DOX to these nanocarriers enhances the drug"s thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX. Doxorubicin 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 254-268 21872924-3 2011 Conjugating the anticancer drug DOX to these nanocarriers enhances the drug"s thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX. Doxorubicin 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 270-274 22927901-3 2012 R-HepG2 and MES-SA/Dx5 cells are doxorubicin induced P-gp over-expressed MDR sublines of human hepatocellular carcinoma HepG2 cells and human uterine carcinoma MES-SA cells respectively. Doxorubicin 33-44 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 22927901-5 2012 Further study showed that the clitocine increased the sensitivity and intracellular accumulation of doxorubicin in R-HepG2 cells accompanying down-regulated MDR1 mRNA level and promoter activity, indicating the reversal effect of MDR by clitocine. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 157-161 22662203-1 2012 The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limited by its toxicity and the development of multidrug resistance (MDR), the latter mainly induced by high expression of efflux pumps (e.g., P-glycoprotein [P-gp]). Doxorubicin 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 237-251 22662203-1 2012 The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limited by its toxicity and the development of multidrug resistance (MDR), the latter mainly induced by high expression of efflux pumps (e.g., P-glycoprotein [P-gp]). Doxorubicin 26-37 ATP binding cassette subfamily B member 1 Homo sapiens 253-257 22011009-10 2011 Expression level of mdr1 gene was downregulated after resveratrol combined with doxorubicin or docetaxel in all tested cell lines. Doxorubicin 80-91 ATP binding cassette subfamily B member 1 Homo sapiens 20-24 21919804-7 2011 For example, single nucleotide polymorphisms (SNPs) in the ABCB1 transporter gene have been shown to influence both pharmacokinetics and outcome following doxorubicin chemotherapy. Doxorubicin 155-166 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 21871878-0 2011 A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells. Doxorubicin 48-58 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 21718141-8 2011 In contrast, three imatinib-resistant K562 Dox lines exhibited only a further increase in ABCB1 expression. Doxorubicin 43-46 ATP binding cassette subfamily B member 1 Homo sapiens 90-95 21805041-10 2011 In summary, the endogenous expression of P-gp, MRP, LRP, GST-pi and TopoIIalpha was different in the four human lung cancer cell lines of different histological types, and this variance may be associated with the variation in chemosensitivity to cisplatin, doxorubicin and VP-16. Doxorubicin 257-268 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 21892492-3 2011 In this work, we first report that the performance and mechanism of an inorganic engineered delivery system based on mesoporous silica nanoparticles (MSNs) loading doxorubicin (DMNs) to overcome the MDR of MCF-7/ADR (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). Doxorubicin 164-175 ATP binding cassette subfamily B member 1 Homo sapiens 237-251 21892492-3 2011 In this work, we first report that the performance and mechanism of an inorganic engineered delivery system based on mesoporous silica nanoparticles (MSNs) loading doxorubicin (DMNs) to overcome the MDR of MCF-7/ADR (a DOX-resistant and P-glycoprotein (P-gp) over-expression cancer cell line). Doxorubicin 164-175 ATP binding cassette subfamily B member 1 Homo sapiens 253-257 21892492-7 2011 The increased cellular uptake and nuclear accumulation of DOX delivered by DMNs in MCF-7/ADR cells was confirmed by confocal laser scanning microscopy, and could result from the down-regulation of P-gp and bypassing the efflux action by MSNs themselves. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 197-201 21801152-0 2011 Chebulagic acid synergizes the cytotoxicity of doxorubicin in human hepatocellular carcinoma through COX-2 dependant modulation of MDR-1. Doxorubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 131-136 21784846-0 2011 Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. Doxorubicin 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 21784846-0 2011 Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. Doxorubicin 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 76-81 21784846-0 2011 Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. Doxorubicin 132-142 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 21868524-5 2011 RESULTS: siRNA down-regulated MDR1 mRNA expression by 50% in breast carcinoma and osteosarcoma cell lines, and significantly inhibited tumor cell proliferation up to 90% (p<0.01), when co-administered with doxorubicin or methotrexate, despite the known chemoresistance of the cell lines. Doxorubicin 209-220 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 21801152-6 2011 The induction of MDR1 expression by PGE(2), a metabolite of COX-2, and its downregulation by COX-2 knockdown or CA implies that the enhanced sensitivity of HepG2 cells to doxorubicin by CA is mediated by the downregulation of MDR1 expression, via COX-2-dependent mechanism. Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 21829205-1 2011 BACKGROUND: Given that HIV-protease inhibitors (HIV-PIs) are substrates/inhibitors of the multidrug transporter ABCB1, can induce ABCB1 expression, and are used in combination with doxorubicin for AIDS-Kaposi"s Sarcoma (KS) treatment, the role that ABCB1 plays in mediating multidrug resistance (MDR) in a fully transformed KS cell line (SLK) was explored. Doxorubicin 181-192 ATP binding cassette subfamily B member 1 Homo sapiens 112-117 21536373-7 2011 DOXO induced MDR1 mRNA and protein expression and alpha-TOS inhibited this event, indicating that alpha-TOS suppressed DOXO efflux via inhibition of MDR1. Doxorubicin 0-4 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 21536373-7 2011 DOXO induced MDR1 mRNA and protein expression and alpha-TOS inhibited this event, indicating that alpha-TOS suppressed DOXO efflux via inhibition of MDR1. Doxorubicin 0-4 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 21536373-7 2011 DOXO induced MDR1 mRNA and protein expression and alpha-TOS inhibited this event, indicating that alpha-TOS suppressed DOXO efflux via inhibition of MDR1. Doxorubicin 119-123 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 21829205-1 2011 BACKGROUND: Given that HIV-protease inhibitors (HIV-PIs) are substrates/inhibitors of the multidrug transporter ABCB1, can induce ABCB1 expression, and are used in combination with doxorubicin for AIDS-Kaposi"s Sarcoma (KS) treatment, the role that ABCB1 plays in mediating multidrug resistance (MDR) in a fully transformed KS cell line (SLK) was explored. Doxorubicin 181-192 ATP binding cassette subfamily B member 1 Homo sapiens 130-135 21829205-1 2011 BACKGROUND: Given that HIV-protease inhibitors (HIV-PIs) are substrates/inhibitors of the multidrug transporter ABCB1, can induce ABCB1 expression, and are used in combination with doxorubicin for AIDS-Kaposi"s Sarcoma (KS) treatment, the role that ABCB1 plays in mediating multidrug resistance (MDR) in a fully transformed KS cell line (SLK) was explored. Doxorubicin 181-192 ATP binding cassette subfamily B member 1 Homo sapiens 130-135 21829205-5 2011 Co-treatment with one of the HIV-PIs in combination with doxorubicin resulted in a synergistic increase in resistance to doxorubicin, and the degree of resistance was found to correlate with the expression of ABCB1. Doxorubicin 57-68 ATP binding cassette subfamily B member 1 Homo sapiens 209-214 21829205-5 2011 Co-treatment with one of the HIV-PIs in combination with doxorubicin resulted in a synergistic increase in resistance to doxorubicin, and the degree of resistance was found to correlate with the expression of ABCB1. Doxorubicin 121-132 ATP binding cassette subfamily B member 1 Homo sapiens 209-214 21829205-7 2011 CONCLUSION: These studies suggest that ABCB1 is primarily responsible for mediating MDR in SLK cells selected with either HIV-PIs alone or in combination with doxorubicin. Doxorubicin 159-170 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 21775090-5 2011 Flow cytometry analyzes showed that the accumulation of P-glycoprotein (P-gp) substrates (rhodamine 123 and doxorubicin) was significantly lower in DLD1-TxR and U87-TxR compared to DLD1 and U87, respectively. Doxorubicin 108-119 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 21775090-5 2011 Flow cytometry analyzes showed that the accumulation of P-glycoprotein (P-gp) substrates (rhodamine 123 and doxorubicin) was significantly lower in DLD1-TxR and U87-TxR compared to DLD1 and U87, respectively. Doxorubicin 108-119 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 21657271-4 2011 Long-term exposure of P-gp-expressing cells to 1 sensitized them to doxorubicin and paclitaxel, both P-gp substrates. Doxorubicin 68-79 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 20716130-1 2011 The anticancer drug doxorubicin induces the synthesis of nitric oxide, a small molecule that enhances the drug cytotoxicity and reduces the drug efflux through the membrane pump P-glycoprotein (Pgp). Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 178-192 20716130-1 2011 The anticancer drug doxorubicin induces the synthesis of nitric oxide, a small molecule that enhances the drug cytotoxicity and reduces the drug efflux through the membrane pump P-glycoprotein (Pgp). Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 194-197 21627074-5 2011 This system was used to improve the efficacy of DOX in multidrug-resistant MDA-MB-435 human tumor models that overexpress P-glycoprotein (P-gp), by simultaneous intracellular delivery of DOX and siRNA against P-gp expression. Doxorubicin 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 122-136 21627074-5 2011 This system was used to improve the efficacy of DOX in multidrug-resistant MDA-MB-435 human tumor models that overexpress P-glycoprotein (P-gp), by simultaneous intracellular delivery of DOX and siRNA against P-gp expression. Doxorubicin 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 21627074-5 2011 This system was used to improve the efficacy of DOX in multidrug-resistant MDA-MB-435 human tumor models that overexpress P-glycoprotein (P-gp), by simultaneous intracellular delivery of DOX and siRNA against P-gp expression. Doxorubicin 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 209-213 21627074-5 2011 This system was used to improve the efficacy of DOX in multidrug-resistant MDA-MB-435 human tumor models that overexpress P-glycoprotein (P-gp), by simultaneous intracellular delivery of DOX and siRNA against P-gp expression. Doxorubicin 187-190 ATP binding cassette subfamily B member 1 Homo sapiens 122-136 21627074-8 2011 This multifunctional polymeric micellar system was shown to be capable of DOX and siRNA delivery to their intracellular targets, leading to the inhibition of P-gp-mediated DOX resistance in vitro and targeting of alphavbeta3-positive tumors in vivo. Doxorubicin 74-77 ATP binding cassette subfamily B member 1 Homo sapiens 158-162 21627074-8 2011 This multifunctional polymeric micellar system was shown to be capable of DOX and siRNA delivery to their intracellular targets, leading to the inhibition of P-gp-mediated DOX resistance in vitro and targeting of alphavbeta3-positive tumors in vivo. Doxorubicin 172-175 ATP binding cassette subfamily B member 1 Homo sapiens 158-162 21491921-0 2011 Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Doxorubicin 22-33 ATP binding cassette subfamily B member 1 Homo sapiens 73-87 21491921-1 2011 The most frequent drawback of doxorubicin is the onset of drug resistance, due to the active efflux through P-glycoprotein (Pgp). Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 21491921-1 2011 The most frequent drawback of doxorubicin is the onset of drug resistance, due to the active efflux through P-glycoprotein (Pgp). Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 124-127 21491921-4 2011 Interestingly, we did not detect any difference in drug accumulation and toxicity between free doxorubicin and Lipodox in HT29 cells, but Lipodox was significantly more effective than doxorubicin in HT29-dx cells, which are rich in Pgp. Doxorubicin 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 232-235 21491921-7 2011 This inhibition was due to a double effect: the liposome shell per se altered the composition of rafts in resistant cells and decreased the lipid raft-associated amount of Pgp, and the doxorubicin-loaded liposomes directly impaired transport and ATPase activity of Pgp. Doxorubicin 185-196 ATP binding cassette subfamily B member 1 Homo sapiens 265-268 21491921-11 2011 Our work describes novel properties of liposomal doxorubicin, investigating the molecular bases that make this formulation an inhibitor of Pgp activity and a vehicle particularly indicated against drug-resistant tumors. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 139-142 21458446-4 2011 In addition, the mechanisms of milbemycins on reversing P-gp-mediated MDR demonstrated that they significantly increased the accumulations of adriamycin and Rh123 via inhibiting P-gp efflux in MCF-7/adr cells. Doxorubicin 142-152 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 21246559-6 2011 M-DOX showed fivefold lower the concentration that caused 50% killing tumor cell than that of free DOX in the P-gp-overexpressing MCF-7 breast cancer (MCF-7/ADR) cells. Doxorubicin 2-5 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 21246559-6 2011 M-DOX showed fivefold lower the concentration that caused 50% killing tumor cell than that of free DOX in the P-gp-overexpressing MCF-7 breast cancer (MCF-7/ADR) cells. Doxorubicin 99-102 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 21246559-10 2011 We conclude that the increased cytotoxicity of DOX encapsulated in PEG-PE micelle is due to the reduced P-gp expression by PEG-PE block molecules, and accordingly enhancing the cellular accumulation of DOX. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 21514380-6 2011 Furthermore, TRAIL significantly potentiated the cytotoxicity of vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells, which resulted in the reversal effect of TRAIL on the MDR phenotype. Doxorubicin 91-102 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 21235729-7 2011 In addition, amoxapine and loxapine, two tetracyclic antidepressant drugs, were discovered to be potent non-competitive inhibitors of P-gp, causing a 3.5-fold decrease in the doxorubicin GI(50) in K562Dox cell line. Doxorubicin 175-186 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 21781495-0 2011 [Effect of regulation of Y-box protein 1 by RNA interference on the doxorubicin induced mdr1 gene expression in K562 cells]. Doxorubicin 68-79 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 21781495-5 2011 The expression of YB-1 gene in K562 cells was inhibited by YB-1 gene specific RNA interference (RNAi), then the expression of mdr1 and P-gp in YB-1 gene silenced cells treated with DOX was detected. Doxorubicin 181-184 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 21781495-5 2011 The expression of YB-1 gene in K562 cells was inhibited by YB-1 gene specific RNA interference (RNAi), then the expression of mdr1 and P-gp in YB-1 gene silenced cells treated with DOX was detected. Doxorubicin 181-184 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 21781495-6 2011 RESULTS: The mdr1 gene as well as its corresponding protein P-gp was highly expressed in DOX exposed K562 cells. Doxorubicin 89-92 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 21781495-6 2011 RESULTS: The mdr1 gene as well as its corresponding protein P-gp was highly expressed in DOX exposed K562 cells. Doxorubicin 89-92 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 21781495-8 2011 On YB-1 gene silenced, the expressions of mdr1 gene and P-gp were obviously down-regulated in DOX treated K562 cells. Doxorubicin 94-97 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 21781495-8 2011 On YB-1 gene silenced, the expressions of mdr1 gene and P-gp were obviously down-regulated in DOX treated K562 cells. Doxorubicin 94-97 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 21781495-9 2011 CONCLUSION: Doxorubicin can induce the expression of mdr1 gene in K562 cells, which may result from the transcription of mdr1 gene by activated YB-1. Doxorubicin 12-23 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 21781495-9 2011 CONCLUSION: Doxorubicin can induce the expression of mdr1 gene in K562 cells, which may result from the transcription of mdr1 gene by activated YB-1. Doxorubicin 12-23 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 21377266-6 2011 Indomethacin and SC236 partially reversed the increase in expression of P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) induced by doxorubicin in R-HepG2 cells. Doxorubicin 158-169 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 21377266-6 2011 Indomethacin and SC236 partially reversed the increase in expression of P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) induced by doxorubicin in R-HepG2 cells. Doxorubicin 158-169 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 20640574-4 2011 The intracellular accumulation and efflux studies with Pgp substrates of doxorubicin and rhodamine 123 were determined by flow cytometry. Doxorubicin 73-84 ATP binding cassette subfamily B member 1 Homo sapiens 55-58 21513295-3 2011 The bridged scaffold of nocardioazine A proved to be a noncytotoxic inhibitor of the membrane protein efflux pump P-glycoprotein, reversing doxorubicin resistance in a multidrug resistant colon cancer cell. Doxorubicin 140-151 ATP binding cassette subfamily B member 1 Homo sapiens 114-128 21300134-10 2011 Electrophoretic mobility shift assay revealed that doxorubicin increased binding of YB-1 to the Y-box of mdr1 promoter. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 21300134-12 2011 The introduction of exogenous YB-1 shRNA into Daudi cells resulted in decreased levels of the expression of mdr1 gene and P-glycoprotein induced by doxorubicin. Doxorubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 21300134-12 2011 The introduction of exogenous YB-1 shRNA into Daudi cells resulted in decreased levels of the expression of mdr1 gene and P-glycoprotein induced by doxorubicin. Doxorubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 122-136 21300134-14 2011 CONCLUSION: Doxorubicin can increase expression of mdr1/P-glycoprotein through activating MAPK/ERK transduction pathway, then increasing expression of YB-1, inducing YB-1 nuclear translocation, and enhancing DNA-binding activity of YB-1. Doxorubicin 12-23 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 21300134-14 2011 CONCLUSION: Doxorubicin can increase expression of mdr1/P-glycoprotein through activating MAPK/ERK transduction pathway, then increasing expression of YB-1, inducing YB-1 nuclear translocation, and enhancing DNA-binding activity of YB-1. Doxorubicin 12-23 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 21354366-2 2011 Doxorubicin (DOX) efflux activity of the cells in spheroid culture was higher than that in monolayer culture due to the higher expression of MDR1 protein of the cells in spheroids compared with those in monolayer. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 21354366-2 2011 Doxorubicin (DOX) efflux activity of the cells in spheroid culture was higher than that in monolayer culture due to the higher expression of MDR1 protein of the cells in spheroids compared with those in monolayer. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 21354366-5 2011 Furthermore, the IC(50) of DOX and epirubicin (EPI) in HepG2 cells, both of which are known to be exported by MDR1, were higher in spheroid compared with monolayer cells, while IC(50) of 5-fluorouracil (5-FU), which is not exported by MDR1 protein, was almost the same in both types of culture. Doxorubicin 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 21354366-5 2011 Furthermore, the IC(50) of DOX and epirubicin (EPI) in HepG2 cells, both of which are known to be exported by MDR1, were higher in spheroid compared with monolayer cells, while IC(50) of 5-fluorouracil (5-FU), which is not exported by MDR1 protein, was almost the same in both types of culture. Doxorubicin 27-30 ATP binding cassette subfamily B member 1 Homo sapiens 235-239 21411714-3 2011 The purpose of the present study was to use the endosomal pH-sensitive MSN (mesoporous silica nanoparticles; MSN-Hydrazone-Dox) for controlled release of doxorubicin (Dox) in an attempt to overcome the PGP-mediated MDR. Doxorubicin 154-165 ATP binding cassette subfamily B member 1 Homo sapiens 202-205 21411714-3 2011 The purpose of the present study was to use the endosomal pH-sensitive MSN (mesoporous silica nanoparticles; MSN-Hydrazone-Dox) for controlled release of doxorubicin (Dox) in an attempt to overcome the PGP-mediated MDR. Doxorubicin 167-170 ATP binding cassette subfamily B member 1 Homo sapiens 202-205 21296067-3 2011 In this study, a doxorubicin-resistant MCF-7/Dox cell was developed to mimic the occurrence of acquired doxorubicin resistance. Doxorubicin 17-28 ATP binding cassette subfamily B member 1 Homo sapiens 104-126 21296067-3 2011 In this study, a doxorubicin-resistant MCF-7/Dox cell was developed to mimic the occurrence of acquired doxorubicin resistance. Doxorubicin 45-48 ATP binding cassette subfamily B member 1 Homo sapiens 104-126 21377266-0 2011 Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 21325069-6 2011 The cell lines expressing MDR-1 acquired resistance to chemotherapeutic agents such as cisplatin and doxorubicin, but not bortezomib. Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 21365663-6 2011 In contrast, in the SMF group and SMF + ADM group, the P-gp expression was decreased compared with the ADM group. Doxorubicin 40-43 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 20857089-3 2011 Thus, the aim of the present work was to evaluate P-gp expression and activity in Caco-2 cells exposed to doxorubicin (a known P-gp inducer) and to correlate these changes with paraquat toxic effects. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 20857089-3 2011 Thus, the aim of the present work was to evaluate P-gp expression and activity in Caco-2 cells exposed to doxorubicin (a known P-gp inducer) and to correlate these changes with paraquat toxic effects. Doxorubicin 106-117 ATP binding cassette subfamily B member 1 Homo sapiens 127-131 20857089-4 2011 Cytotoxicity of doxorubicin (0-100 muM) and paraquat (0-1,000 muM) was evaluated for a maximum period of 96 h. In doxorubicin-exposed cells, P-gp expression and transport activity were evaluated by flow cytometry, using a fluorescein isothiocyanate-conjugated antibody and the P-gp fluorescent subtract rhodamine 123, respectively. Doxorubicin 16-27 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 20857089-4 2011 Cytotoxicity of doxorubicin (0-100 muM) and paraquat (0-1,000 muM) was evaluated for a maximum period of 96 h. In doxorubicin-exposed cells, P-gp expression and transport activity were evaluated by flow cytometry, using a fluorescein isothiocyanate-conjugated antibody and the P-gp fluorescent subtract rhodamine 123, respectively. Doxorubicin 114-125 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 20857089-5 2011 A significant increase in P-gp expression was observed as soon as 6 h after exposure to 5 muM doxorubicin. Doxorubicin 94-105 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 20857089-6 2011 P-gp activity also increased after 6 h, but only at higher doxorubicin concentrations (over 50 muM). Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 20857089-9 2011 Furthermore, when these cells were incubated with a specific P-gp inhibitor (UIC2 antibody) the doxorubicin protective effects were blocked, confirming the involvement of P-gp in the reduction in paraquat cytotoxicity. Doxorubicin 96-107 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 20857089-9 2011 Furthermore, when these cells were incubated with a specific P-gp inhibitor (UIC2 antibody) the doxorubicin protective effects were blocked, confirming the involvement of P-gp in the reduction in paraquat cytotoxicity. Doxorubicin 96-107 ATP binding cassette subfamily B member 1 Homo sapiens 171-175 21365663-6 2011 In contrast, in the SMF group and SMF + ADM group, the P-gp expression was decreased compared with the ADM group. Doxorubicin 103-106 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 20563580-6 2011 This study focuses on the effect of verapamil and promethazine on the expression levels of MDR1 and MRP1 genes and the drug transport activity in doxorubicin-resistant MCF-7 breast carcinoma cell line. Doxorubicin 146-157 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 20563580-0 2011 Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 21880209-6 2011 Human doxorubicin (doxo) resistant sarcoma cells (MES-SA/Dx5) that over-express Pgp were treated with different doses of doxo (2, 4 and 8 muM) in the presence or absence of various concentrations of DEHP (3, 6 and 12 muM) that were clinically achievable in vivo. Doxorubicin 19-23 ATP binding cassette subfamily B member 1 Homo sapiens 80-83 21237614-7 2011 Aim of this study was resensitizing doxorubicin-resistant breast cancer cells to anticancer agent doxorubicin by selective downregulation of P-gp/MDR1 mRNA. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 21518489-1 2011 This study was purposed to explore the mechanisms of preventive effect of tetrandrine (TTD) on doxorubicin (ADM)-induced multidrug resistance (MDR) in human leukemia cell line K562 from two aspects of the transcription control of MDR1 gene and cell apoptosis. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 230-234 21316663-9 2011 The MDR1-transduced KK15 cells were also protected from doxorubicin toxicity (10 nM to 2.5 muM), as shown by cell viability assay. Doxorubicin 56-67 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 21237614-7 2011 Aim of this study was resensitizing doxorubicin-resistant breast cancer cells to anticancer agent doxorubicin by selective downregulation of P-gp/MDR1 mRNA. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 21237614-7 2011 Aim of this study was resensitizing doxorubicin-resistant breast cancer cells to anticancer agent doxorubicin by selective downregulation of P-gp/MDR1 mRNA. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 21237614-7 2011 Aim of this study was resensitizing doxorubicin-resistant breast cancer cells to anticancer agent doxorubicin by selective downregulation of P-gp/MDR1 mRNA. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 21237614-10 2011 XTT cell proliferation assay was performed to determine the effect of MDR1 silencing on doxorubicin sensitivity. Doxorubicin 88-99 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 21237614-13 2011 Silencing of P-gp encoding MDR1 gene resulted in almost complete restoration of the intracellular doxorubicin accumulation and relocalization of the drug in the nuclei. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 21237614-13 2011 Silencing of P-gp encoding MDR1 gene resulted in almost complete restoration of the intracellular doxorubicin accumulation and relocalization of the drug in the nuclei. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 21237614-15 2011 CONCLUSIONS: Selected siRNA duplex was shown to effectively inhibit MDR1 gene expression, restore doxorubicin accumulation and localization, and enhance chemosensitivity of resistant cells, which makes it a suitable candidate for therapeutic applications. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 20946921-1 2011 Doxorubicin is one of the most employed anticancer drugs, but its efficacy is limited by the onset of adverse effects such as drug resistance, due to the drug efflux via P-glycoprotein (Pgp). Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 170-184 19876599-5 2011 These compounds together with compound 3, which has already been demonstrated to act as a potent inhibitor of MDR1 function, were also able to significantly potentiate the activation of the apoptosis machinery triggered by the exposure to doxorubicin. Doxorubicin 239-250 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 19876599-6 2011 In conclusion, our results identify two new molecules structurally related to the calcium-channel blocker nifedipine, but characterized by a very low LTCC blockers activity, able to potentiate the antiproliferative and apoptotic activities of doxorubicin through an increase of its intracellular concentration likely caused by the inhibition of MDR1 function. Doxorubicin 243-254 ATP binding cassette subfamily B member 1 Homo sapiens 345-349 21456294-1 2011 In order to develop a prolonged circulating drug carrier and to overcome p-glycoprotein-mediated multidrug resistance to adriamycin (ADR), which is a potent chemotherapeutic agent in the treatment of various cancers, poly(lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) nanoparticles were prepared and characterized. Doxorubicin 121-131 ATP binding cassette subfamily B member 1 Homo sapiens 73-87 21269489-5 2011 METHODOLOGY AND PRINCIPAL FINDINGS: We report cell-to-cell transfers of functional P-gp in co-cultures of a P-gp overexpressing human breast cancer MCF-7 cell variant, selected for its resistance towards doxorubicin, with the parental sensitive cell line. Doxorubicin 204-215 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 20946921-1 2011 Doxorubicin is one of the most employed anticancer drugs, but its efficacy is limited by the onset of adverse effects such as drug resistance, due to the drug efflux via P-glycoprotein (Pgp). Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 186-189 27516904-3 2011 In the model of combination chemotherapy, the interactions between the anticancer drug doxorubicin and two of the most effective compounds were measured in vitro, on human MDR1 gene transfected mouse lymphoma cells, showing that the type of interaction for one of these compounds was indifferent while that for the other one was additive. Doxorubicin 87-98 ATP binding cassette subfamily B member 1 Homo sapiens 172-176 21282948-2 2011 Our previous studies have shown that the MDR of K562/DOX cells could be reversed by guggulsterone through inhibiting the function and expression of P-glycoprotein. Doxorubicin 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 148-162 20858479-4 2010 The induction of MDR1 expression by PGE2 and its down regulation by C-PC and DPI (Diphenylene iodonium, NADPH oxidase inhibitor) or by COX-2 knockdown suggest that the enhanced sensitivity of HepG2 cells to doxorubicin by C-PC is mediated by the down regulation of MDR1 expression. Doxorubicin 207-218 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 20229271-8 2011 RESULTS: Compared with sensitive MCF-7 cells, MDR1 and its transcription factors c-Jun and NF-kappaB were up-regulated at both mRNA level (P < 0.01) and protein level (P < 0.01) by treatment with 0.05 mug/ml doxorubicin for 7 days. Doxorubicin 214-225 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 20229271-9 2011 After co-incubation with both the same dose of doxorubicin and 10 muM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-kappaB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB were inhibited; and the function of P-gp was decreased (P < 0.01). Doxorubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 20229271-9 2011 After co-incubation with both the same dose of doxorubicin and 10 muM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-kappaB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB were inhibited; and the function of P-gp was decreased (P < 0.01). Doxorubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 328-332 20229271-9 2011 After co-incubation with both the same dose of doxorubicin and 10 muM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-kappaB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB were inhibited; and the function of P-gp was decreased (P < 0.01). Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 20229271-9 2011 After co-incubation with both the same dose of doxorubicin and 10 muM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-kappaB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB were inhibited; and the function of P-gp was decreased (P < 0.01). Doxorubicin 171-182 ATP binding cassette subfamily B member 1 Homo sapiens 328-332 20229271-11 2011 CONCLUSION: Celecoxib effectively prevents the development of chemoresistance in breast cancer cell line MCF-7 induced by doxorubicin, which was partly involved in inhibiting the expression and DNA-binding activity of nuclear transcription factors AP-1 and NF-kappaB and downstream expression and function of P-gp. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 309-313 22358098-8 2011 The compound exhibited synergistic activity with ABCB1 substrate - adriamycin in CCRF-VCR1000 cells, indicating partial but significant MDR reversing ability. Doxorubicin 67-77 ATP binding cassette subfamily B member 1 Homo sapiens 49-54 21957481-3 2011 Despite high expression of resistance-inducing genes like MDR1, Bcl2 and Bcl-xl, 15d-PGJ(2) strongly induced apoptosis in doxorubicin-resistant (A2780/AD) cells similar to the wild-type (A2780). Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 21677772-3 2011 Blockade of activation of STAT3 by STAT3 decoy oligodeoxynucleotide (ODN) promoted the accumulation and increased their sensitivity to adriamycin by down-regulating transcription of mdr1 and expression of P-gp, which were further confirmed by using STAT3-specific inhibitor JSI-124. Doxorubicin 135-145 ATP binding cassette subfamily B member 1 Homo sapiens 182-186 20694526-5 2010 RESULTS: The cellular uptake and cytotoxicity of DOX delivered by NPs were comparable to the free form in MES-SA and SKOV-3, but much higher in MES-SA/Dx5, indicating the capability of the NPs to overcome P-glycoprotein resistance mechanisms. Doxorubicin 49-52 ATP binding cassette subfamily B member 1 Homo sapiens 205-219 21351272-8 2010 Lovastatin bound directly to purified P-gp with high affinity and increased doxorubicin accumulation in MDR tumor cells, potentiating DNA damage, growth arrest and apoptosis. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 20623213-8 2010 The effects of the Cys431Leu variation, due to MDR1 (GT1292-3TG) nucleotide transition, on P-gp-dependent intracellular substrate accumulation appeared to be substrate dependent where doxorubicin, vinblastine, and paclitaxel exhibit an increased accumulation (p < 0.05), while verapamil and Hoechst33342 exhibit a decreased intracellular concentration compared with wild type (p < 0.05). Doxorubicin 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 20623213-8 2010 The effects of the Cys431Leu variation, due to MDR1 (GT1292-3TG) nucleotide transition, on P-gp-dependent intracellular substrate accumulation appeared to be substrate dependent where doxorubicin, vinblastine, and paclitaxel exhibit an increased accumulation (p < 0.05), while verapamil and Hoechst33342 exhibit a decreased intracellular concentration compared with wild type (p < 0.05). Doxorubicin 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 20829196-7 2010 Interestingly, multidrug-resistant cell lines that overexpressed P-glycoprotein (P-gp), multidrug resistance-associated proteins, and breast cancer resistance protein were rendered resistant to docetaxel, vinblastine, SN-38, and doxorubicin, but not to I-387. Doxorubicin 229-240 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 20829196-7 2010 Interestingly, multidrug-resistant cell lines that overexpressed P-glycoprotein (P-gp), multidrug resistance-associated proteins, and breast cancer resistance protein were rendered resistant to docetaxel, vinblastine, SN-38, and doxorubicin, but not to I-387. Doxorubicin 229-240 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 20715163-4 2010 METHODS: Several cationic carriers capable of siRNA complexation were investigated for P-gp down-regulation in the MDA435/LCC6 cell line and, consequently, increased cellular uptake of the chemotherapeutic agents doxorubicin and paclitaxel. Doxorubicin 213-224 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 20532504-0 2010 Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Doxorubicin 214-225 ATP binding cassette subfamily B member 1 Homo sapiens 63-79 20713551-0 2010 Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Doxorubicin 55-66 ATP binding cassette subfamily B member 1 Homo sapiens 105-127 20713551-6 2010 In addition, SIRT1 inhibition reduced both nuclear FoxO1 levels and MDR1 expression in doxorubicin-resistant breast cancer cells (MCF-7/ADR) cells. Doxorubicin 87-98 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 21128720-5 2010 RESULTS: The most active anti-P-gp poloxamines (which enhanced two- to three-fold doxorubicin accumulation compared with verapamil) resulted to be pristine medium-to-high hydrophobic T304, T904, T1301, T901 and T150R1. Doxorubicin 82-93 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 21162905-15 2010 CONCLUSIONS: In our experiment, SST decreases the expression of MDR1 mRNA and P-gp protein so as to reduce the efflux of DOX and elevate DOX concentrations in GBC-SD cells. Doxorubicin 121-124 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 21162905-15 2010 CONCLUSIONS: In our experiment, SST decreases the expression of MDR1 mRNA and P-gp protein so as to reduce the efflux of DOX and elevate DOX concentrations in GBC-SD cells. Doxorubicin 137-140 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 20862794-0 2004 6,7-Dimethoxy-2-[3-(5-[(11)C]methoxy-1,2,3,4-tetrahydro-naphthalen-1-yl)-propyl]-1,2,3,4-tetrahydro-isoquinoline One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by way of a multidrug resistance (MDR-1) gene protein (1, 2). Doxorubicin 218-228 ATP binding cassette subfamily B member 1 Homo sapiens 377-402 20862795-0 2004 6,7-Dimethoxy-2-{3-[4-[(11)C]methoxy-3,4-dihydro-2H-naphthalen-(1E)-ylidene]-propyl}-1,2,3,4-tetrahydro-isoquinoline One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by way of a multidrug resistance (MDR-1) protein (1, 2). Doxorubicin 222-232 ATP binding cassette subfamily B member 1 Homo sapiens 381-401 19685055-3 2010 The induction of MDR1 expression by PGE2 and its downregulation by celecoxib or by COX-2 knockdown suggests that the enhanced sensitivity of HepG2 cells to doxorubicin by celecoxib is mediated by the downregulation of MDR1 expression, through COX-2-dependent mechanism. Doxorubicin 156-167 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 20656007-0 2010 Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells. Doxorubicin 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 20656007-3 2010 In addition, the mechanisms of milbemycins on P-glycoprotein (P-gp)-mediated MDR demonstrated that the milbemycins significantly increased the intracellular accumulations of adriamycin and Rh123 via inhibiting P-gp transport function. Doxorubicin 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 46-60 20656007-3 2010 In addition, the mechanisms of milbemycins on P-glycoprotein (P-gp)-mediated MDR demonstrated that the milbemycins significantly increased the intracellular accumulations of adriamycin and Rh123 via inhibiting P-gp transport function. Doxorubicin 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 62-66 20656007-3 2010 In addition, the mechanisms of milbemycins on P-glycoprotein (P-gp)-mediated MDR demonstrated that the milbemycins significantly increased the intracellular accumulations of adriamycin and Rh123 via inhibiting P-gp transport function. Doxorubicin 174-184 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 20427082-5 2010 Subsequent to P-gp down regulation, increased cellular accumulation of P-gp substrate, doxorubicin (DOX), in the cytoplasm and nucleus of resistant MDA435/LCC6 cells after treatment with peptide decorated polymeric micelle/mdr1 siRNA complexes was observed. Doxorubicin 100-103 ATP binding cassette subfamily B member 1 Homo sapiens 223-227 20427082-8 2010 Results of this study indicated a potential for RGD/TAT-functionalized virus-like micelles as promising carriers for efficient delivery of mdr1 siRNA to MDA435/LCC6 resistant cells as means to reverse the P-gp mediated multidrug resistance to DOX. Doxorubicin 243-246 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 20730973-2 2010 (Leguminosae) on P-glycoprotein (P-gp) function in an adriamycin-resistant human breast cancer cell line, MCF-7/ADR. Doxorubicin 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 17-31 20730973-2 2010 (Leguminosae) on P-glycoprotein (P-gp) function in an adriamycin-resistant human breast cancer cell line, MCF-7/ADR. Doxorubicin 54-64 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 20596658-9 2010 Inhibition of ABCG2 and/or MDR1 revealed that resistance of cancer stem cells to doxorubicin may be mainly due to the expression of these ABC transporters that were highly up-regulated in the resistant subline. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 20596658-10 2010 The poor outcome of chemotherapy with doxorubicin in anaplastic thyroid carcinoma may be partly explained by up-regulation of ABCG2 and MDR1 transporters that confers resistance to cancer stem cells. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 20663232-7 2010 Moreover, TRAIL inhibited P-gp efflux function via caspase-3-dependent degradation of P-gp as well as DNA-PKcs and subsequently sensitized MDR cells to MDR-related drugs such as vinblastine and doxorubicin. Doxorubicin 194-205 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 20014242-6 2010 R-cetirizine significantly increased the efflux ratio of rhodamine-123 and doxorubicin in a fashion indicative of the upregulation of P-gp and MRP activities. Doxorubicin 75-86 ATP binding cassette subfamily B member 1 Homo sapiens 134-138 20088680-0 2010 Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide. Doxorubicin 13-24 ATP binding cassette subfamily B member 1 Homo sapiens 39-53 20088680-3 2010 The uptake of Dox into the leukemia cell line K562 and its P-gp overexpressing subline KD30 increased in the presence of DBM-Tat peptide. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 20088680-8 2010 Thus, combining Dox with DBM-Tat reduces P-gp mediated drug efflux, without a requirement for drug modification or inhibiting P-gp function. Doxorubicin 16-19 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 20112430-4 2010 EBB not only blocked the function of P-glycoprotein confirmed by the fact that EBB increased intracellular accumulation of rhodamine 123 and doxorubicin but also inhibited the expression of P-glycoprotein actualized by downregulating P-glycoprotein. Doxorubicin 141-152 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 20112430-4 2010 EBB not only blocked the function of P-glycoprotein confirmed by the fact that EBB increased intracellular accumulation of rhodamine 123 and doxorubicin but also inhibited the expression of P-glycoprotein actualized by downregulating P-glycoprotein. Doxorubicin 141-152 ATP binding cassette subfamily B member 1 Homo sapiens 190-204 20112430-4 2010 EBB not only blocked the function of P-glycoprotein confirmed by the fact that EBB increased intracellular accumulation of rhodamine 123 and doxorubicin but also inhibited the expression of P-glycoprotein actualized by downregulating P-glycoprotein. Doxorubicin 141-152 ATP binding cassette subfamily B member 1 Homo sapiens 190-204 20540746-9 2010 Doxorubicin treatment induced GCS and MDR1 expression in tumors, but MBO-asGCS treatment eliminated "in-vivo" growth of drug-resistant tumor (NCI/ADR-RES). Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 20525557-10 2010 RESULTS: The MDR of SMMC-7721/ADM cells resistant to 0.05 mg/L adriamycin was mainly attributed to the overexpression of P-gp but not MRP1. Doxorubicin 63-73 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 20455578-4 2010 Compound 1 suppressed doxorubicin efflux, a process mediated by P-glycoprotein, in a Pgp-overexpressed HepG2 subclone (R-HepG2 cells). Doxorubicin 22-33 ATP binding cassette subfamily B member 1 Homo sapiens 64-78 20455578-4 2010 Compound 1 suppressed doxorubicin efflux, a process mediated by P-glycoprotein, in a Pgp-overexpressed HepG2 subclone (R-HepG2 cells). Doxorubicin 22-33 ATP binding cassette subfamily B member 1 Homo sapiens 85-88 19739078-0 2010 Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Doxorubicin 52-63 ATP binding cassette subfamily B member 1 Homo sapiens 17-31 20372866-5 2010 The aim of this study was to investigate the expression of survivin and P-gp, the modulation of survivin by P-gp in PI3K/Akt during the progression of drug resistance (MDR) in MCF-7 breast cancer cells and adriamycin (ADR)-resistant MCF-7/ADR cells. Doxorubicin 206-216 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 20372866-5 2010 The aim of this study was to investigate the expression of survivin and P-gp, the modulation of survivin by P-gp in PI3K/Akt during the progression of drug resistance (MDR) in MCF-7 breast cancer cells and adriamycin (ADR)-resistant MCF-7/ADR cells. Doxorubicin 206-216 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 20388796-3 2010 AEG-1 increases the expression of multidrug resistance gene 1 (MDR1) protein, resulting in increased efflux and decreased accumulation of doxorubicin, promoting doxorubicin resistance. Doxorubicin 138-149 ATP binding cassette subfamily B member 1 Homo sapiens 34-61 20388796-3 2010 AEG-1 increases the expression of multidrug resistance gene 1 (MDR1) protein, resulting in increased efflux and decreased accumulation of doxorubicin, promoting doxorubicin resistance. Doxorubicin 138-149 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 20388796-3 2010 AEG-1 increases the expression of multidrug resistance gene 1 (MDR1) protein, resulting in increased efflux and decreased accumulation of doxorubicin, promoting doxorubicin resistance. Doxorubicin 161-172 ATP binding cassette subfamily B member 1 Homo sapiens 34-61 20388796-3 2010 AEG-1 increases the expression of multidrug resistance gene 1 (MDR1) protein, resulting in increased efflux and decreased accumulation of doxorubicin, promoting doxorubicin resistance. Doxorubicin 161-172 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 20388796-4 2010 Suppression of MDR1 by small interfering RNA or chemical reagents, or inhibition of AEG-1 or a combination of both genes, significantly increases in vitro sensitivity to doxorubicin. Doxorubicin 170-181 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 20944122-0 2010 Caveolin-1 and doxorubicin-induced P-glycoprotein modulate plasma cholesterol membrane accessibility in erythrolymphoblastic cell line. Doxorubicin 15-26 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 20041327-8 2010 Moreover, PXR activation was also shown to reduce the cytotoxic activity of the Pgp substrate doxorubicin in colon cancer cells. Doxorubicin 94-105 ATP binding cassette subfamily B member 1 Homo sapiens 80-83 20460432-9 2010 Finally, Pim-1 inhibition sensitized Pgp-overexpressing cells to doxorubicin. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 37-40 20077420-2 2010 In the present study, we investigated that puerarin, a natural isoflavonoid from Pueraria lobata, down-regulated MDR1 expression in MCF-7/adriamycin (MCF-7/adr), a human breast MDR cancer cell line. Doxorubicin 138-148 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 20077420-4 2010 The suppression of MDR1 was accompanied by partial recovery of intracellular drug accumulation, leading to increased toxicity of adriamycin and fluorescence of rhodamine 123, indicating that puerarin reversed the MDR phenotype by inhibiting the drug efflux function of MDR1. Doxorubicin 129-139 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 20662321-0 2010 Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 94-105 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 20662321-0 2010 Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 149-152 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 19763573-6 2010 RESULTS: The doxorubicin-resistant lung cancer cell subline (SK-MES-1/DX1000), selected from SK-MES-1/WT cells, upregulated MDR1 expression, thereby showing MDR phenotypes. Doxorubicin 13-24 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 19898868-5 2010 RESULTS: The results showed that doxorubicin treatment only resulted in elevated levels of mdr1 mRNA/P-gp expression. Doxorubicin 33-44 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 19898868-6 2010 Doxorubicin also induced up-regulation of P-gp functional activities, as intracellular retention of rhodamine was decreased; however, 2.0 microg/ml tetrandrine significantly inhibited the overexpression of doxorubicin-induced mdr1 mRNA/P-gp. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 226-230 19898868-6 2010 Doxorubicin also induced up-regulation of P-gp functional activities, as intracellular retention of rhodamine was decreased; however, 2.0 microg/ml tetrandrine significantly inhibited the overexpression of doxorubicin-induced mdr1 mRNA/P-gp. Doxorubicin 206-217 ATP binding cassette subfamily B member 1 Homo sapiens 226-230 19898868-12 2010 CONCLUSION: In summary, tetrandrine can prevent doxorubicin-induced mdr1 mRNA/P-gp expression and P-gp functions in a dose-dependent manner through a mechanism that may involve inhibition of doxorubicin-induced NF-kappaB mRNA expression and protein activity. Doxorubicin 48-59 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 20645795-10 2010 The inhibition of p-glycoprotein suggests that HSS may diminish the resistance to Adriamycin and potentially enhance the therapeutic effects. Doxorubicin 82-92 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 20338046-5 2010 Absence of methylation at the ABCB1 promoter correlated with progressive disease during doxorubicin treatment. Doxorubicin 88-99 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 20487633-0 2010 Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 20446917-3 2010 siRNA-mediated knockdown in K562/Dox cell lines provides a unique opportunity to dissect the specific contribution of Pgp to TKIs intracellular disposition. Doxorubicin 33-36 ATP binding cassette subfamily B member 1 Homo sapiens 118-121 20148593-3 2010 In this work, the antibody of P-gp (anti-P-gp) functionalized water-soluble single-walled carbon nanotubes (Ap-SWNTs) loaded with doxorubicin (Dox), Dox/Ap-SWNTs, were synthesized for challenging the MDR of K562 human leukemia cells. Doxorubicin 130-141 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 20148593-3 2010 In this work, the antibody of P-gp (anti-P-gp) functionalized water-soluble single-walled carbon nanotubes (Ap-SWNTs) loaded with doxorubicin (Dox), Dox/Ap-SWNTs, were synthesized for challenging the MDR of K562 human leukemia cells. Doxorubicin 130-141 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 20148593-3 2010 In this work, the antibody of P-gp (anti-P-gp) functionalized water-soluble single-walled carbon nanotubes (Ap-SWNTs) loaded with doxorubicin (Dox), Dox/Ap-SWNTs, were synthesized for challenging the MDR of K562 human leukemia cells. Doxorubicin 143-146 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 20148593-3 2010 In this work, the antibody of P-gp (anti-P-gp) functionalized water-soluble single-walled carbon nanotubes (Ap-SWNTs) loaded with doxorubicin (Dox), Dox/Ap-SWNTs, were synthesized for challenging the MDR of K562 human leukemia cells. Doxorubicin 149-152 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 20148593-3 2010 In this work, the antibody of P-gp (anti-P-gp) functionalized water-soluble single-walled carbon nanotubes (Ap-SWNTs) loaded with doxorubicin (Dox), Dox/Ap-SWNTs, were synthesized for challenging the MDR of K562 human leukemia cells. Doxorubicin 149-152 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 20338046-10 2010 FOXC1 proved to be general prognostic factor, while ABCB1 and GSTP1 might be predictive factors for the response to and efficacy of doxorubicin treatment. Doxorubicin 132-143 ATP binding cassette subfamily B member 1 Homo sapiens 52-57 19724874-3 2009 Compared with respective parental G, G2, G10 cells, the Dox-selected cells showed mdr1 amplification/P-glycoprotein overexpression, Dox resistance and also less intracellular Dox accumulation. Doxorubicin 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 20127023-0 2010 KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 113-127 20127023-4 2010 Doxorubicin dose-dependently inhibited the growth of P-gp-negative K562 human leukemia cells, but did not show substantial inhibition on the growth of P-gp-positive K562/ADR cells even at 10 microM, the highest concentration of KBH-A42 used, which increased the acetylation of histones in these leukemia cells, dose-dependently and effectively inhibited the cell growth, regardless of the presence of P-gp in the cells. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 19963040-5 2010 Functional assessment was accomplished by an established 96-well uptake assay using Rhodamine 123 and Doxorubicin as P-gP substrates and Verapamil as moderate P-gP inhibitor. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 20302569-7 2010 This review comprehensively examines the pharmacogenetics of the regulatory nuclear receptor Pregnane-X Receptor (PXR), influx (SLC22A16) and efflux drug transporters (ABCB1, ABCG2, ABCC5, ABCB5 and RLIP76) and drug metabolizing enzymes (CBR1, CBR3) across the biochemical pathway of doxorubicin in Asian breast cancer patients receiving doxorubicin based adjuvant chemotherapy. Doxorubicin 284-295 ATP binding cassette subfamily B member 1 Homo sapiens 168-173 20201777-4 2010 These results suggest that 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, at subtoxic concentrations, might synergize with scarcely toxic doxorubicin doses to propagate a caspase-independent cytotoxic response, such that P-glycoprotein-dependent drug resistance is circumvented. Doxorubicin 141-152 ATP binding cassette subfamily B member 1 Homo sapiens 224-238 20099200-1 2010 MCF-7/ADR cells, a doxorubicin-resistant human breast cancer cell line, acquires resistance to several chemotherapeutic agents, such as anthracylines and taxol, via overexpression of the multidrug resistance1 (MDR1) gene. Doxorubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 187-208 20641310-0 2004 [N-methyl-(11)C]4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenyl-N-methyl-butanamide One of the mechanisms of tumor cells to escape the cytotoxic effects of chemotherapeutic agents, such as adriamycin, vinca alkaloids, epipodophyllotoxins, actinomycin D, and paclitaxel, is to limit their presence inside the cells by a multidrug resistance (MDR-1) gene protein (1, 2). Doxorubicin 201-211 ATP binding cassette subfamily B member 1 Homo sapiens 353-378 19764771-4 2009 2D-PAGE and MALDI-TOF/MS-based proteomics approach were used to separate and identify differentially expressed proteins between MCF-7 and MCF-7/ADR, a p-glycoprotein-overexpressing adriamycin-resistance breast cancer cell line. Doxorubicin 181-191 ATP binding cassette subfamily B member 1 Homo sapiens 151-165 19647009-2 2009 They are also strong inducers of the P-glycoprotein (Pgp), a transmembrane transporter which extrudes several drugs, including anticancer agents like doxorubicin. Doxorubicin 150-161 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 19647009-2 2009 They are also strong inducers of the P-glycoprotein (Pgp), a transmembrane transporter which extrudes several drugs, including anticancer agents like doxorubicin. Doxorubicin 150-161 ATP binding cassette subfamily B member 1 Homo sapiens 53-56 19647009-7 2009 This one was responsible for the increased expression of Pgp, which actively extruded doxorubicin from the cells and significantly reduced the pro-apoptotic effect of the drug. Doxorubicin 86-97 ATP binding cassette subfamily B member 1 Homo sapiens 57-60 19947169-0 2009 Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 19947169-0 2009 Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 132-135 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 19947169-9 2009 Further study demonstrated that the inhibitory effect of guggulsterone on P-glycoprotein activity was the major cause of increased stagnation of doxorubicin inside K562/DOX cells, indicating that guggulsterone may effectively reverse multidrug resistance in K562/DOX cells via inhibiting expression and drug-transport function of P-glycoprotein. Doxorubicin 145-156 ATP binding cassette subfamily B member 1 Homo sapiens 74-88 19947169-9 2009 Further study demonstrated that the inhibitory effect of guggulsterone on P-glycoprotein activity was the major cause of increased stagnation of doxorubicin inside K562/DOX cells, indicating that guggulsterone may effectively reverse multidrug resistance in K562/DOX cells via inhibiting expression and drug-transport function of P-glycoprotein. Doxorubicin 169-172 ATP binding cassette subfamily B member 1 Homo sapiens 74-88 19947169-9 2009 Further study demonstrated that the inhibitory effect of guggulsterone on P-glycoprotein activity was the major cause of increased stagnation of doxorubicin inside K562/DOX cells, indicating that guggulsterone may effectively reverse multidrug resistance in K562/DOX cells via inhibiting expression and drug-transport function of P-glycoprotein. Doxorubicin 263-266 ATP binding cassette subfamily B member 1 Homo sapiens 74-88 19920924-7 2009 TRG markedly decreased expression of both MDR-1 and BCRP in these cells, resulting in sensitivity to DOX. Doxorubicin 101-104 ATP binding cassette subfamily B member 1 Homo sapiens 42-47 19920924-8 2009 Silencing of MDR-1 expression also sensitized MCF7/DOX cells to DOX. Doxorubicin 51-54 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 19920924-8 2009 Silencing of MDR-1 expression also sensitized MCF7/DOX cells to DOX. Doxorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 20179710-2 2010 Doxorubicin is a substrate for ABCB1 and SLC22A16 transporters. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 31-36 19944135-3 2010 Although all drug resistant sublines showed cross-resistance to DOC, VCR, and doxorubicin (DXR), the expression of ATP-binding cassette (ABC) transporter B1 (ABCB1) gene was found to be strongly induced in DOC but not in VCR resistant A549 sublines by quantitative reverse transcription real-time polymerase chain reaction (qRT-PCR). Doxorubicin 78-89 ATP binding cassette subfamily B member 1 Homo sapiens 158-163 20302569-7 2010 This review comprehensively examines the pharmacogenetics of the regulatory nuclear receptor Pregnane-X Receptor (PXR), influx (SLC22A16) and efflux drug transporters (ABCB1, ABCG2, ABCC5, ABCB5 and RLIP76) and drug metabolizing enzymes (CBR1, CBR3) across the biochemical pathway of doxorubicin in Asian breast cancer patients receiving doxorubicin based adjuvant chemotherapy. Doxorubicin 338-349 ATP binding cassette subfamily B member 1 Homo sapiens 168-173 20037485-7 2010 The QRT - PCR analysis has shown that, when used simultaneously, DOX 1 microM and SUL 50 microM results in decreased mRNA level for MDR-1 and MRP-1. Doxorubicin 65-68 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 20037485-9 2010 The observed effect is due to quenching of MDR-1 and MRP-1 genes expression, which results in blocking of efflux of DOX outside the cells, which in turn correlates with enhanced apoptotic effects. Doxorubicin 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 43-48 19609211-7 2009 In addition, mtDNA-depleted cells displayed a decreased sensitivity and accumulation of chemotherapeutic drugs (doxorubicin, vincristine, and paclitaxel), potentially because of the upregulated expression of multidrug resistance 1 (MDR1) gene and its product P-glycoprotein. Doxorubicin 112-123 ATP binding cassette subfamily B member 1 Homo sapiens 208-230 19725578-1 2009 Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells. Doxorubicin 119-130 ATP binding cassette subfamily B member 1 Homo sapiens 66-96 19725578-1 2009 Here we showed that bivalency approach is effective in modulating multidrug resistance protein 1 (MRP1/ABCC1)-mediated doxorubicin (DOX) and etoposide (VP16) resistance in human 2008/MRP1 ovarian carcinoma cells. Doxorubicin 132-135 ATP binding cassette subfamily B member 1 Homo sapiens 66-96 19724874-3 2009 Compared with respective parental G, G2, G10 cells, the Dox-selected cells showed mdr1 amplification/P-glycoprotein overexpression, Dox resistance and also less intracellular Dox accumulation. Doxorubicin 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 19724874-5 2009 Decay in drug resistance and reduction in mdr1 amplification/P-glycoprotein overexpression were observed in the Dox-selected cells culturing in Dox-free condition. Doxorubicin 112-115 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 19724874-5 2009 Decay in drug resistance and reduction in mdr1 amplification/P-glycoprotein overexpression were observed in the Dox-selected cells culturing in Dox-free condition. Doxorubicin 112-115 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 19724874-5 2009 Decay in drug resistance and reduction in mdr1 amplification/P-glycoprotein overexpression were observed in the Dox-selected cells culturing in Dox-free condition. Doxorubicin 144-147 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 19724874-5 2009 Decay in drug resistance and reduction in mdr1 amplification/P-glycoprotein overexpression were observed in the Dox-selected cells culturing in Dox-free condition. Doxorubicin 144-147 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 19724874-6 2009 Among the Dox-selected cells, G2R cells showed the highest levels of drug resistance, mdr1 amplification, but the least resistance decay. Doxorubicin 10-13 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 19264847-9 2009 Collectively, these findings suggest that the direct inhibitory effects of indomethacin and SC236 on P-gp may contribute to their ability to increase the intracellular retention of doxorubicin and thus enhance its cytotoxicity. Doxorubicin 181-192 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 19410561-4 2009 FG020326 significantly potentiated the cytotoxicity of paclitaxel, doxorubicin, and vincristine in the ABCB1 (P-glycoprotein, P-gp) overexpressing cells KBv200 and MCF-7/adr, but not in the ABCB1 negative parental cell lines KB and MCF-7. Doxorubicin 67-78 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 19550397-5 2009 At the same time, P-glycoprotein overexpression in cells resistant to doxorubicin suggests MDR-dependent mechanism. Doxorubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 19264847-0 2009 Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Doxorubicin 15-26 ATP binding cassette subfamily B member 1 Homo sapiens 210-224 19264847-4 2009 Here we sought to elucidate the effect of COX inhibitors on doxorubicin-induced cytotoxicity in relation to P-gp function in human esophageal squamous cell carcinoma cells. Doxorubicin 60-71 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 19440163-7 2009 Nevertheless, an inhibitor of Akr1c2 (5beta-cholanic acid) almost completely restored sensitivity to doxorubicin in ABCB1-deficient doxorubicin-resistant cells, while having no effect on ABCB1-expressing epirubicin-resistant cells. Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 116-121 19440163-7 2009 Nevertheless, an inhibitor of Akr1c2 (5beta-cholanic acid) almost completely restored sensitivity to doxorubicin in ABCB1-deficient doxorubicin-resistant cells, while having no effect on ABCB1-expressing epirubicin-resistant cells. Doxorubicin 132-143 ATP binding cassette subfamily B member 1 Homo sapiens 116-121 19318911-2 2009 Tryptanthrin, a quinazoline derivative, was reported to sensitize resistant cells to doxorubicin by downregulation of MDR1 expression. Doxorubicin 85-96 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 19123050-4 2009 RESULTS: The recombinant cells MDR1 (wt) and MDR1 ( 1199A ) displayed comparable doxorubicin resistance. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 19123050-4 2009 RESULTS: The recombinant cells MDR1 (wt) and MDR1 ( 1199A ) displayed comparable doxorubicin resistance. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 19264847-10 2009 The combination of indomethacin or SC236 with doxorubicin may have significant potential clinical application, especially in the circumvention of P-gp-mediated MDR in cancer cells. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 18924151-4 2009 Two new drug-resistant cell lines were generated following exposure to doxorubicin or daunorubicin and these upregulated MRP1 or P-glycoprotein expression, respectively. Doxorubicin 71-82 ATP binding cassette subfamily B member 1 Homo sapiens 129-143 19383919-0 2009 Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 19383919-2 2009 Doxorubicin nanoparticles showed 6- to 8-fold lower IC(50) values in P-gp-overexpressing human cancer cells than those of free doxorubicin. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 19383919-5 2009 Enhanced uptake and prolonged retention of doxorubicin were observed with nanoparticle-based formulations in P-gp-overexpressing cells. Doxorubicin 43-54 ATP binding cassette subfamily B member 1 Homo sapiens 109-113 19298255-0 2009 Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 122-136 19298255-2 2009 As the sesquiterpene lactone thapsigargin, a known inhibitor of mammalian SERCA, enhances the expression of P-glycoprotein (Pgp) by increasing the intracellular Ca(++) ([Ca(++)](i)) level, we investigated whether artemisinin and its structural homologue parthenolide could inhibit SERCA in human colon carcinoma HT29 cells and induce a resistance to doxorubicin. Doxorubicin 350-361 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 19298255-2 2009 As the sesquiterpene lactone thapsigargin, a known inhibitor of mammalian SERCA, enhances the expression of P-glycoprotein (Pgp) by increasing the intracellular Ca(++) ([Ca(++)](i)) level, we investigated whether artemisinin and its structural homologue parthenolide could inhibit SERCA in human colon carcinoma HT29 cells and induce a resistance to doxorubicin. Doxorubicin 350-361 ATP binding cassette subfamily B member 1 Homo sapiens 124-127 18493718-6 2009 The decrease of mdr1 and topo II alpha expression (assessed by RT-PCR), was consistent with the DOX accumulation assay and cell cycle analysis. Doxorubicin 96-99 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 19275512-7 2009 The ability of nonpegylated liposomal doxorubicin to overcome excessive drug efflux due to P-glycoprotein (MDR-1) overexpression in NHL might confer on this drug a curative potential for patients with a bad prognosis (e.g., MDR-1 overexpressing, the elderly or frail). Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 19275512-7 2009 The ability of nonpegylated liposomal doxorubicin to overcome excessive drug efflux due to P-glycoprotein (MDR-1) overexpression in NHL might confer on this drug a curative potential for patients with a bad prognosis (e.g., MDR-1 overexpressing, the elderly or frail). Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 19275512-7 2009 The ability of nonpegylated liposomal doxorubicin to overcome excessive drug efflux due to P-glycoprotein (MDR-1) overexpression in NHL might confer on this drug a curative potential for patients with a bad prognosis (e.g., MDR-1 overexpressing, the elderly or frail). Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 224-229 18796331-3 2009 In this study, we investigated whether photodynamic therapy (PDT) using methylene blue, also a P-gp inhibitor, can be used to enhance doxorubicin-induced cytotoxicity in drug-resistant tumor cells. Doxorubicin 134-145 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 19093883-4 2009 In conclusion, experiments lead to the identification of three diltiazem-like molecules able to increase the intracellular accumulation of doxorubicin by inhibiting the MDR1 function, thus potentiating its antiproliferative activity in multidrug resistant A2780/DX3 cells. Doxorubicin 139-150 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 18228136-4 2009 RT(2) Profiler PCR Array was used to identify differentially expressed genes in Dox and/or 2ME treatment groups, based on significance of results 4 genes were selected: MDR1, Bcl2, P53 and Cyclin D1. Doxorubicin 80-83 ATP binding cassette subfamily B member 1 Homo sapiens 169-173 19593673-8 2009 (2) The expression level of MDR1 was the same in both cell lines but 48 and 72 h of drug treatment, MDR1 disappeared in MCF7/WT but still expressed in MCF7/DOX. Doxorubicin 156-159 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 19593673-8 2009 (2) The expression level of MDR1 was the same in both cell lines but 48 and 72 h of drug treatment, MDR1 disappeared in MCF7/WT but still expressed in MCF7/DOX. Doxorubicin 156-159 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 18828019-5 2009 In contrast, the doxorubicin selected resistant cell lines also expressed high level of ABCB1 (but not ABCC1 or ABCG2) but did demonstrate significant cross-resistance to both ET-743 and PM00104. Doxorubicin 17-28 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 18828019-8 2009 siRNA down-regulation of ABCB1 expression in doxorubicin selected cell lines caused partial sensitization to both doxorubicin and paclitaxel but not to either ET-743 or PM00104. Doxorubicin 45-56 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 18828019-8 2009 siRNA down-regulation of ABCB1 expression in doxorubicin selected cell lines caused partial sensitization to both doxorubicin and paclitaxel but not to either ET-743 or PM00104. Doxorubicin 114-125 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 18938236-0 2009 Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Doxorubicin 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 19152447-20 2009 CONCLUSION: pSUPER-shRNA/mdr1 vector system allows simple, stable and durable nonviral knockdown of P-gp by RNAi in malignant cells and animals to restore their sensitivity to adriamycin. Doxorubicin 176-186 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 18228136-8 2009 The array and western blotting showed that Bcl2 and Cyclin D1 expression were down regulated; P53 expression was not affected while MDR1 was over expressed by combination of 2ME with Dox. Doxorubicin 183-186 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 19881253-9 2009 PR-HepG2 cells showed cross-resistance to doxorubicin, a P-gp substrate, but not to cisplatin. Doxorubicin 42-53 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 18851949-3 2008 The acidification resulted in the decreased P-gp activity with increased Rhodamine 123 (Rh123) accumulation in K562/DOX cells, which could be blocked by the P-gp inhibitor verapamil. Doxorubicin 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 18851949-3 2008 The acidification resulted in the decreased P-gp activity with increased Rhodamine 123 (Rh123) accumulation in K562/DOX cells, which could be blocked by the P-gp inhibitor verapamil. Doxorubicin 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 157-161 18851949-0 2008 Down-regulation of P-glycoprotein expression by sustained intracellular acidification in K562/Dox cells. Doxorubicin 94-97 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 18851949-1 2008 We have investigated the involvement of intracellular pH (pH(i)) in the regulation of P-glycoprotein (P-gp) in K562/DOX cells. Doxorubicin 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 86-100 18851949-1 2008 We have investigated the involvement of intracellular pH (pH(i)) in the regulation of P-glycoprotein (P-gp) in K562/DOX cells. Doxorubicin 116-119 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 18851949-7 2008 These data indicate that the tumor multidrug resistance (MDR) mediated by P-gp could be reversed by sustained intracellular acidification through down-regulating the P-gp expression and activity, and there is a regulative link between the pH(i) and P-gp in K562/DOX cells. Doxorubicin 262-265 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 18851949-7 2008 These data indicate that the tumor multidrug resistance (MDR) mediated by P-gp could be reversed by sustained intracellular acidification through down-regulating the P-gp expression and activity, and there is a regulative link between the pH(i) and P-gp in K562/DOX cells. Doxorubicin 262-265 ATP binding cassette subfamily B member 1 Homo sapiens 166-170 18851949-7 2008 These data indicate that the tumor multidrug resistance (MDR) mediated by P-gp could be reversed by sustained intracellular acidification through down-regulating the P-gp expression and activity, and there is a regulative link between the pH(i) and P-gp in K562/DOX cells. Doxorubicin 262-265 ATP binding cassette subfamily B member 1 Homo sapiens 166-170 18809583-6 2008 APE1 downregulation sensitizes MDR1-overexpressing tumor cells to cisplatin or doxorubicin, showing APE1"s critical role in YB-1-mediated gene expression and, thus, drug resistance in tumor cells. Doxorubicin 79-90 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 18588889-3 2008 In a drug-free state, BCRP expression was significantly down-regulated in doxorubicin-resistant SK-MES-1/DX1000 cells overexpressing Pgp. Doxorubicin 74-85 ATP binding cassette subfamily B member 1 Homo sapiens 133-136 18829547-6 2008 Additionally, lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E(2)17betaG by ABCG2. Doxorubicin 68-79 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 18922976-8 2008 RhoA silencing, by acting as an upstream controller of both MRP3 nitration and Pgp expression, was effective to revert the toxicity and accumulation of doxorubicin in both HT29 and HT29-dx cells. Doxorubicin 152-163 ATP binding cassette subfamily B member 1 Homo sapiens 79-82 19020725-6 2008 Increased cytotoxicity of the antitumor drugs adriamycin and vincristine with increased intracellular adriamycin accumulation accompanied inhibition of MDR1 mRNA and P-gp expression. Doxorubicin 46-56 ATP binding cassette subfamily B member 1 Homo sapiens 152-156 18723777-6 2008 Although there was a minimal effect on doxorubicin and daunorubicin, the MDR1-dependent resistance on vinblastine, vincristine, paclitaxel, and etoposide was reduced by approximately 5-fold. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 18813811-4 2008 The human doxorubicin (doxo) resistant uterine sarcoma cells (MES-SA/Dx-5) expressing high levels of P-gp, were treated with different doxo concentrations in the presence or absence of NSAIDs. Doxorubicin 10-21 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 18813811-4 2008 The human doxorubicin (doxo) resistant uterine sarcoma cells (MES-SA/Dx-5) expressing high levels of P-gp, were treated with different doxo concentrations in the presence or absence of NSAIDs. Doxorubicin 23-27 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 18538471-6 2008 The intracellular accumulation of doxorubicin and Rhodamine-123 (Rh123) were increased, which implied that the function of the P-glycoprotein (P-gp) efflux pump was inhibited by YSV. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 127-141 18538471-6 2008 The intracellular accumulation of doxorubicin and Rhodamine-123 (Rh123) were increased, which implied that the function of the P-glycoprotein (P-gp) efflux pump was inhibited by YSV. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 18650266-7 2008 Cif increased the drug sensitivity to doxorubicin in kidney cells expressing Pgp by 10-fold and increased the cellular accumulation of daunorubicin by 2-fold. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 77-80 18650266-8 2008 Thus our studies show that Cif increases the sensitivity of Pgp-overexpressing cells to doxorubicin, consistent with the hypothesis that Cif affects Pgp functional expression. Doxorubicin 88-99 ATP binding cassette subfamily B member 1 Homo sapiens 60-63 18650266-8 2008 Thus our studies show that Cif increases the sensitivity of Pgp-overexpressing cells to doxorubicin, consistent with the hypothesis that Cif affects Pgp functional expression. Doxorubicin 88-99 ATP binding cassette subfamily B member 1 Homo sapiens 149-152 18503785-7 2008 Cross-resistance to adriamycin, vincristine and etoposide (VP-16) was consistent with overexpression of P-glycoprotein (P-gp). Doxorubicin 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 104-118 18503785-7 2008 Cross-resistance to adriamycin, vincristine and etoposide (VP-16) was consistent with overexpression of P-glycoprotein (P-gp). Doxorubicin 20-30 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 18390843-0 2008 Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Doxorubicin 47-57 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 18703598-4 2008 The functional activities of MDR1 shRNA were determined by paclitaxel uptake and sensitivity to doxorubicin. Doxorubicin 96-107 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 18703598-12 2008 Interestingly, the combination of doxorubicin and a radioiodide ((131)I) displayed synergistic cytotoxicity that correlated with MDR1 inhibition and NIS expression in shMDR-NIS-expressing cells. Doxorubicin 34-45 ATP binding cassette subfamily B member 1 Homo sapiens 129-133 18819516-4 2008 In this work, the kinetics of drug uptake and active efflux of doxorubicin (DOX) encapsulated in liposomes in both intact cells and nuclei were studied using P-gp expressing K562/DOX cells. Doxorubicin 63-74 ATP binding cassette subfamily B member 1 Homo sapiens 158-162 18819516-4 2008 In this work, the kinetics of drug uptake and active efflux of doxorubicin (DOX) encapsulated in liposomes in both intact cells and nuclei were studied using P-gp expressing K562/DOX cells. Doxorubicin 76-79 ATP binding cassette subfamily B member 1 Homo sapiens 158-162 18625294-5 2008 These findings suggest that Hexyl-ALA could be used to selectively reduce P-gp expression in overcoming resistance to chemotherapy agents such as doxorubicin and paclitaxel. Doxorubicin 146-157 ATP binding cassette subfamily B member 1 Homo sapiens 74-78 18441325-6 2008 Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells. Doxorubicin 163-174 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 19035180-0 2008 [Effect of tetrandrine on the doxorubicin-induced expression of mdr1 gene in K562 cells]. Doxorubicin 30-41 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 19035180-1 2008 OBJECTIVE: To investigate the effect of tetrandrine (TTD) on doxorubicin-induced mdr1 gene expression and its mechanism. Doxorubicin 61-72 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 19035180-7 2008 RESULTS: After treatment with 0.6 microg/ml doxorubicin for 24 hours, the expressions of mdr1 mRNA, NF-kappa B mRNA and P-gp in K562 cells were increased from 0.171 +/- 0.012, 0.783 +/- 0.090, 7.85 +/- 0.15 to 0.428 +/- 0.012, 1.075 +/- 0.047 and 73.68 +/- 1.84, respectively. Doxorubicin 44-55 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 19035180-7 2008 RESULTS: After treatment with 0.6 microg/ml doxorubicin for 24 hours, the expressions of mdr1 mRNA, NF-kappa B mRNA and P-gp in K562 cells were increased from 0.171 +/- 0.012, 0.783 +/- 0.090, 7.85 +/- 0.15 to 0.428 +/- 0.012, 1.075 +/- 0.047 and 73.68 +/- 1.84, respectively. Doxorubicin 44-55 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 19035180-11 2008 CONCLUSIONS: TTD inhibits the expression of mdr1 mRNA, P-gp and up-regulated P-gp function induced by doxorubicin in a dose dependent manner. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 19035180-11 2008 CONCLUSIONS: TTD inhibits the expression of mdr1 mRNA, P-gp and up-regulated P-gp function induced by doxorubicin in a dose dependent manner. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 19035180-11 2008 CONCLUSIONS: TTD inhibits the expression of mdr1 mRNA, P-gp and up-regulated P-gp function induced by doxorubicin in a dose dependent manner. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 77-81 18512984-0 2008 Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance inHepG2/Dox cells. Doxorubicin 87-90 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 18559609-10 2008 PSC833 (ABCB1 inhibitor) significantly increased the dasatinib IUR (P < 0.05) and reduced IC50(dasatinib) (from 100 to 8 nmol/L) in K562-DOX cell line. Doxorubicin 140-143 ATP binding cassette subfamily B member 1 Homo sapiens 8-13 18520065-3 2008 In present studies, R, S-HZ08 and their racemate reversed the resistance to adriamycin and vincristine of adriamycin-selected human leukemia (K562/ADM) cells that overexpress Pgp. Doxorubicin 106-116 ATP binding cassette subfamily B member 1 Homo sapiens 175-178 17876342-2 2008 We genotyped the transcriptional regulators of CYP3A and ABCB1 in 101 breast cancer patients from 3 Asian ethnic groups, that is, Chinese, Malays and Indians, in correlation with the pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin. Doxorubicin 238-249 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 18377430-0 2008 Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 18377430-3 2008 Pairwise analysis showed increased exposure levels to doxorubicin in patients harboring at least one ABCB1 c.1236T allele (P = 0.03). Doxorubicin 54-65 ATP binding cassette subfamily B member 1 Homo sapiens 101-106 18377430-8 2008 In conclusion, the present exploratory study suggests that the three high frequency linked polymorphisms in the ABCB1 gene might be functionally important with regards to the altered pharmacokinetics of doxorubicin in Asian breast cancer patients, resulting in significantly increased exposure levels and reduced clearance. Doxorubicin 203-214 ATP binding cassette subfamily B member 1 Homo sapiens 112-117 18479598-0 2008 [Comparison of reversal effects of 5-bromotetrandrine and tetrandrine on P-glycoprotein-dependent Resistance to adriamycin in human lukemia cell line K562/A02]. Doxorubicin 112-122 ATP binding cassette subfamily B member 1 Homo sapiens 73-87 18560228-2 2008 METHODS: Doxorubicin-resistant MCF-7/R was developed from sensitive MCF-7 breast carcinoma cell line and acquired resistance was demonstrated by XTT and mRNA analysis of MDR1 and MRP1 genes. Doxorubicin 9-20 ATP binding cassette subfamily B member 1 Homo sapiens 170-174 18510171-9 2008 The data suggest that apart from the known gene alterations in doxorubicin resistance (multidrug resistance 1, topoisomerase IIbeta), others can also contribute to the drug-resistance phenotype. Doxorubicin 63-74 ATP binding cassette subfamily B member 1 Homo sapiens 87-109 18347152-0 2008 Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 83-88 18347152-0 2008 Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 18347152-1 2008 Using the doxorubicin-sensitive K562 cell line and the resistant derivative lines KD30 and KD225 as models, we found that acquisition of multidrug resistance (MDR) is associated with enhanced FOXO3a activity and expression of ABCB1 (MDR1), a plasma membrane P-glycoprotein that functions as an efflux pump for various anticancer agents. Doxorubicin 10-21 ATP binding cassette subfamily B member 1 Homo sapiens 226-231 18347152-1 2008 Using the doxorubicin-sensitive K562 cell line and the resistant derivative lines KD30 and KD225 as models, we found that acquisition of multidrug resistance (MDR) is associated with enhanced FOXO3a activity and expression of ABCB1 (MDR1), a plasma membrane P-glycoprotein that functions as an efflux pump for various anticancer agents. Doxorubicin 10-21 ATP binding cassette subfamily B member 1 Homo sapiens 233-237 18347152-2 2008 Furthermore, induction of ABCB1 mRNA expression on doxorubicin treatment of naive K562 cells was also accompanied by increased FOXO3a activity. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 18383825-8 2008 For the Lovo-Dox cells, P-gp was located in the plasma membrane, in cellular anchorages and in the cytoplasm as well. Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 17964170-3 2008 These compounds were subsequently shown to enhance the uptake of doxorubicin by MCF-7 cells that over-expressed Pgp. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 112-115 18560228-5 2008 RESULTS: Doxorubicin-selected MCF-7 cells were 107-fold resistant to the drug and overexpress MDR1 and MRP1 genes. Doxorubicin 9-20 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 17947497-6 2008 Pgp inhibitors verapamil, cyclosporine A, or PSC833 increased doxorubicin accumulation in the MDR cells up to 79%, and it reversed drug resistance in these cells. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 17947497-9 2008 These studies have added direct in vitro and in vivo information on the capacity of the transporter protein Pgp to efflux doxorubicin and on the reversal of MDR by Pgp inhibitors in resistant cancer cells. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 108-111 17947497-9 2008 These studies have added direct in vitro and in vivo information on the capacity of the transporter protein Pgp to efflux doxorubicin and on the reversal of MDR by Pgp inhibitors in resistant cancer cells. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 164-167 18088459-1 2007 This study was purpose to investigate the expression levels of HSP70 and MDR1 genes under heat shock and/or adriamycin (ADM) chemotherapy stimulation. Doxorubicin 120-123 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 18045954-2 2007 Drug resistance might involve the multi-drug resistance (MDR) 1 gene, encoding a transmembrane glycoprotein p-170 (P-gp), which antagonizes intracellular accumulation of cytotoxic agents, such as doxorubicin. Doxorubicin 196-207 ATP binding cassette subfamily B member 1 Homo sapiens 34-63 18045954-5 2007 MCF7 cells, expressing COX-2 but not MDR1, were treated with increasing doses of doxorubicin, and they became chemoresistant after 10 days of treatment, in association with MDR1 expression induction. Doxorubicin 81-92 ATP binding cassette subfamily B member 1 Homo sapiens 173-177 17852453-5 2007 The expression analyses of MRP1 and MDR1 drug efflux proteins in doxorubicin-sensitive and -resistant HL60 cells revealed that there was an upregulation of MRP1 gene in HL60/DOX cells as compared to parental sensitive cells. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 17852453-5 2007 The expression analyses of MRP1 and MDR1 drug efflux proteins in doxorubicin-sensitive and -resistant HL60 cells revealed that there was an upregulation of MRP1 gene in HL60/DOX cells as compared to parental sensitive cells. Doxorubicin 174-177 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 17852453-6 2007 On the other hand, while there was no expression of MDR1 gene in parental cells, the expression of MDR1 gene was upregulated in HL60/DOX cells. Doxorubicin 133-136 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 18025283-4 2007 Unexpectedly, P-gp-overexpressing cells (SW620/Dox) displayed increased apoptosis following Ad.mda-7 infection compared with parental SW620 cells, which correlated with more MDA-7/IL-24 protein in SW620/Dox than SW620 cell and potentially explains the increased sensitivity of P-gp-overexpressing cells to mda-7/IL-24. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 18025283-4 2007 Unexpectedly, P-gp-overexpressing cells (SW620/Dox) displayed increased apoptosis following Ad.mda-7 infection compared with parental SW620 cells, which correlated with more MDA-7/IL-24 protein in SW620/Dox than SW620 cell and potentially explains the increased sensitivity of P-gp-overexpressing cells to mda-7/IL-24. Doxorubicin 47-50 ATP binding cassette subfamily B member 1 Homo sapiens 277-281 18025283-4 2007 Unexpectedly, P-gp-overexpressing cells (SW620/Dox) displayed increased apoptosis following Ad.mda-7 infection compared with parental SW620 cells, which correlated with more MDA-7/IL-24 protein in SW620/Dox than SW620 cell and potentially explains the increased sensitivity of P-gp-overexpressing cells to mda-7/IL-24. Doxorubicin 203-206 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 18057712-4 2007 Down regulation of survivin in MCF-7/adriamycin (ADR) transfected with RNAi directed against survivin vector psh1/survivin could increase the drug accumulation in cells by inhibiting Pgp. Doxorubicin 37-47 ATP binding cassette subfamily B member 1 Homo sapiens 183-186 18088459-1 2007 This study was purpose to investigate the expression levels of HSP70 and MDR1 genes under heat shock and/or adriamycin (ADM) chemotherapy stimulation. Doxorubicin 108-118 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 18261311-1 2007 OBJECTIVE: To explore the effects of adenovirus-mediated wild-type p53 gene (Ad-p53) on the reversal of multidrug resistance (MDR) and multidrug resistance gene-1 (MDR1) in adriamycin (ADM) resistant human breast cancer cell. Doxorubicin 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 135-162 18261311-1 2007 OBJECTIVE: To explore the effects of adenovirus-mediated wild-type p53 gene (Ad-p53) on the reversal of multidrug resistance (MDR) and multidrug resistance gene-1 (MDR1) in adriamycin (ADM) resistant human breast cancer cell. Doxorubicin 173-183 ATP binding cassette subfamily B member 1 Homo sapiens 164-168 18261311-1 2007 OBJECTIVE: To explore the effects of adenovirus-mediated wild-type p53 gene (Ad-p53) on the reversal of multidrug resistance (MDR) and multidrug resistance gene-1 (MDR1) in adriamycin (ADM) resistant human breast cancer cell. Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 135-162 18261311-1 2007 OBJECTIVE: To explore the effects of adenovirus-mediated wild-type p53 gene (Ad-p53) on the reversal of multidrug resistance (MDR) and multidrug resistance gene-1 (MDR1) in adriamycin (ADM) resistant human breast cancer cell. Doxorubicin 185-188 ATP binding cassette subfamily B member 1 Homo sapiens 164-168 17940500-3 2007 The doxorubicin-resistant MRP1-overexpressing human SCLC cell line GLC(4)-Adr was highly sensitive for indomethacin compared with the parental doxorubicin-sensitive line GLC(4). Doxorubicin 143-154 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 17668300-4 2007 P-glycoprotein over-expression in a doxorubicin-resistant, K562/DOX sub-line did not facilitate doxorubicin efflux from the nucleus. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 17668300-4 2007 P-glycoprotein over-expression in a doxorubicin-resistant, K562/DOX sub-line did not facilitate doxorubicin efflux from the nucleus. Doxorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 17940500-0 2007 Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 17940500-0 2007 Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Doxorubicin 65-76 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 17940500-12 2007 Indomethacin induces apoptosis in a doxorubicin-resistant SCLC cell line through an MRP1-dependent mechanism. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 17940500-3 2007 The doxorubicin-resistant MRP1-overexpressing human SCLC cell line GLC(4)-Adr was highly sensitive for indomethacin compared with the parental doxorubicin-sensitive line GLC(4). Doxorubicin 4-15 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 17912240-4 2007 Here, we show that clinically achievable levels of ZD6474 reverse P-gp-mediated MDR of the P-gp-overexpressing cell lines derived from breast cancer, MCF-7/adriamycin (ADR), and human oral epidermoid carcinoma, KBV200 to ADR, docetaxel, and vinorelbine. Doxorubicin 156-166 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 17704658-1 2007 We investigated the effects of celecoxib on the cell proliferation and the expression and activity of P-glycoprotein in the human gastric carcinoma multidrug resistance sublines SGC7901/adriamycin and SGC7901/vincristine. Doxorubicin 186-196 ATP binding cassette subfamily B member 1 Homo sapiens 102-116 17704658-7 2007 The IC50 value of the MDR1/GAPDH ratio was 5.50 x 10(-6) mol/l in SGC7901/adriamycin and 3.89 x 10(-6) mol/l in SGC7901/vincristine. Doxorubicin 74-84 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 17704658-8 2007 P-glycoprotein expression levels in the two multidrug resistance sublines treated with celecoxib were significantly lower than those in control groups, 0.28 vs. 0.71 in the SGC7901/adriamycin subline and 0.21 vs. 0.83 in the SGC7901/vincristine subline, respectively, P<0.05. Doxorubicin 181-191 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 17852455-6 2007 MATERIALS AND METHODS: The Pgp expressing cell line was established from a parental K562 (Erythroleukemia) cell line with increasing concentrations of doxorubicin, and named KDI/20. Doxorubicin 151-162 ATP binding cassette subfamily B member 1 Homo sapiens 27-30 17520676-5 2007 Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP(1)) as effectively as in their parental cells. Doxorubicin 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 187-201 17662692-3 2007 We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells. Doxorubicin 234-237 ATP binding cassette subfamily B member 1 Homo sapiens 96-101 17662692-3 2007 We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells. Doxorubicin 234-237 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 17662692-3 2007 We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells. Doxorubicin 234-237 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 17662692-3 2007 We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells. Doxorubicin 234-237 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 17520676-5 2007 Here, we demonstrated that flavopiridol induced the cleavage of poly-ADP-ribose polymerase (PARP) in a time and dose dependent manner in adriamycin-resistant OS and EFTs cells expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP(1)) as effectively as in their parental cells. Doxorubicin 137-147 ATP binding cassette subfamily B member 1 Homo sapiens 203-207 17526808-8 2007 The P-gp function was enhanced by DOX and HAAP, and it was further stimulated during combined treatment, leading to decreased DOX retention. Doxorubicin 34-37 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 18025283-5 2007 Transient overexpression of MDR1 in SW620 cells significantly increased apoptosis, decreased anchorage-independent growth, and increased MDA-7/IL-24 protein following Ad.mda-7 infection, whereas down-modulation of MDR1 in SW620/Dox cells by small interfering RNA decreased apoptosis following Ad.mda-7 infection. Doxorubicin 228-231 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 17526808-8 2007 The P-gp function was enhanced by DOX and HAAP, and it was further stimulated during combined treatment, leading to decreased DOX retention. Doxorubicin 126-129 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 17526808-12 2007 These findings suggest that the antagonistic effect of concomitant DOX + HAAP treatment occurs as a result of interactive stimulation of P-gp, generating decreased intracellular drug concentrations. Doxorubicin 67-70 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 17072745-0 2007 The 4"-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Doxorubicin 20-31 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 17457659-6 2007 Suppressing ABCB1 in multidrug resistant cells (NCI/ADR-RES and K562/DOX) and ABCB1-transfected cells (BC19) increased sensitivity to GA analogues, as expected for substrates. Doxorubicin 69-72 ATP binding cassette subfamily B member 1 Homo sapiens 12-17 17457659-7 2007 Moreover, ABCB1-mediated efflux of daunorubicin in K562/DOX cells could be blocked markedly by GA analogues in a dose-dependent fashion. Doxorubicin 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 10-15 17486684-3 2007 In HeLa cells, the sensitivity to paclitaxel and doxorubicin, substrates of MDR1, was unchanged in the presence of propolis. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 17459558-1 2007 Effective silencing of MDR1, one of the genes involved in the multidrug resistance phenotype, can be achieved by the use of an efficient siRNA transfected into the doxorubicin-selected MCF7-R human cell line, alone or combined with a moderately efficient siRNA. Doxorubicin 164-175 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 17483874-8 2007 The ELP-bound Dox was shown to accumulate in MES-SA/Dx5 cells, as opposed to free Dox, which was rapidly pumped out by the P-gp transporter. Doxorubicin 14-17 ATP binding cassette subfamily B member 1 Homo sapiens 123-127 17526808-0 2007 High-dose acetaminophen inhibits the lethal effect of doxorubicin in HepG2 cells: the role of P-glycoprotein and mitogen-activated protein kinase p44/42 pathway. Doxorubicin 54-65 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 125-136 ATP binding cassette subfamily B member 1 Homo sapiens 18-41 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 125-136 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 125-136 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 18-41 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 18-41 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 17297456-2 2007 Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicin-resistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 17637197-0 2007 CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 17637197-0 2007 CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. Doxorubicin 133-136 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 17487377-4 2007 Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells. Doxorubicin 222-232 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 17487377-4 2007 Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells. Doxorubicin 222-232 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 17487377-4 2007 Expression of the ATP binding cassette transporter, P-glycoprotein (P-gp), in breast tumours has previously been found to correlate with poor prognosis in vivo and, accordingly, we confirmed overexpression of P-gp in both adriamycin- and paclitaxel-resistant MCF-7 cells. Doxorubicin 222-232 ATP binding cassette subfamily B member 1 Homo sapiens 209-213 17072745-1 2007 BACKGROUND: The synthetic 4"-O-benzylated doxorubicin analog WP744 was designed to abrogate transport by the multidrug resistance (MDR)-associated ATP-binding cassette (ABC) proteins P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1). Doxorubicin 42-53 ATP binding cassette subfamily B member 1 Homo sapiens 183-197 17072745-1 2007 BACKGROUND: The synthetic 4"-O-benzylated doxorubicin analog WP744 was designed to abrogate transport by the multidrug resistance (MDR)-associated ATP-binding cassette (ABC) proteins P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1). Doxorubicin 42-53 ATP binding cassette subfamily B member 1 Homo sapiens 199-202 17342096-1 2007 Doxorubicin (DOX) selection of CCRF-CEM leukaemia cell line resulted in multidrug resistance (MDR) CEM/A7R cell line, which overexpresses MDR, 1 coded P-glycoprotein (Pgp). Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 138-144 16936711-5 2007 The IC(50) values of RSP for inhibiting P-gp-mediated transport of Rh123 and DOX were 63.26 and 15.78 microM, respectively, whereas the IC(50) values of PALI were >100 microM, indicating that PALI is a less potent P-gp inhibitor. Doxorubicin 77-80 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 17342096-1 2007 Doxorubicin (DOX) selection of CCRF-CEM leukaemia cell line resulted in multidrug resistance (MDR) CEM/A7R cell line, which overexpresses MDR, 1 coded P-glycoprotein (Pgp). Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 151-165 17342096-1 2007 Doxorubicin (DOX) selection of CCRF-CEM leukaemia cell line resulted in multidrug resistance (MDR) CEM/A7R cell line, which overexpresses MDR, 1 coded P-glycoprotein (Pgp). Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 167-170 17342096-1 2007 Doxorubicin (DOX) selection of CCRF-CEM leukaemia cell line resulted in multidrug resistance (MDR) CEM/A7R cell line, which overexpresses MDR, 1 coded P-glycoprotein (Pgp). Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 138-144 17342096-1 2007 Doxorubicin (DOX) selection of CCRF-CEM leukaemia cell line resulted in multidrug resistance (MDR) CEM/A7R cell line, which overexpresses MDR, 1 coded P-glycoprotein (Pgp). Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 151-165 17342096-1 2007 Doxorubicin (DOX) selection of CCRF-CEM leukaemia cell line resulted in multidrug resistance (MDR) CEM/A7R cell line, which overexpresses MDR, 1 coded P-glycoprotein (Pgp). Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 167-170 17279585-8 2007 In the osteosarcoma cell lines, etoposide and doxorubicin were better inducers of P450 3A4 and MDR1 than rifampin. Doxorubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 16997518-0 2007 Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Doxorubicin 50-61 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 17407711-1 2007 OBJECTIVE: To investigate if an adenovirus vector carrying antisense multidrug resistance gene 1 (MDR1) could reverse multidrug resistance (MDR) of HepG2/ adriamycin (ADM) cells in tumors transplanted in athymic mice. Doxorubicin 155-165 ATP binding cassette subfamily B member 1 Homo sapiens 69-96 17407711-1 2007 OBJECTIVE: To investigate if an adenovirus vector carrying antisense multidrug resistance gene 1 (MDR1) could reverse multidrug resistance (MDR) of HepG2/ adriamycin (ADM) cells in tumors transplanted in athymic mice. Doxorubicin 155-165 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 17035027-6 2007 Furthermore, in the model of combination chemotherapy, the interaction between the doxorubicine and latilagascene B (6) was studied in vitro, on human MDR1 gene transfected mouse lymphoma cells, showing that the type of interaction was synergistic. Doxorubicin 83-95 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 17097285-7 2007 Therefore, the finding that the P-glycoprotein (P-gp) blocker PSC833 also increased cellular accumulation of dox was unexpected. Doxorubicin 109-112 ATP binding cassette subfamily B member 1 Homo sapiens 32-46 17097285-7 2007 Therefore, the finding that the P-glycoprotein (P-gp) blocker PSC833 also increased cellular accumulation of dox was unexpected. Doxorubicin 109-112 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 17290610-9 2006 Compared with parental cells, the values of resistant fold for KBv200, MCF-7/ADR and HepG2/mdr1 cells to lidamycin were 6.8, 1.6 and 1.3 fold; to adriamycin were 37.2, 181.3 and 8.8 fold; to taxol were 336.8, 49.2 and 40.3 fold, respectively. Doxorubicin 146-156 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 16410038-11 2006 OBPHA and CuNG exposure resulted in an increased doxorubicin accumulation after 1-3h incubation by down-regulation of P-gp expression after 24h incubation. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 16406853-5 2006 The down-regulation of P-glycoprotein was accompanied with a partial recovery of the intracellular drug accumulation, and of the sensitivities toward adriamycin. Doxorubicin 150-160 ATP binding cassette subfamily B member 1 Homo sapiens 23-37 17088985-6 2006 In osteosarcoma patients treated with doxorubicin-based chemotherapy protocols, P-glycoprotein overexpression at diagnosis is an important adverse prognostic factor for outcome. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 80-94 16917872-6 2006 Compared to MDR1(wt), MDR1(G1199A) exhibited an increased resistance to doxorubicin, paclitaxel, vinblastine, and vincristine. Doxorubicin 72-83 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 16917872-9 2006 These data were consistent with the variation in intracellular doxorubicin concentrations measured in MDR1 recombinant cells. Doxorubicin 63-74 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 16410038-8 2006 CuNG, a known depleting agent for glutathione (GSH) and inhibitor of glutathione S-transferase (GST) and multidrug resistance-related protein 1 (MRP1), also inhibited P-gp-mediated doxorubicin accumulation and retention. Doxorubicin 181-192 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 16544145-7 2006 In addition, M4N was found to inhibit doxorubicin-induced MDR1 gene expression in drug sensitive MCF-7 breast cancer cells. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 17045162-6 2006 MNNG/HOS and U-2OS cells expressing high levels of MDR1 were highly resistant to DOX and showed reduced accumulation and higher efflux for radiotracers. Doxorubicin 81-84 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 17045162-9 2006 The chemosensitivity of OS cells to DOX was strongly dependent on mRNA MDR1 expression and could be circumvented by adding CsA. Doxorubicin 36-39 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 17045162-10 2006 The kinetic parameters of radiotracers correlated with MDR1 expression levels, hence predicting DOX resistance. Doxorubicin 96-99 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 17094479-10 2006 The results of checkerboard experiments indicated that the type of interaction was additive between doxorubicin and compound 2 on the human MDR1 gene-transfected mouse lymphoma cells. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 16545134-5 2006 The aim of the present study is to test the hypothesis that permeability of several MDR1 over-expressing tumor cell lines to the chemotherapic agent doxorubicin is enhanced by low frequency, low intensity AC stimulation. Doxorubicin 149-160 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 16331495-0 2006 Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1). Doxorubicin 23-34 ATP binding cassette subfamily B member 1 Homo sapiens 62-93 16331495-0 2006 Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1). Doxorubicin 23-34 ATP binding cassette subfamily B member 1 Homo sapiens 95-99 16331495-8 2006 These data strongly suggest that the cyclooxygenase inhibitor, indomethacin, increased the cytotoxicity of doxorubicin with decreasing expression of MRP1 through inhibition of MRP1 promoter activity. Doxorubicin 107-118 ATP binding cassette subfamily B member 1 Homo sapiens 176-180 16953094-4 2006 An adriamycin (ADM)-resistant feline lymphoma subline, FT-1/ADM, showed a high level of MDR1 mRNA expression compared with parental FT-1 cells. Doxorubicin 3-13 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 16953094-4 2006 An adriamycin (ADM)-resistant feline lymphoma subline, FT-1/ADM, showed a high level of MDR1 mRNA expression compared with parental FT-1 cells. Doxorubicin 15-18 ATP binding cassette subfamily B member 1 Homo sapiens 88-92 16547167-1 2006 The objectives of this study were to evaluate the potential of a polymer-lipid hybrid nanoparticle (PLN) system to enhance cellular accumulation and retention of doxorubicin (Dox), a widely used anticancer drug and an established P-glycoprotein (Pgp) substrate, in Pgp-overexpressing cancer cell lines and to explore the underlying mechanisms. Doxorubicin 162-173 ATP binding cassette subfamily B member 1 Homo sapiens 230-244 16547167-1 2006 The objectives of this study were to evaluate the potential of a polymer-lipid hybrid nanoparticle (PLN) system to enhance cellular accumulation and retention of doxorubicin (Dox), a widely used anticancer drug and an established P-glycoprotein (Pgp) substrate, in Pgp-overexpressing cancer cell lines and to explore the underlying mechanisms. Doxorubicin 175-178 ATP binding cassette subfamily B member 1 Homo sapiens 230-244 16547167-1 2006 The objectives of this study were to evaluate the potential of a polymer-lipid hybrid nanoparticle (PLN) system to enhance cellular accumulation and retention of doxorubicin (Dox), a widely used anticancer drug and an established P-glycoprotein (Pgp) substrate, in Pgp-overexpressing cancer cell lines and to explore the underlying mechanisms. Doxorubicin 175-178 ATP binding cassette subfamily B member 1 Homo sapiens 246-249 16547167-1 2006 The objectives of this study were to evaluate the potential of a polymer-lipid hybrid nanoparticle (PLN) system to enhance cellular accumulation and retention of doxorubicin (Dox), a widely used anticancer drug and an established P-glycoprotein (Pgp) substrate, in Pgp-overexpressing cancer cell lines and to explore the underlying mechanisms. Doxorubicin 175-178 ATP binding cassette subfamily B member 1 Homo sapiens 265-268 16564522-3 2006 Here we report that endonuclease-prepared small interfering RNA (esiRNA) at concentrations as low as 10 ng/ml (about 0.7 nM) can decrease MDR1 expression and increase chemosensitivity in the Adriamycin-induced resistant MCF-7/R cells. Doxorubicin 191-201 ATP binding cassette subfamily B member 1 Homo sapiens 138-142 16499877-0 2006 Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Doxorubicin 61-72 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 16545134-10 2006 The relationship between MDR1 expression and the intracellular accumulation of doxorubicin as well as the cellular distribution of MDR1 was investigated by computerized image analysis immunohistochemistry and Western blot techniques. Doxorubicin 79-90 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 16579640-7 2006 Conversely, cells selected with Dox alone showed an elevated level in the expression of the MDR1 gene along with a corresponding increase in the expression level of the drug efflux transporter, Pgp, and likely contributing to the high resistance of the cells to Dox. Doxorubicin 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 16223781-3 2006 The combination of ATRA and the novel histone deacetylase inhibitor (HDACI) depsipeptide (FK228) induced P-gp expression and prevented growth inhibition and apoptosis in NB4 APL cells subsequently exposed to doxorubicin (DOX). Doxorubicin 208-219 ATP binding cassette subfamily B member 1 Homo sapiens 105-109 16442095-4 2006 At 5 microM the same three increased sensitivity of p-glycoprotein-expressing SW620/R to doxorubicin and stimulated ATPase activity associated with BCRP expressed in bacterial membrane vesicles. Doxorubicin 89-100 ATP binding cassette subfamily B member 1 Homo sapiens 52-66 16750009-4 2006 RESULTS: The results of semi-quantitative RT-PCR analysis showed that the expression level of MDR1 was higher in RCC cells transferred by PKCalpha cDNA than in RCC cells, the reversal effectiveness of PKC inhibitors in combination with adriamycin (ADM) was apparently favorable. Doxorubicin 236-246 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 16750009-4 2006 RESULTS: The results of semi-quantitative RT-PCR analysis showed that the expression level of MDR1 was higher in RCC cells transferred by PKCalpha cDNA than in RCC cells, the reversal effectiveness of PKC inhibitors in combination with adriamycin (ADM) was apparently favorable. Doxorubicin 248-251 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 16547167-5 2006 Treatment of Pgp-overexpressing cell lines with Dox-PLNs resulted in significantly enhanced Dox uptake and more substantial increases in drug retention after the end of treatment compared with free Dox solutions (p < 0.05). Doxorubicin 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 13-16 16547167-5 2006 Treatment of Pgp-overexpressing cell lines with Dox-PLNs resulted in significantly enhanced Dox uptake and more substantial increases in drug retention after the end of treatment compared with free Dox solutions (p < 0.05). Doxorubicin 92-95 ATP binding cassette subfamily B member 1 Homo sapiens 13-16 16547167-5 2006 Treatment of Pgp-overexpressing cell lines with Dox-PLNs resulted in significantly enhanced Dox uptake and more substantial increases in drug retention after the end of treatment compared with free Dox solutions (p < 0.05). Doxorubicin 92-95 ATP binding cassette subfamily B member 1 Homo sapiens 13-16 16547167-6 2006 Fluorescence microscopic images showed improved nuclear localization of Dox and uptake of lipid when the drug was delivered in the Dox-PLN form to MDA435/LCC6/MDR1 cells. Doxorubicin 131-134 ATP binding cassette subfamily B member 1 Homo sapiens 159-163 16547167-8 2006 These findings suggest that some of the Dox physically associated with the nanoparticles bypass the membrane-associated Pgp when delivered as Dox-PLNs, and in this form, the drug is better retained within the Pgp-overexpressing cells than the free drug. Doxorubicin 40-43 ATP binding cassette subfamily B member 1 Homo sapiens 120-123 16547167-8 2006 These findings suggest that some of the Dox physically associated with the nanoparticles bypass the membrane-associated Pgp when delivered as Dox-PLNs, and in this form, the drug is better retained within the Pgp-overexpressing cells than the free drug. Doxorubicin 40-43 ATP binding cassette subfamily B member 1 Homo sapiens 209-212 16547167-8 2006 These findings suggest that some of the Dox physically associated with the nanoparticles bypass the membrane-associated Pgp when delivered as Dox-PLNs, and in this form, the drug is better retained within the Pgp-overexpressing cells than the free drug. Doxorubicin 142-145 ATP binding cassette subfamily B member 1 Homo sapiens 120-123 16451059-6 2006 FACS assay demonstrated that these new compounds abolished P-gp drug efflux and accumulated high intracellular concentration in the drug-resistant leukemia K562/Dox. Doxorubicin 161-164 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 16572896-5 2006 Gene expression data confirmed the induction of mdr1 (P-gp), as judged by the observed 15-fold increase in its mRNA concentration in doxorubicin-resistant NCI-H460/R cells. Doxorubicin 133-144 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 16579640-7 2006 Conversely, cells selected with Dox alone showed an elevated level in the expression of the MDR1 gene along with a corresponding increase in the expression level of the drug efflux transporter, Pgp, and likely contributing to the high resistance of the cells to Dox. Doxorubicin 262-265 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 16356834-7 2006 We hypothesize that acquirement of doxorubicin resistance of MCF-7 cells is associated with DNA hypomethylation of the promoter regions of the MDR1, GSTpi, MGMT, and Upa genes. Doxorubicin 35-46 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 16319528-6 2006 Compared KBv200/MDR1sh cells with KBv200 cells, resistance to vincristine and doxorubicin decreased from 62.4-fold to 10.5-fold and from 74.5-fold to 9.5-fold respectively, and intracellular doxorubicin accumulation enhanced from 0.30 +/- 0.08 nmoles/10(6) cells to 0.86 +/- 0.16 nmoles/10(6) cells, and the fluorescence intensity of intracellular Rhodamine 123 accumulation increased from 3.58 +/- 1.63/10(6) cells to 13.96 +/- 3.07/10(6) cells. Doxorubicin 78-89 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 16377671-2 2006 The in vitro experiments revealed that the intracellular accumulation of telithromycin in adriamycin-resistant human chronic myelogenous leukemia cells (K562/ADR) overexpressing P glycoprotein was significantly lower than that in human chronic myelogenous leukemia cells (K562/S) not expressing P glycoprotein. Doxorubicin 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 178-192 16377671-2 2006 The in vitro experiments revealed that the intracellular accumulation of telithromycin in adriamycin-resistant human chronic myelogenous leukemia cells (K562/ADR) overexpressing P glycoprotein was significantly lower than that in human chronic myelogenous leukemia cells (K562/S) not expressing P glycoprotein. Doxorubicin 90-100 ATP binding cassette subfamily B member 1 Homo sapiens 295-309 16319528-6 2006 Compared KBv200/MDR1sh cells with KBv200 cells, resistance to vincristine and doxorubicin decreased from 62.4-fold to 10.5-fold and from 74.5-fold to 9.5-fold respectively, and intracellular doxorubicin accumulation enhanced from 0.30 +/- 0.08 nmoles/10(6) cells to 0.86 +/- 0.16 nmoles/10(6) cells, and the fluorescence intensity of intracellular Rhodamine 123 accumulation increased from 3.58 +/- 1.63/10(6) cells to 13.96 +/- 3.07/10(6) cells. Doxorubicin 191-202 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 17357504-0 2006 Reversal of adriamycin resistance in human mammary cancer cells by small interfering RNA of MDR1 and MDR3 genes. Doxorubicin 12-22 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 16049968-5 2006 Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 16049968-5 2006 Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 16049968-5 2006 Here, we demonstrated that FK228 and apicidin exhibited strong resistance in doxorubicin-resistant clones of OS and EFTs expressing P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) and that P-gp and MRP1 might play a crucial role in the resistance mechanism to FK228 and apicidin. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 216-220 17357504-7 2006 MDR1 and MDR3 gene silencing can enhance intracellular adriamycin accumulation in MCF-7/ADR cells, improve sensitivity of MCF-7/ADR cells to adriamycin, and induce cell apoptosis. Doxorubicin 55-65 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 17357504-7 2006 MDR1 and MDR3 gene silencing can enhance intracellular adriamycin accumulation in MCF-7/ADR cells, improve sensitivity of MCF-7/ADR cells to adriamycin, and induce cell apoptosis. Doxorubicin 141-151 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 17357504-8 2006 The reversal effect of adriamycin resistance by siRNA of MDR1 was more effective than that of MDR3. Doxorubicin 23-33 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 17357504-1 2006 The purpose of this paper is to investigate the reversal effect of small interfering RNA (siRNA) targeting MDR1 and MDR3 genes on the resistance of MCF-7/ADR cells to adriamycin. Doxorubicin 167-177 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 15946544-1 2005 OBJECTIVE: To investigate the reversal effect of haloperidol (Hal) on doxorubicin (Dox) resistance and its inhibition effect on P-glycoprotein and swelling-activated chloride channel in Dox-resistant erythro-leukemic cell line K562/Dox. Doxorubicin 186-189 ATP binding cassette subfamily B member 1 Homo sapiens 128-142 18528466-12 2006 We went on to show that p53 regulated the expression of MRP1 and that this produced resistance to doxorubicin and vinblastine. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 15967469-0 2005 Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 95-106 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 15967469-0 2005 Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Doxorubicin 150-153 ATP binding cassette subfamily B member 1 Homo sapiens 12-26 16093797-5 2005 Liposomal encapsulation of doxorubicin when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) seems to overcome P-glycoprotein-mediated drug resistance in AIDS-related lymphoma. Doxorubicin 27-38 ATP binding cassette subfamily B member 1 Homo sapiens 167-181 16093797-7 2005 Treatment with liposomal encapsulated doxorubicin seems to overcome the P-glycoprotein-related drug resistance. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 72-86 16083877-6 2005 In DU-145Nox1 tumor spheroids, expression of HIF-1alpha as well as P-gp was significantly decreased as compared to DU-145 spheroids, which resulted in an increased retention of the anticancer agent doxorubicin. Doxorubicin 198-209 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 16001980-5 2005 In the present study, we asked if a human lung cancer cell line (INER-51) grown as multicellular spheroids can modify the P-gp activity to decrease the levels of doxorubicin (DXR) retained and increase their drug resistance. Doxorubicin 162-173 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 15963852-3 2005 METHODS: We constructed a nonviral, transposon-based vector system for the stable knockdown of PgP in chronic myeloid leukemia cell lines resistant to imatinib and doxorubicin. Doxorubicin 164-175 ATP binding cassette subfamily B member 1 Homo sapiens 95-98 15963852-5 2005 Cellular efflux of the PgP substates rhodamine and doxorubicin was abolished. Doxorubicin 51-62 ATP binding cassette subfamily B member 1 Homo sapiens 23-26 15906164-0 2005 P-glycoprotein induction and tumor cell-kill dynamics in response to differential doxorubicin dosing strategies: a theoretical pharmacodynamic model. Doxorubicin 82-93 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 15906164-1 2005 PURPOSE: The objectives of this work were 1) to develop a theoretical pharmacodynamic model that captures dynamic changes resulting from drug/therapy mediated P-glycoprotein (P-gp) induction and 2) to compare the pharmacodynamic outcomes of several doxorubicin (DOX) dosing schemes through simulations. Doxorubicin 249-260 ATP binding cassette subfamily B member 1 Homo sapiens 175-179 15906164-1 2005 PURPOSE: The objectives of this work were 1) to develop a theoretical pharmacodynamic model that captures dynamic changes resulting from drug/therapy mediated P-glycoprotein (P-gp) induction and 2) to compare the pharmacodynamic outcomes of several doxorubicin (DOX) dosing schemes through simulations. Doxorubicin 262-265 ATP binding cassette subfamily B member 1 Homo sapiens 175-179 15906164-2 2005 METHODS: We developed a theoretical model that included a pharmacokinetic (PK) model for intracellular DOX-mediated P-gp induction and a pharmacodynamic (PD) model using a threshold trigger function for tumor cell-kill. Doxorubicin 103-106 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 15906164-3 2005 In this model, both the level of P-gp induction and rate of tumor cell death were modulated by intracellular DOX concentration. Doxorubicin 109-112 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 16696319-4 2005 The Rz- transfected HepG2 cells became doxorubicin-sensitive, which was concomitant with the decreased MDR1 expression. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 103-107 17657173-7 2006 SNU-449, the most resistant cell line and the only one overexpressing P-glycoprotein, was 3- to 39-fold more resistant to paclitaxel, docetaxel, and doxorubicin than were other cell lines. Doxorubicin 149-160 ATP binding cassette subfamily B member 1 Homo sapiens 70-84 16330681-11 2005 In addition, acute ACT was associated with the Gly671Val variant of the doxorubicin efflux transporter multidrug resistance protein 1 (MRP1) (OR, 3.6; 95% CI, 1.6 to 8.4) and with the Val1188Glu-Cys1515Tyr (rs8187694-rs8187710) haplotype of the functionally similar MRP2 (OR, 2.3; 95% CI, 1.0 to 5.4). Doxorubicin 72-83 ATP binding cassette subfamily B member 1 Homo sapiens 103-133 16330681-11 2005 In addition, acute ACT was associated with the Gly671Val variant of the doxorubicin efflux transporter multidrug resistance protein 1 (MRP1) (OR, 3.6; 95% CI, 1.6 to 8.4) and with the Val1188Glu-Cys1515Tyr (rs8187694-rs8187710) haplotype of the functionally similar MRP2 (OR, 2.3; 95% CI, 1.0 to 5.4). Doxorubicin 72-83 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 15945097-11 2005 In conclusion, we could remark that proteasome inhibitors (especially PS341) attenuate the resistance of MCF7/ADR cells for P-gp substrate drugs of doxorubicin and paclitaxel. Doxorubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 124-128 16214115-5 2005 20% total P-gp expression remaining) in the doxorubicin selected MCF7-R human cell line. Doxorubicin 44-55 ATP binding cassette subfamily B member 1 Homo sapiens 10-14 16039989-3 2005 Western blot analysis showed that incubation of cells with doxorubicin induced P-gp expression in a reversible manner. Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 16039989-6 2005 Intracellular dialysis of MDR+ cells with C219 anti-P-gp antibody abolished the sensitivity of I(Cl-swell) to doxorubicin and led to a response pattern very close to that of MDR- cells. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 15378274-14 2005 BrTet also inhibited the overexpression of P-gp in MCF-7/Dox cells, but had no effect on mdr1 expression. Doxorubicin 57-60 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 15695394-3 2005 Doxorubicin is a substrate of Pgp; it has been suggested that its ability to induce synthesis of nitric oxide (NO) could explain, at least in part, its cytotoxic effects. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 30-33 15695394-4 2005 Culturing the human epithelial colon cell line HT29 in the presence of doxorubicin, we obtained a doxorubicin-resistant (HT29-dx) cell population: these cells accumulated less intracellular doxorubicin, were less sensitive to the cytotoxic effects of doxorubicin and cisplatin, overexpressed Pgp and MRP3, and exhibited a lower NO production (both under basal conditions and after doxorubicin stimulation). Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 292-295 15695394-4 2005 Culturing the human epithelial colon cell line HT29 in the presence of doxorubicin, we obtained a doxorubicin-resistant (HT29-dx) cell population: these cells accumulated less intracellular doxorubicin, were less sensitive to the cytotoxic effects of doxorubicin and cisplatin, overexpressed Pgp and MRP3, and exhibited a lower NO production (both under basal conditions and after doxorubicin stimulation). Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 292-295 15695394-4 2005 Culturing the human epithelial colon cell line HT29 in the presence of doxorubicin, we obtained a doxorubicin-resistant (HT29-dx) cell population: these cells accumulated less intracellular doxorubicin, were less sensitive to the cytotoxic effects of doxorubicin and cisplatin, overexpressed Pgp and MRP3, and exhibited a lower NO production (both under basal conditions and after doxorubicin stimulation). Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 292-295 15695394-4 2005 Culturing the human epithelial colon cell line HT29 in the presence of doxorubicin, we obtained a doxorubicin-resistant (HT29-dx) cell population: these cells accumulated less intracellular doxorubicin, were less sensitive to the cytotoxic effects of doxorubicin and cisplatin, overexpressed Pgp and MRP3, and exhibited a lower NO production (both under basal conditions and after doxorubicin stimulation). Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 292-295 15501994-0 2005 Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 70-92 15501994-2 2005 Doxorubicin, an important anti-AML drug, is a known MDR1 substrate and inducer. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 15501994-8 2005 Interestingly, incubation of AML cells with doxorubicin not only induced functionally active MDR1 overexpression but also mediated increased cyclooxygenase-2 mRNA and protein expressions with subsequent PGE(2) release (determined by flow cytometry, rhodamine123 efflux assay, reverse transcription-polymerase chain reaction, and enzyme-linked immunosorbent assay). Doxorubicin 44-55 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 15501994-11 2005 In conclusion, the cyclooxygenase system, especially the cyclooxygenase-2 isoform, might be involved in regulating doxorubicin-induced MDR1 overexpression in AML cells, with PGE(2) seeming to be a mediating factor. Doxorubicin 115-126 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 20641303-3 2004 One of the mechanisms of cells to escape the cytotoxic effects of chemotherapeutic agents, such as Adriamycin, Vinca alkaloids, epipodophyllotoxins, actinomycin D, and taxol, is to limit their presence inside the cells by a multidrug resistance (MDR-1) gene protein. Doxorubicin 99-109 ATP binding cassette subfamily B member 1 Homo sapiens 246-251 15946544-1 2005 OBJECTIVE: To investigate the reversal effect of haloperidol (Hal) on doxorubicin (Dox) resistance and its inhibition effect on P-glycoprotein and swelling-activated chloride channel in Dox-resistant erythro-leukemic cell line K562/Dox. Doxorubicin 186-189 ATP binding cassette subfamily B member 1 Homo sapiens 128-142 15946544-3 2005 mRNA expressions of P-glycoprotein (MDR1), glutathione S-transferase Pi (GSTpi) and MDR-associated protein (MRP) of K562/Dox treated with Hal were assayed by RT-PCR. Doxorubicin 121-124 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 15736412-1 2004 Doxorubicin (dox) encapsulated in polyisohexylcyanoacrylate nanospheres (PIHCA-dox) can circumvent P-glycoprotein-mediated multidrug resistance (MDR). Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 15736412-1 2004 Doxorubicin (dox) encapsulated in polyisohexylcyanoacrylate nanospheres (PIHCA-dox) can circumvent P-glycoprotein-mediated multidrug resistance (MDR). Doxorubicin 13-16 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 15736412-6 2004 MDR1 gene overexpression was consistently higher in free dox-selected cells than in PIHCA-dox-selected cells, while this was the reverse for the BCRP gene. Doxorubicin 57-60 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 15736412-6 2004 MDR1 gene overexpression was consistently higher in free dox-selected cells than in PIHCA-dox-selected cells, while this was the reverse for the BCRP gene. Doxorubicin 90-93 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 15498565-0 2004 Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. Doxorubicin 56-59 ATP binding cassette subfamily B member 1 Homo sapiens 15-29 15501458-2 2004 A series of Dox analogs with bulky substitutions at the C-4" at amino-sugar have been designed to impair interactions between the drug and P-glycoprotein (P-gp), a multidrug drug resistance (MDR) transporter. Doxorubicin 12-15 ATP binding cassette subfamily B member 1 Homo sapiens 139-153 15464074-2 2004 The in vitro experiments showed that the intracellular accumulation of pazufloxacin in adriamycin-resistant human chronic myelogenous leukemia cells (K562/ADR) overexpressing P-glycoprotein was significantly lower than that in human chronic myelogenous leukemia cells (K562/S) not expressing P-glycoprotein. Doxorubicin 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 175-189 15464074-2 2004 The in vitro experiments showed that the intracellular accumulation of pazufloxacin in adriamycin-resistant human chronic myelogenous leukemia cells (K562/ADR) overexpressing P-glycoprotein was significantly lower than that in human chronic myelogenous leukemia cells (K562/S) not expressing P-glycoprotein. Doxorubicin 87-97 ATP binding cassette subfamily B member 1 Homo sapiens 292-306 15507937-13 2004 Both AN-152 and doxorubicin induced surface expression of MDR-1 gene product Pgp, but the effect of AN-152 was smaller than that of doxorubicin. Doxorubicin 16-27 ATP binding cassette subfamily B member 1 Homo sapiens 58-63 15507937-13 2004 Both AN-152 and doxorubicin induced surface expression of MDR-1 gene product Pgp, but the effect of AN-152 was smaller than that of doxorubicin. Doxorubicin 16-27 ATP binding cassette subfamily B member 1 Homo sapiens 77-80 15528968-12 2004 In medium containing FCS, both AN-152 and doxorubicin induced surface expression of MDR-1 gene product Pgp, but the effect of AN-152 was weaker. Doxorubicin 42-53 ATP binding cassette subfamily B member 1 Homo sapiens 84-89 15501458-2 2004 A series of Dox analogs with bulky substitutions at the C-4" at amino-sugar have been designed to impair interactions between the drug and P-glycoprotein (P-gp), a multidrug drug resistance (MDR) transporter. Doxorubicin 12-15 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 15501458-13 2004 WP744 was more cytotoxic than Dox against both P-gp+ and P-gp- cells. Doxorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 15501458-13 2004 WP744 was more cytotoxic than Dox against both P-gp+ and P-gp- cells. Doxorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 15239129-3 2004 We demonstrated for the first time that Hs578T doxorubicin resistant cells (Hs578T/Doxo), which contain low levels of endogenous caveolin-1 and high levels of P-glycoprotein, are rendered drug-sensitive by overexpression of exogenous caveolin-1. Doxorubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 159-173 15100388-6 2004 Cytotoxicity studies have shown that MDR1wt and MDR11199 cells exhibited similar resistance, as measured by EC50 values, to doxorubicin (155 +/- 68 versus 120 +/- 32 nM); however, MDR11199 cells were more resistant to vinblastine (1.41 +/- 0.51 versus 15.7 +/- 4.0 nM; p < 0.001) and vincristine (1.18 +/- 0.56 versus 3.41 +/- 1.47 nM; p < 0.05). Doxorubicin 124-135 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 15453960-9 2004 The enhanced doxorubicin chemosensitivity of MDR+ cells in the presence of verapamil, a modulator of P-glycoprotein, was reflected by the reduced uptake of 18F-deoxyglucose, 125I-deoxyuridineribose, and 125I-methyltyrosine. Doxorubicin 13-24 ATP binding cassette subfamily B member 1 Homo sapiens 101-115 15285842-0 2004 Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin--a comparison with tamoxifen. Doxorubicin 97-108 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 15240128-0 2004 Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox. Doxorubicin 110-113 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 15329202-5 2004 Treated with TRAIL combination with ADM (0.1 mg/L), it showed significant inhibitory effect on the growth of HepG2/ADM, the percentage of apoptosis was increased as comparison with control at 24 h. CONCLUSION: MDR1 might not take part in resistance to TRAIL-induced apoptosis. Doxorubicin 36-39 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 15312340-7 2004 After being treated with antisense oligodeoxynucleotides of NF-H and mdr1, the cellular adriamycin concentration increased significantly, but antisense NF-H alone did not have significant effect on drug resistance phenotype. Doxorubicin 88-98 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 15226333-13 2004 CONCLUSION: Liposomal doxorubicin in combination with cyclophosphamide, vincristine, and prednisone is active in AIDS-NHL, with complete remissions achieved in 75% independent of HIV viral control or tissue MDR-1 expression. Doxorubicin 22-33 ATP binding cassette subfamily B member 1 Homo sapiens 207-212 15233869-7 2004 Finally, the expression of MDR genes (MDR1 and MRP1) in MCF-7/dox cells following the exposure to doxorubicin alone and in combination with monensin liposomes was evaluated by semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Doxorubicin 62-65 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 15235109-5 2004 Following transient transfection of TEL/AML1 protein into Adriamycin-resistant K562/Adr cells, we also demonstrate that TEL/AML1 can down-regulate the expression of P-glycoprotein, a product of the MDR-1 gene, and restore the chemosensitivity to the cells. Doxorubicin 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 165-179 15235109-5 2004 Following transient transfection of TEL/AML1 protein into Adriamycin-resistant K562/Adr cells, we also demonstrate that TEL/AML1 can down-regulate the expression of P-glycoprotein, a product of the MDR-1 gene, and restore the chemosensitivity to the cells. Doxorubicin 58-68 ATP binding cassette subfamily B member 1 Homo sapiens 198-203 15269137-5 2004 MRP1 splice variants were expressed as enhanced green fluorescent fusion proteins in HEK293T cells to demonstrate their localization in the cell and their activity in conferring resistance to doxorubicin. Doxorubicin 192-203 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 15269137-13 2004 We expressed 3 of these MRP1 splice variants in HEK293T cells and found that they appeared to localize to the plasma membrane and were functional in conferring resistance to doxorubicin. Doxorubicin 174-185 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 15233869-7 2004 Finally, the expression of MDR genes (MDR1 and MRP1) in MCF-7/dox cells following the exposure to doxorubicin alone and in combination with monensin liposomes was evaluated by semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 15233869-11 2004 RT-PCR studies demonstrated that the expression of MDR1 and MRP1 was increased by 33 and 57%, respectively, in MCF-7/dox cells following treatment with doxorubicin (2.5 microg mL(-1)) for 72 h as compared with control MCF-7/dox cells. Doxorubicin 117-120 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 15233869-11 2004 RT-PCR studies demonstrated that the expression of MDR1 and MRP1 was increased by 33 and 57%, respectively, in MCF-7/dox cells following treatment with doxorubicin (2.5 microg mL(-1)) for 72 h as compared with control MCF-7/dox cells. Doxorubicin 152-163 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 15233869-11 2004 RT-PCR studies demonstrated that the expression of MDR1 and MRP1 was increased by 33 and 57%, respectively, in MCF-7/dox cells following treatment with doxorubicin (2.5 microg mL(-1)) for 72 h as compared with control MCF-7/dox cells. Doxorubicin 152-155 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 15233869-12 2004 Furthermore, the levels of MDR1 and MRP1 in MCF-7/dox cells exposed to both doxorubicin and monensin liposomes showed a modest decrease as compared with MCF-7/dox cells treated with doxorubicin alone. Doxorubicin 50-53 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 15233869-12 2004 Furthermore, the levels of MDR1 and MRP1 in MCF-7/dox cells exposed to both doxorubicin and monensin liposomes showed a modest decrease as compared with MCF-7/dox cells treated with doxorubicin alone. Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 15233869-12 2004 Furthermore, the levels of MDR1 and MRP1 in MCF-7/dox cells exposed to both doxorubicin and monensin liposomes showed a modest decrease as compared with MCF-7/dox cells treated with doxorubicin alone. Doxorubicin 76-79 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 15233869-12 2004 Furthermore, the levels of MDR1 and MRP1 in MCF-7/dox cells exposed to both doxorubicin and monensin liposomes showed a modest decrease as compared with MCF-7/dox cells treated with doxorubicin alone. Doxorubicin 182-193 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 15034547-2 2004 Limitations to the efficacy and therapeutic index of doxorubicin include poor tumor selectivity, high systemic toxicity, and the development of resistance, especially p-glycoprotein (p-gp)-mediated. Doxorubicin 53-64 ATP binding cassette subfamily B member 1 Homo sapiens 167-181 15141021-7 2004 In breast cancer, detailed analysis of MCF-7 wild-type and MCF-7-AdrR cells (Adriamycin-resistant) demonstrated enhanced glucosylceramide synthase message and protein, P-gp message and protein, and high levels of glucosylceramide in resistant cells. Doxorubicin 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 168-172 15034547-2 2004 Limitations to the efficacy and therapeutic index of doxorubicin include poor tumor selectivity, high systemic toxicity, and the development of resistance, especially p-glycoprotein (p-gp)-mediated. Doxorubicin 53-64 ATP binding cassette subfamily B member 1 Homo sapiens 183-187 14726695-6 2004 It was found that overexpression of ZNRD1 could sensitize SGC7901 cells to P-glycoprotein (P-gp)-related anticancer drugs (vincristine, adriamycin, etoposide) but not to P-gp-nonrelated drugs (5-fluorouracil and cisplatin), which was accompanied with significantly decreased adriamycin accumulation and retention and increased adriamycin releasing in SGC7901 cells. Doxorubicin 275-285 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 14726695-6 2004 It was found that overexpression of ZNRD1 could sensitize SGC7901 cells to P-glycoprotein (P-gp)-related anticancer drugs (vincristine, adriamycin, etoposide) but not to P-gp-nonrelated drugs (5-fluorouracil and cisplatin), which was accompanied with significantly decreased adriamycin accumulation and retention and increased adriamycin releasing in SGC7901 cells. Doxorubicin 275-285 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 14767548-3 2004 We examined the effect of Cepharanthin (CEP), a natural alkaloid extracted from Stephania cepharantha Hayata, in overcoming P-glycoprotein (P-gp)-associated doxorubicine (DOX) resistance, using 2 DOX-resistant HCC cell lines, and their DOX-sensitive parental cell lines. Doxorubicin 157-169 ATP binding cassette subfamily B member 1 Homo sapiens 124-138 14767548-3 2004 We examined the effect of Cepharanthin (CEP), a natural alkaloid extracted from Stephania cepharantha Hayata, in overcoming P-glycoprotein (P-gp)-associated doxorubicine (DOX) resistance, using 2 DOX-resistant HCC cell lines, and their DOX-sensitive parental cell lines. Doxorubicin 157-169 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 14767548-3 2004 We examined the effect of Cepharanthin (CEP), a natural alkaloid extracted from Stephania cepharantha Hayata, in overcoming P-glycoprotein (P-gp)-associated doxorubicine (DOX) resistance, using 2 DOX-resistant HCC cell lines, and their DOX-sensitive parental cell lines. Doxorubicin 171-174 ATP binding cassette subfamily B member 1 Homo sapiens 124-138 14767548-3 2004 We examined the effect of Cepharanthin (CEP), a natural alkaloid extracted from Stephania cepharantha Hayata, in overcoming P-glycoprotein (P-gp)-associated doxorubicine (DOX) resistance, using 2 DOX-resistant HCC cell lines, and their DOX-sensitive parental cell lines. Doxorubicin 171-174 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 14655754-4 2003 Inhibition of PGP activity by verapamil or PSC 833 enhanced the cytotoxic effects of vincristine, doxorubicin, teniposide and taxol. Doxorubicin 98-109 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 14741713-8 2004 Mammalian cells that overexpress P-glycoprotein, which is a transmembrane protein that is involved in the efflux of certain drugs, are resistant to both adriamycin and actinomycin D but not to aclarubicin. Doxorubicin 153-163 ATP binding cassette subfamily B member 1 Homo sapiens 33-47 14744620-7 2004 The present findings suggest that azithromycin overcomes P-glycoprotein-dependent anticancer drug resistance of tumors by inhibiting the binding of doxorubicin to P-glycoprotein in K562/ADR cells and inhibits the hepatobiliary excretion of drugs that are substrates for P-glycoprotein and Mrp2. Doxorubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 14744620-7 2004 The present findings suggest that azithromycin overcomes P-glycoprotein-dependent anticancer drug resistance of tumors by inhibiting the binding of doxorubicin to P-glycoprotein in K562/ADR cells and inhibits the hepatobiliary excretion of drugs that are substrates for P-glycoprotein and Mrp2. Doxorubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 163-177 14744620-7 2004 The present findings suggest that azithromycin overcomes P-glycoprotein-dependent anticancer drug resistance of tumors by inhibiting the binding of doxorubicin to P-glycoprotein in K562/ADR cells and inhibits the hepatobiliary excretion of drugs that are substrates for P-glycoprotein and Mrp2. Doxorubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 163-177 12955471-7 2004 Furthermore, we evaluated in vitro the impact of P-gp expression on the cytotoxicity of DOX and IDA in cells from three parental chemosensitive leukemia and lymphoma cell lines (HL60, U937, CCRF) and their resistant sublines, as well as in CD34-positive HSC. Doxorubicin 88-91 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 12955471-9 2004 In cell line models the numbers of viable cells in a P-gp-expressing resistant CCRF-VCR100 subline were significantly more reduced by IDA ( P<0.001), but there was no difference in the cytotoxicities of IDA and DOX in chemosensitive CCRF cells and in the (non-P-gp-expressing) resistant U937 and HL60 sublines. Doxorubicin 214-217 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 16305369-5 2004 Also, at the single-cell level, an inverse relationship between Pgp-EGFP expression and nuclear doxorubicin accumulation was demonstrated. Doxorubicin 96-107 ATP binding cassette subfamily B member 1 Homo sapiens 64-67 14764032-1 2004 The aim of this study was to investigate the reversal of adriamycin resistance in human ovarian cancer cells by ultrasound exposure from perspectives of apoptosis and mdr1 gene. Doxorubicin 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 167-171 15051924-6 2004 METHODS: Therefore, these cells were treated with antisense oligodeoxynucleotides (asn-ODN) directed against the P-gp mRNA in order to increase the intracellular retention of doxorubicin (DOX) which had been given previously. Doxorubicin 175-186 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 15051924-8 2004 CONCLUSION: These results suggest that asn-ODN-mediated inhibition of P-gp expression is an efficient way to increase intracellular retention of DOX. Doxorubicin 145-148 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 15015586-0 2004 A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways. Doxorubicin 39-50 ATP binding cassette subfamily B member 1 Homo sapiens 2-16 12964004-1 2003 Previous studies have demonstrated that doxorubicin (DOX) encapsulated in polyisohexylcyano-acrylate nanospheres (NS-DOX) circumvented the resistance of breast cancer cells overexpressing P-glycoprotein (Pgp). Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 188-202 12964004-1 2003 Previous studies have demonstrated that doxorubicin (DOX) encapsulated in polyisohexylcyano-acrylate nanospheres (NS-DOX) circumvented the resistance of breast cancer cells overexpressing P-glycoprotein (Pgp). Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 204-207 12964004-1 2003 Previous studies have demonstrated that doxorubicin (DOX) encapsulated in polyisohexylcyano-acrylate nanospheres (NS-DOX) circumvented the resistance of breast cancer cells overexpressing P-glycoprotein (Pgp). Doxorubicin 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 188-202 12964004-1 2003 Previous studies have demonstrated that doxorubicin (DOX) encapsulated in polyisohexylcyano-acrylate nanospheres (NS-DOX) circumvented the resistance of breast cancer cells overexpressing P-glycoprotein (Pgp). Doxorubicin 53-56 ATP binding cassette subfamily B member 1 Homo sapiens 204-207 12767063-7 2003 Our results show that AMR competitively inhibits P-gp-mediated DOX efflux, suggestive of a mechanism underlying the enhanced DOX accumulation and reversal of multidrug resistance by AMR. Doxorubicin 63-66 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 12932639-10 2003 This provided initial evidence that Pgp may be useful as a gene expression marker for predicting potential responses to doxorubicin/Pluronic formulation in chemotherapy of cancer. Doxorubicin 120-131 ATP binding cassette subfamily B member 1 Homo sapiens 36-39 12904281-3 2003 Proliferation and sensitivity to adriamycin of K562/ADM cells treated with MDR1-PNA- and MDR1-ASODN were analyzed with a MTT colorimetric assay. Doxorubicin 33-43 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 12904281-3 2003 Proliferation and sensitivity to adriamycin of K562/ADM cells treated with MDR1-PNA- and MDR1-ASODN were analyzed with a MTT colorimetric assay. Doxorubicin 33-43 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 12904281-5 2003 RESULTS: MDR1-PNA 1 to 10 micromol/L and MDR1-ASODN 2 to 20 micromol/L alone had no inhibitory effects on the proliferation of K562/ADM cells, but significantly inhibited the growth of K562/ADM cells cultured in adriamycin-containing medium. Doxorubicin 212-222 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 12904281-6 2003 After treatment with MDR1-PNA and MDR1-ASODN, intracellular adriamycin accumulation in K562/ADM cells increased greatly and P-gp synthesis was strikingly reduced. Doxorubicin 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 12904281-6 2003 After treatment with MDR1-PNA and MDR1-ASODN, intracellular adriamycin accumulation in K562/ADM cells increased greatly and P-gp synthesis was strikingly reduced. Doxorubicin 60-70 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 12948017-1 2003 PURPOSE: The purpose of this work was to elucidate transport pathways of the P-glycoprotein (P-gp) substrates rhodamine 123 (R123) and doxorubicin across Caco-2 cells. Doxorubicin 135-146 ATP binding cassette subfamily B member 1 Homo sapiens 77-91 12948017-1 2003 PURPOSE: The purpose of this work was to elucidate transport pathways of the P-glycoprotein (P-gp) substrates rhodamine 123 (R123) and doxorubicin across Caco-2 cells. Doxorubicin 135-146 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 12940627-0 2003 Repetitive doxorubicin treatment of glioblastoma enhances the PGP expression--a special role for endothelial cells. Doxorubicin 11-22 ATP binding cassette subfamily B member 1 Homo sapiens 62-65 12940627-8 2003 It was concluded that DOX enhanced the constitutive PGP expression which led to a subsequent exclusion of DOX in tumor cells but also in the endothelial cells of the tumor vasculature. Doxorubicin 22-25 ATP binding cassette subfamily B member 1 Homo sapiens 52-55 12940627-8 2003 It was concluded that DOX enhanced the constitutive PGP expression which led to a subsequent exclusion of DOX in tumor cells but also in the endothelial cells of the tumor vasculature. Doxorubicin 106-109 ATP binding cassette subfamily B member 1 Homo sapiens 52-55 12940627-9 2003 Since the vascularization is a prerequisite for tumor growth, the inhibition of the PGP expression in tumor endothelial cells might be a clinical approach to make the DOX treatment more effective. Doxorubicin 167-170 ATP binding cassette subfamily B member 1 Homo sapiens 84-87 12799644-5 2003 The doxorubicin-resistant cells 2R120 (MRP1) and 2R160 (P-gP) were nine- and 28-fold more sensitive to gemcitabine than their parental SW1573 cells, respectively (P<0.01), which was completely reverted by 25 micro M verapamil. Doxorubicin 4-15 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 14575561-2 2003 METHODS: The expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). Doxorubicin 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 14575561-2 2003 METHODS: The expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). Doxorubicin 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 14575561-2 2003 METHODS: The expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). Doxorubicin 148-158 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 14575561-2 2003 METHODS: The expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). Doxorubicin 216-226 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 14575561-2 2003 METHODS: The expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). Doxorubicin 216-226 ATP binding cassette subfamily B member 1 Homo sapiens 37-51 14575561-2 2003 METHODS: The expression of mdr-1 and p-glycoprotein (p-gp) was studied by confocal laser microscope (Confocal), RT-PCR and Western blot analysis in adriamycin-resistant human ovarian cancer cell line (A2780/ADM) and adriamycin-sensitive one (A2780). Doxorubicin 216-226 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 12767063-7 2003 Our results show that AMR competitively inhibits P-gp-mediated DOX efflux, suggestive of a mechanism underlying the enhanced DOX accumulation and reversal of multidrug resistance by AMR. Doxorubicin 125-128 ATP binding cassette subfamily B member 1 Homo sapiens 49-53 12604704-6 2003 Biochanin A and silymarin potentiated doxorubicin cytotoxicity in P-gp positive cells. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 66-70 12894558-4 2003 MDR1 antisense S-ODN I reduced the DOX IC50 value 9-fold in multidrug-resistant SW620 Ad300 human colon carcinoma cells and 7 to 10-fold in breast carcinoma cells in vitro. Doxorubicin 35-38 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 12894558-5 2003 The increase in DOX cytotoxicity correlated with a significant reduction of MDR1 mRNA in antisense S-ODN I-treated SW620 Ad300 cells. Doxorubicin 16-19 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 12695554-12 2003 Second, MDR1 transfected cells selected with either doxorubicin or neomycin showed distinct expression profiles that could be related to differential selection. Doxorubicin 52-63 ATP binding cassette subfamily B member 1 Homo sapiens 8-12 12711306-3 2003 This reduction was associated with a decrease of CFTR mRNA and simultaneous up-regulation of MDR1 mRNA in the presence of doxorubicin. Doxorubicin 122-133 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 12687290-6 2003 RESULTS: Ketotifen was found to restore the sensitivity of P-glycoprotein-overexpressing multidrug-resistant MCF-7/adr cells to doxorubicin, mitoxantrone, VP-16 and vinblastine, but not to methotrexate or camptothecin. Doxorubicin 128-139 ATP binding cassette subfamily B member 1 Homo sapiens 59-73 12609962-4 2003 Thus, cells from the K562/DOX line, described as resistant to doxorubicin due to MDR1 gene overexpression, grew continuously in the presence of 1 microM imatinib, but died in 4 to 5 days if the Pgp pump modulators verapamil or PSC833 were added to the imatinib-treated culture. Doxorubicin 26-29 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 12609962-4 2003 Thus, cells from the K562/DOX line, described as resistant to doxorubicin due to MDR1 gene overexpression, grew continuously in the presence of 1 microM imatinib, but died in 4 to 5 days if the Pgp pump modulators verapamil or PSC833 were added to the imatinib-treated culture. Doxorubicin 62-73 ATP binding cassette subfamily B member 1 Homo sapiens 81-85 12822513-1 2003 We studied the possibility of increasing sensitization of drug-resistant MDA435/LCC6 multidrug-resistant (MDR) human breast cancer cells to doxorubicin (DOX) by increasing cellular drug retention with P-glycoprotein (P-gp) inhibitor PSC833 in combination with induction of cell death through down-regulation of Bcl-2 protein using Bcl-2 antisense (G3139). Doxorubicin 140-151 ATP binding cassette subfamily B member 1 Homo sapiens 201-215 12822513-1 2003 We studied the possibility of increasing sensitization of drug-resistant MDA435/LCC6 multidrug-resistant (MDR) human breast cancer cells to doxorubicin (DOX) by increasing cellular drug retention with P-glycoprotein (P-gp) inhibitor PSC833 in combination with induction of cell death through down-regulation of Bcl-2 protein using Bcl-2 antisense (G3139). Doxorubicin 140-151 ATP binding cassette subfamily B member 1 Homo sapiens 217-221 12822513-1 2003 We studied the possibility of increasing sensitization of drug-resistant MDA435/LCC6 multidrug-resistant (MDR) human breast cancer cells to doxorubicin (DOX) by increasing cellular drug retention with P-glycoprotein (P-gp) inhibitor PSC833 in combination with induction of cell death through down-regulation of Bcl-2 protein using Bcl-2 antisense (G3139). Doxorubicin 153-156 ATP binding cassette subfamily B member 1 Homo sapiens 201-215 12822513-1 2003 We studied the possibility of increasing sensitization of drug-resistant MDA435/LCC6 multidrug-resistant (MDR) human breast cancer cells to doxorubicin (DOX) by increasing cellular drug retention with P-glycoprotein (P-gp) inhibitor PSC833 in combination with induction of cell death through down-regulation of Bcl-2 protein using Bcl-2 antisense (G3139). Doxorubicin 153-156 ATP binding cassette subfamily B member 1 Homo sapiens 217-221 12586499-4 2003 By inhibiting the P-glycoprotein (P-gp)-mediated doxorubicin efflux from the cells and enhancing the passive influx, the microgels were shown to enhance the overall cell absorption of doxorubicin. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 12586499-4 2003 By inhibiting the P-glycoprotein (P-gp)-mediated doxorubicin efflux from the cells and enhancing the passive influx, the microgels were shown to enhance the overall cell absorption of doxorubicin. Doxorubicin 49-60 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 12586499-4 2003 By inhibiting the P-glycoprotein (P-gp)-mediated doxorubicin efflux from the cells and enhancing the passive influx, the microgels were shown to enhance the overall cell absorption of doxorubicin. Doxorubicin 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 12586499-4 2003 By inhibiting the P-glycoprotein (P-gp)-mediated doxorubicin efflux from the cells and enhancing the passive influx, the microgels were shown to enhance the overall cell absorption of doxorubicin. Doxorubicin 184-195 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 12586499-6 2003 Microgels exhibited synergism of the doxorubicin transport enhancement with Verapamil, a known inhibitor of the P-gp. Doxorubicin 37-48 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 12566319-0 2003 Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. Doxorubicin 77-87 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 12566319-4 2003 Because of the latter association, we have examined potential relationships between LANCL2 and the expression of multidrug-resistance (MDR)1, as well as its cognate protein, P-glycoprotein (P-gp), because elevated expression of P-gp is known to increase cell resistance to many cytotoxic drugs, including Adriamycin. Doxorubicin 305-315 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 12566319-5 2003 Using the Dx5 derivative of MES-SA cells in which P-gp is overexpressed, we show that the level of endogenous P-gp decreases with increased expression of exogenous LanCl-2 and that cells with reduced P-gp show increased sensitivity to Adriamycin. Doxorubicin 235-245 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 12566319-5 2003 Using the Dx5 derivative of MES-SA cells in which P-gp is overexpressed, we show that the level of endogenous P-gp decreases with increased expression of exogenous LanCl-2 and that cells with reduced P-gp show increased sensitivity to Adriamycin. Doxorubicin 235-245 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 12566319-5 2003 Using the Dx5 derivative of MES-SA cells in which P-gp is overexpressed, we show that the level of endogenous P-gp decreases with increased expression of exogenous LanCl-2 and that cells with reduced P-gp show increased sensitivity to Adriamycin. Doxorubicin 235-245 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 12566319-7 2003 With respect to this study, our data indicate that LanCl-2 increases cellular sensitivity to Adriamycin by decreasing the expression of P-gp, but more generally, these results indicate that the identification of bystander gene amplification in human tumors can have clinical implications. Doxorubicin 93-103 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 12608535-8 2003 Cotreatment with a Pgp inhibitor, verapamil, abolished the difference in intracellular accumulation of doxorubicin as well as the differences in apoptosis between MCF7 and BC19 cells. Doxorubicin 103-114 ATP binding cassette subfamily B member 1 Homo sapiens 19-22 12669953-0 2003 Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Doxorubicin 173-184 ATP binding cassette subfamily B member 1 Homo sapiens 86-90 12669953-6 2003 RESULTS: The combination of DOX and ASO targeted to MDR1 and BCL-2 mRNA in one LDDS exhibited a dramatic increase in the anticancer action of DOX. Doxorubicin 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 12669953-6 2003 RESULTS: The combination of DOX and ASO targeted to MDR1 and BCL-2 mRNA in one LDDS exhibited a dramatic increase in the anticancer action of DOX. Doxorubicin 142-145 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 12608535-9 2003 This finding confirms that the lower apoptosis of doxorubicin in BC19 cells, in the absence of verapamil, was a result of lower intracellular drug accumulation secondary to high Pgp expression in BC19 cells. Doxorubicin 50-61 ATP binding cassette subfamily B member 1 Homo sapiens 178-181 12516966-9 2002 Third, Et-743 pretreatment enhanced the cytotoxicity and the cellular accumulation of doxorubicin and vincristine in P-gp/MDR1-overexpressing KB-8-5/KB-C-2 cell lines. Doxorubicin 86-97 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 12528803-0 2003 Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Doxorubicin 11-22 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 12516966-9 2002 Third, Et-743 pretreatment enhanced the cytotoxicity and the cellular accumulation of doxorubicin and vincristine in P-gp/MDR1-overexpressing KB-8-5/KB-C-2 cell lines. Doxorubicin 86-97 ATP binding cassette subfamily B member 1 Homo sapiens 122-126 12138343-0 2002 In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. Doxorubicin 144-155 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 12431060-6 2002 Moreover, at noncytotoxic concentrations, these compounds potently sensitized MDR cells to Pgp substrates vinblastine and adriamycin. Doxorubicin 122-132 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 12297834-8 2002 Adenoviral delivery of CMV promoter-driven anti-MDR1 ribozymes resulted in a reduced IC(50) for epirubicin and doxorubicin (60- and 20-fold, respectively). Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 12364568-3 2002 Expression of transport proteins in the heart could be an important factor modifying cardiac concentrations of drugs known to be transported by P-gp (e.g., beta-blockers, cardiac glycosides, doxorubicin). Doxorubicin 191-202 ATP binding cassette subfamily B member 1 Homo sapiens 144-148 12384433-9 2002 Furthermore, a doxorubicin-resistant clone of HL60, HL60/ADR, obtained by the transfection of the MDR-1 gene, was equally sensitive to AN-9 cytotoxicity as the parental cells. Doxorubicin 15-26 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 12489924-3 2002 The analysis of the P-gp encoding MDR1 gene overexpression by reverse transcriptase - polymerase chain reaction provided evidence of increased MDR1 mRNA levels when the adriamycin concentration used for the MDR cell selection increased. Doxorubicin 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 20-24 12489924-3 2002 The analysis of the P-gp encoding MDR1 gene overexpression by reverse transcriptase - polymerase chain reaction provided evidence of increased MDR1 mRNA levels when the adriamycin concentration used for the MDR cell selection increased. Doxorubicin 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 12489924-3 2002 The analysis of the P-gp encoding MDR1 gene overexpression by reverse transcriptase - polymerase chain reaction provided evidence of increased MDR1 mRNA levels when the adriamycin concentration used for the MDR cell selection increased. Doxorubicin 169-179 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 12370750-6 2002 The anti-MRP Rz and anti-MDR1 Rz significantly down-regulated resistance to DOX and VP-16, while anti-MRP Rz and anti-MDR1 Rz did not affect resistance to cisplatin, methotrexate and 5-fluorouracil. Doxorubicin 76-79 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 12407543-0 2002 MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro. Doxorubicin 77-88 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 12407543-9 2002 CONCLUSIONS: MDR1 modulators significantly improve the response of HB to DOXO in vitro. Doxorubicin 73-77 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 12112526-6 2002 MDR1 gene amplification precedes the emergence of a mutant allele in cells that were coselected with doxorubicin and a cyclosporin inhibitor of P-glycoprotein (P-gp). Doxorubicin 101-112 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 12112526-8 2002 Reselection of revertant cells with doxorubicin in either the presence or the absence of the P-gp inhibitor resulted in exclusive reexpression of the mutant MDR1 allele, regardless of the presence of multiple wild-type MDR1 alleles. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 157-161 12138343-0 2002 In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. Doxorubicin 144-155 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 12138343-9 2002 Moreover, HIV PIs possess an inhibitory effect on P-gp function that may improve DOX sensitivity in KS spindle cells. Doxorubicin 81-84 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 12115804-6 2002 In MCF7/DoX cells, preferentially overexpressing Pgp, but also a significant level of MRP1, the IC(50) of CPT was 0.64 microM and thus presented a resistance index of 3.26 against CPT. Doxorubicin 8-11 ATP binding cassette subfamily B member 1 Homo sapiens 49-52 12180485-3 2002 Generally, the incidence of MDR1/Pgp expression was higher in pretreated samples, and treatments with doxorubicin and/or vincristine were more effective in MDR1/Pgp expression than with alkylating agents. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 12085207-2 2002 In a variety of malignancies, high expression of multidrug resistance-associated protein1 and P-glycoprotein has been associated with resistance to doxorubicin, whereas 5-fluorouracil resistance has correlated with the level of thymidylate synthase expression. Doxorubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 94-108 11976833-10 2002 P-gp antigen and MDR1 mRNA were highly expressed in both the MOLT-4/DNR and MOLT-4/DOX sublines. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 11976833-10 2002 P-gp antigen and MDR1 mRNA were highly expressed in both the MOLT-4/DNR and MOLT-4/DOX sublines. Doxorubicin 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 11809535-0 2002 Inhibition of P-glycoprotein by flavonoid derivatives in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Doxorubicin 57-67 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 12064912-5 2002 We used CCRF-CEM parental cells and doxorubicin-selected P-glycoprotein (P-gp)/MDR1-expressing CEM/ADR5000, vinblastine-selected P-gp/MDR1-expressing CEM/VLB(100), and epirubicin-selected multidrug resistance-related protein 1 (MRP1)-expressing CEM/E1000 sublines thereof. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 12064912-5 2002 We used CCRF-CEM parental cells and doxorubicin-selected P-glycoprotein (P-gp)/MDR1-expressing CEM/ADR5000, vinblastine-selected P-gp/MDR1-expressing CEM/VLB(100), and epirubicin-selected multidrug resistance-related protein 1 (MRP1)-expressing CEM/E1000 sublines thereof. Doxorubicin 36-47 ATP binding cassette subfamily B member 1 Homo sapiens 79-83 11911975-5 2002 In fact, the P-gp inhibitor verapamil reversed only partially the resistance to Dox-induced apoptosis of the MDR cells. Doxorubicin 80-83 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 11992683-11 2002 In contrast to application of DOX alone, a cocktail of DOX with CsA as a blocker of P-glycoprotein (Pgp) incorporated into HPMA-hydrogel blocked the proliferation of Pgp-overexpressing multidrug resistant cell lines in vitro by induction of apoptosis. Doxorubicin 30-33 ATP binding cassette subfamily B member 1 Homo sapiens 166-169 11992683-11 2002 In contrast to application of DOX alone, a cocktail of DOX with CsA as a blocker of P-glycoprotein (Pgp) incorporated into HPMA-hydrogel blocked the proliferation of Pgp-overexpressing multidrug resistant cell lines in vitro by induction of apoptosis. Doxorubicin 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 84-98 11992683-11 2002 In contrast to application of DOX alone, a cocktail of DOX with CsA as a blocker of P-glycoprotein (Pgp) incorporated into HPMA-hydrogel blocked the proliferation of Pgp-overexpressing multidrug resistant cell lines in vitro by induction of apoptosis. Doxorubicin 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 100-103 11992683-11 2002 In contrast to application of DOX alone, a cocktail of DOX with CsA as a blocker of P-glycoprotein (Pgp) incorporated into HPMA-hydrogel blocked the proliferation of Pgp-overexpressing multidrug resistant cell lines in vitro by induction of apoptosis. Doxorubicin 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 166-169 12415630-2 2002 METHODS: We investigated if P-gp expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six commonly used chemotherapeutic agents (doxorubicin, daunorubicin, mitoxantrone, vinblastine, paclitaxel, and colchicine). Doxorubicin 169-180 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 11850258-4 2002 Expression of P-gp and MDR1 mRNA was determined in samples from MCF-7 cells that were treated in culture with doxorubicin (positive control) and the antimicrobial drugs doxycycline, piperacillin, and cefoperazone. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 11850258-4 2002 Expression of P-gp and MDR1 mRNA was determined in samples from MCF-7 cells that were treated in culture with doxorubicin (positive control) and the antimicrobial drugs doxycycline, piperacillin, and cefoperazone. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 11850258-5 2002 The functional status of P-gp was assessed using laser cytometry to determine intracellular doxorubicin concentrations. Doxorubicin 92-103 ATP binding cassette subfamily B member 1 Homo sapiens 25-29 11850258-10 2002 P-gp expression was induced only by experimental drugs that were cytotoxic (doxorubicin and doxycycline). Doxorubicin 76-87 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 11839680-2 2002 Expression of P-glycoprotein (P-gp) in cancer cells causes resistance against paclitaxel and docetaxel, as well as against vincristine and doxorubicin (ADM). Doxorubicin 139-150 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 11839680-2 2002 Expression of P-glycoprotein (P-gp) in cancer cells causes resistance against paclitaxel and docetaxel, as well as against vincristine and doxorubicin (ADM). Doxorubicin 139-150 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 11818209-8 2002 Accumulation and efflux studies with the P-gp substrates, Dox and Fura-2, demonstrated that Tet inhibited the P-gp-mediated drug efflux. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 11818209-8 2002 Accumulation and efflux studies with the P-gp substrates, Dox and Fura-2, demonstrated that Tet inhibited the P-gp-mediated drug efflux. Doxorubicin 58-61 ATP binding cassette subfamily B member 1 Homo sapiens 110-114 12003193-1 2002 Previously, we have reported partial circumvention of P-glycoprotein (Pgp)-associated resistance to doxorubicin (Dox) in MCF7/R human breast carcinoma and P388/R murine leukemia cell lines by doxorubicin-14-O-hemiadipate (H-Dox) [Povarov L.S. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 12003193-1 2002 Previously, we have reported partial circumvention of P-glycoprotein (Pgp)-associated resistance to doxorubicin (Dox) in MCF7/R human breast carcinoma and P388/R murine leukemia cell lines by doxorubicin-14-O-hemiadipate (H-Dox) [Povarov L.S. Doxorubicin 100-111 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 12003193-1 2002 Previously, we have reported partial circumvention of P-glycoprotein (Pgp)-associated resistance to doxorubicin (Dox) in MCF7/R human breast carcinoma and P388/R murine leukemia cell lines by doxorubicin-14-O-hemiadipate (H-Dox) [Povarov L.S. Doxorubicin 113-116 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 12003193-1 2002 Previously, we have reported partial circumvention of P-glycoprotein (Pgp)-associated resistance to doxorubicin (Dox) in MCF7/R human breast carcinoma and P388/R murine leukemia cell lines by doxorubicin-14-O-hemiadipate (H-Dox) [Povarov L.S. Doxorubicin 113-116 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 11784143-8 2002 Potency for restoring doxorubicin accumulation in MDR1-transduced human breast cancer cells is increased up to 60-fold as compared with progesterone. Doxorubicin 22-33 ATP binding cassette subfamily B member 1 Homo sapiens 50-54 11809686-5 2002 Our data showed that the expression of MRP1-EGFP results in significantly decreased cellular accumulation of tetramethylrhodamine ethyl ester (TMRE) and daunorubicin, mildly decreased cellular accumulation of mitoxantrone, and decreased nuclear accumulation of doxorubicin. Doxorubicin 261-272 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 11801563-2 2002 This includes multidrug resistance mediated by P-glycoprotein (Pgp) to multiple lipophilic natural compounds such as taxanes, doxorubicin (Adriamycin), and vinblastine. Doxorubicin 126-137 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 11801563-2 2002 This includes multidrug resistance mediated by P-glycoprotein (Pgp) to multiple lipophilic natural compounds such as taxanes, doxorubicin (Adriamycin), and vinblastine. Doxorubicin 126-137 ATP binding cassette subfamily B member 1 Homo sapiens 63-66 11801563-2 2002 This includes multidrug resistance mediated by P-glycoprotein (Pgp) to multiple lipophilic natural compounds such as taxanes, doxorubicin (Adriamycin), and vinblastine. Doxorubicin 139-149 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 11801563-2 2002 This includes multidrug resistance mediated by P-glycoprotein (Pgp) to multiple lipophilic natural compounds such as taxanes, doxorubicin (Adriamycin), and vinblastine. Doxorubicin 139-149 ATP binding cassette subfamily B member 1 Homo sapiens 63-66 12180485-3 2002 Generally, the incidence of MDR1/Pgp expression was higher in pretreated samples, and treatments with doxorubicin and/or vincristine were more effective in MDR1/Pgp expression than with alkylating agents. Doxorubicin 102-113 ATP binding cassette subfamily B member 1 Homo sapiens 156-160 12180485-4 2002 A significant association was observed between MDR1 /Pgp-positiveness and the ability of verapmil to increase doxorubicin sensitivity, suggesting functional relevance of MDR1/Pgp expression. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 12180485-4 2002 A significant association was observed between MDR1 /Pgp-positiveness and the ability of verapmil to increase doxorubicin sensitivity, suggesting functional relevance of MDR1/Pgp expression. Doxorubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 170-174 11602652-2 2001 Tumor cell resistance to doxorubicin is often associated with expression of the multidrug resistance gene MDR1, which codes for the drug efflux pump P-glycoprotein, and a multidrug-resistant phenotype. Doxorubicin 25-36 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 11911247-1 2001 BACKGROUND: MDR1 or MRP1 drug resistance mechanisms seriously limit the efficacy of anthracyclines such as doxorubicin, in the treatment of acute myeloid leukemia (AML). Doxorubicin 107-118 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 11745426-3 2001 Increased expression of MDR1, MRP5 and SMRP mRNA was observed 48 hr after the initiation of Adriamycin exposure in human lung cancer PC-14 cells and cisplatin-resistant PC-14/CDDP cells, in a dose-dependent manner as measured by TaqMan real-time RT-PCR. Doxorubicin 92-102 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 11602652-2 2001 Tumor cell resistance to doxorubicin is often associated with expression of the multidrug resistance gene MDR1, which codes for the drug efflux pump P-glycoprotein, and a multidrug-resistant phenotype. Doxorubicin 25-36 ATP binding cassette subfamily B member 1 Homo sapiens 149-163 11595714-10 2001 Characterization of the resistant cell lines indicated the presence of increased mdr-1 and P-gp expression, which resulted in resistance to the agents doxorubicin, etoposide, and vincristine but not cisplatin. Doxorubicin 151-162 ATP binding cassette subfamily B member 1 Homo sapiens 81-86 11595714-10 2001 Characterization of the resistant cell lines indicated the presence of increased mdr-1 and P-gp expression, which resulted in resistance to the agents doxorubicin, etoposide, and vincristine but not cisplatin. Doxorubicin 151-162 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 11290872-0 2001 Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Doxorubicin 179-190 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 11745235-0 2001 Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Doxorubicin 54-65 ATP binding cassette subfamily B member 1 Homo sapiens 85-107 11780384-11 2001 Compared with SKOV3/mdr1 cells in the control group, under a certain range of drug concentrations, the number of drug resistance colonies in mdr1 antisense ODNs treated SKOV3/mdr1 cells for taxol and doxorubicin decreased by 8.6 +/- 0.8 fold and 3.1 +/- 0.6 fold, respectively. Doxorubicin 200-211 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 11780384-11 2001 Compared with SKOV3/mdr1 cells in the control group, under a certain range of drug concentrations, the number of drug resistance colonies in mdr1 antisense ODNs treated SKOV3/mdr1 cells for taxol and doxorubicin decreased by 8.6 +/- 0.8 fold and 3.1 +/- 0.6 fold, respectively. Doxorubicin 200-211 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 11516098-6 2001 After 4 weeks of treatment, a functional P-gp was detected in HL-60/Dox cells. Doxorubicin 68-71 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 11552225-5 2001 The paclitaxel/doxorubicin interaction was found to be paclitaxel-dose dependent, doxorubicin concentration-dependant, and may be the result of competition for elimination mechanisms, possibly competition for hepatic and biliary transporter proteins such as p-glycoprotein, as a result of the formulation vehicle polyethoxylated castor oil (cremophor EL). Doxorubicin 15-26 ATP binding cassette subfamily B member 1 Homo sapiens 258-272 11473730-5 2001 SBC-3 / ADM cells expressing P-gp were highly resistant to etoposide (VP-16), adriamycin (ADM), and vincristine (VCR) in vitro, compared with parental SBC-3 cells lacking P-gp expression. Doxorubicin 78-88 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 11473730-5 2001 SBC-3 / ADM cells expressing P-gp were highly resistant to etoposide (VP-16), adriamycin (ADM), and vincristine (VCR) in vitro, compared with parental SBC-3 cells lacking P-gp expression. Doxorubicin 8-11 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 11473730-5 2001 SBC-3 / ADM cells expressing P-gp were highly resistant to etoposide (VP-16), adriamycin (ADM), and vincristine (VCR) in vitro, compared with parental SBC-3 cells lacking P-gp expression. Doxorubicin 8-11 ATP binding cassette subfamily B member 1 Homo sapiens 171-175 11351295-0 2001 Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Doxorubicin 111-122 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 11351295-1 2001 While P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP1) are known to be important in acquired doxorubicin resistance, the role of glutathione S-transferases (GST) remains unclear. Doxorubicin 118-129 ATP binding cassette subfamily B member 1 Homo sapiens 6-20 11351295-1 2001 While P-glycoprotein (Pgp) and multidrug resistance-associated protein 1 (MRP1) are known to be important in acquired doxorubicin resistance, the role of glutathione S-transferases (GST) remains unclear. Doxorubicin 118-129 ATP binding cassette subfamily B member 1 Homo sapiens 22-25 11351295-5 2001 In the resistant HEp2A cells, cytotoxicity was markedly enhanced by the Pgp/MRP inhibitor verapamil at low doxorubicin concentrations. Doxorubicin 107-118 ATP binding cassette subfamily B member 1 Homo sapiens 72-75 11311122-0 2001 Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Doxorubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 55-69 11311122-2 2001 In the present study, with stably transfected Madin-Darby canine kidney C7 epithelial cells expressing a human Pgp tagged with green fluorescent protein under the proximal human MDR1 gene promoter, we demonstrated that MMC and doxorubicin have differential effects on Pgp expression and function. Doxorubicin 227-238 ATP binding cassette subfamily B member 1 Homo sapiens 111-114 11311122-2 2001 In the present study, with stably transfected Madin-Darby canine kidney C7 epithelial cells expressing a human Pgp tagged with green fluorescent protein under the proximal human MDR1 gene promoter, we demonstrated that MMC and doxorubicin have differential effects on Pgp expression and function. Doxorubicin 227-238 ATP binding cassette subfamily B member 1 Homo sapiens 268-271 11311122-3 2001 Doxorubicin caused a progressive increase in the cell-surface expression of Pgp and function. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 76-79 11379779-0 2001 Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Doxorubicin 12-23 ATP binding cassette subfamily B member 1 Homo sapiens 54-68 11379779-5 2001 Verapamil, and even more markedly, lomerizine, increased cellular uptake of calcein transported by P-gp in a P-gp-expressing erythroleukemia cell line, K562-Dox. Doxorubicin 157-160 ATP binding cassette subfamily B member 1 Homo sapiens 99-103 11313874-7 2001 Analysis of genomic amplifications and deletions revealed specific genetic alterations common to both intrinsic and acquired DOX resistance including ABCB1, PGY3 (ABCB4) and BAK. Doxorubicin 125-128 ATP binding cassette subfamily B member 1 Homo sapiens 150-155 11552980-4 2001 We investigated the in vitro cross-resistance to AraC in a doxorubicin-resistant HL60 cell line, with an elevated expression of the MDR-1 gene. Doxorubicin 59-70 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 11504769-8 2001 RESULTS: Pgp-expressing cells treated with IDN-5109 or with the taxane-based drug resistance reversal agent tRA96023, which blocks Pgp activity, retained 8.1- and 9.4-fold more Rh-123 (P =.0001), respectively, and 1.7- and 1.9-fold more doxorubicin (P =.001), respectively, than cells treated with paclitaxel. Doxorubicin 237-248 ATP binding cassette subfamily B member 1 Homo sapiens 9-12 11290872-0 2001 Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Doxorubicin 179-190 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 11290872-0 2001 Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines. Doxorubicin 179-190 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 11290872-1 2001 Previous studies have reported that P-glycoprotein (P-gp), a transmembrane efflux pump involved in multidrug resistance (MDR), was overexpressed in the doxorubicin (Dox)-resistant human erythroleukemia cell line K562. Doxorubicin 152-163 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 11290872-1 2001 Previous studies have reported that P-glycoprotein (P-gp), a transmembrane efflux pump involved in multidrug resistance (MDR), was overexpressed in the doxorubicin (Dox)-resistant human erythroleukemia cell line K562. Doxorubicin 152-163 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 11290872-1 2001 Previous studies have reported that P-glycoprotein (P-gp), a transmembrane efflux pump involved in multidrug resistance (MDR), was overexpressed in the doxorubicin (Dox)-resistant human erythroleukemia cell line K562. Doxorubicin 165-168 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 11290872-1 2001 Previous studies have reported that P-glycoprotein (P-gp), a transmembrane efflux pump involved in multidrug resistance (MDR), was overexpressed in the doxorubicin (Dox)-resistant human erythroleukemia cell line K562. Doxorubicin 165-168 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 11261883-2 2001 To overcome this problem, we tested the capability of two peptide vectors that are able to cross cellular membranes to deliver doxorubicin in P-gp-expressing cells. Doxorubicin 127-138 ATP binding cassette subfamily B member 1 Homo sapiens 142-146 11161402-2 2001 Doxorubicin flow cytometry is used to monitor Pgp function in haematological specimens and biopsies from other cancers, and radionuclide imaging with sestamibi has recently shown promise for non-invasive monitoring. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 46-49 11108808-4 2000 Adriamycin-resistant human breast cancer MCF-7/DOX cells, presenting a comparable GSH concentration, but a 14-fold increase of the GST P1-1 activity relative to the sensitive MCF-7 cells, have been treated with adriamycin in the presence of verapamil, an inhibitor of the 170 P-glycoprotein (P-gp) drug transport protein, and scrutinized for any production of GSH-adriamycin conjugates. Doxorubicin 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 276-290 11729998-3 2001 In particular, by using immunocytochemical and cytofluorimetric methods, we revealed that in MDR breast cancer cells (MCF-7) a significant level of P-gp was expressed in the Golgi apparatus, which is the major site of accumulation of the antitumoral compound doxorubicin. Doxorubicin 259-270 ATP binding cassette subfamily B member 1 Homo sapiens 148-152 11125025-2 2001 The resulting Pgp-stationary phase was used in frontal and zonal chromatographic studies to investigate the binding of vinblastine (VBL), doxorubicin (DOX), verapamil (VER), and cyclosporin A (CsA) to the immobilized Pgp. Doxorubicin 138-149 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 11125025-2 2001 The resulting Pgp-stationary phase was used in frontal and zonal chromatographic studies to investigate the binding of vinblastine (VBL), doxorubicin (DOX), verapamil (VER), and cyclosporin A (CsA) to the immobilized Pgp. Doxorubicin 151-154 ATP binding cassette subfamily B member 1 Homo sapiens 14-17 11108808-4 2000 Adriamycin-resistant human breast cancer MCF-7/DOX cells, presenting a comparable GSH concentration, but a 14-fold increase of the GST P1-1 activity relative to the sensitive MCF-7 cells, have been treated with adriamycin in the presence of verapamil, an inhibitor of the 170 P-glycoprotein (P-gp) drug transport protein, and scrutinized for any production of GSH-adriamycin conjugates. Doxorubicin 0-10 ATP binding cassette subfamily B member 1 Homo sapiens 292-296 11042226-0 2000 Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Doxorubicin 15-26 ATP binding cassette subfamily B member 1 Homo sapiens 61-75 10974159-11 2000 (124)I and (76)Br radiolabeled doxorubicin analogues are also useful to examine P-gp mediated transport. Doxorubicin 31-42 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 11069027-3 2000 Herein, we studied the DNA methylation patterns at the enhancer and repressor binding sites of the MDR-1 gene using the human erythroleukemia cell line K562 and its multidrug resistant derivative K562/ADM (adriamycin). Doxorubicin 206-216 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 11218898-8 2000 Under effect of Doxorubicin 100 ng/ml, the relative percents of drug-resistant colony in mdr1-ASON treated SKOV3/mdr1 cells and in SKOV3/mdr1 cells was 34% and 79%, respectively, (P < 0.01). Doxorubicin 16-27 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 11042226-2 2000 Both rhodamine-123 and doxorubicin showed highly polarised transport in the Caco-2 cell line and the LLC-PK1:MDR1 cell line, indicating that P-gp is actively transporting these drugs. Doxorubicin 23-34 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 11042226-4 2000 Polarised transport of doxorubicin in the Caco-2 and the LLC-PK1:MDR1 cell lines could be inhibited by the P-gp inhibitors SDZ-PSC 833 (PSC 833), cyclosporin A (CsA), verapamil and quinine, but not by the inhibitors for the organic cation carrier systems cimetidine and tetraethylammonium (TEA). Doxorubicin 23-34 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 11042226-9 2000 Doxorubicin appears to be a more selective P-gp substrate and therefore more useful in studying P-gp functionality in vitro. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 11042226-9 2000 Doxorubicin appears to be a more selective P-gp substrate and therefore more useful in studying P-gp functionality in vitro. Doxorubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 96-100 10925353-7 2000 Modulation of P-gp function by cyclosporin A was found to alter DOX accumulation and efflux in LoVo 7 cells, indicating that intracellular P-gp plays a functional role in drug trafficking and suggesting possible implications in determining the intrinsic resistance displayed by this clone. Doxorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 10925353-7 2000 Modulation of P-gp function by cyclosporin A was found to alter DOX accumulation and efflux in LoVo 7 cells, indicating that intracellular P-gp plays a functional role in drug trafficking and suggesting possible implications in determining the intrinsic resistance displayed by this clone. Doxorubicin 64-67 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 11036963-3 2000 PSC 833 in serum restored the IC50 of doxorubicin in the P-glycoprotein (P-gp)-positive resistant subline to the same level as in the sensitive cells at 1 microg/ml, which has been shown to be an achievable concentration in clinical trials. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 57-71 11036963-3 2000 PSC 833 in serum restored the IC50 of doxorubicin in the P-glycoprotein (P-gp)-positive resistant subline to the same level as in the sensitive cells at 1 microg/ml, which has been shown to be an achievable concentration in clinical trials. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 73-77 10912951-3 2000 In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, overexpression of P-glycoprotein (P-gp) and a correlative reduction in drug accumulation and typical drug-sensitivity pattern were confirmed. Doxorubicin 16-26 ATP binding cassette subfamily B member 1 Homo sapiens 91-105 10912951-3 2000 In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, overexpression of P-glycoprotein (P-gp) and a correlative reduction in drug accumulation and typical drug-sensitivity pattern were confirmed. Doxorubicin 16-26 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 10912954-1 2000 We previously showed that conjugating doxorubicin to very large 70-500 kDa dextran decreased its removal rate from P-glycoprotein (P-gp) over-expressing, multidrug-resistant KB-V1 cells. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 115-129 10912954-1 2000 We previously showed that conjugating doxorubicin to very large 70-500 kDa dextran decreased its removal rate from P-glycoprotein (P-gp) over-expressing, multidrug-resistant KB-V1 cells. Doxorubicin 38-49 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 10891551-0 2000 Overexpression of P-glycoprotein is associated with a decreased mitochondrial transmembrane potential in doxorubicin-selected K562 human leukemia cells. Doxorubicin 105-116 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 10891551-2 2000 We show elevation of Pgp associated with decreased MTP in doxorubicin-selected K562Dox subline as compared with parental K562 cells. Doxorubicin 58-69 ATP binding cassette subfamily B member 1 Homo sapiens 21-24 10867652-2 2000 Using a human uterine sarcoma cell line (MES-SA) and a doxorubicin (DOX)-resistant variant cell line (Dx-5), which expresses p-glycoprotein (PGP), we have addressed the relationship between multidrug resistance, vesicular acidification, and vesicular drug accumulation. Doxorubicin 55-66 ATP binding cassette subfamily B member 1 Homo sapiens 141-144 10953345-4 2000 In M14Dx lines, the appearance of surface P-gp, but not of MRP1 or lung resistance related protein (LRP), occurred in cells grown in the presence of DOX concentrations higher than 60 nM. Doxorubicin 149-152 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 11031728-4 2000 Since doxorubicin resistance in these cells is associated with the expression of high levels of P-glycoprotein, we evaluated the effect of mefloquine and of P-glycoprotein activity in cytofluorographic efflux experiments with the fluorescent dye rhodamine 123. Doxorubicin 6-17 ATP binding cassette subfamily B member 1 Homo sapiens 96-110